

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
Saul Ewing LLP
One Riverfront Plaza, Suite 1520
Newark, NJ 07102-5426
(973) 286-6700
clizza@saul.com

*Attorneys for Plaintiff
Supernus Pharmaceuticals, Inc.*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

SUPERNUS PHARMACEUTICALS, INC.,

Plaintiff,

v.

ACTAVIS INC., et al.,

Defendants.

Civil Action No. 14-6102 (SDW) (SCM)

SUPERNUS PHARMACEUTICALS, INC.,

Plaintiff,

v.

**ZYDUS PHARMACEUTICALS (USA)
INC., et al.,**

Defendants.

Civil Action No. 14-7272 (SDW) (SCM)

(Filed Electronically)

SUPERNUS PHARMACEUTICALS, INC.,

Plaintiff,

v.

**PAR PHARMACEUTICAL COMPANIES,
INC., et al.,**

Defendants.

Civil Action No. 15-326 (SDW) (SCM)

**SECOND AMENDED COMPLAINT AGAINST
ZYDUS PHARMACEUTICALS (USA) INC. AND CADILA HEALTHCARE LIMITED**

Plaintiff Supernus Pharmaceuticals, Inc. (“Supernus”) by its undersigned attorneys, for its Second Amended Complaint against defendants Zydus Pharmaceuticals (USA) Inc. (“Zydus USA”) and Cadila Healthcare Limited (“Zydus Cadila”) (collectively, “Defendants”),¹ herein alleges as follows:

NATURE OF THE ACTION

1. This is a civil action for patent infringement arising under the patent laws of the United States, Title 35, United States Code, involving United States Patent Nos. 8,298,576 (“the ’576 patent”), 8,298,580 (“the ’580 patent”), 8,663,683 (“the ’683 patent”), 8,877,248 (“the ’248 patent”), 8,889,191 (“the ’191 patent”), and 8,992,989 (“the ’989 patent”) attached hereto as Exhibits A, B, C, D, E, and F respectively.

THE PARTIES

2. Plaintiff Supernus is a corporation organized and existing under the laws of Delaware, having its principal place of business at 1550 East Gude Drive, Rockville, Maryland 20850.

3. Upon information and belief, Zydus Cadila is a public limited liability company organized and existing under the laws of India, having its principal place of business at Zydus Tower, Satellite Cross Roads, Ahmedabad-380015 Gujarat, India.

4. Upon information and belief, Zydus Cadila is in the business of, *inter alia*: (i) the development and manufacture of generic pharmaceutical products for sale throughout the United States, including throughout the State of New Jersey; (ii) through its various subsidiaries, including defendant Zydus USA, the preparation, submission, and filing of Abbreviated New

¹ Defendants have consented to Supernus’s amendment of its Complaint pursuant to Fed. R. Civ. P. 15(a)(2). (ECF No. 24 at 14.)

Drug Applications (“ANDAs”) seeking U.S. Food and Drug Administration (“FDA”) approval to market generic drugs throughout the United States; and (iii) through its various subsidiaries, including defendant Zydus USA, the distribution of generic pharmaceutical products for sale throughout the United States, including throughout the State of New Jersey.

5. Zydus Cadila’s Annual Report 2013-14 states that “[t]he Company’s operations in the US are spearheaded by its wholly-owned subsidiary Zydus Pharmaceuticals (USA) Inc” and that “[t]he Company filed a record 50 ANDAs with the USFDA during the year, taking the cumulative ANDA filings to 227.” Cadila Healthcare Limited Annual Report 2013-14, at 9. Zydus Cadila’s Annual Report 2013-14 further states, “[o]ur US business was the key driver in growth. We are currently the 8th largest generic company in the US in terms of prescriptions.” *Id.* at 5.

6. Upon information and belief, Zydus USA is a corporation organized and existing under the laws of New Jersey, having its principal place of business at 73 Route 31 North, Pennington, New Jersey 08534. Upon information and belief, Zydus USA is registered as a wholesale drug distributor in the State of New Jersey under the registration number 5003171.

7. Upon information and belief, Zydus USA is wholly owned by defendant Zydus Cadila. Upon information and belief, Zydus USA acts at the direction of, under the control of, and for the direct benefit of Zydus Cadila and is controlled and/or dominated by Zydus Cadila. Upon information and belief, Zydus USA and Zydus Cadila have at least one officer and/or director in common.

8. Upon information and belief, Zydus USA is in the business of: (i) developing generic pharmaceutical products for sale throughout the United States, including throughout the State of New Jersey; (ii) preparing, submitting, and filing Abbreviated New Drug Applications (“ANDAs”) seeking U.S. Food and Drug Administration (“FDA”) approval to market generic

drugs throughout the United States; and (iii) distributing generic pharmaceutical products for sale throughout the United States, including throughout the State of New Jersey.

9. Upon information and belief, Zydus USA prepared and then submitted and filed ANDA No. 207382 (“the Zydus ANDA”) with the FDA seeking approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of generic “topiramate extended-release capsules,” 25 mg, 50 mg, and 100 mg (“the Zydus Products”).

10. Upon information and belief, Zydus Cadila manufactures and Zydus USA distributes generic pharmaceutical products for which Zydus USA is the named ANDA applicant, including Donepezil Hydrochloride Tablets (5 mg and 10 mg); Divalproex Sodium Capsules (125 mg); and Gabapentin Tablets (600 mg and 800 mg). Upon information and belief, Defendants derive substantial revenue from the sale of such generic pharmaceutical products.

JURISDICTION AND VENUE

11. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

12. This Court has personal jurisdiction over Zydus Cadila because, *inter alia*: (i) Zydus Cadila, together with its subsidiary Zydus USA, has committed, induced, or contributed to acts of patent infringement in New Jersey; (ii) Zydus Cadila regularly does or solicits business in New Jersey and/or derives substantial revenue from services or things used or consumed in New Jersey; (iii) Zydus Cadila is doing business in New Jersey and maintains continuous and systemic contacts with this Judicial District; and (iv) Zydus Cadila has availed itself of the rights, benefits, and privileges of this Court by asserting claims in at least five prior New Jersey actions (*Zydus Pharms. (USA) Inc., et al. v. Gilead Sciences, Inc.*, Civil Action No. 14-7080; *Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., et al.*, Civil Action No. 14-3168; *Actelion Pharms. Ltd., et al. v. Apotex Inc., et al.*, Civil Action No. 12-5743; *Depomed, Inc. v.*

Zydus Pharms. USA Inc., et al., Civil Action No. 12-2813; and *Takeda Pharm. Co. Ltd., et al. v. Zydus Pharms. (USA) Inc., et al.*, Civil Action No. 10-1723).

13. This Court has personal jurisdiction over Zydus USA because, *inter alia*: (i) Zydus USA's principal place of business is located in New Jersey; (ii) Zydus USA, together with Zydus Cadila, has committed, induced, or contributed to acts of patent infringement in New Jersey; (iii) Zydus USA regularly does or solicits business in New Jersey and/or derives substantial revenue from services or things used or consumed in New Jersey; (iv) Zydus USA is doing business in New Jersey and maintains continuous and systematic contacts with this Judicial District; and (v) Zydus USA has availed itself of the rights, benefits, and privileges of this Court by asserting claims in at least five prior New Jersey actions (*Zydus Pharms. (USA) Inc., et al. v. Gilead Sciences, Inc.*, Civil Action No. 14-7080; *Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., et al.*, Civil Action No. 14-3168; *Actelion Pharms. Ltd., et al. v. Apotex Inc., et al.*, Civil Action No. 12-5743; *Depomed, Inc. v. Zydus Pharms. USA Inc., et al.*, Civil Action No. 12-2813; and *Takeda Pharm. Co. Ltd., et al. v. Zydus Pharms. (USA) Inc., et al.*, Civil Action No. 10-1723).

14. Venue is proper in this Judicial District under 28 U.S.C. §§ 1391(b) and (c), and § 1400(b).

FACTS AS TO ALL COUNTS

15. Supernus owns New Drug Application ("NDA") No. 201635, which was approved by the FDA for the manufacture and sale of topiramate extended-release capsules, 25 mg, 50 mg, 100 mg, and 200 mg, which Supernus markets under the name Trokendi XR[®].

16. Trokendi XR[®] is an antiepileptic drug indicated for: (i) initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; (ii) adjunctive therapy in patients 6 years of age and older with partial onset or primary

generalized tonic-clonic seizures; and (iii) adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome.

17. The '576 patent, entitled "Sustained-Release Formulations of Topiramate" was duly and legally issued by the United States Patent and Trademark Office on October 30, 2012, to Supernus upon assignment from inventors Likan Liang, Hua Wang, Padmanabh P. Bhatt, and Michael L. Vieira. Supernus owns all rights, title, and interest in the '576 patent.

18. The '580 patent, entitled "Sustained-Release Formulations of Topiramate" was duly and legally issued by the United States Patent and Trademark Office on October 30, 2012, to Supernus upon assignment from inventors Likan Liang, Hua Wang, Padmanabh P. Bhatt, and Michael L. Vieira. Supernus owns all rights, title, and interest in the '580 patent.

19. The '683 patent, entitled "Sustained-Release Formulations of Topiramate" was duly and legally issued by the United States Patent and Trademark Office on March 4, 2014, to Supernus upon assignment from inventors Likan Liang, Hua Wang, Padmanabh P. Bhatt, and Michael L. Vieira. Supernus owns all rights, title, and interest in the '683 patent.

20. The '248 patent, entitled "Sustained-Release Formulations of Topiramate" was duly and legally issued by the United States Patent and Trademark Office on November 4, 2014, to Supernus upon assignment from inventors Likan Liang, Hua Wang, Padmanabh P. Bhatt, and Michael L. Vieira. Supernus owns all rights, title, and interest in the '248 patent.

21. The '191 patent, entitled "Sustained-Release Formulations of Topiramate" was duly and legally issued by the United States Patent and Trademark Office on November 18, 2014, to Supernus upon assignment from inventors Likan Liang, Hua Wang, Padmanabh P. Bhatt, and Michael L. Vieira. Supernus owns all rights, title, and interest in the '191 patent.

22. The '989 patent, entitled "Sustained-Release Formulations of Topiramate" was duly and legally issued by the United States Patent and Trademark Office on March 31, 2015, to

Supernus upon assignment from inventors Likan Liang, Hua Wang, Padmanabh P. Bhatt, and Michael L. Vieira. Supernus owns all rights, title, and interest in the '989 patent.

23. Pursuant to 21 U.S.C. § 355(b)(1), the '576, '580, '683, '248, '191, and '989 patents are listed in the FDA's publication titled "Approved Drug Products with Therapeutic Equivalence Evaluations" (commonly known as the "*Orange Book*") as covering Trokendi XR[®]. Supernus submitted the '576, '580, '683, '248, '191, and '989 patents to the FDA to be listed in the *Orange Book* for NDA No. 201635.

24. Upon information and belief, Defendants worked in concert to prepare, and then submit and file the Zydus ANDA with the FDA under § 505(j) of the Federal Food, Drug, and Cosmetic Act ("FDCA") (codified at 21 U.S.C. § 355(j)), seeking approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products and included a "paragraph IV" certification seeking approval before the expiration of the '576, '580, '683, '248, '191, and '989 patents.

25. 21 U.S.C. § 355(j)(2)(B)(iv)(II) requires that a letter notifying a patent holder of the filing of an ANDA containing a paragraph IV certification "include a detailed statement of the factual and legal basis of the opinion of the applicant that the patent is invalid or will not be infringed." Likewise, 21 C.F.R. § 314.95(c)(6) requires that such a letter include "[a] detailed statement of the factual and legal basis of the applicant's opinion that the patent is not valid, unenforceable, or will not be infringed." The detailed statement must include "(i) [f]or each claim of a patent alleged not to be infringed, a full and detailed explanation of why the claim is not infringed" and "(ii) [f]or each claim of a patent alleged to be invalid or unenforceable, a full and detailed explanation of the grounds supporting the allegation." 21 C.F.R. § 314.95(c)(6)(i)-(ii).

26. Supernus received a letter dated October 9, 2014, which was purportedly sent pursuant to § 505(j)(2)(B)(iv) of the FDCA, regarding the Zydus Products and the '576, '580, and '683 patents (the "October 9 Notice Letter").

27. The October 9 Notice Letter was signed by Brij Khera, Ph.D., Executive Vice President and Chief Legal Officer, Zydus Pharmaceuticals (USA) Inc.

28. The October 9 Notice Letter does not include any non-infringement contentions unique to claims 2-14, 16-18, 20-26, or 28-30 of the '576 patent, claims 2-12, 14-16, 18-27, or 29-31 of the '580 patent, or claims 2-17, 19, or 20-24 of the '683 patent.

29. The October 9 Notice Letter does not include any invalidity contentions to any claim of the '576, '580, or '683 patent.

30. Supernus received a letter dated February 19, 2015, which was purportedly sent pursuant to § 505(j)(2)(B)(iv) of the FDCA, regarding the Zydus Products and the '248 and '191 patents (the "February 19 Notice Letter").

31. The February 19 Notice Letter was signed by Brij Khera, Ph.D., Executive Vice President and Chief Legal Officer, Zydus Pharmaceuticals (USA) Inc.

32. The February 19 Notice Letter does not include any non-infringement contentions to claims 1-2, 4-12, and 14-20 of the '248 patent.

33. The February 19 Notice Letter does not include any non-infringement contentions unique to claims 2-24 of the '191 patent.

34. The February 19 Notice Letter does not include any invalidity contentions to any claim of the '191 patent.

35. Supernus received a letter dated April 21, 2015, which was purportedly sent pursuant to § 505(j)(2)(B)(iv) of the FDCA, regarding the Zydus Products and the '989 patent (the "April 21 Notice Letter").

36. The April 21 Notice Letter was signed by Brij Khera, Ph.D., Executive Vice President and Chief Legal Officer, Zydus Pharmaceuticals (USA) Inc.

37. The April 21 Notice Letter does not include any non-infringement contentions to claims 14 and 18-20 of the '989 patent.

FIRST COUNT
(Defendants' Infringement of the '576 Patent)

38. Plaintiff repeats and re-alleges each of the foregoing Paragraphs as if fully set forth herein.

39. Upon information and belief, Defendants seek FDA approval for the manufacture, use, marketing, sale, and/or distribution of the Zydus Products.

40. Upon information and belief, Defendants included in ANDA No. 207382 a paragraph IV certification to the '576 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products before the expiration of the '576 patent.

41. Upon information and belief, Defendants will commercially manufacture, use, sell, offer for sale, and/or import the Zydus Products upon, or in anticipation of, FDA approval.

42. The submission and filing of ANDA No. 207382 with a paragraph IV certification to the '576 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products before the expiration of the '576 patent is an act of infringement by Defendants of one or more claims of the '576 patent under 35 U.S.C. § 271(e)(2)(A).

43. Upon information and belief, Defendants' commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products that are the subject of ANDA No. 207382 will infringe, directly and/or indirectly (including by inducement and/or

contributory infringement), one or more claims of the '576 patent under 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c).

44. Upon information and belief, the sale or offer for sale of the Zydus Products by Defendants would induce and/or contribute to third party infringement of one or more claims of the '576 patent under 35 U.S.C. § 271.

45. Upon information and belief, Zydus Cadila is jointly and severally liable for Zydus USA's infringement of one or more claims of the '576 patent.

46. Upon information and belief, Zydus Cadila knowingly induced Zydus USA to infringe and/or contributed to Zydus USA's infringement of one or more claims of the '576 patent.

47. Upon information and belief, Zydus Cadila actively induced, encouraged, aided, or abetted Zydus USA's preparation, submission and filing of ANDA No. 207382 with a paragraph IV certification to the '576 patent.

48. Zydus Cadila's inducement, encouragement, aiding, or abetting of Zydus USA's preparation, submission, and filing of ANDA No. 207382 with a paragraph IV certification constitutes infringement of the '576 patent under 35 U.S.C. § 271(e)(2)(A). Further, Zydus Cadila's commercial use, sale, offer for sale, and/or importation of the Zydus Products would induce and/or contribute to Zydus USA's infringement of the '576 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

49. Upon information and belief, Zydus Cadila's inducement, encouragement, aiding, and/or abetting of the sale or offer for sale of the Zydus Products by Zydus USA would induce and/or contribute to third party infringement of one or more claims of the '576 patent under 35 U.S.C. § 271.

50. Upon information and belief, Zydus Cadila has, continues to, and will actively induce, encourage, aid, or abet Zydus USA's infringement of the '576 patent with knowledge of infringement in contravention of the rights of Supernus.

51. Defendants' infringement of the '576 patent has caused and will cause Supernus to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Supernus has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '576 patent.

52. As of the date of the October 9 Notice Letter, Defendants were aware of the existence of the '576 patent—as well as the statutory provisions and regulations set forth in 21 U.S.C. § 355 and 21 C.F.R. § 314.95—and acted without a reasonable basis for believing that they would not be liable for infringement of the '576 patent, thus rendering this case “exceptional” under 35 U.S.C. § 285.

SECOND COUNT
(Defendants' Infringement of the '580 Patent)

53. Plaintiff repeats and re-alleges each of the foregoing Paragraphs as if fully set forth herein.

54. Upon information and belief, Defendants seek FDA approval for the manufacture, use, marketing, sale, and/or distribution of the Zydus Products.

55. Upon information and belief, Defendants included in ANDA No. 207382 a paragraph IV certification to the '580 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products before the expiration of the '580 patent.

56. Upon information and belief, Defendants will commercially manufacture, use, sell, offer for sale, and/or import the Zydus Products upon, or in anticipation of, FDA approval.

57. The submission and filing of ANDA No. 207382 with a paragraph IV certification to the '580 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products before the expiration of the '580 patent is an act of infringement by Defendants of one or more claims of the '580 patent under 35 U.S.C. § 271(e)(2)(A).

58. Upon information and belief, Defendants' commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products that are the subject of ANDA No. 207382 will infringe, directly and/or indirectly (including by inducement and/or contributory infringement), one or more claims of the '580 patent under 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c).

59. Upon information and belief, the sale or offer for sale of the Zydus Products by Defendants would induce and/or contribute to third party infringement of one or more claims of the '580 patent under 35 U.S.C. § 271.

60. Upon information and belief, Zydus Cadila is jointly and severally liable for Zydus USA's infringement of one or more claims of the '580 patent.

61. Upon information and belief, Zydus Cadila knowingly induced Zydus USA to infringe and/or contributed to Zydus USA's infringement of one or more claims of the '580 patent.

62. Upon information and belief, Zydus Cadila actively induced, encouraged, aided, or abetted Zydus USA's preparation, submission and filing of ANDA No. 207382 with a paragraph IV certification to the '580 patent.

63. Zydus Cadila's inducement, encouragement, aiding, or abetting of Zydus USA's preparation, submission, and filing of ANDA No. 207382 with a paragraph IV certification constitutes infringement of the '580 patent under 35 U.S.C. § 271(e)(2)(A). Further, Zydus Cadila's commercial use, sale, offer for sale, and/or importation of the Zydus Products would

induce and/or contribute to Zydus USA's infringement of the '580 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

64. Upon information and belief, Zydus Cadila's inducement, encouragement, aiding, and/or abetting of the sale or offer for sale of the Zydus Products by Zydus USA would induce and/or contribute to third party infringement of one or more claims of the '580 patent under 35 U.S.C. § 271.

65. Upon information and belief, Zydus Cadila has, continues to, and will actively induce, encourage, aid, or abet Zydus USA's infringement of the '580 patent with knowledge of infringement in contravention of the rights of Supernus.

66. Defendants' infringement of the '580 patent has caused and will cause Supernus to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Supernus has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '580 patent.

67. As of the date of the October 9 Notice Letter, Defendants were aware of the existence of the '580 patent—as well as the statutory provisions and regulations set forth in 21 U.S.C. § 355 and 21 C.F.R. § 314.95—and acted without a reasonable basis for believing that they would not be liable for infringement of the '580 patent, thus rendering this case “exceptional” under 35 U.S.C. § 285.

THIRD COUNT
(Defendants' Infringement of the '683 Patent)

68. Plaintiff repeats and re-alleges each of the foregoing Paragraphs as if fully set forth herein.

69. Upon information and belief, Defendants seek FDA approval for the manufacture, use, marketing, sale, and/or distribution of the Zydus Products.

70. Upon information and belief, Defendants included in ANDA No. 207382 a paragraph IV certification to the '683 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products before the expiration of the '683 patent.

71. Upon information and belief, Defendants will commercially manufacture, use, sell, offer for sale, and/or import the Zydus Products upon, or in anticipation of, FDA approval.

72. The submission and filing of ANDA No. 207382 with a paragraph IV certification to the '683 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products before the expiration of the '683 patent is an act of infringement by Defendants of one or more claims of the '683 patent under 35 U.S.C. § 271(e)(2)(A).

73. Upon information and belief, Defendants' commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products that are the subject of ANDA No. 207382 will infringe, directly and/or indirectly (including by inducement and/or contributory infringement), one or more claims of the '683 patent under 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c).

74. Upon information and belief, the sale or offer for sale of the Zydus Products by Defendants would induce and/or contribute to third party infringement of one or more claims of the '683 patent under 35 U.S.C. § 271.

75. Upon information and belief, Zydus Cadila is jointly and severally liable for Zydus USA's infringement of one or more claims of the '683 patent.

76. Upon information and belief, Zydus Cadila knowingly induced Zydus USA to infringe and/or contributed to Zydus USA's infringement of one or more claims of the '683 patent.

77. Upon information and belief, Zydus Cadila actively induced, encouraged, aided, or abetted Zydus USA's preparation, submission and filing of ANDA No. 207382 with a paragraph IV certification to the '683 patent.

78. Zydus Cadila's inducement, encouragement, aiding, or abetting of Zydus USA's preparation, submission, and filing of ANDA No. 207382 with a paragraph IV certification constitutes infringement of the '683 patent under 35 U.S.C. § 271(e)(2)(A). Further, Zydus Cadila's commercial use, sale, offer for sale, and/or importation of the Zydus Products would induce and/or contribute to Zydus USA's infringement of the '683 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

79. Upon information and belief, Zydus Cadila's inducement, encouragement, aiding, and/or abetting of the sale or offer for sale of the Zydus Products by Zydus USA would induce and/or contribute to third party infringement of one or more claims of the '683 patent under 35 U.S.C. § 271.

80. Upon information and belief, Zydus Cadila has, continues to, and will actively induce, encourage, aid, or abet Zydus USA's infringement of the '683 patent with knowledge of infringement in contravention of the rights of Supernus.

81. Defendants' infringement of the '683 patent has caused and will cause Supernus to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Supernus has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '683 patent.

82. As of the date of the October 9 Notice Letter, Defendants were aware of the existence of the '683 patent—as well as the statutory provisions and regulations set forth in 21 U.S.C. § 355 and 21 C.F.R. § 314.95—and acted without a reasonable basis for believing that they would not be liable for infringement of the '683 patent, thus rendering this case “exceptional” under 35 U.S.C. § 285.

FOURTH COUNT
(Defendants' Infringement of the '248 Patent)

83. Plaintiff repeats and re-alleges each of the foregoing Paragraphs as if fully set forth herein.

84. Upon information and belief, Defendants seek FDA approval for the manufacture, use, marketing, sale, and/or distribution of the Zydus Products.

85. Upon information and belief, Defendants included in ANDA No. 207382 a paragraph IV certification to the '248 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products before the expiration of the '248 patent.

86. Upon information and belief, Defendants will commercially manufacture, use, sell, offer for sale, and/or import the Zydus Products upon, or in anticipation of, FDA approval.

87. The submission and filing of ANDA No. 207382 with a paragraph IV certification to the '248 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products before the expiration of the '248 patent is an act of infringement by Defendants of one or more claims of the '248 patent under 35 U.S.C. § 271(e)(2)(A).

88. Upon information and belief, Defendants' commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products that are the subject of ANDA No. 207382 will infringe, directly and/or indirectly (including by inducement and/or contributory infringement), one or more claims of the '248 patent under 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c).

89. Upon information and belief, the sale or offer for sale of the Zydus Products by Defendants would induce and/or contribute to third party infringement of one or more claims of the '248 patent under 35 U.S.C. § 271.

90. Upon information and belief, Zydus Cadila is jointly and severally liable for Zydus USA's infringement of one or more claims of the '248 patent.

91. Upon information and belief, Zydus Cadila knowingly induced Zydus USA to infringe and/or contributed to Zydus USA's infringement of one or more claims of the '248 patent.

92. Upon information and belief, Zydus Cadila actively induced, encouraged, aided, or abetted Zydus USA's preparation, submission and filing of ANDA No. 207382 with a paragraph IV certification to the '248 patent.

93. Zydus Cadila's inducement, encouragement, aiding, or abetting of Zydus USA's preparation, submission, and filing of ANDA No. 207382 with a paragraph IV certification constitutes infringement of the '248 patent under 35 U.S.C. § 271(e)(2)(A). Further, Zydus Cadila's commercial use, sale, offer for sale, and/or importation of the Zydus Products would induce and/or contribute to Zydus USA's infringement of the '248 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

94. Upon information and belief, Zydus Cadila's inducement, encouragement, aiding, and/or abetting of the sale or offer for sale of the Zydus Products by Zydus USA would induce and/or contribute to third party infringement of one or more claims of the '248 patent under 35 U.S.C. § 271.

95. Upon information and belief, Zydus Cadila has, continues to, and will actively induce, encourage, aid, or abet Zydus USA's infringement of the '248 patent with knowledge of infringement in contravention of the rights of Supernus.

96. Defendants' infringement of the '248 patent has caused and will cause Supernus to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Supernus has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '248 patent.

97. As of the date of the February 19 Notice Letter, Defendants were aware of the existence of the '248 patent—as well as the statutory provisions and regulations set forth in 21 U.S.C. § 355 and 21 C.F.R. § 314.95—and acted without a reasonable basis for believing that they would not be liable for infringement of the '248 patent, thus rendering this case “exceptional” under 35 U.S.C. § 285.

FIFTH COUNT
(Defendants' Infringement of the '191 Patent)

98. Plaintiff repeats and re-alleges each of the foregoing Paragraphs as if fully set forth herein.

99. Upon information and belief, Defendants seek FDA approval for the manufacture, use, marketing, sale, and/or distribution of the Zydus Products.

100. Upon information and belief, Defendants included in ANDA No. 207382 a paragraph IV certification to the '191 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products before the expiration of the '191 patent.

101. Upon information and belief, Defendants will commercially manufacture, use, sell, offer for sale, and/or import the Zydus Products upon, or in anticipation of, FDA approval.

102. The submission and filing of ANDA No. 207382 with a paragraph IV certification to the '191 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products before the expiration of the '191 patent is an act of infringement by Defendants of one or more claims of the '191 patent under 35 U.S.C. § 271(e)(2)(A).

103. Upon information and belief, Defendants' commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products that are the subject of ANDA No. 207382 will infringe indirectly (including by inducement and/or contributory

infringement) one or more claims of the '191 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

104. Upon information and belief, the sale or offer for sale of the Zydus Products by Defendants would induce and/or contribute to third party infringement of one or more claims of the '191 patent under 35 U.S.C. § 271.

105. Upon information and belief, Zydus Cadila is jointly and severally liable for Zydus USA's infringement of one or more claims of the '191 patent.

106. Upon information and belief, Zydus Cadila knowingly induced Zydus USA to infringe and/or contributed to Zydus USA's infringement of one or more claims of the '191 patent.

107. Upon information and belief, Zydus Cadila actively induced, encouraged, aided, or abetted Zydus USA's preparation, submission and filing of ANDA No. 207382 with a paragraph IV certification to the '191 patent.

108. Zydus Cadila's inducement, encouragement, aiding, or abetting of Zydus USA's preparation, submission, and filing of ANDA No. 207382 with a paragraph IV certification constitutes infringement of the '191 patent under 35 U.S.C. § 271(e)(2)(A). Further, Zydus Cadila's commercial use, sale, offer for sale, and/or importation of the Zydus Products would induce and/or contribute to Zydus USA's infringement of the '191 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

109. Upon information and belief, Zydus Cadila's inducement, encouragement, aiding, and/or abetting of the sale or offer for sale of the Zydus Products by Zydus USA would induce and/or contribute to third party infringement of one or more claims of the '191 patent under 35 U.S.C. § 271.

110. Upon information and belief, Zydus Cadila has, continues to, and will actively induce, encourage, aid, or abet Zydus USA's infringement of the '191 patent with knowledge of infringement in contravention of the rights of Supernus.

111. Defendants' infringement of the '191 patent has caused and will cause Supernus to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Supernus has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '191 patent.

112. As of the date of the February 19 Notice Letter, Defendants were aware of the existence of the '191 patent—as well as the statutory provisions and regulations set forth in 21 U.S.C. § 355 and 21 C.F.R. § 314.95—and acted without a reasonable basis for believing that they would not be liable for infringement of the '191 patent, thus rendering this case “exceptional” under 35 U.S.C. § 285.

SIXTH COUNT
(Defendants' Infringement of the '989 Patent)

113. Plaintiff repeats and re-alleges each of the foregoing Paragraphs as if fully set forth herein.

114. Upon information and belief, Defendants seek FDA approval for the manufacture, use, marketing, sale, and/or distribution of the Zydus Products.

115. Upon information and belief, Defendants included in ANDA No. 207382 a paragraph IV certification to the '989 patent to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of the Zydus Products before the expiration of the '989 patent.

116. Upon information and belief, Defendants will commercially manufacture, use, sell, offer for sale, and/or import the Zydus Products upon, or in anticipation of, FDA approval.

117. The submission and filing of ANDA No. 207382 with a paragraph IV certification to the '989 patent for the purpose of obtaining approval to engage in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products before the expiration of the '989 patent is an act of infringement by Defendants of one or more claims of the '989 patent under 35 U.S.C. § 271(e)(2)(A).

118. Upon information and belief, Defendants' commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products that are the subject of ANDA No. 207382 will infringe, directly and/or indirectly (including by inducement and/or contributory infringement), one or more claims of the '989 patent under 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c).

119. Upon information and belief, the sale or offer for sale of the Zydus Products by Defendants would induce and/or contribute to third party infringement of one or more claims of the '989 patent under 35 U.S.C. § 271.

120. Upon information and belief, Zydus Cadila is jointly and severally liable for Zydus USA's infringement of one or more claims of the '989 patent.

121. Upon information and belief, Zydus Cadila knowingly induced Zydus USA to infringe and/or contributed to Zydus USA's infringement of one or more claims of the '989 patent.

122. Upon information and belief, Zydus Cadila actively induced, encouraged, aided, or abetted Zydus USA's preparation, submission and filing of ANDA No. 207382 with a paragraph IV certification to the '989 patent.

123. Zydus Cadila's inducement, encouragement, aiding, or abetting of Zydus USA's preparation, submission, and filing of ANDA No. 207382 with a paragraph IV certification constitutes infringement of the '989 patent under 35 U.S.C. § 271(e)(2)(A). Further, Zydus Cadila's commercial use, sale, offer for sale, and/or importation of the Zydus Products would

induce and/or contribute to Zydus USA's infringement of the '248 patent under 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c).

124. Upon information and belief, Zydus Cadila's inducement, encouragement, aiding, and/or abetting of the sale or offer for sale of the Zydus Products by Zydus USA would induce and/or contribute to third party infringement of one or more claims of the '989 patent under 35 U.S.C. § 271.

125. Upon information and belief, Zydus Cadila has, continues to, and will actively induce, encourage, aid, or abet Zydus USA's infringement of the '989 patent with knowledge of infringement in contravention of the rights of Supernus.

126. Defendants' infringement of the '989 patent has caused and will cause Supernus to suffer irreparable harm. Defendants' infringement will continue unless enjoined by the Court. Supernus has no adequate remedy at law and thus preliminary and permanent injunctions are appropriate to prohibit Defendants from infringing the '989 patent.

127. As of the date of the April 21 Notice Letter, Defendants were aware of the existence of the '989 patent—as well as the statutory provisions and regulations set forth in 21 U.S.C. § 355 and 21 C.F.R. § 314.95—and acted without a reasonable basis for believing that they would not be liable for infringement of the '989 patent, thus rendering this case “exceptional” under 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, Plaintiff respectfully requests the following relief:

- i. A Judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA and filing of ANDA No. 207382 with a paragraph IV certification to obtain approval for the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products was an act of infringement of the '576, '580, '683, '248, '191, and '989 patents by Defendants;

- ii. A Judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), the submission to the FDA and filing of ANDA No. 207382 with a paragraph IV certification to obtain approval for the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the Zydus Products was an act of infringement of the '576, '580, '683, '248, '191, and '989 patents by Defendants indirectly, including by inducement and/or contributory infringement;
- iii. A Judgment declaring that, pursuant to 35 U.S.C. § 271(b) and/or 35 U.S.C. § 271(c), the commercial manufacture, use, sale, offer for sale, and/or importation in the United States of the products that are the subject of ANDA No. 207382 by Defendants would induce and/or contribute to third party infringement of the '576, '580, '683, '248, '191, and '989 patents;
- iv. A Judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c), the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the products that are the subject of ANDA No. 207382 prior to the expiration of the '576, '580, '683, '248, '191, and '989 patents, including any regulatory extensions, will constitute an act of infringement by Defendants;
- v. A Judgment declaring that, pursuant to 35 U.S.C. § 271(e)(2)(A), 35 U.S.C. § 271(a), 35 U.S.C. § 271(b), and/or 35 U.S.C. § 271(c), the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of the products that are the subject of ANDA No. 207382 prior to the expiration of the '576, '580, '683, '248, '191, and '989 patents, including any regulatory extensions, will constitute an act of infringement by Defendants indirectly, including by inducement and/or contributory infringement;

- vi. An Order that, pursuant to 35 U.S.C. §§ 271(e)(4)(A), 281, and 283, the effective date of any approval of the products that are the subject of ANDA No. 207382 shall be no earlier than the date on which the '576, '580, '683, '248, '191, and '989 patents expire, including any regulatory extensions;
- vii. A Judgment pursuant to 35 U.S.C. §§ 271(e)(4)(B), 281, and 283, preliminarily and permanently enjoining Defendants and their officers, agents, servants, employees, and attorneys, and those persons in active concert or participation or privity with them or any of them, from engaging in the commercial manufacture, use, sale, offer for sale, and/or importation in the United States any product that is the subject of ANDA No. 207382 until the expiration of the '576, '580, '683, '248, '191, and '989 patents, including any regulatory extensions;
- viii. A Judgment awarding Supernus damages or other monetary relief, pursuant to 35 U.S.C. §§ 271(e)(4)(C) and 284, if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 207382 that infringes the '576, '580, '683, '248, '191, and/or '989 patents;
- ix. A Judgment declaring that infringement of the '576, '580, '683, '248, '191, and '989 patents is willful if Defendants commercially manufacture, use, sell, offer to sell, and/or import any product that is the subject of ANDA No. 207382 that infringes '576, '580, '683, '248, '191, and '989 patents;
- x. A Judgment declaring that, pursuant to 35 U.S.C. § 285, this is an exceptional case and awarding Supernus its attorneys' fees and costs; and
- xi. Such other and further relief as this Court may deem just and proper.

Dated: April 28, 2015

Respectfully submitted,

By: s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
Sarah A. Sullivan
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, NJ 07102-5426
(973) 286-6700
clizza@saul.com
wbaton@saul.com
ssullivan@saul.com

Of Counsel:

Edgar H. Haug
Sandra Kuzmich, Ph.D.
Elizabeth Murphy
Richard F. Kurz
FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue
New York, NY 10151
(212) 588-0800
ehaug@flhlaw.com
skuzmich@flhlaw.com
emurphy@flhlaw.com
rkurz@flhlaw.com

*Attorneys for Plaintiff
Supernus Pharmaceuticals, Inc.*

Exhibit A



US008298576B2

(12) **United States Patent**
Liang et al.

(10) **Patent No.:** **US 8,298,576 B2**

(45) **Date of Patent:** **Oct. 30, 2012**

(54) **SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE**

(75) Inventors: **Likan Liang**, Boyds, MD (US); **Hua Wang**, Clarksville, MD (US); **Padmanabh P. Bhatt**, Rockville, MD (US); **Michael L. Vieira**, Gaithersburg, MD (US)

(73) Assignee: **Supernus Pharmaceuticals, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 488 days.

(21) Appl. No.: **11/941,475**

(22) Filed: **Nov. 16, 2007**

(65) **Prior Publication Data**

US 2008/0118557 A1 May 22, 2008

Related U.S. Application Data

(60) Provisional application No. 60/859,502, filed on Nov. 17, 2006.

(51) **Int. Cl.**

A61K 31/357 (2006.01)

A61K 9/14 (2006.01)

A61K 9/24 (2006.01)

A61K 9/54 (2006.01)

(52) **U.S. Cl.** **424/458**; 424/494; 424/472; 424/490; 514/455

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,528,378 A 10/1950 Mannheimer et al.
2,675,619 A 4/1954 Cone
2,677,700 A 5/1954 Jackson et al.
2,781,354 A 2/1957 Mannheimer et al.
2,979,578 A 4/1961 Curtis
2,996,431 A 8/1961 Barry
3,036,118 A 5/1962 Jackson et al.
3,139,383 A 6/1964 Neville et al.
3,535,307 A 10/1970 Moss et al.
3,811,444 A 5/1974 Heller et al.
3,829,506 A 8/1974 Schmolka et al.
3,962,414 A 6/1976 Michaels
3,992,518 A 11/1976 Chien et al.
4,066,747 A 1/1978 Capozza
4,070,347 A 1/1978 Schmitt
4,079,038 A 3/1978 Choi et al.
4,083,949 A 4/1978 Benedikt
4,093,709 A 6/1978 Choi et al.
4,290,426 A 9/1981 Luschen et al.
4,434,153 A 2/1984 Urquhart et al.
4,513,006 A 4/1985 Maryanoff et al.
4,721,613 A 1/1988 Urquhart et al.
4,727,064 A 2/1988 Pitha
4,752,470 A 6/1988 Mehta
4,757,128 A 7/1988 Domb et al.
4,853,229 A 8/1989 Theeuwes
4,938,763 A 7/1990 Dunn et al.

4,997,904 A 3/1991 Domb
5,030,447 A 7/1991 Joshi et al.
5,175,235 A 12/1992 Domb et al.
5,180,589 A 1/1993 Joshi et al.
5,225,202 A 7/1993 Hodges et al.
5,256,440 A 10/1993 Appel et al.
5,378,475 A 1/1995 Smith et al.
5,478,577 A 12/1995 Sackler et al.
5,500,227 A 3/1996 Oshlack et al.
5,576,311 A 11/1996 Guy
5,753,693 A 5/1998 Shank
5,760,007 A 6/1998 Shank et al.
5,773,019 A 6/1998 Ashton et al.
5,935,933 A 8/1999 Shank et al.
5,955,096 A 9/1999 Santos et al.
5,985,312 A 11/1999 Jacob et al.
5,998,380 A 12/1999 Ehrenberg et al.
6,123,965 A 9/2000 Jacob et al.
6,156,348 A 12/2000 Santos et al.
6,191,117 B1 2/2001 Kozachuk
6,197,346 B1 3/2001 Mathiowitz et al.
6,201,010 B1 3/2001 Cottrell
6,217,908 B1 4/2001 Mathiowitz et al.
6,235,311 B1 5/2001 Ullah et al.
6,248,363 B1 6/2001 Patel et al.
6,294,192 B1 9/2001 Patel et al.
6,319,903 B1 11/2001 Carrazana et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1130352 A 9/1996

(Continued)

OTHER PUBLICATIONS

Lui et al, 2006. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin. International Journal of Pharmaceutics, vol. 312:137-147.*
Non-Final Office Action dated Apr. 14, 2009, in copending U.S. Appl. No. 11/987,806.
Non-Final Office Action dated Dec. 22, 2009, in copending U.S. Appl. No. 11/987,806.
US 6,103,281, 08/15/2000, DelDuca et al. (withdrawn).
International Search Report and Written Opinion mailed Sep. 2, 2008, in PCT/US2007/19208, 10 pages.
Adin et al., "Topiramate Serum Concentration-to-Dose Ratio," Therapeutic Drug Monitoring, Jun. 2004; 26(3):251-257.
Bahk et al., "Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study," Progress in Neuropsychopharmacology & Biological Psychiatry, 2005, 29(1):115-121.

(Continued)

Primary Examiner — Suzanne Ziska

(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP; Stephen B. Maebius; Sunit Talapatra

(57) **ABSTRACT**

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

30 Claims, 6 Drawing Sheets

US 8,298,576 B2

Page 2

U.S. PATENT DOCUMENTS

6,365,187	B2	4/2002	Mathiowitz et al.	
6,368,586	B1	4/2002	Jacob et al.	
6,479,467	B1	11/2002	Buchanan et al.	
6,503,884	B1	1/2003	Ehrenberg et al.	
6,514,531	B1 *	2/2003	Alaux et al.	424/468
6,524,620	B2 *	2/2003	Chen et al.	424/490
6,559,293	B1	5/2003	Almarsson et al.	
6,562,865	B1	5/2003	Codd et al.	
6,569,463	B2	5/2003	Patel et al.	
6,696,091	B2	2/2004	Thakur et al.	
6,699,840	B2	3/2004	Almarsson et al.	
6,797,283	B1	9/2004	Edgren et al.	
6,923,988	B2	8/2005	Patel et al.	
7,018,609	B2	3/2006	Hwang Pun et al.	
7,195,778	B2	3/2007	Fleshner-Barak et al.	
7,611,722	B2	11/2009	Lerner et al.	
7,763,635	B2 *	7/2010	Kidane et al.	514/299
2002/0044962	A1	4/2002	Cherukuri et al.	
2002/0054907	A1 *	5/2002	Devane et al.	424/469
2002/0064563	A1	5/2002	Thakur et al.	
2002/0150616	A1	10/2002	Vandecruys	
2003/0017972	A1	1/2003	Pun et al.	
2003/0064097	A1	4/2003	Patel et al.	
2003/0072802	A1	4/2003	Cutler	
2003/0091630	A1	5/2003	Louie-Helm et al.	
2003/0133985	A1	7/2003	Louie-Helm et al.	
2003/0147952	A1	8/2003	Lim et al.	
2003/0166581	A1	9/2003	Almarsson et al.	
2003/0215496	A1	11/2003	Patel et al.	
2003/0225002	A1	12/2003	Livingstone	
2004/0002462	A1	1/2004	Najarian	
2004/0022844	A1	2/2004	Hasenzahl et al.	
2004/0028735	A1	2/2004	Kositprapa	
2004/0052843	A1	3/2004	Lerner et al.	
2004/0053853	A1	3/2004	Almarsson et al.	
2004/0082519	A1	4/2004	Hedner et al.	
2004/0091529	A1	5/2004	Edgren et al.	
2004/0096501	A1	5/2004	Vaya et al.	
2004/0109894	A1	6/2004	Shefer et al.	
2004/0115262	A1	6/2004	Jao et al.	
2004/0122104	A1	6/2004	Hirsh et al.	
2004/0132826	A1	7/2004	Hirsh et al.	
2004/0156901	A1	8/2004	Thakur et al.	
2004/0157785	A1	8/2004	Connor	
2004/0185097	A1	9/2004	Kannan et al.	
2004/0234601	A1	11/2004	Legrand et al.	
2004/0258758	A1	12/2004	Gustow et al.	
2005/0053653	A1	3/2005	Kidane et al.	
2005/0058707	A1	3/2005	Reyes et al.	
2005/0069587	A1 *	3/2005	Modi et al.	424/473
2005/0106242	A1	5/2005	Yan et al.	
2005/0106247	A1 *	5/2005	Venkatesh et al.	424/469
2005/0129765	A1	6/2005	Li et al.	
2005/0136108	A1	6/2005	Yam et al.	
2005/0169982	A1	8/2005	Almarsson et al.	
2005/0169992	A1	8/2005	Jao et al.	
2005/0175697	A1	8/2005	Edgren et al.	
2005/0191343	A1	9/2005	Liang	
2005/0220596	A1	10/2005	Gaedy et al.	
2006/0018933	A1	1/2006	Vaya et al.	
2006/0018934	A1	1/2006	Vaya et al.	
2006/0024365	A1	2/2006	Vaya et al.	
2006/0034927	A1	2/2006	Casadevall et al.	
2006/0105045	A1	5/2006	Buchanan et al.	
2006/0121112	A1	6/2006	Jenkins et al.	
2006/0223762	A1	10/2006	Ehrenberg et al.	
2006/0233892	A1	10/2006	Hendrix	
2007/0212411	A1	9/2007	Fawzy et al.	
2008/0085306	A1 *	4/2008	Nangia et al.	424/458
2008/0131501	A1	6/2008	Liang et al.	

FOREIGN PATENT DOCUMENTS

WO	WO 93/21906	A1	11/1993
WO	WO 01/37808	A1	5/2001
WO	WO 02/03984	A2	1/2002
WO	WO 02/43731	A3	6/2002
WO	WO 2004/022037	A1	3/2004

WO	WO 2004078162	A1	9/2004
WO	WO 2004078163	A2	9/2004
WO	WO 2005/079748	A2	9/2005
WO	WO 2006/003403	*	1/2006
WO	WO 2006/009403	*	1/2006
WO	WO 2006/009403	A1	1/2006
WO	WO 2006/119153	A2	11/2006
WO	WO 2007/002318		1/2007

OTHER PUBLICATIONS

Beaumanoir, Anne, "The Landau-Kleffner syndrome", in: Roger et al., Eds. *Epileptic Syndromes in Infancy, Childhood, and Adolescence*, 2nd Ed., London, England: John Libby, pp. 231-244, 1992.

Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., Jan. 1977, 66(1): 1-19.

Berlant, Jeffery L., M.D., Ph.D., "Topiramate in Posttraumatic Stress Disorder: Preliminary Clinical Observations," J. Clin. Psychiatry, 2001, 62(Suppl 17):60-63.

Brandes et al., "Topiramate for Migraine Prevention," JAMA, Feb. 25, 2004, 291(8):965-973.

Carpenter et al., "Do obese depressed patients respond to topiramate? A retrospective chart review," J. Affect. Disord., 2002, 69(1-3):251-255.

Chen et al., "Combination Treatment of Clozapine and Topiramate in Resistant Rapid-Cycling Bipolar Disorder," Clin. Neuropharmacol., May-Jun. 2005, 28(3):136-138.

Coleman et al., "Polymer reviewed: A practical guide to polymer miscibility," Jul. 1990, 31:1187-1230.

Contin et al., "Topiramate Therapeutic Monitoring in Patients with Epilepsy: Effect of Concomitant Antiepileptic Drugs," Ther. Drug Monit., 2002, 24(3):332-337.

D'Amico et al., "Topiramate in migraine prophylaxis," Neurological Sciences, 2005, 26(Suppl 2):S130-S133.

Deckers et al., "Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed," Epilepsia, 2000, 41(11):1364-1374.

Diener et al., "Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control," J. Neurol., 2004, 251(8):943-950.

Duchene et al., "Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration," Drug Dev. Ind. Pharm., 1988, 14(2&3):283-318.

Erfurth et al., "Bupropion as Add-On Strategy in Difficult-to-Treat Bipolar Depressive Patients," Neuropsychobiology, 2002, 45(Suppl 1):33-36.

Felmeister, Alvin Ph.D., "Powders," Remington's Pharm. Sci., 14th Ed., 1970, Chapter 86, 1626-1628.

Ferrari et al., "Influence of Dosage, Age, and Co-Medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response," Therapeutic Drug Monitoring, 2003, 25(6):700-708.

Ferrari et al., "Rizatriptan: a new milestone in migraine treatment," Cephalalgia, 2000, 20(Suppl 1):1.

Fincher, Julian H., "Particle Size of Drugs and Its Relationship to Absorption and Activity," J. Pharm. Sci., Nov. 1968, 57(11):1825-1835.

Fisher et al., "Synergism between Topiramate and Budipine in Refractory Status Epilepticus in the Rat," Epilepsia, 2004, 45(11):1300-1307.

François et al., "The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy," Epilepsy Research, 2006, 72:147-163.

Gurny et al., "Bioadhesive intraoral release systems: design, testing and analysis," Biomaterials, Nov. 1984, 5:336-340.

Hershey et al., "Effectiveness of Topiramate in the Prevention of Childhood Headaches," Headache, Sep. 2002;42(8):810-818.

Hoes et al., "The Application of Drug-Polymer Conjugates in Chemotherapy," Drug Carrier Systems, 1989, 9:57-109.

Hollander et al., "Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder," Int. Clin. Psychopharmacol., 2006, 21(3): 189-191.

US 8,298,576 B2

Page 3

- Ioannides-Demos et al., "Pharmacotherapy for Obesity," *Drugs*, 2005, 65(10):1391-1418.
- Johnson et al., "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial," *The Lancet*, May 17, 2003, 361(9370):1677-1685.
- Kellett et al., "Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic," *J. Neurol. Neurosurg. and Psych.*, 1999;66:759-763.
- Lainez et al., "Topiramate in the Prophylactic Treatment of Cluster Headache," *Headache*, Jul./Aug. 2003, 43(7):784-789.
- Lalonde et al., "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese *ob/ob* mice," *Physiology & Behavior*, 2004, 80(4):415-420.
- Lee et al., "The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy," *Epilepsia*, 2003; 44(3):339-347.
- Lehr et al., "Intestinal Transit of Bioadhesive Microspheres in an in situ Loop in the Rat—A Comparative Study with Copolymers and Blends Based on Poly(acrylic acid)," *Journal of Controlled Release*, 1990, 13:51-62.
- Leong et al., "Polymeric controlled drug delivery," *Adv. Drug Delivery Rev.*, 1987, 1:199-233.
- Linhardt, Robert J. "Biodegradable Polymers for Controlled Release of Drugs," *Controlled Release of Drugs*, 1989, Chapter 2, 53-95.
- Longer, Mark A., Ph.D., "Sustained-Release Drug Delivery Systems," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 91, 1676-1693.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis," *Inter. J. of Pharm.*, 1994, 112:105-116.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment," *Inter. J. of Pharm.*, 1994, 112:117-124.
- Luszczki et al., "Interactions of Lamotrigine with Topiramate and First-Generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis," *Epilepsia*, 2003, 44(8):1003-1013.
- Mathew et al., "Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate," *Headache*, Sep. 2002, 42(8):796-803.
- McElroy et al., "Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A Randomized, Placebo-Controlled Trial," *Am. J. Psychiatry*, Feb. 2003, 160(2):255-261.
- Meador et al., "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers," *Neurology*, Jun. 2005, 64:2108-2114.
- Mikos et al., "Interaction of Polymer Microspheres with Mucin Gels as a Means of Characterizing Polymer Retention on Mucus," *Journal of Colloid and Interface Science*, May 1991, 143(2): 366-373.
- Morton et al., "Diagnosis and treatment of epilepsy in children and adolescents," *Drugs*, Mar. 1996, 51(3):399-414.
- Mosek et al., "Topiramate in the treatment of refractory chronic daily headache. An open trial," *Journal of Headache and Pain*, 2005, 6:77-80.
- O'Connor et al., "Powders," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 88, 1615-1632.
- Park et al., "Alternative Approaches to Oral Controlled Drug Delivery: Bioadhesives and In-Situ Systems," *Recent Advances in Drug Delivery*, Plenum Press, New York, 1984, 163-183.
- Pascual et al., "Testing the combination beta-blocker plus topiramate in refractory migraine," *Acta Neurol. Scand.*, 2007, 115(2):81-83.
- Physicians' Desk Reference 59th edition, 2541-2548 (2005).
- Physician's Desk Reference, 56th ed., 2590-2595 (2002).
- Pies, Ronald M.D., "Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review," *Annals of Clinical Psychiatry*, Dec. 2002, 14(4):223-232.
- Porter, Stuart C., Ph.D., "Coating of Pharmaceutical Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 90, 1666-1675.
- Potter et al., "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Determine the Efficacy of Topiramate in the Prophylactic Treatment of Migraine," *Neurology*, Apr. 2000, 54(Suppl 3):A15.
- Rudnic et al., "Oral Solid Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 89, 1633-1665.
- Silberstein et al., "Topiramate in Migraine Prevention," *Arch. Neurol.*, Apr. 2004, 61(4):490-495.
- Siniscalchi et al., "Combined topiramate and clonazepam therapy in a patient affected by essential tremor," *Parkinsonism Relat. Disord.*, 2007, 13(2):129-130.
- Smart et al., "An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery," *J. Pharm. Pharmacol.*, 1984, 36:295-299.
- Sofuoglu et al., "Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers," *Psychopharmacology*, 2006, 184(3-4): 645-651.
- Storey et al., "Topiramate in Migraine Prevention: A Double-Blind Placebo-Controlled Study," *Headache*, Nov./Dec. 2001, 41(10):968-975.
- Thompson et al., "Effects of topiramate on cognitive function," *J. Neurol. Neurosurg. and Psych.*, 2000; 69:634-641.
- Toplak et al., "Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind placebo-controlled study," *Int. J. Obes.*, 2007, 31(1):138-146.
- Von Seggern et al., "Efficacy of Topiramate in Migraine Prophylaxis: A Retrospective Chart Analysis," *Neurology*, Apr. 2000, 54(Suppl 3):A267-A268.
- Weber, Marcus Vinicius Keche, M.D., "Topiramate for Obstructive Sleep Apnea and Snoring," *Am. J. Psychiatry*, May 2002, 159(5):872-873.
- Winkelman, John W., "Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate," *Sleep Medicine*, 2003, 4(3):243-246.
- Dorado et al., "Topiramato en enfermedades comorbidas: epilepsia y migraña," *Rev. Neurol.*, 2006, 43(4):193-196.
- Physician's Desk Reference, 60th Edition, 2006, pp. 2438-2447, entry for TOPAMAX®.
- U.S. Appl. No. 12/926,931, filed Dec. 17, 2010, Liang et al.
- U.S. Appl. No. 12/926,936, filed Dec. 17, 2010, Liang et al.

* cited by examiner

U.S. Patent

Oct. 30, 2012


Sheet 1 of 6

US 8,298,576 B2

Fig.1

80% release time vs. %Wt. gain of Release-Controlling Coating

For Surelease® coated Extended Release Beads



U.S. Patent

Oct. 30, 2012

Sheet 2 of 6

US 8,298,576 B2

Fig. 2

80% release time vs. % Wt. gain of Release-Controlling Coating

For Surelease®/ Opadry® coated Extended Release Beads





Fig. 3

Mean (n= 16) PK Profiles from Bead Populations XR1, XR2 and XR3



U.S. Patent


Oct. 30, 2012

Sheet 4 of 6

US 8,298,576 B2

Fig. 4

Mean (n= 16) PK Profiles from the Immediate Release Formulations



U.S. Patent


Oct. 30, 2012

Sheet 5 of 6

US 8,298,576 B2

Fig.5

Dissolution Profiles of Immediate Release Formulations




U.S. Patent

Oct. 30, 2012

Sheet 6 of 6

US 8,298,576 B2

Fig.6. Mean PK Profiles for Sustained Release Formulations A, B, and C



US 8,298,576 B2

1

**SUSTAINED-RELEASE FORMULATIONS OF
TOPIRAMATE****CROSS-REFERENCE TO RELATED
APPLICATIONS**

The present application claims benefit of U.S. Provisional Application No. 60/859,502, filed Nov. 17, 2006, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Topiramate is a sulfamate substituted monosaccharide which under the trade name TOPAMAX® (Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J., U.S.A.) has been approved for use as an antiepileptic agent, as an adjuvant therapy for patients with partial onset seizures or primary generalized tonic-clonic seizures, and for the prevention of migraine. See generally, Physician's Desk Reference, 60th ed., 2538-2447 (2006); see also, U.S. Pat. No. 4,513,006.

For the treatment of epilepsy, the recommended dose of TOPAMAX® is 400 mg/day in one or multiple doses (Physician's Desk Reference, 60th ed., 2538-2447 (2006)). For adults with epilepsy, treatment is initiated with a dose of 25-50 mg/day, with the dose being titrated in increments of 25-50 mg at weekly intervals to the recommended or effective dose.

TOPAMAX® is an immediate release formulation. Adverse effects associated with the administration of TOPAMAX® include, but are not limited to, somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, diplopia, renal calculi (kidney stones), hepatic failure, pancreatitis, renal tubular acidosis, acute myopia and secondary angle closure glaucoma (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Hence, though topiramate has a relatively long half-life of 21 hours in vivo, it has not been prescribed (or formulated) as a single, daily-dose, in part due to severe side-effects that often result with peak plasma levels of the drug when taken in high doses. Instead, TOPAMAX® is typically taken in multiple, "divided" doses, usually twice-daily ("BID"). However, administration of the medicament in this manner is cumbersome and patients can forget to take their medication in a timely manner. What is more, each administration of a dose is associated with a peak in plasma concentrations of the drug, and the fluctuations associated with the peaks and valleys of blood plasma levels of the drug are undesirable. Therefore, there is a need for a formulation of topiramate, which reduces or eliminates the side effects associated with peaking and fluctuating plasma levels of the drug and preferably may be administered in a once-daily regimen.

New, highly soluble and bioavailable forms of topiramate are also needed in order to increase the safety and effectiveness of the drug.

The instant invention addresses these and other needs by providing a modified formulation of topiramate characterized by a sustained, non-pulsatile release of an active ingredient. This invention additionally provides an effective, once-daily dosage form of topiramate or salts thereof, which not only enables an effective single daily dose regimen to improve patient compliance but may also reduce some of the side effects of topiramate compared to the current or higher daily doses of immediate release topiramate formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sustained release formulation of topiramate for the treatment or preven-

2

tion of a pathological condition in a mammalian subject, characterized by a sustained rate of topiramate release along a pre-determined release profile.

It is yet another object of the present invention to provide topiramate formulation wherein topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect associated with the topiramate treatment.

It is a further object of the present invention to provide a sustained release formulation of topiramate that can be administered orally once a day.

It is an object of the present invention to provide a sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient, wherein the active ingredient is released from the formulation at a sustained rate along a pre-determined release profile, and wherein the sustained release formulation comprises an extended release (XR) component and an optional immediate release (IR) component.

In one embodiment of the invention, the extended release component is contained in at least one population of beads coated with a release controlling coating. The above-mentioned coating is specific for every bead population and determines its rate of release. Thus, every given bead population included into the formulation is characterized by its own specific rate of release.

In another embodiment of the invention, the sustained release topiramate formulation comprises an immediate release component in addition to an extended release component.

In a preferred embodiment of the invention, the immediate release component is an enhanced immediate release (EIR) composition.

The formulation of the present invention may be incorporated in any oral dosage form such as represented by, but not limited to, a tablet, a pill, a capsule, a troche, a sachet, and sprinkles.

It is yet another object of the present invention to provide a method of preparation of a sustained release formulation of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile, the method comprising the steps of:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method of preparation additionally includes a process for providing an XR component contained in at least one population of beads, wherein every population of beads is characterized by its own rate of release. This process comprises the steps of

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The method may optionally include a process for preparation of an IR component, which optionally is an enhanced immediate release (EIR) composition. The enhanced immediate release composition includes at least one agent selected

US 8,298,576 B2

3

from a group comprising complexing agents and enhancing agents. Without any limitations, the enhancing agents useful in the present invention may be selected from solubilizing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors or combinations thereof.

It is yet another object of the present invention to provide a method of treatment or prevention of a pathological condition in a mammalian subject by orally administering to the subject a therapeutically effective amount of a sustained release topiramate formulation of the instant invention. The pathological conditions that may be treated by the method of the present invention include neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by topiramate administration.

Definitions:

For the purposes of this invention, the term "topiramate" includes topiramate or any pharmaceutically acceptable salts thereof.

An "immediate release formulation" refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.

For the purposes of this application, an enhancing agent ("enhancer") is defined as any non-pharmaceutically active ingredient that improves the therapeutic potential of a formulation.

The term "enhanced immediate release composition" as used herein describes an immediate release composition improved in terms of a therapeutic potential or treatment modality.

"Sustained release" is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.

By "prolonged period of time" it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.

As used herein, unless otherwise noted, "rate of release" or "release rate" of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the "T.sub.x" value, where "x" is the percent of drug that has been released.

The release rates referred to herein are determined by placing a dosage form to be tested in a medium in an appropriate dissolution bath. Aliquots of the medium, collected at pre-set intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.

"C" denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as "drug plasma concentration", "plasma drug concentration" or "plasma concentration" which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or

4

tissue. The plasma drug concentration at any time following drug administration is referenced as C_{time}, as in C_{9hr} or C_{4hr}, etc.

The maximum plasma drug concentration during the dosing period is referenced as C_{max}, while C_{min} refers to the minimum blood plasma drug concentration at the end of a dosing interval; and C_{ave} refers to an average concentration during the dosing interval.

The "degree of fluctuation" is defined as a quotient (C_{max}-C_{min})/C_{ave}.

Persons of skill in the art will appreciate that blood plasma drug concentrations obtained in individual subjects will vary due to interpatient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a drug plasma concentration is listed, the value listed is the calculated mean value based on values obtained from a groups of subjects tested.

The term "bioavailability" refers to an extent to which—and sometimes rate at which—the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.

"AUC" is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.

Side effect is defined herein as a secondary and usually adverse effect of a drug.

The term "beads", as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured SURELEASE® (ethylcellulose dispersion) coated extended release beads.

FIG. 2 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured SURELEASE®/OPADRY® Clear (HPMC with PEG) coated extended release beads.

FIG. 3 shows mean (n=16) pharmacokinetic profiles for bead populations XR1, XR2 and XR3.

FIG. 4 shows mean (n=16) pharmacokinetic profiles for the immediate release formulations.

FIG. 5 shows the dissolution profiles of TOPAMAX®, topiramate IR beads, and topiramate enhanced immediate release beads.


FIG. 6 shows mean PK Profiles for Sustained Release Formulations A, B, and C.

DETAILED DESCRIPTION OF THE INVENTION

Topiramate is a sulfamate-substituted monosaccharide having the chemical name 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate. The molecular formula of topiramate is C₁₂H₂₁NO₈S, and its chemical structure is represented by formula below:

US 8,298,576 B2

5



Topiramate is a white crystalline powder that is soluble in alkaline solutions containing sodium hydroxide or sodium phosphate, soluble in acetone, dimethylsulfoxide and ethanol. However, the solubility of topiramate in water at room temperature is only about 9.8 mg/ml. Topiramate is not extensively metabolized and is excreted largely through the urine (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Topiramate pharmacokinetics are linear, producing a dose proportional increase in blood plasma concentration levels with increased dosing, and is not significantly affected by food. Patients taking topiramate over prolonged period of time did not develop resistance to the drug. Following oral administration of an immediate release dosage form, topiramate is rapidly absorbed with plasma drug concentrations peaking in approximately 2 hours. The mean elimination half-life is reported to be about 21 hours.

Currently, topiramate is administered in multiple daily doses in part due to the severe side effects exhibited by the immediate release product, especially when taken in a high single dose.

A sustained release topiramate formulation that will be suitable for once-a-day administration and will result in the diminished level or severity of side effects is needed.

The present invention provides sustained release formulation of topiramate wherein the total daily dose of topiramate is provided in an effective once-daily dose while minimizing fluctuations in the blood plasma drug concentration.

The current invention also provides for formulations of topiramate wherein the maximum plasma concentration of topiramate is attenuated as compared to the same amount of topiramate administered as an immediate release formulation BID; therefore some of the side effects of topiramate, such as CNS side effects including but not limited to dizziness, paresthesia, nervousness, psychomotor slowing, confusion, and difficulty with concentration/attention, observed when taking the immediate release product, may be reduced or eliminated.

Formulations of the instant invention are characterized by a maximum steady state plasma concentration (C_{max}) of topiramate which is higher than the minimal therapeutically effective concentration, and is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. In one embodiment, the novel formulations provide for a relative C_{max} in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID. In the other embodiment, the invention provides for the C_{max} which is lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. The C_{min} of the topiramate formulation of the present invention is about equal or higher than a C_{min} of an equivalent amount of immediate release topiramate formulation given BID.

Compared to the immediate release topiramate formulation, the sustained release topiramate formulations attenuate the C_{max} of topiramate while extending the coverage of plasma concentration above the minimum plasma concentration required therapeutic efficacy. The formulation of the current invention provides for a relative steady state AUC in

6

the range of 80% to 125%, while minimizing the degree of fluctuation, which is preferably in the range of 25% to 90%, as compared to an equivalent amount of immediate release topiramate formulation given in two divided doses (Table 5 and 6).

The present invention additionally provides a sustained release topiramate formulation for the treatment or prevention of a pathological condition in a mammalian subject wherein topiramate is released from the formulation at a sustained rate along a pre-determined release profile. Such release is achieved by incorporation into the formulation of an extended release component (XR) and an optional immediate release component (IR).

The relative amount of each component in the topiramate formulation of the present invention is determined according to the purpose of administration and a pre-determined release profile, and the total amount of topiramate in the formulation varies from 0.5 mg to about 3000 mg. In other words, topiramate or its salt is present in the composition in an amount of from about 0.5% to about 85% by weight, and preferably of from about 2% to about 70% by weight. The term "about" has been recited here and throughout the specification to account for variations, which can arise from inaccuracies in measurement inherent and understood by those of ordinary skill in the chemical and pharmaceutical arts.

The XR component of the formulation of the present invention releases topiramate in a continuous manner and is adjusted in such a way that 80% of the active ingredient is released in vitro in the predetermined period of time. By way of example, and by no means limiting the scope of the invention, the period of time may be not more than 24 hours, not more than 16 hours, not more than 12 hours, not more than 8 hours, or not more than 4 hours, depending on desired attributes of the final product.

In one embodiment, the extended release (XR) component is contained in at least one population of beads coated with a coating that modifies and controls the release of topiramate from the beads (release controlling coating). The release controlling coating is specific for every population of beads and determines the rate of release of topiramate from the given bead population.

The beads useful in the formulation of the present invention comprise an inert carrier, topiramate, a binder, an aforementioned release controlling coating and optionally, an overcoat that provides additional protection from moisture, static charge reduction, taste masking and coloring attributes to the particulates.

The inert carriers useful in the present invention may be selected from, but are not limited to, a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres. The inert carrier is present in an amount of from about 15% to about 99% by weight, and preferably in an amount of from about 40% to about 97% by weight.

Topiramate is introduced to the inert carrier by techniques known to one skilled in the art, such as drug layering, powder coating, extrusion/spheronization, roller compaction or granulation. Preferably, the introduction method is drug layering by spraying a suspension of topiramate and a binder onto the inert carrier.

The binder may be present in the bead formulation in an amount of from about 0.1% to about 15% by weight, and preferably of from about 0.2% to about 10% by weight. Binders include, but are not limited to starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, or polyvinylpyrrolidone.

US 8,298,576 B2

7

The release controlling coating specific for every bead population comprises a coating material, and, optionally, a pore former and other excipients. The coating material is preferably selected from a group comprising cellulosic polymers, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and cellulose acetate phthalate; polyvinyl alcohol; acrylic polymers such as polyacrylates, polymethacrylates and copolymers thereof, and other water-based or solvent-based coating materials. The release-controlling coating is population-specific in the sense that the rate of release of topiramate from every bead population is controlled by at least one parameter of the release controlling coating, such as the nature of the coating, coating level, type and concentration of a pore former, process parameters and combinations thereof. Thus, changing a parameter, such as a pore former concentration, or the conditions of the curing, as will be discussed in more details below, (see Example 5) allows to change the release of topiramate from any given bead population and to selectively adjust the formulation to the pre-determined release profile. The release profile, in its turn, may be chosen or modified in such a way as to achieve the best treatment modality depending on the specific needs of the patient population and the nature of the condition.

For example, with all things being equal, there exists a mathematical relationship between the release controlling coating level among the cured beads and the 80% *in vitro* release time. Pre-determined target profiles can therefore be achieved by the interpolation or extrapolation of the relationship curve. For example, when the release controlling coating comprises only ethylcellulose (SURELEASE®) as a coating material, a logarithmic relationship exists between the % weight gain with the coating and the 80% release time in an *in-vitro* dissolution test (FIG. 1):

$$\text{Log}(T_{80\% \text{ release}}) = a(\% \text{ coating}) + b.$$

When ethylcellulose/HPMC (SURELEASE®/OPADRY®) mixture is used, for example, 85:15 mixture or 80:20 mixture, a linear relationship exists between the % weight gain with the coating and the 80% release time in an *in-vitro* dissolution test (FIG. 2):

$$T_{80\% \text{ release}} = a(\% \text{ coating}) + b.$$

Pore formers suitable for use in the release controlling coating herein can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, Carbowaxes, Carbopol, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like.

The release controlling coating in the current invention can further comprise other additives known in the art such as plasticizers, anti-adherents, glidants, and antifoams.

8

In some embodiments, it may be further desirable to optionally coat the XR beads with an "overcoat," to provide, e.g., moisture protection, static charge reduction, taste-masking, flavoring, coloring, and/or polish or other cosmetic appeal to the beads. Suitable coating materials for such an overcoat are known in the art, and include, but are not limited to, cellulosic polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and microcrystalline cellulose, or combinations thereof (for example various OPADRY® coating materials).

Topiramate-containing beads of the present invention may additionally contain enhancers that may be exemplified by, but not limited to, solubility enhancers, dissolution enhancers, absorption enhancers, permeability enhancers, stabilizers, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, and multidrug resistance protein inhibitors. Alternatively, the formulation can also contain enhancers that are separated from the topiramate beads, for example in a separate population of beads or as a powder. In yet another embodiment, the enhancer(s) may be contained in a separate layer on a topiramate-containing bead either under or above the release controlling coating.

The beads may further comprise other pharmaceutically active agents suitable for use in combination with topiramate for treatment or prevention of a pathological condition. The additional pharmaceutically active agents, without limitation, may be represented by analgesic and anti-inflammatory compounds such as COX-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs such as opiates and morphinomimetics, synthetic drugs with narcotic properties such as tramadol; anticonvulsants such as valproic acid or its derivatives, carbamazepine, oxcarbazepine, gabapentin, and lamotrigine; anorectics or anti-obesity agents such as sibutramine or other, orlistat or other pancreatic lipase inhibitors, diethylpropion, fluoxetine, bupropion, amphetamine, methamphetamine, sertraline, zonisamide, and metformin, as well as medications associated with weight-gain, such as sulfonylurea derivatives, insulin, and thiazolidinediones whose weight-gain effect is tempered by topiramate; anti-hypertensive agents such as diuretics, anti-adrenergics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, vasodilators, centrally acting adrenergic drugs, and adrenergic neuron blockers; mood stabilizers such as various forms/salts of lithium, Omega-3 fatty acids and others known in the art, drugs for treatment or prevention of migraines, such as ergot derivatives or triptans, or any other pharmaceutical or nutraceutical ingredient that can be safely and beneficially combined with topiramate.

A relative amount of every bead population in the complete formulation is determined on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile and will be discussed in more detail in Example 6.

In another embodiment, the formulation of the present invention comprises an extended release component as described above, and an immediate release component. The IR component may be an enhanced immediate release composition. The enhanced immediate release composition may be characterized by a faster *in vitro* topiramate release as compared to the IR formulation. Preferably, at least 80% of an active compound from the enhanced immediate release composition is released in a time period of not more than 30 minutes. More preferably, at least 50% of an active compound from the enhanced immediate release composition is released in a time period of not more than 10 minutes, and at least 25% is dissolved in a time period of not more than 5 minutes after the oral administration. In the most preferred embodiment of

US 8,298,576 B2

9

the present invention, at least 75% of the active compound is released from the EIR composition in a time period of not more than 10 minutes. The embodiment in which the IR component is an enhanced immediate release composition will be discussed in more details below.

In addition to topiramate and inactive excipients, the EIR composition of the present invention comprises at least one agent selected from a group consisting of complexing agents and enhancing agents.

Without any limitation, the enhancing agents suitable for the present invention may be selected from the solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. The representative, but non-limiting examples of these compounds are Vitamin E TPGS, amino acid such as glutamic acid and glycine, sorbitol, mannose, amylose, maltose, man-
nitrol, lactose, sucrose, glucose, xylitol, dextrans such as maltodextrin, Cremophor RH40 (glycerol-polyethylene glycol oxystearate), Gelucire 50/13 (PEG-32 glyceryl palmito-
stearate), sodium lauryl sulfate, Tween 80 (polyoxyethylene sorbitan monooleate), benzyl alcohol, Span 20 (sorbitan monolaurate), Poloxamer 407, PEG3350, PVP K25, oleic acid, Capmul GMO (glyceryl monooleate), sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, crosscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose, sodium bicar-
bonate, calcium citrate, sodium docusate, and menthol, among others. Enhancers can be combined to achieve multiple enhancement effects, for example, solubility enhance-
ment combined with permeability enhancement and p-glyco-
protein inhibition, or to provide a synergistic enhancement effect to achieve greater and more efficient enhancement. For example, polyglycolized glycerides (different grades of Gelucire) can be combined with sodium lauryl sulfate to achieve higher solubility enhancement as well as faster dis-
solution of topiramate.

In one embodiment, the EIR composition comprises a highly soluble complex of topiramate with a complexing agent that is represented by, but not limited to, cyclodextrins, including cyclodextrin derivatives, such as hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and alpha-cyclodextrin. The ratio of cyclodextrin to topira-
mate in the EIR formulation is preferably less than 20:1 and more preferably less than 5:1. In the most preferred embodi-
ment, the complexing agent is hydroxypropyl beta cyclodex-
trin.

The highly soluble complex of topiramate and cyclodextrin is prepared by mixing topiramate and cyclodextrin together in the presence of water. The concentration of cyclodextrin is preferably high to facilitate the formation of topiramate-enhancer complex. In the case when the complexing agent is hydroxypropyl-beta-cyclodextrin, the concentration of the hydroxypropyl-beta-cyclodextrin solution used for mixing with topiramate is greater than 2%, preferably greater than 20%, and more preferably at least about 40%. The amount of topiramate is determined by a desired ratio of hydroxypropyl-beta-cyclodextrin to topiramate, which is preferably less than 20:1, and more preferably less than 5:1. The mixing time of the complex solution is from about one hour to about 48 hours, and preferably from about 5 hours to about 24 hours. The addition of hydroxypropyl-beta-cyclodextrin and topira-

10

mate can be incremental to reduce the viscosity of the complex solution and to achieve better complexation.

In a further embodiment, the EIR component of the present invention is contained in at least one bead population. Topiramate EIR beads can be prepared using processes suitable for bead manufacturing, such as coating of a topiramate sus-
pension, dispersion or solution onto an inert carrier, or by roller compaction, granulation, extrusion/spheronization, or powder coating, and are not limited by the examples cited therein. The enhancing agents of the present invention can be incorporated into the topiramate containing beads, or may be contained in other beads separated from the topiramate containing beads. By way of a non-limiting example, topiramate-containing EIR beads were prepared by coating topiramate dispersion onto an inert carrier such as sugar spheres. The topiramate dispersion, in addition to topiramate in the micronized form or in non-micronized form, can contain one or more enhancers, water and optionally a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

When the formulation is enhanced with complexing agents, the agents may be first mixed with topiramate and a suitable solvent such as water to form the complex. The topiramate-containing complex is then mixed with a binder solution prepared separately to give the coating dispersion. The coating dispersion is then sprayed onto the inert carrier such as sugar spheres using a fluid bed processor.

In an alternative embodiment of the invention, the formulation comprises at least one XR bead population, and at least one additional combination bead population consisting of the extended release beads that have an additional immediate release component layer coated on top of the release controlling coating. This layer may be formed by a suitable loading method such as solution/suspension/dispersion coating, powder coating or wet granulation.

In yet another embodiment, at least part (i.e., more than 0.01%, preferably at least 1%) of the active ingredient may be present in the formulation in a form of micronized particles with the size of from 1 μ m to 1000 μ m, preferably from 2 μ m to about 200 μ m, more preferably from 2 μ m to about 100 μ m. Further, one or more enhancers may be present in the formulations covered by this embodiment. The enhancers are selected from solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. Preferably, the enhancer is a solubility enhancer or a dissolution enhancer.

The topiramate formulation of the present invention may be formulated in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, sprinkles, or any other form suitable for oral administration.

In one embodiment of the invention, the dosage form is a gelatin capsule containing the XR component in a form of at least one population of beads, and an optional IR component. The IR component, when present, may be in a form of a powder, or may also be contained in at least one population of beads to achieve faster dissolution of topiramate (FIG. 5).

In an alternative embodiment, part of the total amount of the active ingredient may be incorporated into the aforementioned bead populations that will be contained inside an enclosure such as a capsule, and the rest of the active ingredient can be loaded on the outside of the enclosure by a suitable loading method such as solution/suspension/disper-

US 8,298,576 B2

11

sion coating or powder coating or wet granulation. For example, a part of the immediate release topiramate formulation can be loaded by coating on the outside of a capsule that contains within it other populations of topiramate such as extended release topiramate. This dosage form can provide almost instantaneous dissolution of the initial portion of topiramate dose from the outside of the capsule, followed by a sustained release of the rest of topiramate from inside the capsule.

In a further embodiment of the invention, the dosage form is a tablet. Without imposing any limitations, this embodiment may be exemplified by a multilayered tablet that comprises at least one layer containing the extended release component, and at least one layer comprising the immediate release component, wherein the IR component may or may be not an EIR composition.

The last two embodiments are especially beneficial when fast onset of action followed by sustained release is preferred, as is for example in the cases of a breakthrough migraine episode.

The current invention additionally encompasses a method of preparing formulations of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile. The method comprises the following steps:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method comprises a step for providing an immediate release component, which may be an enhanced immediate release composition.

In another embodiment, the method includes a process for providing an extended release component contained in at least one population of beads characterized by its own rate of release, wherein the process includes the steps of:

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The exact amount of beads of every population incorporated into the formulation and into the final dosage form is determined using the linear superposition principle (WinNonLin) on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile (Example 6).

Release profiles of XR topiramate beads can be selectively adjusted, modified or stabilized by curing the beads at an elevated temperature. This process is well known in the art. However, it was unexpectedly discovered that curing the beads in the curing apparatus in the presence of at least one suitable solvent dramatically reduces the curing time necessary to produce a desired release profile and a level of stability. The curing process that previously required up to two weeks can be carried out by the method of current invention in several hours.

The assisting solvents can be selected from those solvents that can dissolve or partially dissolve the coating material, or those that can induce or assist the coalescence or molecular relaxation of the coating material, or those that can reduce

12

electrostatic charge on the dosage forms during curing and those that can facilitate curing at a higher temperature. Examples of these solvents include but are not limited to organic solvents, such as alcohols, ketones, ethers, esters, amides, amines, hydrocarbons including substituted hydrocarbons such as chlorinated hydrocarbons and aromatic hydrocarbons, furans, sulfoxides, organic acids, phenols, super-critical fluids; ammonia; and water, buffered water, or water solutions of other inorganic or organic compounds, and their combinations. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

The curing of the dosage form normally is done in an apparatus that can operate at elevated temperatures and that can deliver the assisting solvents by means such as spray, injection, or vaporization. In the embodiment of the invention when the assisting solvent is sprayed or injected into the curing apparatus, the stream of solvent is introduced directly onto the coated beads. The amount of the solvent necessary to produce the desired effect, such as the desired release parameters and stabilization of the coating, depends on the nature of the solvent and the method of solvent delivery.

Typically, when the vaporization method is used, the organic solvents and aqueous solutions may be used in the wide range of vapor concentrations varying from 2% to more than 100%, providing an unsaturated, saturated or an oversaturated atmosphere. The pure water, however, has to be used in such an amount as to provide at least a saturated or, preferably, an oversaturated atmosphere in the curing apparatus. At least during the delivery of assisting solvents, the coated beads are mixed or agitated either continuously or in a pulsed manner.

In an alternative embodiment of the invention, hot water steam is introduced into the curing apparatus for a pre-selected period of time. The steam serves simultaneously as a solvent and as a source of heat for the beads. Introduction of steam is followed by a drying period.

This method of curing the release controlling coating results in many benefits including the dramatically shortened curing time, increased stability and modification of the release profile, and is not limited to topiramate containing beads, but includes the curing of any microparticles regardless of the drug.

Specifically, active ingredient containing beads, with or without the optional over-coat, are charged to a fluid bed processor or a pan coater and heated to a desired curing temperature range, for example 40° C. to 80° C. for sustained release dosage forms containing ethylcellulose (SURELEASE®), and 40° C. to 70° C. for sustained release dosage forms containing acrylic polymers (EUDRAGIT® RS and EUDRAGIT® RL ammonio methacrylate copolymer dispersion, type A and B)). The assisting solvent or solvents, such as water or alcohol-water mixture, are sprayed onto the beads while mixing by, for example, fluidizing or rotating. Alternatively, the process is carried out in an oven where hot steam is introduced as previously discussed. Solvent-assisted curing is carried out to a desired curing time length, either in one curing period or in multiple, separate curing periods. The dosage forms can be further dried for a short period of time to remove residual solvents.

The solvent-assisted curing process significantly accelerates the curing of release controlling coating on active ingredient containing beads as compared to the heat-only curing of the same. In most instances, less than 4 hours of solvent-assisted curing resulted in more complete curing of the

US 8,298,576 B2

13

extended release dosage forms than 2 weeks of heat-only oven curing of the same dosage forms.

The present invention also presents a method of treatment or prevention of a pathological condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a novel topiramate formulation of the instant invention, wherein topiramate is released from the formulation at a sustained rate along the pre-determined release profile. The method of the current invention possesses the flexibility to selectively adjust the pharmacokinetics of the administered formulations depending on the nature of the condition and needs of the patients due to the novel design of the topiramate formulation that comprises an extended release component and an optional immediate release component, and the release profiles of both components can be selectively modified during the preparation process as described above to comply with the predetermined release profile.

The pathological condition that may be treated by a method of the present invention is a neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by the topiramate administration.

The neurological disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to, epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, perinatal hypoxia ischemia and related damage, chronic neurodegenerative disorders, acute neurodegeneration, and ALS.

Psychiatric disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, ADHD, impulse control disorders, border line personality disorder, addiction, and autism.

Formulations of the present invention may be also used for the treatment and prevention of diabetes and related disorders, such as type II diabetes mellitus, diabetic retinopathy, impaired oral glucose tolerance, diabetic skin lesions, diabetic neuropathy, Syndrome X and elevated blood glucose

14

levels; ocular disorders, including but not limited to glaucoma and macular degeneration; cardiovascular disorders represented but not limited to elevated blood pressure and elevated lipids; obesity; asthma; autoimmune disorders; sleep apnea and sleep disorders. The formulations may be also used for inducing weight loss or promoting wound healing, or for any other condition, not specified above, wherein the use of topiramate is indicated.

The invention will be further illustrated by the following Examples, however, without restricting its scope to these embodiments.

EXAMPLES

Example 1

Extended Release Beads Preparation

Topiramate Drug Layering on Sugar Spheres—The “Core”

An aqueous suspension of 10-20% (w/w) topiramate (particle size 90% vol. NMT 30 micrometer, 50% vol. NMT 15 micrometer and 10% vol. NMT 5 micrometer) and 0.5-4% (w/w) HPMC or other aqueous binder can be used as the drug layering coating solution. A fluid bed suited for Wurster-spray is assembled and charged with inert carriers such as sugar spheres. The coating suspension is sprayed onto the bed to evenly coat the inert carriers to a desired topiramate loading level. Higher binder concentration in the coating solution may be used for smaller size inert carrier and higher topiramate loading. Inlet airflow rate and product temperature are adjusted to keep the batch from spray-drying the coating material or over-wetting the spheres.

Coating of the Core with a Release Controlling Coating

A dispersion of a cellulosic polymer such as ethylcellulose and methylcellulose can be used to coat the core in the current invention. Ethylcellulose dispersion (SURELEASE®) can be diluted to a final concentration of about 10% to about 20% and with or without the use of other ingredients such as pore formers. A fluid bed suited for Wurster-spray is assembled and charged with the cores prepared in Example 1. The release controlling coating dispersion is sprayed onto the bed to evenly coat the core to a desired coating level as exemplified in Table 1.

TABLE 1

Composition and process Parameters for the extended Release Topiramate Beads							
	XR1a	XR1b	XR1c	XR2a	XR2b	XR2c	XR2d
RC* coating material	Ethylcellulose (SURELEASE®)	Ethylcellulose (SURELEASE®)	Ethylcellulose (SURELEASE®)	Ethylcellulose (SURELEASE®)	Ethylcellulose (SURELEASE®)	Ethylcellulose (SURELEASE®)	Ethylcellulose (SURELEASE®)
Pore-former	—	—	OPARDY® Clear	—	—	OPARDY® Clear	OPARDY® Clear
RC coating material to pore-former ratio	—	—	80:20	—	—	80:20	80:20
RC coating level	2%	4%	3%	3%	3%	6.5%	6.5%
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.
Over-coat material	—	OPARDY® AMB White	OPARDY® AMB White	—	OPARDY® AMB White	—	OPARDY® AMB White
Over-coat coating level	—	1.5%	1.5%	—	1.5%	—	1.5%

US 8,298,576 B2

15

16

TABLE 1-continued

Composition and process Parameters for the extended Release Topiramate Beads							
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven
	XR3	XR4	XR5	XR6	XR7	XR8	
RC coating material	Ethylcellulose SURE- LEASE ®	Ethylcellulose SURE- LEASE ®	Ethylcellulose SURE- LEASE ®	Ethylcellulose SURE- LEASE ®	Ethylcellulose SURE- LEASE ®	Ethylcellulose SURE- LEASE ®	Acrylic polymers (EUDRAGIT ® RL30D/ RS30D)
Pore-former	—	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	—
RC coating material to pore-former ratio	—	80:20	80:20	80:20	85:15	—	—
RC coating level	3.7%	3.1%	5.2%	9.5%	15%	15%	15%
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.
Over-coat material	—	—	—	—	—	—	—
Over-coat coating level	—	—	—	—	—	—	—
Curing method	Fluid bed/water, or oven	Fluid bed/water, or oven	Fluid bed/ water, or oven	Fluid bed/water, or oven	Fluid bed/ water, fluid bed/5% alcohol- water, or oven	Fluid bed/ water, fluid bed/5% alcohol- water, or oven	Fluid bed/ water, or oven

*RC—Release Controlling

Example 2

30

Example 3

Method of
Topiramate-Hydroxypropyl-beta-cyclodextrin
Complex Bead Preparation

35

Topiramate EIR Beads Containing Non-Complexing
Enhancers

Approximately half of the intended amount of topiramate was added to the water with constant mixing followed by sprinkling of hydroxypropyl-beta-cyclodextrin into the dispersion. Once the dispersion became significantly less viscous, more drug substance was added followed by sprinkling of more hydroxypropyl-beta-cyclodextrin. The drug and hydroxypropyl-beta-cyclodextrin addition steps were repeated, and the dispersion was mixed for 12-18 hours. Separately, hydroxypropylmethylcellulose was dissolved in water. The above topiramate-hydroxypropyl-beta-cyclodextrin dispersion and hydroxypropylmethylcellulose solution were mixed together for 15 to 30 minutes and the mixture was screened through an 80-mesh sieve. The resultant dispersion was sprayed onto sugar spheres using a fluid bed processor to yield the enhanced immediate release beads (Table 2).

Topiramate is dispersed in a binder solution, such as hydroxypropylmethylcellulose solution, that contains an appropriate amount of enhancer or enhancers such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) and sodium lauryl sulfate combination, polyoxyl hydrogenated castor oil (different grades of Cremophor RH), polyglycolized glycerides (different grades of Gelucire), polyglycolized glycerides (different grades of Gelucire) combined with sodium lauryl sulfate, or combinations thereof. The resultant dispersion is sprayed onto an inert carrier such as sugar spheres using a fluid bed processor to achieve a desired drug load (Table 3).

TABLE 2

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions				
Percentage (w/w) in Beads				
Component	EIR-1 (HPBCD:Drug = 3:2)*	EIR-2 (HPBCD:Drug = 3:2)*	EIR-3 (HPBCD:Drug = 1:1)*	EIR-4 (HPBCD:Drug = 1:2)*
Topiramate	25.0	3.3	28.9	33.3
Hydroxypropyl-beta-cyclodextrin	37.5	4.95	28.9	16.7
Hydroxypropylmethylcellulose	3.1	0.41	2.4	4.2
Sugar spheres	34.4	91.34	39.8	45.8

*HPBCD:Drug - Hydroxypropyl-beta-cyclodextrin to drug substance ratio

US 8,298,576 B2

17

TABLE 3

Enhanced Immediate Release Topiramate Bead Compositions			
Component	Percentage (w/w) in Beads		
	EIR-5	EIR-6	EIR-7
Topiramate	36.8	37.9	36.4
Sodium lauryl sulfate	0.7	0.5	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	7.3	—	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	9.1
Polyglycolized glycerides (Gelucire 50/13)	—	4.7	—
Hydroxypropylmethylcellulose	4.6	4.8	4.5
Sugar spheres	50.6	52.1	50.0

Example 4

Topiramate EIR Beads Containing Micronized Particles

Miconized or non-miconized topiramate is dispersed in a solution with or without heating, optionally containing dissolution enhancing agents such as mannose, maltose, mannitol, lactose, maltodextrin and sodium starch glucolate, and optionally containing one or more additional enhancers such as PEG3350, sodium lauryl sulfate, sodium docusate, polyoxyethylene sorbitan monooleate and Poloxamers, under such process parameters that topiramate particles that remain undissolved have a particle size of about 2 micron to about 30 micron. A particle size reduction device such as a homogenizer can also be used to reduce the particle size of undissolved topiramate. The resultant topiramate dispersion is then sprayed onto inert carriers such as sugar spheres in a coating processor such as a fluid bed processor. The formulations obtained are represented in the Table 4:

TABLE 4

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Topiramate	3.2	26.0	25.0	3.2	26.0	26.0
Mannose	0.4	5.0	3.3	2.0	10.0	10.0
Maltrin 250	—	—	1.0	1.0	—	—
PEG3350	1.0	15.0	—	—	—	10.0
Sodium lauryl sulfate	—	—	—	—	0.5	—
Hydroxypropyl-beta-cyclodextrin	—	—	37.5	—	—	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	—	—	—	—	2.0	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	—	—	—	2.0
Sugar spheres	95.4	54.0	33.2	93.8	61.5	52.0

Example 5

Method of Curing Beads

The topiramate beads coated with a release controlling coating, with or without an overcoat, can be cured using the

18

above-mentioned solvent-assisted curing process, or using the heat-only curing process, to a desired curing level and preferably to complete curing.

Specifically, the core is coated to a desired coating level with a solution or dispersion of the release controlling coating material, with or without the above-mentioned additives such as pore-formers, using a fluid bed processor or any other suitable apparatus for coating of the core. Product temperature is controlled at a desirable range, for example 20° C. to 60° C. for the coating of ethylcellulose (SURELEASE®) and 20° C. to 60° C. for acrylic polymers (EUDRAGIT® RL and Eudragit® EUDRAGIT® RS grades).

An optional overcoat with materials such as cellulosic polymers (various OPADRY®) is applied thereafter. Curing of the sustained release topiramate beads is carried out either in an oven at 40° C. to 80° C. for SURELEASE® containing beads or at 40° C. to 70° C. for EUDRAGIT® RL or RS containing beads, or in a fluid bed processor with or without the use of assisting solvents at similar product temperatures.

For curing that uses assisting solvents, the assisting solvent can be delivered through top spray, bottom spray, side spray or injection, or introduced by vaporization. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

Example 6

Sustained Release Formulations of Topiramate

a. Plasma concentration versus time curves for the topiramate formulations containing extended release and immediate release bead populations are simulated using WinNonlin Version 5.0.1 based on the pharmacokinetic data on the separate bead populations that were generated in a comparative randomized single-dose 6-way crossover study in healthy adult volunteers. The study included administration of a 50 mg oral dose of three extended release compositions, designated here as XR1, XR2 and XR3, two immediate release compositions ((TOPAMAX®, Ortho-McNeil Neurologics, Inc.) (25 mg BID), and an immediate release bead formulation) and an enhanced immediate release (IR) bead composition. The single dose topiramate plasma concentration profiles for XR1, XR2 and XR3 are shown in FIG. 3. The single dose topiramate plasma concentration profiles for IR are shown in FIG. 4. The data are projected to a steady-state (SS) with a 24 h dosing interval for the sustained release compositions and a 12 h dosing interval for TOPAMAX®, using the linear superposition principle (WinNonlin). The extended release populations XR1, XR2 and XR3, and an immediate release (IR) population are selected in such a way as to be defined by at least one of the three following sets of conditions:

- for the steady state,
for XR1, $1.70 C_{maxIR} \geq C_{maxXR1} \geq 1.30 C_{maxIR}$
for XR2, $0.40 C_{maxIR} \geq C_{maxXR2} \geq 0.20 C_{maxIR}$
for XR3, $0.25 C_{maxIR} \geq C_{maxXR3} \geq 0.05 C_{maxIR}$
- for in-vitro dissolution,
for XR1, $1.5 h \leq T_{80\%} \leq 4 h$
for XR2, $5 h \leq T_{80\%} \leq 8 h$
for XR3, $8 h \leq T_{80\%} \leq 10 h$
- for a single initial dose in-vivo,
for XR1, $4 h \leq T_{max} \leq 8.5 h$
for XR2, $T_{max} \geq 16 h$
for XR3, $T_{max} \geq 16 h$.

US 8,298,576 B2

19

Optionally, the immediate release bead population is composed of enhanced immediate release (EIR) beads such that at least one condition is true: a. for the steady state, $2.40 C_{maxIR} \geq C_{maxEIR} \geq 1.20 C_{maxIR}$; b. for in-vitro dissolution, $T80\% \leq 30$ min; c. for a single initial dose in-vivo, $T_{max} \leq 2$ h.

The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 5 below. These formulations are selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.

TABLE 5

Composition and Pharmacokinetic data of Multi-bead Formulations							
	#1	#2	#3	#4	#5	#6	#7
% XR1	20	50	0	10	10	15	0
% XR2	80	0	85	85	80	70	100
% XR3	0	50	0	0		15	0
% IR	0	0	15	5	10	0	0
Rel. BA (%), SS	98.5	100.5	96.6	97.4	97.6	97.3	96.0
Degree of fluctuation, SS	0.15	0.22	0.14	0.14	0.15	0.13	0.09

b. based on the results of WinNonlin simulation discussed in part (a), formulations #1 (A), #3 (B), and #4 (C) were tested in the comparative randomized multi-dose 4-way study following a once a day 50 mg oral dose of three controlled release formulations and a 25 mg twice a day oral doses of TOPAMAX® in healthy adult volunteers.

The results of the study are summarized in Table 6 and FIG. 6:

TABLE 6

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (TOPAMAX®)
% XR1	20	0	10	—
% XR2	80	86	84	—
% XR3	0	0	0	—
% IR	0	14	6	—
Rel. BA (%), SS	92	93	95	100
Relative Degree of fluctuation, SS	73%	72%	66%	100%

What is claimed is:

1. A sustained release formulation of topiramate for oral administration to a mammalian subject comprising an immediate release bead population (IR), a first extended release bead population (XR1), and a second extended release bead population (XR2), wherein:

(a) the IR bead population comprises topiramate up to 10% by wt of the total amount of topiramate in the formulation and 0.1-10% by wt of a binder, wherein the topiramate and binder form a coating on inert carrier particles, wherein the coated inert carrier particles are not coated with a release controlling coating, and wherein the IR bead population releases greater than or equal to 80% of its topiramate in a continuous manner over less than or equal to 1 hour;

(b) the XR1 bead population comprises topiramate up to 20% by wt of the total amount of topiramate in the formulation, wherein the topiramate is a coating on inert

20

carrier particles, wherein the topiramate coated inert carrier particles are further coated with a release controlling coating material, wherein the coating material comprises 2-15% by weight of the topiramate coated inert carrier particles, and wherein the XR1 bead population releases 80% of its topiramate in a continuous manner over less than or equal to 4 hours; and,

(c) the XR2 bead population comprises topiramate at least 80% by weight of the total amount of topiramate in the formulation, wherein the topiramate is a coating on inert carrier particles, wherein the topiramate coated inert carrier particles are coated with a release controlling coating material, wherein the coating material comprises 2-15% by weight of the topiramate coated inert carrier particles, and wherein the XR2 bead population releases 80% of its topiramate in a continuous manner over less than 8 hours;

wherein the release controlling coating materials comprise methylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates or copolymers thereof, and wherein the XR1 and XR2 bead populations have their own specific rates of release.

2. The sustained release foimulation according to claim 1, wherein the binder is selected from the group consisting of starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

3. The sustained release formulation according to claim 1, wherein the IR bead population further comprises an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof.

4. The sustained release formulation according to claim 1, wherein the IR bead population further comprises a complexing agent selected from the group consisting of cyclodextrin, hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, and derivatives thereof.

5. The sustained release formulation according to claim 1, wherein the XR1 and/or XR2 bead populations further comprises a pore former selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomer, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; alkali metal salts and alkaline earth metal salts, and combinations thereof.

6. The formulation of claim 1, wherein the IR bead population releases greater than or equal to 80% of its topiramate in less than or equal to 30 minutes.

US 8,298,576 B2

21

7. The formulation of claim 1, wherein at least a part of the active ingredient is in a form of micronized particles.

8. The formulation of claim 1, wherein said formulation is in a dosage form of a tablet, a pill, a capsule, a caplet, a troche, a pouch, or sprinkles.

9. The formulation of claim 1, wherein the total amount of topiramate in the formulation is from 0.5 to 3000 mg.

10. The formulation of claim 1, wherein the inert carrier particles comprise cellulose spheres, silicon dioxide, starch or sugar spheres.

11. The sustained release formulation according to claim 1, wherein the coating material comprises methylcellulose, ethylcellulose, hydroxypropyl cellulose, or hydroxypropylmethyl cellulose.

12. The formulation of claim 1, wherein said formulation provides for a maximum steady state plasma concentration (C_{max}) of topiramate which is in the range from 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

13. The formulation of claim 1, wherein said formulation provides for a relative steady state AUC in the range of 80% to 125% of the AUC of the same amount of topiramate administered as an immediate release formulation BID.

14. The formulation of claim 1, further comprising an additional pharmaceutically active ingredient in combination with topiramate.

15. A method of treatment of a neurological and/or psychiatric condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of the sustained release formulation of claim 1.

16. The method of claim 15, wherein said condition is selected from a group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, amyotrophic lateral sclerosis.

17. The method of claim 15, wherein the condition is epilepsy.

18. The method of claim 15, wherein the condition is migraine.

19. A sustained release formulation of topiramate comprising:

(a) a first extended release bead population (XR1) comprising up to 20% by wt of the total amount of topiramate in the formulation, wherein the topiramate is a coating on inert carrier particles and further coated with a release controlling coating material, wherein the release controlling material releases 80% of the topiramate in a continuous manner over less than or equal to 4 hours; and,

(b) a second extended release bead population (XR2) comprising at least 80% by weight of the total amount of topiramate in the formulation, wherein the topiramate is coated onto inert carrier particles and further coated with a release controlling coating material,

wherein the release controlling material releases 80% of the topiramate in a continuous manner over less than 8 hours;

wherein the release controlling coating materials comprise methylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate,

22

cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates or copolymers thereof; and wherein the XR1 and XR2 bead populations have their own specific rates of release.

20. The sustained release formulation according to claim 19, further comprising:

(c) an immediate release (IR) bead population comprises topiramate up to 10% by wt of the total amount of topiramate in the formulation and 0.1-10% by wt of a binder, wherein the topiramate and binder form a coating on inert carrier particles, and wherein the IR bead population releases greater than or equal to 80% of its topiramate in a continuous manner over less than or equal to 1 hour.

21. The sustained release formulation according to claim 20, wherein the IR bead population further comprises an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose, substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof.

22. The sustained release formulation according to claim 19, further comprising:

(c) a third extended release bead population (XR3) comprising up to 15% by weight of the total amount of topiramate in the formulation, wherein the topiramate is coated onto inert carrier particles and further coated with a release controlling coating material, wherein the release controlling material releases 80% of the topiramate in a continuous manner over less than or equal to 10 hours.

23. The sustained release formulation according to claim 19, wherein the XR1 and/or XR2 bead populations further comprises a pore former selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomer, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; alkali metal salts and alkaline earth metal salts, and combinations thereof.

24. The sustained release formulation according to claim 19, wherein the coating material comprises methylcellulose, ethylcellulose, hydroxypropyl cellulose, or hydroxypropylmethyl cellulose.

25. The formulation of claim 19, wherein said formulation provides for a relative steady state AUC in the range of 80% to 125% of the AUC of the same amount of topiramate administered as an immediate release formulation BID.

26. The formulation of claim 19, further comprising an additional pharmaceutically active ingredient in combination with topiramate.

27. A method of treatment of a neurological and/or psychiatric condition in a mammalian subject, comprising orally

US 8,298,576 B2

23

administering to the subject a therapeutically effective amount of the sustained release formulation of claim **19**.

28. The method of claim **27**, wherein said condition is selected from a group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, impulse control disorders, border line person-

24

ality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, amyotrophic lateral sclerosis.

29. The method of claim **28**, wherein the condition is epilepsy.

30. The method of claim **28**, wherein the condition is migraine.

* * * * *

Exhibit B



US008298580B2

(12) **United States Patent**
Liang et al.

(10) **Patent No.:** **US 8,298,580 B2**

(45) **Date of Patent:** ***Oct. 30, 2012**

(54) **SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE**

(75) Inventors: **Likan Liang**, Boyds, MD (US); **Hua Wang**, Clarksville, MD (US); **Padmanabh P. Bhatt**, Rockville, MD (US); **Michael L. Vieira**, Gaithersburg, MD (US)

(73) Assignee: **Supernus Pharmaceuticals, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/926,931**

(22) Filed: **Dec. 17, 2010**

(65) **Prior Publication Data**

US 2011/0287099 A1 Nov. 24, 2011

Related U.S. Application Data

(63) Continuation of application No. 11/941,475, filed on Nov. 16, 2007.

(60) Provisional application No. 60/859,502, filed on Nov. 17, 2006.

(51) **Int. Cl.**

A61K 9/22 (2006.01)

A61K 9/14 (2006.01)

A61K 31/357 (2006.01)

A61P 25/00 (2006.01)

(52) **U.S. Cl.** **424/468; 424/497; 424/495; 424/494; 424/490; 424/489; 514/454**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,528,378 A 10/1950 Mannheimer et al.
2,675,619 A 4/1954 Cone
2,677,700 A 5/1954 Jackson et al.
2,781,354 A 2/1957 Mannheimer et al.
2,979,578 A 4/1961 Curtis
2,996,431 A 8/1961 Barry
3,036,118 A 5/1962 Jackson et al.
3,139,383 A 6/1964 Neville et al.
3,535,307 A 10/1970 Moss et al.
3,811,444 A 5/1974 Heller et al.
3,829,506 A 8/1974 Schmolka et al.
3,962,414 A 6/1976 Michaels
3,992,518 A 11/1976 Chien et al.
4,066,747 A 1/1978 Capozza
4,070,347 A 1/1978 Schmitt
4,079,038 A 3/1978 Choi et al.
4,083,949 A 4/1978 Benedikt
4,093,709 A 6/1978 Choi et al.
4,290,426 A 9/1981 Luschen et al.
4,434,153 A 2/1984 Urquhart et al.
4,513,006 A 4/1985 Maryanoff et al.

4,721,613 A 1/1988 Urquhart et al.

4,727,064 A 2/1988 Pitha

4,752,470 A 6/1988 Mehta

4,757,128 A 7/1988 Domb et al.

4,853,229 A 8/1989 Theeuwes

4,938,763 A 7/1990 Dunn et al.

4,997,904 A 3/1991 Domb

5,030,447 A 7/1991 Joshi et al.

5,175,235 A 12/1992 Domb et al.

5,180,589 A 1/1993 Joshi et al.

5,225,202 A 7/1993 Hodges et al.

5,256,440 A 10/1993 Appel et al.

5,378,475 A 1/1995 Smith et al.

5,478,577 A 12/1995 Sackler et al.

5,500,227 A 3/1996 Oshlack et al.

5,576,311 A 11/1996 Guy

5,753,693 A 5/1998 Shank

5,760,007 A 6/1998 Shank et al.

5,773,019 A 6/1998 Ashton et al.

5,935,933 A 8/1999 Shank et al.

5,955,096 A 9/1999 Santos et al.

5,985,312 A 11/1999 Jacob et al.

5,998,380 A 12/1999 Ehrenberg et al.

6,123,965 A 9/2000 Jacob et al.

6,156,348 A 12/2000 Santos et al.

6,191,117 B1 2/2001 Kozachuk

6,197,346 B1 3/2001 Mathiowitz et al.

6,201,010 B1 3/2001 Cottrell

6,217,908 B1 4/2001 Mathiowitz et al.

6,235,311 B1 5/2001 Ullah et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1130352 A 9/1996

(Continued)

OTHER PUBLICATIONS

US 6,103,281, 08/2000, DelDuca et al. (withdrawn).

Adin et al., "Topiramate Serum Concentration-to-Dose Ratio," *Therapeutic Drug Monitoring*, Jun. 2004; 26(3):251-257.

U.S. Appl. No. 12/926,936, filed Dec. 17, 2010, Liang et al.

Bahk et al., "Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study," *Progress in Neuropsychopharmacology & Biological Psychiatry*, 2005, 29(1):115-121.

Baumanoir, Anne, "The Landau-Kleffner syndrome", In: Roger et al., Eds. *Epileptic Syndromes in Infancy, Childhood, and Adolescence*, 2nd Ed., London, England: John Libby, pp. 231-244, 1992.

Berge et al., "Pharmaceutical Salts", *J. Pharm. Sci.*, Jan. 1977, 66(1): 1-19.

(Continued)

Primary Examiner — Suzanne Ziska

(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP; Stephen B. Maebius; Sunit Talapatra

(57) **ABSTRACT**

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

31 Claims, 6 Drawing Sheets

US 8,298,580 B2

Page 2

U.S. PATENT DOCUMENTS

6,248,363	B1	6/2001	Patel et al.	
6,294,192	B1	9/2001	Patel et al.	
6,319,903	B1	11/2001	Carrazana et al.	
6,365,187	B2	4/2002	Mathiowitz et al.	
6,368,586	B1	4/2002	Jacob et al.	
6,479,467	B1	11/2002	Buchanan et al.	
6,503,884	B1	1/2003	Ehrenberg et al.	
6,514,531	B1	2/2003	Alaux et al.	
6,524,620	B2	2/2003	Cheng et al.	
6,559,293	B1	5/2003	Almarsson et al.	
6,562,865	B1	5/2003	Codd et al.	
6,569,463	B2	5/2003	Patel et al.	
6,696,091	B2	2/2004	Thakur et al.	
6,699,840	B2	3/2004	Almarsson et al.	
6,797,283	B1	9/2004	Edgren et al.	
6,923,988	B2	8/2005	Patel et al.	
7,018,609	B2	3/2006	Hwang Pun et al.	
7,195,778	B2	3/2007	Fleshner-Barak et al.	
7,611,722	B2	11/2009	Lerner et al.	
7,763,635	B2 *	7/2010	Kidane et al.	514/299
2002/0044962	A1	4/2002	Cherukuri et al.	
2002/0054907	A1	5/2002	Devane et al.	
2002/0064563	A1	5/2002	Thakur et al.	
2002/0150616	A1	10/2002	Vandecruys	
2003/0017972	A1	1/2003	Pun et al.	
2003/0064097	A1	4/2003	Patel et al.	
2003/0072802	A1	4/2003	Cutler	
2003/0091630	A1	5/2003	Louie-Helm et al.	
2003/0133985	A1	7/2003	Louie-Helm et al.	
2003/0147952	A1	8/2003	Lim et al.	
2003/0166581	A1	9/2003	Almarsson et al.	
2003/0215496	A1	11/2003	Patel et al.	
2003/0225002	A1	12/2003	Livingstone	
2004/0002462	A1	1/2004	Najarian	
2004/0022844	A1	2/2004	Hasenzahl et al.	
2004/0028735	A1	2/2004	Kositprapa	
2004/0052843	A1	3/2004	Lerner et al.	
2004/0053853	A1	3/2004	Almarsson et al.	
2004/0082519	A1	4/2004	Hedner et al.	
2004/0091529	A1	5/2004	Edgren et al.	
2004/0096501	A1	5/2004	Vaya et al.	
2004/0109894	A1	6/2004	Shefer et al.	
2004/0115262	A1	6/2004	Jao et al.	
2004/0122104	A1	6/2004	Hirsh et al.	
2004/0132826	A1	7/2004	Hirsh et al.	
2004/0156901	A1	8/2004	Thakur et al.	
2004/0157785	A1	8/2004	Connor	
2004/0185097	A1	9/2004	Kannan et al.	
2004/0234601	A1	11/2004	Legrand et al.	
2004/0258758	A1	12/2004	Gustow et al.	
2005/0053653	A1	3/2005	Kidane et al.	
2005/0058707	A1	3/2005	Reyes et al.	
2005/0069587	A1	3/2005	Modi et al.	
2005/0106242	A1	5/2005	Yan et al.	
2005/0106247	A1	5/2005	Venkatesh et al.	
2005/0129765	A1	6/2005	Li et al.	
2005/0136108	A1	6/2005	Yam et al.	
2005/0169982	A1	8/2005	Almarsson et al.	
2005/0169992	A1	8/2005	Jao et al.	
2005/0175697	A1	8/2005	Edgren et al.	
2005/0191343	A1	9/2005	Liang	
2005/0220596	A1	10/2005	Gaeddy et al.	
2006/0018933	A1	1/2006	Vaya et al.	
2006/0018934	A1	1/2006	Vaya et al.	
2006/0024365	A1	2/2006	Vaya et al.	
2006/0034927	A1	2/2006	Casadevall et al.	
2006/0105045	A1	5/2006	Buchanan et al.	
2006/0121112	A1	6/2006	Jenkins et al.	
2006/0223762	A1	10/2006	Ehrenberg et al.	
2006/0233892	A1	10/2006	Hendrix	
2007/0212411	A1	9/2007	Fawzy et al.	
2008/0085306	A1 *	4/2008	Nangia et al.	424/458
2008/0131501	A1	6/2008	Liang et al.	

FOREIGN PATENT DOCUMENTS

WO	WO 93/21906	A1	11/1993
WO	WO 01/37808	A1	5/2001

WO	WO 02/03984	A2	1/2002
WO	WO 02/43731	A3	6/2002
WO	WO 2004/022037	A1	3/2004
WO	WO 2004/078162	A1	9/2004
WO	WO 2004/078163	A2	9/2004
WO	WO 2005/079748	A2	9/2005
WO	WO 2006/009403	A1	1/2006
WO	WO 2006/119153	A2	11/2006
WO	WO 2007/002318		1/2007

OTHER PUBLICATIONS

Berlant, Jeffery L., M.D., Ph.D., "Topiramate in Posttraumatic Stress Disorder: Preliminary Clinical Observations," J. Clin. Psychiatry, 2001, 62(Suppl 17):60-63.

Brandes et al., "Topiramate for Migraine Prevention," JAMA, Feb. 25, 2004, 291(8):965-973.

Carpenter et al., "Do obese depressed patients respond to topiramate? A retrospective chart review," J. Affect. Disord., 2002, 69(1-3):251-255.

Chen et al., "Combination Treatment of Clozapine and Topiramate in Resistant Rapid-Cycling Bipolar Disorder," Clin. Neuropharmacol., May-Jun. 2005, 28(3):136-138.

Coleman et al., "Polymer reviewed: A practical guide to polymer miscibility," Jul. 1990, 31:1187-1230.

Contin et al., "Topiramate Therapeutic Monitoring in Patients with Epilepsy: Effect of Concomitant Antiepileptic Drugs," Ther. Drug Monit., 2002, 24(3):332-337.

D'Amico et al., "Topiramate in migraine prophylaxis," Neurological Sciences, 2005, 26(Suppl 2):S130-S133.

Deckers et al., "Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed," Epilepsia, 2000, 41(11):1364-1374.

Diener et al., "Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control," J. Neurol., 2004, 251(8):943-950.

Dorado et al., "Topiramato en enfermedades comorbidas: epilepsia y migraña," Rev. Neurol., 2006, 43(4):193-196.

Duchene et al., "Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration," Drug Dev. Ind. Pharm., 1988, 14(2&3):283-318.

Erfurth et al., "Bupropion as Add-On Strategy in Difficult-to-Treat Bipolar Depressive Patients," Neuropsychobiology, 2002, 45(Suppl 1):33-36.

Felmeister, Alvin Ph.D., "Powders," Remington's Pharm. Sci., 14th Ed., 1970, Chapter 86, 1626-1628.

Ferrari et al., "Influence of Dosage, Age, and Co-Medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response," Therapeutic Drug Monitoring, 2003, 25(6):700-708.

Ferrari et al., "Rizatriptan: a new milestone in migraine treatment," Cephalalgia, 2000, 20(Suppl 1):1.

Fincher, Julian H., "Particle Size of Drugs and Its Relationship to Absorption and Activity," J. Pharm. Sci., Nov. 1968, 57(11):1825-1835.

Fisher et al., "Synergism between Topiramate and Budipine in Refractory Status Epilepticus in the Rat," Epilepsia, 2004, 45(11):1300-1307.

François et al., "The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy," Epilepsy Research, 2006, 72:147-163.

Gurny et al., "Bioadhesive intraoral release systems: design, testing and analysis," Biomaterials, Nov. 1984, 5:336-340.

Hershey et al., "Effectiveness of Topiramate in the Prevention of Childhood Headaches," Headache, Sep. 2002;42(8):810-818.

Hoes et al., "The Application of Drug-Polymer Conjugates in Chemotherapy," Drug Carrier Systems, 1989, 9:57-109.

Hollander et al., "Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder," Int. Clin. Psychopharmacol., 2006, 21(3): 189-191.

International Search Report and Written Opinion mailed Sep. 2, 2008, in PCT/US2007/19208, 10 pages.

US 8,298,580 B2

Page 3

- Ioannides-Demos et al., "Pharmacotherapy for Obesity," *Drugs*, 2005, 65(10):1391-1418.
- Johnson et al., "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial," *The Lancet*, May 17, 2003, 361(9370):1677-1685.
- Kellett et al., "Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic," *J. Neurol. Neurosurg. and Psych.*, 1999;66:759-763.
- Lainez et al., "Topiramate in the Prophylactic Treatment of Cluster Headache," *Headache*, Jul./Aug. 2003, 43(7):784-789.
- Lalonde et al., "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese *ob/ob* mice," *Physiology & Behavior*, 2004, 80(4):415-420.
- Lee et al., "The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy," *Epilepsia*, 2003; 44(3):339-347.
- Lehr et al., "Intestinal Transit of Bioadhesive Microspheres in an in situ Loop in the Rat—A Comparative Study with Copolymers and Blends Based on Poly(acrylic acid)," *Journal of Controlled Release*, 1990, 13:51-62.
- Leong et al., "Polymeric controlled drug delivery," *Adv. Drug Delivery Rev.*, 1987, 1:199-233.
- Linhardt, Robert J. "Biodegradable Polymers for Controlled Release of Drugs," *Controlled Release of Drugs*, 1989, Chapter 2, 53-95.
- Liu et al., "Preparation, characterization and in vivo evaluation of formulation of baicalin with hydroxypropyl-beta-cyclodextrin," *International Journal of Pharmaceutics*, 2006, 312:137-147.
- Longer, Mark A., Ph.D., "Sustained-Release Drug Delivery Systems," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 91, 1676-1693.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis," *Inter. J. of Pharm.*, 1994, 112:105-116.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment," *Inter. J. of Pharm.*, 1994, 112:117-124.
- Luszczki et al., "Interactions of Lamotrigine with Topiramate and First-Generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis," *Epilepsia*, 2003, 44(8):1003-1013.
- Mathew et al., "Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate," *Headache*, Sep. 2002, 42(8):796-803.
- McElroy et al., "Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A Randomized, Placebo-Controlled Trial," *Am. J. Psychiatry*, Feb. 2003, 160(2):255-261.
- Meador et al., "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers," *Neurology*, Jun. 2005, 64:2108-2114.
- Mikos et al., "Interaction of Polymer Microspheres with Mucin Gels as a Means of Characterizing Polymer Retention on Mucus," *Journal of Colloid and Interface Science*, May 1991, 143(2): 366-373.
- Morton et al., "Diagnosis and treatment of epilepsy in children and adolescents," *Drugs*, Mar. 1996, 51(3):399-414.
- Mosek et al., "Topiramate in the treatment of refractory chronic daily headache. An open trial," *Journal of Headache and Pain*, 2005, 6:77-80.
- O'Connor et al., "Powders," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 88, 1615-1632.
- Park et al., "Alternative Approaches to Oral Controlled Drug Delivery: Bioadhesives and In-Situ Systems," *Recent Advances in Drug Delivery*, Plenum Press, New York, 1984, 163-183.
- Pascual et al., "Testing the combination beta-blocker plus topiramate in refractory migraine," *Acta Neurol. Scand.*, 2007, 115(2):81-83.
- Physician's Desk Reference, 60th Edition, 2006, pp. 2438-2447, entry for TOPAMAX®.
- Physicians' Desk Reference 59th edition, 2541-2548 (2005).
- Physician's Desk Reference, 56th ed., 2590-2595 (2002).
- Pies, Ronald M.D., "Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review," *Annals of Clinical Psychiatry*, Dec. 2002, 14(4):223-232.
- Porter, Stuart C., Ph.D., "Coating of Pharmaceutical Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 90, 1666-1675.
- Potter et al., "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Determine the Efficacy of Topiramate in the Prophylactic Treatment of Migraine," *Neurology*, Apr. 2000, 54(Suppl 3):A15.
- Rudnic et al., "Oral Solid Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 89, 1633-1665.
- Silberstein et al., "Topiramate in Migraine Prevention," *Arch. Neurol.*, Apr. 2004, 61(4):490-495.
- Siniscalchi et al., "Combined topiramate and clonazepam therapy in a patient affected by essential tremor," *Parkinsonism Relat. Disord.*, 2007, 13(2):129-130.
- Smart et al., "An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery," *J. Pharm. Pharmacol.*, 1984, 36:295-299.
- Sofuoglu et al., "Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers," *Psychopharmacology*, 2006, 184(3-4): 645-651.
- Storey et al., "Topiramate in Migraine Prevention: A Double-Blind Placebo-Controlled Study," *Headache*, Nov./Dec. 2001, 41(10):968-975.
- Thompson et al., "Effects of topiramate on cognitive function," *J. Neurol. Neurosurg and Psych.*, 2000; 69:634-641.
- Toplak et al., "Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind placebo-controlled study," *Int. J. Obes.*, 2007, 31(1):138-146.
- Von Seggem et al., "Efficacy of Topiramate in Migraine Prophylaxis: A Retrospective Chart Analysis," *Neurology*, Apr. 2000, 54(Suppl 3):A267-A268.
- Weber, Marcus Vinicius Keche, M.D., "Topiramate for Obstructive Sleep Apnea and Snoring," *Am. J. Psychiatry*, May 2002, 159(5):872-873.
- Winkelman, John W., "Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate," *Sleep Medicine*, 2003, 4(3):243-246.

* cited by examiner

U.S. Patent

Oct. 30, 2012

Sheet 1 of 6

US 8,298,580 B2

Fig.1

80% release time vs. %Wt. gain of Release-Controlling Coating

For Surelease® coated Extended Release Beads





Fig. 2

80% release time vs. % Wt. gain of Release-Controlling Coating

For Surelease®/ Opadry® coated Extended Release Beads



U.S. Patent


Oct. 30, 2012

Sheet 3 of 6

US 8,298,580 B2

Fig. 3

Mean (n= 16) PK Profiles from Bead Populations XR1, XR2 and XR3



U.S. Patent


Oct. 30, 2012

Sheet 4 of 6

US 8,298,580 B2

Fig. 4

Mean (n= 16) PK Profiles from the Immediate Release Formulations



U.S. Patent

Oct. 30, 2012

Sheet 5 of 6

US 8,298,580 B2

Fig.5

Dissolution Profiles of Immediate Release Formulations





Fig. 6. Mean PK Profiles for Sustained Release Formulations A, B, and C



US 8,298,580 B2

1

**SUSTAINED-RELEASE FORMULATIONS OF
TOPIRAMATE****CROSS-REFERENCE TO RELATED
APPLICATIONS**

The present application is a Continuation of U.S. application Ser. No. 11/941,475, filed Nov. 16, 2007, which claims benefit of U.S. Provisional Application No. 60/859,502, filed Nov. 17, 2006, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Topiramate is a sulfamate substituted monosaccharide which under the trade name TOPAMAX® (Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J., U.S.A.) has been approved for use as an antiepileptic agent, as an adjuvant therapy for patients with partial onset seizures or primary generalized tonic-clonic seizures, and for the prevention of migraine. See generally, Physician's Desk Reference, 60th ed., 2538-2447 (2006); see also, U.S. Pat. No. 4,513,006.

For the treatment of epilepsy, the recommended dose of Topamax® is 400 mg/day in one or multiple doses (Physician's Desk Reference, 60th ed., 2538-2447 (2006)). For adults with epilepsy, treatment is initiated with a dose of 25-50 mg/day, with the dose being titrated in increments of 25-50 mg at weekly intervals to the recommended or effective dose.

Topamax® is an immediate release formulation. Adverse effects associated with the administration of Topamax® include, but are not limited to, somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, diplopia, renal calculi (kidney stones), hepatic failure, pancreatitis, renal tubular acidosis, acute myopia and secondary angle closure glaucoma (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Hence, though topiramate has a relatively long half-life of 21 hours in vivo, it has not been prescribed (or formulated) as a single, daily-dose, in part due to severe side-effects that often result with peak plasma levels of the drug when taken in high doses. Instead, Topamax® is typically taken in multiple, "divided" doses, usually twice-daily ("BID"). However, administration of the medicament in this manner is cumbersome and patients can forget to take their medication in a timely manner. What is more, each administration of a dose is associated with a peak in plasma concentrations of the drug, and the fluctuations associated with the peaks and valleys of blood plasma levels of the drug are undesirable. Therefore, there is a need for a formulation of topiramate, which reduces or eliminates the side effects associated with peaking and fluctuating plasma levels of the drug and preferably may be administered in a once-daily regimen.

New, highly soluble and bioavailable forms of topiramate are also needed in order to increase the safety and effectiveness of the drug.

The instant invention addresses these and other needs by providing a modified formulation of topiramate characterized by a sustained, non-pulsatile release of an active ingredient. This invention additionally provides an effective, once-daily dosage form of topiramate or salts thereof, which not only enables an effective single daily dose regimen to improve patient compliance but may also reduce some of the side

2

effects of topiramate compared to the current or higher daily doses of immediate release topiramate formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sustained release formulation of topiramate for the treatment or prevention of a pathological condition in a mammalian subject, characterized by a sustained rate of topiramate release along a pre-determined release profile.

It is yet another object of the present invention to provide topiramate formulation wherein topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect associated with the topiramate treatment.

It is a further object of the present invention to provide a sustained release formulation of topiramate that can be administered orally once a day.

It is an object of the present invention to provide a sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient, wherein the active ingredient is released from the formulation at a sustained rate along a pre-determined release profile, and wherein the sustained release formulation comprises an extended release (XR) component and an optional immediate release (IR) component.

In one embodiment of the invention, the extended release component is contained in at least one population of beads coated with a release controlling coating. The above-mentioned coating is specific for every bead population and determines its rate of release. Thus, every given bead population included into the formulation is characterized by its own specific rate of release.

In another embodiment of the invention, the sustained release topiramate formulation comprises an immediate release component in addition to an extended release component.

In a preferred embodiment of the invention, the immediate release component is an enhanced immediate release (EIR) composition.

The formulation of the present invention may be incorporated in any oral dosage form such as represented by, but not limited to, a tablet, a pill, a capsule, a troche, a sachet, and sprinkles.

It is yet another object of the present invention to provide a method of preparation of a sustained release formulation of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile, the method comprising the steps of:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method of preparation additionally includes a process for providing an XR component contained in at least one population of beads, wherein every population of beads is characterized by its own rate of release. This process comprises the steps of

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;

US 8,298,580 B2

3

3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and

4. incorporating the beads into the formulation.

The method may optionally include a process for preparation of an IR component, which optionally is an enhanced immediate release (EIR) composition. The enhanced immediate release composition includes at least one agent selected from a group comprising complexing agents and enhancing agents. Without any limitations, the enhancing agents useful in the present invention may be selected from solubilizing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors or combinations thereof.

It is yet another object of the present invention to provide a method of treatment or prevention of a pathological condition in a mammalian subject by orally administering to the subject a therapeutically effective amount of a sustained release topiramate formulation of the instant invention. The pathological conditions that may be treated by the method of the present invention include neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by topiramate administration.

DEFINITIONS

For the purposes of this invention, the term "topiramate" includes topiramate or any pharmaceutically acceptable salts thereof.

An "immediate release formulation" refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.

For the purposes of this application, an enhancing agent ("enhancer") is defined as any non-pharmaceutically active ingredient that improves the therapeutic potential of a formulation.

The term "enhanced immediate release composition" as used herein describes an immediate release composition improved in terms of a therapeutic potential or treatment modality.

"Sustained release" is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.

By "prolonged period of time" it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.

As used herein, unless otherwise noted, "rate of release" or "release rate" of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the "T.sub.x" value, where "x" is the percent of drug that has been released.

The release rates referred to herein are determined by placing a dosage form to be tested in a medium in an appropriate dissolution bath. Aliquots of the medium, collected at pre-set

4

intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.

"C" denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as "drug plasma concentration", "plasma drug concentration" or "plasma concentration" which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as C_{time}, as in C_{9 hr} or C_{4 hr}, etc.

The maximum plasma drug concentration during the dosing period is referenced as C_{max}, while C_{min} refers to the minimum blood plasma drug concentration at the end of a dosing interval; and C_{ave} refers to an average concentration during the dosing interval.

The "degree of fluctuation" is defined as a quotient (C_{max}-C_{min})/C_{ave}.

Persons of skill in the art will appreciate that blood plasma drug concentrations obtained in individual subjects will vary due to interpatient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a drug plasma concentration is listed, the value listed is the calculated mean value based on values obtained from a groups of subjects tested.

The term "bioavailability" refers to an extent to which—and sometimes rate at which—the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.

"AUC" is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.

Side effect is defined herein as a secondary and usually adverse effect of a drug.

The term "beads", as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease® coated extended release beads.

FIG. 2 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease®/Opadry® coated extended release beads.

FIG. 3 shows mean (n=16) pharmacokinetic profiles for bead populations XR1, XR2 and XR3.

FIG. 4 shows mean (n=16) pharmacokinetic profiles for the immediate release formulations.

FIG. 5 shows the dissolution profiles of Topamax®, topiramate IR beads, and topiramate enhanced immediate release beads.

FIG. 6 shows mean PK Profiles for Sustained Release Formulations A, B, and C.


DETAILED DESCRIPTION OF THE INVENTION

Topiramate is a sulfamate-substituted monosaccharide having the chemical name 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate. The molecular formula of

US 8,298,580 B2

5

topiramate is $C_{12}H_{21}NO_8S$, and its chemical structure is represented by formula below:



Topiramate is a white crystalline powder that is soluble in alkaline solutions containing sodium hydroxide or sodium phosphate, soluble in acetone, dimethylsulfoxide and ethanol. However, the solubility of topiramate in water at room temperature is only about 9.8 mg/ml. Topiramate is not extensively metabolized and is excreted largely through the urine (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Topiramate pharmacokinetics are linear, producing a dose proportional increase in blood plasma concentration levels with increased dosing, and is not significantly affected by food. Patients taking topiramate over prolonged period of time did not develop resistance to the drug. Following oral administration of an immediate release dosage form, topiramate is rapidly absorbed with plasma drug concentrations peaking in approximately 2 hours. The mean elimination half-life is reported to be about 21 hours.

Currently, topiramate is administered in multiple daily doses in part due to the severe side effects exhibited by the immediate release product, especially when taken in a high single dose.

A sustained release topiramate formulation that will be suitable for once-a-day administration and will result in the diminished level or severity of side effects is needed.

The present invention provides sustained release formulation of topiramate wherein the total daily dose of topiramate is provided in an effective once-daily dose while minimizing fluctuations in the blood plasma drug concentration.

The current invention also provides for formulations of topiramate wherein the maximum plasma concentration of topiramate is attenuated as compared to the same amount of topiramate administered as an immediate release formulation BID; therefore some of the side effects of topiramate, such as CNS side effects including but not limited to dizziness, paresthesia, nervousness, psychomotor slowing, confusion, and difficulty with concentration/attention, observed when taking the immediate release product, may be reduced or eliminated.

Formulations of the instant invention are characterized by a maximum steady state plasma concentration (C_{max}) of topiramate which is higher than the minimal therapeutically effective concentration, and is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. In one embodiment, the novel formulations provide for a relative C_{max} in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID. In the other embodiment, the invention provides for the C_{max} which is lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. The C_{min} of the topiramate formulation of the present invention is about equal or higher than a C_{min} of an equivalent amount of immediate release topiramate formulation given BID.

Compared to the immediate release topiramate formulation, the sustained release topiramate formulations attenuate the C_{max} of topiramate while extending the coverage of

6

plasma concentration above the minimum plasma concentration required therapeutic efficacy. The formulation of the current invention provides for a relative steady state AUC in the range of 80% to 125%, while minimizing the degree of fluctuation, which is preferably in the range of 25% to 90%, as compared to an equivalent amount of immediate release topiramate formulation given in two divided doses (Table 5 and 6).

The present invention additionally provides a sustained release topiramate formulation for the treatment or prevention of a pathological condition in a mammalian subject wherein topiramate is released from the formulation at a sustained rate along a pre-determined release profile. Such release is achieved by incorporation into the formulation of an extended release component (XR) and an optional immediate release component (IR).

The relative amount of each component in the topiramate formulation of the present invention is determined according to the purpose of administration and a pre-determined release profile, and the total amount of topiramate in the formulation varies from 0.5 mg to about 3000 mg. In other words, topiramate or its salt is present in the composition in an amount of from about 0.5% to about 85% by weight, and preferably of from about 2% to about 70% by weight. The term "about" has been recited here and throughout the specification to account for variations, which can arise from inaccuracies in measurement inherent and understood by those of ordinary skill in the chemical and pharmaceutical arts.

The XR component of the formulation of the present invention releases topiramate in a continuous manner and is adjusted in such a way that 80% of the active ingredient is released in vitro in the predetermined period of time. By way of example, and by no means limiting the scope of the invention, the period of time may be not more than 24 hours, not more than 16 hours, not more than 12 hours, not more than 8 hours, or not more than 4 hours, depending on desired attributes of the final product.

In one embodiment, the extended release (XR) component is contained in at least one population of beads coated with a coating that modifies and controls the release of topiramate from the beads (release controlling coating). The release controlling coating is specific for every population of beads and determines the rate of release of topiramate from the given bead population.

The beads useful in the formulation of the present invention comprise an inert carrier, topiramate, a binder, an aforementioned release controlling coating and optionally, an overcoat that provides additional protection from moisture, static charge reduction, taste masking and coloring attributes to the particulates.

The inert carriers useful in the present invention may be selected from, but are not limited to, a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres. The inert carrier is present in an amount of from about 15% to about 99% by weight, and preferably in an amount of from about 40% to about 97% by weight.

Topiramate is introduced to the inert carrier by techniques known to one skilled in the art, such as drug layering, powder coating, extrusion/spheronization, roller compaction or granulation. Preferably, the introduction method is drug layering by spraying a suspension of topiramate and a binder onto the inert carrier.

The binder may be present in the bead formulation in an amount of from about 0.1% to about 15% by weight, and preferably of from about 0.2% to about 10% by weight. Binders include, but are not limited, to starches, microcrs-

US 8,298,580 B2

7

talline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, or polyvinylpyrrolidone.

The release controlling coating specific for every bead population comprises a coating material, and, optionally, a pore former and other excipients. The coating material is preferably selected from a group comprising cellulosic polymers, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and cellulose acetate phthalate; polyvinyl alcohol; acrylic polymers such as polyacrylates, polymethacrylates and copolymers thereof, and other water-based or solvent-based coating materials. The release-controlling coating is population-specific in the sense that the rate of release of topiramate from every bead population is controlled by at least one parameter of the release controlling coating, such as the nature of the coating, coating level, type and concentration of a pore former, process parameters and combinations thereof. Thus, changing a parameter, such as a pore former concentration, or the conditions of the curing, as will be discussed in more details below, (see Example 5) allows to change the release of topiramate from any given bead population and to selectively adjust the formulation to the pre-determined release profile. The release profile, in its turn, may be chosen or modified in such a way as to achieve the best treatment modality depending on the specific needs of the patient population and the nature of the condition.

For example, with all things being equal, there exists a mathematical relationship between the release controlling coating level among the cured beads and the 80% *in vitro* release time. Pre-determined target profiles can therefore be achieved by the interpolation or extrapolation of the relationship curve. For example, when the release controlling coating comprises only ethylcellulose (Surelease®) as a coating material, a logarithmic relationship exists between the % weight gain with the coating and the 80% release time in an *in-vitro* dissolution test (FIG. 1):

$$\text{Log}(T_{80\% \text{ release}}) = a(\% \text{ coating}) + b.$$

When ethylcellulose/HPMC (Surelease®/Opadry®) mixture is used, for example, 85:15 mixture or 80:20 mixture, a linear relationship exists between the % weight gain with the coating and the 80% release time in an *in-vitro* dissolution test (FIG. 2):

$$T_{80\% \text{ release}} = a(\% \text{ coating}) + b.$$

Pore formers suitable for use in the release controlling coating herein can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, Carbowaxes, Carbopol, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like.

8

The release controlling coating in the current invention can further comprise other additives known in the art such as plasticizers, anti-adherents, glidants, and antifoams.

In some embodiments, it may be further desirable to optionally coat the XR beads with an "overcoat," to provide, e.g., moisture protection, static charge reduction, taste-masking, flavoring, coloring, and/or polish or other cosmetic appeal to the beads. Suitable coating materials for such an overcoat are known in the art, and include, but are not limited to, cellulosic polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and microcrystalline cellulose, or combinations thereof (for example various Opadry® coating materials).

Topiramate-containing beads of the present invention may additionally contain enhancers that may be exemplified by, but not limited to, solubility enhancers, dissolution enhancers, absorption enhancers, permeability enhancers, stabilizers, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, and multidrug resistance protein inhibitors. Alternatively, the formulation can also contain enhancers that are separated from the topiramate beads, for example in a separate population of beads or as a powder. In yet another embodiment, the enhancer(s) may be contained in a separate layer on a topiramate-containing bead either under or above the release controlling coating.

The beads may further comprise other pharmaceutically active agents suitable for use in combination with topiramate for treatment or prevention of a pathological condition. The additional pharmaceutically active agents, without limitation, may be represented by analgesic and anti-inflammatory compounds such as COX-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs such as opiates and morphinomimetics, synthetic drugs with narcotic properties such as tramadol; anticonvulsants such as valproic acid or its derivatives, carbamazepine, oxcarbazepine, gabapentin, and lamotrigine; anorectics or anti-obesity agents such as sibutramine or other, orlistat or other pancreatic lipase inhibitors, diethylpropion, fluoxetine, bupropion, amphetamine, methamphetamine, sertraline, zonisamide, and metformin, as well as medications associated with weight-gain, such as sulfonylurea derivatives, insulin, and thiazolidinediones whose weight-gain effect is tempered by topiramate; anti-hypertensive agents such as diuretics, anti-adrenergics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, vasodilators, centrally acting adrenergic drugs, and adrenergic neuron blockers; mood stabilizers such as various forms/salts of lithium, Omega-3 fatty acids and others known in the art, drugs for treatment or prevention of migraines, such as ergot derivatives or triptans, or any other pharmaceutical or nutraceutical ingredient that can be safely and beneficially combined with topiramate.

A relative amount of every bead population in the complete formulation is determined on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile and will be discussed in more detail in Example 6.

In another embodiment, the formulation of the present invention comprises an extended release component as described above, and an immediate release component. The IR component may be an enhanced immediate release composition. The enhanced immediate release composition may be characterized by a faster *in vitro* topiramate release as compared to the IR formulation. Preferably, at least 80% of an active compound from the enhanced immediate release composition is released in a time period of not more than 30 minutes. More preferably, at least 50% of an active compound from the enhanced immediate release composition is released

US 8,298,580 B2

9

in a time period of not more than 10 minutes, and at least 25% is dissolved in a time period of not more than 5 minutes after the oral administration. In the most preferred embodiment of the present invention, at least 75% of the active compound is released from the EIR composition in a time period of not more than 10 minutes. The embodiment in which the IR component is an enhanced immediate release composition will be discussed in more details below.

In addition to topiramate and inactive excipients, the EIR composition of the present invention comprises at least one agent selected from a group consisting of complexing agents and enhancing agents.

Without any limitation, the enhancing agents suitable for the present invention may be selected from the solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. The representative, but non-limiting examples of these compounds are Vitamin E TPGS, amino acid such as glutamic acid and glycine, sorbitol, mannose, amylose, maltose, manitol, lactose, sucrose, glucose, xylitol, dextrans such as maltodextrin, Cremophor RH40 (glycerol-polyethylene glycol oxystearate), Gelucire 50/13 (PEG-32 glyceryl palmitostearate), sodium lauryl sulfate, Tween 80 (polyoxyethylene sorbitan monooleate), benzyl alcohol, Span 20 (sorbitan monolaurate), Poloxamer 407, PEG3350, PVP K25, oleic acid, Capmul GMO (glyceryl monooleate), sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, crosscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose, sodium bicarbonate, calcium citrate, sodium docusate, and menthol, among others. Enhancers can be combined to achieve multiple enhancement effects, for example, solubility enhancement combined with permeability enhancement and p-glycoprotein inhibition, or to provide a synergistic enhancement effect to achieve greater and more efficient enhancement. For example, polyglycolized glycerides (different grades of Gelucire) can be combined with sodium lauryl sulfate to achieve higher solubility enhancement as well as faster dissolution of topiramate.

In one embodiment, the EIR composition comprises a highly soluble complex of topiramate with a complexing agent that is represented by, but not limited to, cyclodextrins, including cyclodextrin derivatives, such as hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and alpha-cyclodextrin. The ratio of cyclodextrin to topiramate in the EIR formulation is preferably less than 20:1 and more preferably less than 5:1. In the most preferred embodiment, the complexing agent is hydroxypropyl beta cyclodextrin.

The highly soluble complex of topiramate and cyclodextrin is prepared by mixing topiramate and cyclodextrin together in the presence of water. The concentration of cyclodextrin is preferably high to facilitate the formation of topiramate-enhancer complex. In the case when the complexing agent is hydroxypropyl-beta-cyclodextrin, the concentration of the hydroxypropyl-beta-cyclodextrin solution used for mixing with topiramate is greater than 2%, preferably greater than 20%, and more preferably at least about 40%. The amount of topiramate is determined by a desired ratio of hydroxypropyl-beta-cyclodextrin to topiramate, which is preferably less than 20:1, and more preferably less than 5:1. The mixing time of

10

the complex solution is from about one hour to about 48 hours, and preferably from about 5 hours to about 24 hours. The addition of hydroxypropyl-beta-cyclodextrin and topiramate can be incremental to reduce the viscosity of the complex solution and to achieve better complexation.

In a further embodiment, the EIR component of the present invention is contained in at least one bead population. Topiramate EIR beads can be prepared using processes suitable for bead manufacturing, such as coating of a topiramate suspension, dispersion or solution onto an inert carrier, or by roller compaction, granulation, extrusion/spheronization, or powder coating, and are not limited by the examples cited therein. The enhancing agents of the present invention can be incorporated into the topiramate containing beads, or may be contained in other beads separated from the topiramate containing beads. By way of a non-limiting example, topiramate-containing EIR beads were prepared by coating topiramate dispersion onto an inert carrier such as sugar spheres. The topiramate dispersion, in addition to topiramate in the micronized form or in non-micronized form, can contain one or more enhancers, water and optionally a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

When the formulation is enhanced with complexing agents, the agents may be first mixed with topiramate and a suitable solvent such as water to form the complex. The topiramate-containing complex is then mixed with a binder solution prepared separately to give the coating dispersion. The coating dispersion is then sprayed onto the inert carrier such as sugar spheres using a fluid bed processor.

In an alternative embodiment of the invention, the formulation comprises at least one XR bead population, and at least one additional combination bead population consisting of the extended release beads that have an additional immediate release component layer coated on top of the release controlling coating. This layer may be formed by a suitable loading method such as solution/suspension/dispersion coating, powder coating or wet granulation.

In yet another embodiment, at least part (i.e., more than 0.01%, preferably at least 1%) of the active ingredient may be present in the formulation in a form of micronized particles with the size of from 1 μ m to 1000 μ m, preferably from 2 μ m to about 200 μ m, more preferably from 2 μ m to about 100 μ m. Further, one or more enhancers may be present in the formulations covered by this embodiment. The enhancers are selected from solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. Preferably, the enhancer is a solubility enhancer or a dissolution enhancer.

The topiramate formulation of the present invention may be formulated in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, sprinkles, or any other form suitable for oral administration.

In one embodiment of the invention, the dosage form is a gelatin capsule containing the XR component in a form of at least one population of beads, and an optional IR component. The IR component, when present, may be in a form of a powder, or may also be contained in at least one population of beads to achieve faster dissolution of topiramate (FIG. 5).

In an alternative embodiment, part of the total amount of the active ingredient may be incorporated into the aforementioned bead populations that will be contained inside an

US 8,298,580 B2

11

enclosure such as a capsule, and the rest of the active ingredient can be loaded on the outside of the enclosure by a suitable loading method such as solution/suspension/dispersion coating or powder coating or wet granulation. For example, a part of the immediate release topiramate formulation can be loaded by coating on the outside of a capsule that contains within it other populations of topiramate such as extended release topiramate. This dosage form can provide almost instantaneous dissolution of the initial portion of topiramate dose from the outside of the capsule, followed by a sustained release of the rest of topiramate from inside the capsule.

In a further embodiment of the invention, the dosage form is a tablet. Without imposing any limitations, this embodiment may be exemplified by a multilayered tablet that comprises at least one layer containing the extended release component, and at least one layer comprising the immediate release component, wherein the IR component may or may not be an EIR composition.

The last two embodiments are especially beneficial when fast onset of action followed by sustained release is preferred, as is for example in the cases of a breakthrough migraine episode.

The current invention additionally encompasses a method of preparing formulations of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile. The method comprises the following steps:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method comprises a step for providing an immediate release component, which may be an enhanced immediate release composition.

In another embodiment, the method includes a process for providing an extended release component contained in at least one population of beads characterized by its own rate of release, wherein the process includes the steps of:

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The exact amount of beads of every population incorporated into the formulation and into the final dosage form is determined using the linear superposition principle (WinNonLin) on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile (Example 6).

Release profiles of XR topiramate beads can be selectively adjusted, modified or stabilized by curing the beads at an elevated temperature. This process is well known in the art. However, it was unexpectedly discovered that curing the beads in the curing apparatus in the presence of at least one suitable solvent dramatically reduces the curing time necessary to produce a desired release profile and a level of stability. The curing process that previously required up to two weeks can be carried out by the method of current invention in several hours.

12

The assisting solvents can be selected from those solvents that can dissolve or partially dissolve the coating material, or those that can induce or assist the coalescence or molecular relaxation of the coating material, or those that can reduce electrostatic charge on the dosage forms during curing and those that can facilitate curing at a higher temperature. Examples of these solvents include but are not limited to organic solvents, such as alcohols, ketones, ethers, esters, amides, amines, hydrocarbons including substituted hydrocarbons such as chlorinated hydrocarbons and aromatic hydrocarbons, furans, sulfoxides, organic acids, phenols, super-critical fluids; ammonia; and water, buffered water, or water solutions of other inorganic or organic compounds, and their combinations. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

The curing of the dosage form normally is done in an apparatus that can operate at elevated temperatures and that can deliver the assisting solvents by means such as spray, injection, or vaporization. In the embodiment of the invention when the assisting solvent is sprayed or injected into the curing apparatus, the stream of solvent is introduced directly onto the coated beads. The amount of the solvent necessary to produce the desired effect, such as the desired release parameters and stabilization of the coating, depends on the nature of the solvent and the method of solvent delivery.

Typically, when the vaporization method is used, the organic solvents and aqueous solutions may be used in the wide range of vapor concentrations varying from 2% to more than 100%, providing an unsaturated, saturated or an oversaturated atmosphere. The pure water, however, has to be used in such an amount as to provide at least a saturated or, preferably, an oversaturated atmosphere in the curing apparatus. At least during the delivery of assisting solvents, the coated beads are mixed or agitated either continuously or in a pulsed manner.

In an alternative embodiment of the invention, hot water steam is introduced into the curing apparatus for a pre-selected period of time. The steam serves simultaneously as a solvent and as a source of heat for the beads. Introduction of steam is followed by a drying period.

This method of curing the release controlling coating results in many benefits including the dramatically shortened curing time, increased stability and modification of the release profile, and is not limited to topiramate containing beads, but includes the curing of any microparticles regardless of the drug.

Specifically, active ingredient containing beads, with or without the optional over-coat, are charged to a fluid bed processor or a pan coater and heated to a desired curing temperature range, for example 40° C. to 80° C. for sustained release dosage forms containing ethylcellulose (Surelease®), and 40° C. to 70° C. for sustained release dosage forms containing acrylic polymers (Eudragit® RS and Eudragit® RL). The assisting solvent or solvents, such as water or alcohol-water mixture, are sprayed onto the beads while mixing by, for example, fluidizing or rotating. Alternatively, the process is carried out in an oven where hot steam is introduced as previously discussed. Solvent-assisted curing is carried out to a desired curing time length, either in one curing period or in multiple, separate curing periods. The dosage forms can be further dried for a short period of time to remove residual solvents.

The solvent-assisted curing process significantly accelerates the curing of release controlling coating on active ingredient containing beads as compared to the heat-only curing of

US 8,298,580 B2

13

the same. In most instances, less than 4 hours of solvent-assisted curing resulted in more complete curing of the extended release dosage forms than 2 weeks of heat-only oven curing of the same dosage forms.

The present invention also presents a method of treatment or prevention of a pathological condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a novel topiramate formulation of the instant invention, wherein topiramate is released from the formulation at a sustained rate along the pre-determined release profile. The method of the current invention possesses the flexibility to selectively adjust the pharmacokinetics of the administered formulations depending on the nature of the condition and needs of the patients due to the novel design of the topiramate formulation that comprises an extended release component and an optional immediate release component, and the release profiles of both components can be selectively modified during the preparation process as described above to comply with the predetermined release profile.

The pathological condition that may be treated by a method of the present invention is a neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by the topiramate administration.

The neurological disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to, epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, perinatal hypoxia ischemia and related damage, chronic neurodegenerative disorders, acute neurodegeneration, and ALS.

Psychiatric disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, ADHD, impulse control disorders, border line personality disorder, addiction, and autism.

Formulations of the present invention may be also used for the treatment and prevention of diabetes and related disorders, such as type II diabetes mellitus, diabetic retinopathy, impaired oral glucose tolerance, diabetic skin lesions, dia-

14

betic neuropathy; Syndrome X and elevated blood glucose levels; ocular disorders, including but not limited to glaucoma and macular degeneration; cardiovascular disorders represented but not limited to elevated blood pressure and elevated lipids; obesity; asthma; autoimmune disorders; sleep apnea and sleep disorders. The formulations may be also used for inducing weight loss or promoting wound healing, or for any other condition, not specified above, wherein the use of topiramate is indicated.

The invention will be further illustrated by the following Examples, however, without restricting its scope to these embodiments.

EXAMPLES

Example 1

Extended Release Beads Preparation

Topiramate Drug Layering on Sugar Spheres—the “Core”

An aqueous suspension of 10-20° A) (w/w) topiramate (particle size 90% vol. NMT 30 micrometer, 50% vol. NMT 15 micrometer and 10% vol. NMT 5 micrometer) and 0.5-4% (w/w) HPMC or other aqueous binder can be used as the drug layering coating solution. A fluid bed suited for Wurster-spray is assembled and charged with inert carriers such as sugar spheres. The coating suspension is sprayed onto the bed to evenly coat the inert carriers to a desired topiramate loading level. Higher binder concentration in the coating solution may be used for smaller size inert carrier and higher topiramate loading. Inlet airflow rate and product temperature are adjusted to keep the batch from spray-drying the coating material or over-wetting the spheres.

Coating of the Core with a Release Controlling Coating

A dispersion of a cellulosic polymer such as ethylcellulose and methylcellulose can be used to coat the core in the current invention. Ethylcellulose dispersion (Surelease®) can be diluted to a final concentration of about 10% to about 20% and with or without the use of other ingredients such as pore formers. A fluid bed suited for Wurster-spray is assembled and charged with the cores prepared in Example 1. The release controlling coating dispersion is sprayed onto the bed to evenly coat the core to a desired coating level as exemplified in Table 1.

TABLE 1

[illegible]

US 8,298,580 B2

15

16

TABLE 1-continued

Composition and process Parameters for the extended Release						
	oven	oven	oven	oven	oven	oven
Topiramate Beads						
	XR3	XR4	XR5	XR6	XR7	XR8
RC coating material	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Acrylic polymers (Eudragit ® RL30D/RS30D)
Pore-former	—	Cellulosic polymers (Opadry ® Clear)	Cellulosic polymers (Opadry ® Clear)	Cellulosic polymers (Opadry ® Clear)	Cellulosic polymers (Opadry ® Clear)	—
RC coating material to pore-former ratio	—	80:20	80:20	80:20	85:15	—
RC coating level	3.7%	3.1%	5.2%	9.5%	15%	15%
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.
Over-coat material	—	—	—	—	—	—
Over-coat coating level	—	—	—	—	—	—
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, fluid bed/5% alcohol-water, or oven	Fluid bed/ water, fluid bed/5% alcohol-water, or oven

*RC—Release Controlling

Example 2

Method of
Topiramate-Hydroxypropyl-Beta-Cyclodextrin
Complex Bead Preparation

Approximately half of the intended amount of topiramate was added to the water with constant mixing followed by sprinkling of hydroxypropyl-beta-cyclodextrin into the dispersion. Once the dispersion became significantly less vis-
cous, more drug substance was added followed by sprinkling

of more hydroxypropyl-beta-cyclodextrin. The drug and hydroxypropyl-beta-cyclodextrin addition steps were repeated, and the dispersion was mixed for 12-18 hours. Separately, hydroxypropylmethylcellulose was dissolved in water. The above topiramate-hydroxypropyl-beta-cyclodextrin dispersion and hydroxypropylmethylcellulose solution were mixed together for 15 to 30 minutes and the mixture was screened through an 80-mesh sieve. The resultant dispersion was sprayed onto sugar spheres using a fluid bed processor to yield the enhanced immediate release beads (Table 2).

TABLE 2

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions				
Component	Percentage (w/w) in Beads			
	EIR-1	EIR-2	EIR-3	EIR-4
	(HPBCD:Drug = 3:2)*	(HPBCD:Drug = 3:2)*	(HPBCD:Drug = 1:1)*	(HPBCD:Drug = 1:2)*
Topiramate	25.0	3.3	28.9	33.3
Hydroxypropyl-beta-cyclodextrin	37.5	4.95	28.9	16.7
Hydroxypropylmethylcellulose	3.1	0.41	2.4	4.2
Sugar spheres	34.4	91.34	39.8	45.8

*HPBCD:Drug—Hydroxypropyl-beta-cyclodextrin to drug substance ratio

US 8,298,580 B2

17

Example 3

Topiramate EIR Beads Containing Non-Complexing Enhancers

Topiramate is dispersed in a binder solution, such as hydroxypropylmethylcellulose solution, that contains an appropriate amount of enhancer or enhancers such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) and sodium lauryl sulfate combination, polyoxyl hydrogenated castor oil (different grades of Cremophor RH), polyglycolized glycerides (different grades of Gelucire), polyglycolized glycerides (different grades of Gelucire) combined with sodium lauryl sulfate, or combinations thereof. The resultant dispersion is sprayed onto an inert carrier such as sugar spheres using a fluid bed processor to achieve a desired drug load (Table 3).

TABLE 3

Enhanced Immediate Release Topiramate Bead Compositions			
Component	Percentage (w/w) in Beads		
	EIR-5	EIR-6	EIR-7
Topiramate	36.8	37.9	36.4
Sodium lauryl sulfate	0.7	0.5	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	7.3	—	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	9.1
Polyglycolized glycerides (Gelucire 50/13)	—	4.7	—
Hydroxypropylmethylcellulose	4.6	4.8	4.5
Sugar spheres	50.6	52.1	50.0

Example 4

Topiramate EIR Beads Containing Micronized Particles

Miconized or non-micronized topiramate is dispersed in a solution with or without heating, optionally containing dissolution enhancing agents such as mannose, maltose, mannitol, lactose, maltodextrin and sodium starch glucolate, and optionally containing one or more additional enhancers such as PEG3350, sodium lauryl sulfate, sodium docusate, polyoxyethylene sorbitan monooleate and Poloxamers, under such process parameters that topiramate particles that remain undissolved have a particle size of about 2 micron to about 30 micron. A particle size reduction device such as a homogenizer can also be used to reduce the particle size of undissolved topiramate. The resultant topiramate dispersion is then sprayed onto inert carriers such as sugar spheres in a coating processor such as a fluid bed processor. The formulations obtained are represented in the Table 4:

TABLE 4

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Topiramate	3.2	26.0	25.0	3.2	26.0	26.0
Mannose	0.4	5.0	3.3	2.0	10.0	10.0

18

TABLE 4-continued

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Maltrin 250	—	—	1.0	1.0	—	—
PEG3350	1.0	15.0	—	—	—	10.0
Sodium lauryl sulfate	—	—	—	—	0.5	—
Hydroxypropyl-beta-cyclodextrin	—	—	37.5	—	—	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	—	—	—	—	2.0	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	—	—	—	2.0
Sugar spheres	95.4	54.0	33.2	93.8	61.5	52.0

Example 5

Method of Curing Beads

The topiramate beads coated with a release controlling coating, with or without an overcoat, can be cured using the above-mentioned solvent-assisted curing process, or using the heat-only curing process, to a desired curing level and preferably to complete curing.

Specifically, the core is coated to a desired coating level with a solution or dispersion of the release controlling coating material, with or without the above-mentioned additives such as pore-formers, using a fluid bed processor or any other suitable apparatus for coating of the core. Product temperature is controlled at a desirable range, for example 20° C. to 60° C. for the coating of ethylcellulose (Surelease®) and 20° C. to 60° C. for acrylic polymers (Eudragit® RL and Eudragit® RS grades). An optional overcoat with materials such as cellulosic polymers (various Opadry®) is applied thereafter. Curing of the sustained release topiramate beads is carried out either in an oven at 40° C. to 80° C. for Surelease® containing beads or at 40° C. to 70° C. for Eudragit® RL or RS containing beads, or in a fluid bed processor with or without the use of assisting solvents at similar product temperatures.

For curing that uses assisting solvents, the assisting solvent can be delivered through top spray, bottom spray, side spray or injection, or introduced by vaporization. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

Example 6

Sustained Release Formulations of Topiramate

a. Plasma concentration versus time curves for the topiramate formulations containing extended release and immediate release bead populations are simulated using WinNonlin Version 5.0.1 based on the pharmacokinetic data on the separate bead populations that were generated in a comparative randomized single-dose 6-way crossover study in healthy adult volunteers. The study included administration of a 50 mg oral dose of three extended release compositions, designated here as XR1, XR2 and XR3, two immediate release

US 8,298,580 B2

19

compositions ((Topamax®, Ortho-McNeil Neurologics, Inc.) (25 mg BID), and an immediate release bead formulation) and an enhanced immediate release (IR) bead composition. The single dose topiramate plasma concentration profiles for XR1, XR2 and XR3 are shown in FIG. 3. The single dose topiramate plasma concentration profiles for IR are shown in FIG. 4. The data are projected to a steady-state (SS) with a 24 h dosing interval for the sustained release compositions and a 12 h dosing interval for Topamax, using the linear superposition principle (WinNonlin). The extended release populations XR1, XR2 and XR3, and an immediate release (IR) population are selected in such a way as to be defined by at least one of the three following sets of conditions:

1. for the steady state,
for XR1, $1.70C_{maxIR} \geq C_{maxXR1} \geq 1.30C_{maxIR}$
for XR2, $0.40C_{maxIR} \geq C_{maxXR2} \geq 0.20C_{maxIR}$
for XR3, $0.25C_{maxIR} \geq C_{maxXR3} \geq 0.05C_{maxIR}$
2. for in-vitro dissolution,
for XR1, $1.5 \text{ h} \leq T_{80\%} \leq 4 \text{ h}$
for XR2, $5 \text{ h} \leq T_{80\%} \leq 8 \text{ h}$
for XR3, $8 \text{ h} \leq T_{80\%} \leq 10 \text{ h}$
3. for a single initial dose in-vivo,
for XR1, $4 \text{ h} \leq T_{max} \leq 8.5 \text{ h}$
for XR2, $T_{max} \geq 16 \text{ h}$
for XR3, $T_{max} \geq 16 \text{ h}$.

Optionally, the immediate release bead population is composed of enhanced immediate release (EIR) beads such that at least one condition is true: a. for the steady state, $2.40C_{maxIR} \geq C_{maxEIR} \geq 1.20C_{maxIR}$; b. for in-vitro dissolution, $T_{80\%} \leq 30 \text{ min}$; c. for a single initial dose in-vivo, $T_{max} \leq 2 \text{ h}$.

The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 5 below. These formulations are selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.

TABLE 5

Composition and Pharmacokinetic data of Multi-bead Formulations							
	#1	#2	#3	#4	#5	#6	#7
% XR1	20	50	0	10	10	15	0
% XR2	80	0	85	85	80	70	100
% XR3	0	50	0	0		15	0
% IR	0	0	15	5	10	0	0
Rel. BA (%), SS	98.5	100.5	96.6	97.4	97.6	97.3	96.0
Degree of fluctuation, SS	0.15	0.22	0.14	0.14	0.15	0.13	0.09

b. Based on the results of WinNonlin simulation discussed in part (a), formulations #1 (A), #3 (B), and #4 (C) were tested in the comparative randomized multi-dose 4-way study following a once a day 50 mg oral dose of three controlled release formulations and a 25 mg twice a day oral doses of Topamax® in healthy adult volunteers.

The results of the study are summarized in Table 6 and FIG. 6:

TABLE 6

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (Topamax®)
% XR1	20	0	10	—
% XR2	80	86	84	—

20

TABLE 6-continued

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (Topamax®)
% XR3	0	0	0	—
% IR	0	14	6	—
Rel. BA (%), SS	92	93	95	100
Relative Degree of fluctuation, SS	73%	72%	66%	100%

What is claimed is:

1. A sustained release formulation of topiramate comprising topiramate as an active ingredient, which is released from the formulation along a pre-determined release profile, the formulation comprising:

(a) at least two different extended release topiramate-containing components, wherein each component comprises a release controlling coating specific for its component and comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,

(b) an immediate release (IR) topiramate-containing component comprising:

- (i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or
- (ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, croscopolidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof;

wherein all of the components release topiramate in a continuous manner and at least one of the two XR components releases the topiramate contained therein such that greater than or equal to about 80% of the topiramate is released in vitro in less than or equal to about 4 hours.

2. The formulation of claim 1, wherein the IR component exhibits a release profile such that 80% of the active ingredient is dissolved in not more than 1 hour.

3. The formulation according to claim 1, wherein at least one of the two XR components further comprises a binder selected from the group consisting of starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

4. The formulation according to claim 1, wherein at least one of the two XR components further comprises a pore former selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dext-

US 8,298,580 B2

21

ran, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomer, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; alkali metal salts and alkaline earth metal salts, and combinations thereof.

5 The formulation of claim 1, wherein at least a part of the active ingredient is in a form of micronized particles.

10 The formulation of claim 1, wherein the formulation is in a dosage form of a tablet, a pill, a capsule, a caplet, a troche, a pouch, or sprinkles.

15 The formulation of claim 1, wherein the total amount of topiramate in the formulation is from 0.5 to 3000 mg.

20 The formulation of claim 1, wherein at least one of the two XR components comprises an inert carrier selected from the group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres.

25 The formulation of claim 1, wherein the release controlling coating comprises ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates or copolymers thereof.

30 The formulation of claim 1, wherein the formulation provides for a maximum steady state plasma concentration (C_{max}) of topiramate which is in the range from 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

35 The formulation of claim 1, wherein the formulation provides for a relative steady state AUC in the range of 80% to 125% of the AUC of the same amount of topiramate administered as an immediate release formulation BID.

40 The formulation of claim 1, further comprising an additional pharmaceutically active ingredient in combination with topiramate.

45 13. A method of treatment of a neurological and/or psychiatric condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a sustained release formulation of topiramate according to claim 1.

50 14. The method of claim 13, wherein said condition is selected from a group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), impulse control disorders, borderline personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, amyotrophic lateral sclerosis (ALS).

55 15. The method of claim 14, wherein the condition is epilepsy.

16. The method of claim 14, wherein the condition is migraine.

60 17. A sustained release formulation of topiramate comprising topiramate as an active ingredient, which is released from the formulation along a pre-determined release profile, the formulation comprising:

(a) at least two different extended release topiramate-containing components, wherein each component comprises a release controlling coating specific for its component and comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,

22

(b) an immediate release (IR) topiramate-containing component comprising:

(i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or

(ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrins, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof;

wherein all of the components release topiramate in a continuous manner and at least one of the two XR components releases the topiramate contained therein such that greater than or equal to about 80% of the topiramate is released in vitro in less than or equal to about 4 hours, and wherein the components in the formulation are present according to the following proportions:

	F. No.				
	1	2	3	4	5
% XR1	20	50	10	10	15
% XR2	80	0	84	80	70
% XR3	0	50	0	0	15
% IR	0	0	6	10	0

wherein XR1, XR2, XR3, and IR release topiramate in a continuous manner such that:

1. for in-vitro dissolution,
for XR1, $1.5 \text{ h} \leq T_{80\%} \leq 4 \text{ h}$;
for XR2, $5 \text{ h} \leq T_{80\%} \leq 8 \text{ h}$;
for XR3, $8 \text{ h} \leq T_{80\%} \leq 10 \text{ h}$;
for IR, $T_{80\%} \leq 1 \text{ h}$; and/or

2. for a single initial dose in vivo,
for XR1, $4 \text{ h} \leq T_{max} \leq 8.5 \text{ h}$;
for XR2, $T_{max} \geq 16 \text{ h}$;
for XR3, $T_{max} \geq 16 \text{ h}$.

18. The formulation of claim 17, wherein the IR component exhibits:

a. for in-vitro dissolution, $T_{80\%} \leq 30 \text{ min}$; and/or
b. for a single initial dose in vivo, $T_{max} \leq 2 \text{ h}$.

19. The formulation according to claim 17, wherein at least one of the two XR components further comprises a binder selected from the group consisting of starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

20. The formulation according to claim 17, wherein at least one of the two XR components further comprises a pore former selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dext-

US 8,298,580 B2

23

ran, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomer, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α - β)alkylenediols; alkali metal salts and alkaline earth metal salts, and combinations thereof.

21. The formulation of claim 17, wherein at least a part of the active ingredient is in a form of micronized particles.

22. The formulation of claim 17, wherein the formulation is in a dosage form of a tablet, a pill, a capsule, a caplet, a troche, a pouch, or sprinkles.

23. The formulation of claim 17, wherein the total amount of topiramate in the formulation is from 0.5 to 3000 mg.

24. The formulation of claim 17, wherein at least one of the two XR components comprises an inert carrier selected from the group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres.

25. The formulation of claim 17, wherein the formulation provides for a maximum steady state plasma concentration (C_{max}) of topiramate which is in the range from 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

26. The formulation of claim 17, wherein the formulation provides for a relative steady state AUC in the range of 80%

24

to 125% of the AUC of the same amount of topiramate administered as an immediate release formulation BID.

27. The formulation of claim 17, further comprising an additional pharmaceutically active ingredient in combination with topiramate.

28. A method of treatment of a neurological and/or psychiatric condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a sustained release formulation of topiramate according to claim 17.

29. The method of claim 28, wherein said condition is selected from a group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, ADHD, impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, ALS.

30. The method of claim 29, wherein the condition is epilepsy.

31. The method of claim 29, wherein the condition is migraine.

* * * * *

Exhibit C



US008663683B2

(12) **United States Patent**
Liang et al.

(10) **Patent No.:** **US 8,663,683 B2**

(45) **Date of Patent:** ***Mar. 4, 2014**

(54) **SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE**

(75) Inventors: **Likan Liang**, Boyds, MD (US); **Hua Wang**, Clarksville, MD (US); **Padmanabh P. Bhatt**, Rockville, MD (US); **Michael L. Vieira**, Gaithersburg, MD (US)

(73) Assignee: **Supernus Pharmaceuticals, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/595,103**

(22) Filed: **Aug. 27, 2012**

(65) **Prior Publication Data**

US 2012/0321708 A1 Dec. 20, 2012

Related U.S. Application Data

(63) Continuation of application No. 11/941,475, filed on Nov. 16, 2007, now Pat. No. 8,298,576.

(60) Provisional application No. 60/859,502, filed on Nov. 17, 2006.

(51) Int. Cl.

A61K 31/35 (2006.01)

A61K 9/24 (2006.01)

A61K 9/54 (2006.01)

A61P 3/10 (2006.01)

A61P 25/02 (2006.01)

A61P 25/06 (2006.01)

(52) U.S. Cl.

USPC **424/458**; 424/472; 424/490; 424/493; 424/494; 424/497; 514/454

(58) Field of Classification Search

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

2,528,378 A 10/1950 Mannheimer et al.
2,675,619 A 4/1954 Cone
2,677,700 A 5/1954 Jackson et al.
2,781,354 A 2/1957 Mannheimer et al.
2,979,578 A 4/1961 Curtis
2,996,431 A 8/1961 Barry
3,036,118 A 5/1962 Jackson et al.
3,139,383 A 6/1964 Neville et al.
3,535,307 A 10/1970 Moss et al.
3,811,444 A 5/1974 Heller et al.
3,829,506 A 8/1974 Schmolka et al.
3,962,414 A 6/1976 Michaels
3,992,518 A 11/1976 Chien et al.
4,066,747 A 1/1978 Capozza
4,070,347 A 1/1978 Schmitt
4,079,038 A 3/1978 Choi et al.

4,083,949 A 4/1978 Benedikt
4,093,709 A 6/1978 Choi et al.
4,290,426 A 9/1981 Luschen et al.
4,434,153 A 2/1984 Urquhart et al.
4,513,006 A 4/1985 Maryanoff et al.
4,721,613 A 1/1988 Urquhart et al.
4,727,064 A 2/1988 Pitha
4,752,470 A 6/1988 Mehta
4,757,128 A 7/1988 Domb et al.
4,853,229 A 8/1989 Theeuwes
4,938,763 A 7/1990 Dunn et al.
4,997,904 A 3/1991 Domb
5,030,447 A 7/1991 Joshi et al.
5,175,235 A 12/1992 Domb et al.
5,180,589 A 1/1993 Joshi et al.
5,225,202 A 7/1993 Hodges et al.
5,256,440 A 10/1993 Appel et al.
5,378,475 A 1/1995 Smith et al.
5,478,577 A 12/1995 Sackler et al.
5,500,227 A 3/1996 Oschlack et al.
5,576,311 A 11/1996 Guy
5,753,693 A 5/1998 Shank
5,760,007 A 6/1998 Shank et al.
5,773,019 A 6/1998 Ashton et al.
5,935,933 A 8/1999 Shank et al.
5,955,096 A 9/1999 Santos et al.
5,985,312 A 11/1999 Jacob et al.
5,998,380 A 12/1999 Ehrenberg et al.
6,123,965 A 9/2000 Jacob et al.
6,156,348 A 12/2000 Santos et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1130352 A 9/1996
WO WO 93/21906 A1 11/1993

(Continued)

OTHER PUBLICATIONS

Adin et al., "Topiramate Serum Concentration-to-Dose Ratio," Therapeutic Drug Monitoring, Jun. 2004; 26(3):251-257.

Bahk et al., "Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study," Progress in Neuropsychopharmacology & Biological Psychiatry, 2005, 29(1):115-121.

Baumanoir, Anne, "The Landau-Kleffner syndrome", In: Roger et al., Eds. *Epileptic Syndromes in Infancy, Childhood, and Adolescence*, 2nd Ed., London, England: John Libby, pp. 231-244, 1992.

Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., Jan. 1977, 66(1): 1-19.

(Continued)

Primary Examiner — Suzanne Ziska

(74) Attorney, Agent, or Firm — Foley & Lardner LLP; Stephen B. Maebius; Sunit Talapatra

(57) ABSTRACT

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

24 Claims, 6 Drawing Sheets

US 8,663,683 B2

Page 2

(56)

References Cited

U.S. PATENT DOCUMENTS

6,191,117 B1 2/2001 Kozachuk
 6,197,346 B1 3/2001 Mathiowitz et al.
 6,201,010 B1 3/2001 Cottrell
 6,217,908 B1 4/2001 Mathiowitz et al.
 6,235,311 B1 5/2001 Ullah et al.
 6,248,363 B1 6/2001 Patel et al.
 6,294,192 B1 9/2001 Patel et al.
 6,319,903 B1 11/2001 Carrazana et al.
 6,365,187 B2 4/2002 Mathiowitz et al.
 6,368,586 B1 4/2002 Jacob et al.
 6,479,467 B1 11/2002 Buchanan et al.
 6,503,884 B1 1/2003 Ehrenberg et al.
 6,514,531 B1 2/2003 Alaux et al.
 6,524,620 B2 2/2003 Chen et al.
 6,559,293 B1 5/2003 Almarsson et al.
 6,562,865 B1 5/2003 Codd et al.
 6,569,463 B2 5/2003 Patel et al.
 6,696,091 B2 2/2004 Thakur et al.
 6,699,840 B2 3/2004 Almarsson et al.
 6,797,283 B1 9/2004 Edgren et al.
 6,923,988 B2 8/2005 Patel et al.
 7,018,609 B2 3/2006 Hwang Pun et al.
 7,195,778 B2 3/2007 Fleshner-Barak et al.
 7,611,722 B2 11/2009 Lerner et al.
 7,763,635 B2 7/2010 Kidane et al.
 2002/0044962 A1 4/2002 Cherukuri et al.
 2002/0054907 A1 5/2002 Devane et al.
 2002/0064563 A1 5/2002 Thakur et al.
 2002/0150616 A1 10/2002 Vandecruys
 2003/0017972 A1 1/2003 Pun et al.
 2003/0064097 A1 4/2003 Patel et al.
 2003/0072802 A1 4/2003 Cutler
 2003/0091630 A1 5/2003 Louie-Helm et al.
 2003/0133985 A1 7/2003 Louie-Helm et al.
 2003/0147952 A1 8/2003 Lim et al.
 2003/0157173 A1 8/2003 Percel et al.
 2003/0166581 A1 9/2003 Almarsson et al.
 2003/0215496 A1 11/2003 Patel et al.
 2003/0225002 A1 12/2003 Livingstone
 2004/0002462 A1 1/2004 Najarian
 2004/0022844 A1 2/2004 Hasenzahl et al.
 2004/0028735 A1 2/2004 Kositprapa
 2004/0052843 A1 3/2004 Lerner et al.
 2004/0053853 A1 3/2004 Almarsson et al.
 2004/0082519 A1 4/2004 Hedner et al.
 2004/0091529 A1 5/2004 Edgren et al.
 2004/0096501 A1 5/2004 Vaya et al.
 2004/0109894 A1 6/2004 Shefer et al.
 2004/0115262 A1 6/2004 Jao et al.
 2004/0122104 A1 6/2004 Hirsh et al.
 2004/0132826 A1 7/2004 Hirsh et al.
 2004/0156901 A1 8/2004 Thakur et al.
 2004/0157785 A1 8/2004 Connor
 2004/0185097 A1 9/2004 Kannan et al.
 2004/0234601 A1 11/2004 Legrand et al.
 2004/0258758 A1 12/2004 Gustow et al.
 2005/0053653 A1 3/2005 Kidane et al.
 2005/0058707 A1 3/2005 Reyes et al.
 2005/0069587 A1 3/2005 Modi et al.
 2005/0106242 A1 5/2005 Yan et al.
 2005/0106247 A1 5/2005 Venkatesh et al.
 2005/0129765 A1 6/2005 Li et al.
 2005/0136108 A1 6/2005 Yam et al.
 2005/0169982 A1 8/2005 Almarssoo et al.
 2005/0169992 A1 8/2005 Jao et al.
 2005/0175697 A1 8/2005 Edgren et al.
 2005/0191343 A1 9/2005 Liang
 2005/0220596 A1 10/2005 Gaedy et al.
 2006/0018933 A1 1/2006 Vaya et al.
 2006/0018934 A1 1/2006 Vaya et al.
 2006/0024365 A1 2/2006 Vaya et al.
 2006/0034927 A1 2/2006 Casadevall et al.
 2006/0105045 A1 5/2006 Buchanan et al.
 2006/0121112 A1 6/2006 Jenkins et al.
 2006/0223762 A1 10/2006 Ehrenberg et al.

2006/0233892 A1 10/2006 Hendrix
 2007/0212411 A1 9/2007 Fawzy et al.
 2008/0085306 A1 4/2008 Nangia et al.
 2008/0131501 A1 6/2008 Liang et al.
 2011/0287099 A1 11/2011 Liang et al.
 2011/0287103 A1 11/2011 Liang et al.

FOREIGN PATENT DOCUMENTS

WO WO 01/37808 A1 5/2001
 WO WO 02/03984 A2 1/2002
 WO WO 02/43731 A3 6/2002
 WO WO 2004/022037 A1 3/2004
 WO WO 2004078162 A1 9/2004
 WO WO 2004078163 A2 9/2004
 WO WO 2005/030166 A1 4/2005
 WO WO 2005/079748 A2 9/2005
 WO WO 2006/009403 A1 1/2006
 WO WO 2006/119153 A2 11/2006
 WO WO 2007/002318 1/2007

OTHER PUBLICATIONS

Berlant, Jeffery L., M.D., Ph.D., "Topiramate in Posttraumatic Stress Disorder: Preliminary Clinical Observations," J. Clin. Psychiatry, 2001, 62(Suppl 17):60-63.
 Brandes et al., "Topiramate for Migraine Prevention," JAMA, Feb. 25, 2004, 291(8):965-973.
 Carpenter et al., "Do obese depressed patients respond to topiramate? A retrospective chart review," J. Affect. Disord., 2002, 69(1-3):251-255.
 Chen et al., "Combination Treatment of Clozapine and Topiramate in Resistant Rapid-Cycling Bipolar Disorder," Clin. Neuropharmacol., May-Jun. 2005, 28(3):136-138.
 Coleman et al., "Polymer reviewed: A practical guide to polymer miscibility," Jul. 1990, 31:1187-1230.
 Contin et al., "Topiramate Therapeutic Monitoring in Patients with Epilepsy: Effect of Concomitant Antiepileptic Drugs," Ther. Drug Monit., 2002, 24(3):332-337.
 D'Amico et al., "Topiramate in migraine prophylaxis," Neurological Sciences, 2005, 26(Suppl 2):S130-S133.
 Deckers et al., "Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed," Epilepsia, 2000, 41(11):1364-1374.
 Diener et al., "Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control," J. Neurol., 2004, 251(8):943-950.
 Dorado et al., "Topiramato en enfermedades comorbidas: epilepsia y migraña," Rev. Neurol., 2006, 43(4):193-196.
 Duchene et al., "Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration," Drug Dev. Ind. Pharm., 1988, 14(2&3):283-318.
 Erfurth et al., "Bupropion as Add-On Strategy in Difficult-to-Treat Bipolar Depressive Patients," Neuropsychobiology, 2002, 45(Suppl 1):33-36.
 Felmeister, Alvin Ph.D., "Powders," Remington's Pharm. Sci., 14th Ed., 1970, Chapter 86, 1626-1628.
 Ferrari et al., "Influence of Dosage, Age, and Co-Medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response," Therapeutic Drug Monitoring, 2003, 25(6):700-708.
 Ferrari et al., "Rizatriptan: a new milestone in migraine treatment," Cephalalgia, 2000, 20(Suppl 1):1.
 Fincher, Julian H., "Particle Size of Drugs and Its Relationship to Absorption and Activity," J. Pharm. Sci., Nov. 1968, 57(11):1825-1835.
 Fisher et al., "Synergism between Topiramate and Budipine in Refractory Status Epilepticus in the Rat," Epilepsia, 2004, 45(11):1300-1307.
 François et al., "The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy," Epilepsy Research, 2006, 72:147-163.

US 8,663,683 B2

Page 3

(56)

References Cited

OTHER PUBLICATIONS

- Gurny et al., "Bioadhesive intraoral release systems: design, testing and analysis," *Biomaterials*, Nov. 1984, 5:336-340.
- Hershey et al., "Effectiveness of Topiramate in the Prevention of Childhood Headaches," *Headache*, Sep. 2002;42(8):810-818.
- Hoes et al., "The Application of Drug-Polymer Conjugates in Chemotherapy," *Drug Carrier Systems*, 1989, 9:57-109.
- Hollander et al., "Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder," *Int. Clin. Psychopharmacol.*, 2006, 21(3): 189-191.
- International Search Report and Written Opinion mailed Sep. 2, 2008, in PCT/US2007/19208, 10 pages.
- Ioannides-Demos et al., "Pharmacotherapy for Obesity," *Drugs*, 2005, 65(10):1391-1418.
- Johnson et al., "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial," *The Lancet*, May 17, 2003, 361(9370):1677-1685.
- Kellett et al., "Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic," *J. Neurol. Neurosurg. and Psych.*, 1999;66:759-763.
- Lainez et al., "Topiramate in the Prophylactic Treatment of Cluster Headache," *Headache*, Jul./Aug. 2003, 43(7):784-789.
- Lalonde et al., "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese *ob/ob* mice," *Physiology & Behavior*, 2004, 80(4):415-420.
- Lee et al., "The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy," *Epilepsia*, 2003; 44(3):339-347.
- Lehr et al., "Intestinal Transit of Bioadhesive Microspheres in an in situ Loop in the Rat—A Comparative Study with Copolymers and Blends Based on Poly(acrylic acid)," *Journal of Controlled Release*, 1990, 13:51-62.
- Leong et al., "Polymeric controlled drug delivery," *Adv. Drug Delivery Rev.*, 1987, 1:199-233.
- Linhardt, Robert J., "Biodegradable Polymers for Controlled Release of Drugs," *Controlled Release of Drugs*, 1989, Chapter 2, 53-95.
- Liu et al., "Preparation, characterization and in vivo evaluation of formulation of baicalin with hydroxypropyl-beta-cyclodextrin," *International Journal of Pharmaceutics*, 2006, 312:137-147.
- Longer, Mark A., Ph.D., "Sustained-Release Drug Delivery Systems," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 91, 1676-1693.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis," *Inter. J. of Pharm.*, 1994, 112:105-116.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment," *Inter. J. of Pharm.*, 1994, 112:117-124.
- Luszczki et al., "Interactions of Lamotrigine with Topiramate and First-Generation Antiepileptic Drugs in the Maximal Electroschock Test in Mice: An Isobolographic Analysis," *Epilepsia*, 2003, 44(8):1003-1013.
- Mathew et al., "Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate," *Headache*, Sep. 2002, 42(8):796-803.
- McElroy et al., "Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A Randomized, Placebo-Controlled Trial," *Am. J. Psychiatry*, Feb. 2003, 160(2):255-261.
- Meador et al., "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers," *Neurology*, Jun. 2005, 64:2108-2114.
- Mikos et al., "Interaction of Polymer Microspheres with Mucin Gels as a Means of Characterizing Polymer Retention on Mucus," *Journal of Colloid and Interface Science*, May 1991, 143(2): 366-373.
- Morton et al., "Diagnosis and treatment of epilepsy in children and adolescents," *Drugs*, Mar. 1996, 51(3):399-414.
- Mosek et al., "Topiramate in the treatment of refractory chronic daily headache. An open trial," *Journal of Headache and Pain*, 2005, 6:77-80.
- O'Connor et al., "Powders," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 88, 1615-1632.
- Park et al., "Alternative Approaches to Oral Controlled Drug Delivery: Bioadhesives and In-Situ Systems," *Recent Advances in Drug Delivery*, Plenum Press, New York, 1984, 163-183.
- Pascual et al., "Testing the combination beta-blocker plus topiramate in refractory migraine," *Acta Neurol. Scand.*, 2007, 115(2):81-83.
- Physician's Desk Reference, 60th Edition, 2006, pp. 2438-2447, entry for TOPAMAX®.
- Physician's Desk Reference 59th edition, 2541-2548 (2005).
- Physician's Desk Reference, 56th ed., 2590-2595 (2002).
- Pies, Ronald M.D., "Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review," *Annals of Clinical Psychiatry*, Dec. 2002, 14(4):223-232.
- Porter, Stuart C., Ph.D., "Coating of Pharmaceutical Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 90, 1666-1675.
- Potter et al., "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Determine the Efficacy of Topiramate in the Prophylactic Treatment of Migraine," *Neurology*, Apr. 2000, 54(Suppl 3):A15.
- Rudnic et al., "Oral Solid Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 89, 1633-1665.
- Silberstein et al., "Topiramate in Migraine Prevention," *Arch. Neurol.*, Apr. 2004, 61(4):490-495.
- Siniscalchi et al., "Combined topiramate and clonazepam therapy in a patient affected by essential tremor," *Parkinsonism Relat. Disord.*, 2007, 13(2):129-130.
- Smart et al., "An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery," *J. Pharm. Pharmacol.*, 1984, 36:295-299.
- Sofuoglu et al., "Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers," *Psychopharmacology*, 2006, 184(3-4): 645-651.
- Storey et al., "Topiramate in Migraine Prevention: A Double-Blind Placebo-Controlled Study," *Headache*, Nov./Dec. 2001, 41(10):968-975.
- Thompson et al., "Effects of topiramate on cognitive function," *J. Neurol. Neurosurg. and Psych.*, 2000; 69:634-641.
- Toplak et al., "Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blinded placebo-controlled study," *Int. J. Obes.*, 2007, 31(1):138-146.
- Von Seggern et al., "Efficacy of Topiramate in Migraine Prophylaxis: A Retrospective Chart Analysis," *Neurology*, Apr. 2000, 54(Suppl 3):A267-A268.
- Weber, Marcus Vinicius Keche, M.D., "Topiramate for Obstructive Sleep Apnea and Snoring," *Am. J. Psychiatry*, May 2002, 159(5):872-873.
- Winkelman, John W., "Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate," *Sleep Medicine*, 2003, 4(3):243-246.
- US 6,103,281, 08/2000, DelDuca et al. (withdrawn)

U.S. Patent

Mar. 4, 2014


Sheet 1 of 6

US 8,663,683 B2

Fig.1

80% release time vs. %Wt. gain of Release-Controlling Coating

For Surelease® coated Extended Release Beads




U.S. Patent

Mar. 4, 2014

Sheet 2 of 6

US 8,663,683 B2

Fig. 2

*80% release time vs. % Wt. gain of Release-Controlling Coating**For Surelease®/ Opadry® coated Extended Release Beads*

U.S. Patent


Mar. 4, 2014

Sheet 3 of 6

US 8,663,683 B2

Fig. 3

Mean (n= 16) PK Profiles from Bead Populations XR1, XR2 and XR3



U.S. Patent


Mar. 4, 2014

Sheet 4 of 6

US 8,663,683 B2

Fig. 4

Mean (n= 16) PK Profiles from the Immediate Release Formulations



U.S. Patent


Mar. 4, 2014

Sheet 5 of 6

US 8,663,683 B2

Fig.5

Dissolution Profiles of Immediate Release Formulations




U.S. Patent

Mar. 4, 2014

Sheet 6 of 6

US 8,663,683 B2

Fig.6. Mean PK Profiles for Sustained Release Formulations A, B, and C



US 8,663,683 B2

1

**SUSTAINED-RELEASE FORMULATIONS OF
TOPIRAMATE****CROSS-REFERENCE TO RELATED
APPLICATIONS**

The present application is a Continuation of U.S. application Ser. No. 11/941,475, filed Nov. 16, 2007, which claims benefit of U.S. Provisional Application No. 60/859,502, filed Nov. 17, 2006, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Topiramate is a sulfamate substituted monosaccharide which under the trade name TOPAMAX® (Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J., U.S.A.) has been approved for use as an antiepileptic agent, as an adjuvant therapy for patients with partial onset seizures or primary generalized tonic-clonic seizures, and for the prevention of migraine. See generally, Physician's Desk Reference, 60th ed., 2538-2447 (2006); see also, U.S. Pat. No. 4,513,006.

For the treatment of epilepsy, the recommended dose of TOPAMAX® is 400 mg/day in one or multiple doses (Physician's Desk Reference, 60th ed., 2538-2447 (2006)). For adults with epilepsy, treatment is initiated with a dose of 25-50 mg/day, with the dose being titrated in increments of 25-50 mg at weekly intervals to the recommended or effective dose.

TOPAMAX® is an immediate release formulation. Adverse effects associated with the administration of TOPAMAX® include, but are not limited to, somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, diplopia, renal calculi (kidney stones), hepatic failure, pancreatitis, renal tubular acidosis, acute myopia and secondary angle closure glaucoma (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Hence, though topiramate has a relatively long half-life of 21 hours in vivo, it has not been prescribed (or formulated) as a single, daily-dose, in part due to severe side-effects that often result with peak plasma levels of the drug when taken in high doses. Instead, TOPAMAX® is typically taken in multiple, "divided" doses, usually twice-daily ("BID"). However, administration of the medicament in this manner is cumbersome and patients can forget to take their medication in a timely manner. What is more, each administration of a dose is associated with a peak in plasma concentrations of the drug, and the fluctuations associated with the peaks and valleys of blood plasma levels of the drug are undesirable. Therefore, there is a need for a formulation of topiramate, which reduces or eliminates the side effects associated with peaking and fluctuating plasma levels of the drug and preferably may be administered in a once-daily regimen.

New, highly soluble and bioavailable forms of topiramate are also needed in order to increase the safety and effectiveness of the drug.

The instant invention addresses these and other needs by providing a modified formulation of topiramate characterized by a sustained, non-pulsatile release of an active ingredient. This invention additionally provides an effective, once-daily dosage form of topiramate or salts thereof, which not only enables an effective single daily dose regimen to improve patient compliance but may also reduce some of the side

2

effects of topiramate compared to the current or higher daily doses of immediate release topiramate formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sustained release formulation of topiramate for the treatment or prevention of a pathological condition in a mammalian subject, characterized by a sustained rate of topiramate release along a pre-determined release profile.

It is yet another object of the present invention to provide topiramate formulation wherein topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect associated with the topiramate treatment.

It is a further object of the present invention to provide a sustained release formulation of topiramate that can be administered orally once a day.

It is an object of the present invention to provide a sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient, wherein the active ingredient is released from the formulation at a sustained rate along a pre-determined release profile, and wherein the sustained release formulation comprises an extended release (XR) component and an optional immediate release (IR) component.

In one embodiment of the invention, the extended release component is contained in at least one population of beads coated with a release controlling coating. The above-mentioned coating is specific for every bead population and determines its rate of release. Thus, every given bead population included into the formulation is characterized by its own specific rate of release.

In another embodiment of the invention, the sustained release topiramate formulation comprises an immediate release component in addition to an extended release component.

In a preferred embodiment of the invention, the immediate release component is an enhanced immediate release (EIR) composition.

The formulation of the present invention may be incorporated in any oral dosage form such as represented by, but not limited to, a tablet, a pill, a capsule, a troche, a sachet, and sprinkles.

It is yet another object of the present invention to provide a method of preparation of a sustained release formulation of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile, the method comprising the steps of:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method of preparation additionally includes a process for providing an XR component contained in at least one population of beads, wherein every population of beads is characterized by its own rate of release. This process comprises the steps of

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;

US 8,663,683 B2

3

3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and

4. incorporating the beads into the formulation.

The method may optionally include a process for preparation of an IR component, which optionally is an enhanced immediate release (EIR) composition. The enhanced immediate release composition includes at least one agent selected from a group comprising complexing agents and enhancing agents. Without any limitations, the enhancing agents useful in the present invention may be selected from solubilizing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors or combinations thereof.

It is yet another object of the present invention to provide a method of treatment or prevention of a pathological condition in a mammalian subject by orally administering to the subject a therapeutically effective amount of a sustained release topiramate formulation of the instant invention. The pathological conditions that may be treated by the method of the present invention include neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by topiramate administration.

DEFINITIONS

For the purposes of this invention, the term "topiramate" includes topiramate or any pharmaceutically acceptable salts thereof.

An "immediate release formulation" refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.

For the purposes of this application, an enhancing agent ("enhancer") is defined as any non-pharmaceutically active ingredient that improves the therapeutic potential of a formulation.

The term "enhanced immediate release composition" as used herein describes an immediate release composition improved in terms of a therapeutic potential or treatment modality.

"Sustained release" is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.

By "prolonged period of time" it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.

As used herein, unless otherwise noted, "rate of release" or "release rate" of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the "T.sub.x" value, where "x" is the percent of drug that has been released.

The release rates referred to herein are determined by placing a dosage form to be tested in a medium in an appropriate dissolution bath. Aliquots of the medium, collected at pre-set

4

intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.

"C" denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as "drug plasma concentration", "plasma drug concentration" or "plasma concentration" which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as C_{time}, as in C_{9 hr} or C_{4 hr}, etc.

The maximum plasma drug concentration during the dosing period is referenced as C_{max}, while C_{min} refers to the minimum blood plasma drug concentration at the end of a dosing interval; and C_{ave} refers to an average concentration during the dosing interval.

The "degree of fluctuation" is defined as a quotient (C_{max} - C_{min})/C_{ave}.

Persons of skill in the art will appreciate that blood plasma drug concentrations obtained in individual subjects will vary due to interpatient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a drug plasma concentration is listed, the value listed is the calculated mean value based on values obtained from a groups of subjects tested.

The term "bioavailability" refers to an extent to which—and sometimes rate at which—the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.

"AUC" is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.

Side effect is defined herein as a secondary and usually adverse effect of a drug.

The term "beads", as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured SURELEASE® (ethylcellulose dispersion) coated extended release beads.

FIG. 2 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured SURELEASE®/OPADRY® coated extended release beads.

FIG. 3 shows mean (n=16) pharmacokinetic profiles for bead populations XR1, XR2 and XR3.

FIG. 4 shows mean (n=16) pharmacokinetic profiles for the immediate release formulations.

FIG. 5 shows the dissolution profiles of TOPAMAX®, topiramate IR beads, and topiramate enhanced immediate release beads.

FIG. 6 shows mean PK Profiles for Sustained Release Formulations A, B, and C.


DETAILED DESCRIPTION OF THE INVENTION

Topiramate is a sulfamate-substituted monosaccharide having the chemical name 2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate. The molecular formula of

US 8,663,683 B2

5

topiramate is C₁₂H₂₁NO₈S, and its chemical structure is represented by formula below:



Topiramate is a white crystalline powder that is soluble in alkaline solutions containing sodium hydroxide or sodium phosphate, soluble in acetone, dimethylsulfoxide and ethanol. However, the solubility of topiramate in water at room temperature is only about 9.8 mg/ml. Topiramate is not extensively metabolized and is excreted largely through the urine (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Topiramate pharmacokinetics are linear, producing a dose proportional increase in blood plasma concentration levels with increased dosing, and is not significantly affected by food. Patients taking topiramate over prolonged period of time did not develop resistance to the drug. Following oral administration of an immediate release dosage form, topiramate is rapidly absorbed with plasma drug concentrations peaking in approximately 2 hours. The mean elimination half-life is reported to be about 21 hours.

Currently, topiramate is administered in multiple daily doses in part due to the severe side effects exhibited by the immediate release product, especially when taken in a high single dose.

A sustained release topiramate formulation that will be suitable for once-a-day administration and will result in the diminished level or severity of side effects is needed.

The present invention provides sustained release formulation of topiramate wherein the total daily dose of topiramate is provided in an effective once-daily dose while minimizing fluctuations in the blood plasma drug concentration.

The current invention also provides for formulations of topiramate wherein the maximum plasma concentration of topiramate is attenuated as compared to the same amount of topiramate administered as an immediate release formulation BID; therefore some of the side effects of topiramate, such as CNS side effects including but not limited to dizziness, paresthesia, nervousness, psychomotor slowing, confusion, and difficulty with concentration/attention, observed when taking the immediate release product, may be reduced or eliminated.

Formulations of the instant invention are characterized by a maximum steady state plasma concentration (C_{max}) of topiramate which is higher than the minimal therapeutically effective concentration, and is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. In one embodiment, the novel formulations provide for a relative C_{max} in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID. In the other embodiment, the invention provides for the C_{max} which is lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. The C_{min} of the topiramate formulation of the present invention is about equal or higher than a C_{min} of an equivalent amount of immediate release topiramate formulation given BID.

Compared to the immediate release topiramate formulation, the sustained release topiramate formulations attenuate

6

the C_{max} of topiramate while extending the coverage of plasma concentration above the minimum plasma concentration required therapeutic efficacy. The formulation of the current invention provides for a relative steady state AUC in the range of 80% to 125%, while minimizing the degree of fluctuation, which is preferably in the range of 25% to 90%, as compared to an equivalent amount of immediate release topiramate formulation given in two divided doses (Table 5 and 6).

The present invention additionally provides a sustained release topiramate formulation for the treatment or prevention of a pathological condition in a mammalian subject wherein topiramate is released from the formulation at a sustained rate along a pre-determined release profile. Such release is achieved by incorporation into the formulation of an extended release component (XR) and an optional immediate release component (IR).

The relative amount of each component in the topiramate formulation of the present invention is determined according to the purpose of administration and a pre-determined release profile, and the total amount of topiramate in the formulation varies from 0.5 mg to about 3000 mg. In other words, topiramate or its salt is present in the composition in an amount of from about 0.5% to about 85% by weight, and preferably of from about 2% to about 70% by weight. The term "about" has been recited here and throughout the specification to account for variations, which can arise from inaccuracies in measurement inherent and understood by those of ordinary skill in the chemical and pharmaceutical arts.

The XR component of the formulation of the present invention releases topiramate in a continuous manner and is adjusted in such a way that 80% of the active ingredient is released in vitro in the predetermined period of time. By way of example, and by no means limiting the scope of the invention, the period of time may be not more than 24 hours, not more than 16 hours, not more than 12 hours, not more than 8 hours, or not more than 4 hours, depending on desired attributes of the final product.

In one embodiment, the extended release (XR) component is contained in at least one population of beads coated with a coating that modifies and controls the release of topiramate from the beads (release controlling coating). The release controlling coating is specific for every population of beads and determines the rate of release of topiramate from the given bead population.

The beads useful in the formulation of the present invention comprise an inert carrier, topiramate, a binder, an aforementioned release controlling coating and optionally, an overcoat that provides additional protection from moisture, static charge reduction, taste masking and coloring attributes to the particulates.

The inert carriers useful in the present invention may be selected from, but are not limited to, a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres. The inert carrier is present in an amount of from about 15% to about 99% by weight, and preferably in an amount of from about 40% to about 97% by weight.

Topiramate is introduced to the inert carrier by techniques known to one skilled in the art, such as drug layering, powder coating, extrusion/spheronization, roller compaction or granulation. Preferably, the introduction method is drug layering by spraying a suspension of topiramate and a binder onto the inert carrier.

The binder may be present in the bead formulation in an amount of from about 0.1% to about 15% by weight, and preferably of from about 0.2% to about 10% by weight. Binders include, but are not limited to starches, microcrystal-

US 8,663,683 B2

7

line cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, or polyvinylpyrrolidone.

The release controlling coating specific for every bead population comprises a coating material, and, optionally, a pore former and other excipients. The coating material is preferably selected from a group comprising cellulosic polymers, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and cellulose acetate phthalate; polyvinyl alcohol; acrylic polymers such as polyacrylates, polymethacrylates and copolymers thereof, and other water-based or solvent-based coating materials. The release-controlling coating is population-specific in the sense that the rate of release of topiramate from every bead population is controlled by at least one parameter of the release controlling coating, such as the nature of the coating, coating level, type and concentration of a pore former, process parameters and combinations thereof. Thus, changing a parameter, such as a pore former concentration, or the conditions of the curing, as will be discussed in more details below, (see Example 5) allows to change the release of topiramate from any given bead population and to selectively adjust the formulation to the pre-determined release profile. The release profile, in its turn, may be chosen or modified in such a way as to achieve the best treatment modality depending on the specific needs of the patient population and the nature of the condition.

For example, with all things being equal, there exists a mathematical relationship between the release controlling coating level among the cured beads and the 80% *in vitro* release time. Pre-determined target profiles can therefore be achieved by the interpolation or extrapolation of the relationship curve. For example, when the release controlling coating comprises only ethylcellulose (SURELEASE®) as a coating material, a logarithmic relationship exists between the % weight gain with the coating and the 80% release time in an *in-vitro* dissolution test (FIG. 1):

$$\text{Log}(T_{80\% \text{ release}}) = a(\% \text{ coating}) + b.$$

When ethylcellulose/HPMC(SURELEASE®/OPADRY®) mixture is used, for example, 85:15 mixture or 80:20 mixture, a linear relationship exists between the % weight gain with the coating and the 80% release time in an *in-vitro* dissolution test (FIG. 2):

$$T_{80\% \text{ release}} = a(\% \text{ coating}) + b.$$

Pore formers suitable for use in the release controlling coating herein can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, Carbopaxes, Carbopol, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like.

8

The release controlling coating in the current invention can further comprise other additives known in the art such as plasticizers, anti-adherents, glidants, and antifoams.

In some embodiments, it may be further desirable to optionally coat the XR beads with an "overcoat," to provide, e.g., moisture protection, static charge reduction, taste-masking, flavoring, coloring, and/or polish or other cosmetic appeal to the beads. Suitable coating materials for such an overcoat are known in the art, and include, but are not limited to, cellulosic polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and microcrystalline cellulose, or combinations thereof (for example various OPADRY® coating materials).

Topiramate-containing beads of the present invention may additionally contain enhancers that may be exemplified by, but not limited to, solubility enhancers, dissolution enhancers, absorption enhancers, permeability enhancers, stabilizers, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, and multidrug resistance protein inhibitors. Alternatively, the formulation can also contain enhancers that are separated from the topiramate beads, for example in a separate population of beads or as a powder. In yet another embodiment, the enhancer(s) may be contained in a separate layer on a topiramate-containing bead either under or above the release controlling coating.

The beads may further comprise other pharmaceutically active agents suitable for use in combination with topiramate for treatment or prevention of a pathological condition. The additional pharmaceutically active agents, without limitation, may be represented by analgesic and anti-inflammatory compounds such as COX-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs such as opiates and morphinomimetics, synthetic drugs with narcotic properties such as tramadol; anticonvulsants such as valproic acid or its derivatives, carbamazepine, oxcarbazepine, gabapentin, and lamotrigine; anorectics or anti-obesity agents such as sibutramine or other, orlistat or other pancreatic lipase inhibitors, diethylpropion, fluoxetine, bupropion, amphetamine, methamphetamine, sertraline, zonisamide, and metformin, as well as medications associated with weight-gain, such as sulfonylurea derivatives, insulin, and thiazolidinediones whose weight-gain effect is tempered by topiramate; anti-hypertensive agents such as diuretics, anti-adrenergics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, vasodilators, centrally acting adrenergic drugs, and adrenergic neuron blockers; mood stabilizers such as various forms/salts of lithium, Omega-3 fatty acids and others known in the art, drugs for treatment or prevention of migraines, such as ergot derivatives or triptans, or any other pharmaceutical or nutraceutical ingredient that can be safely and beneficially combined with topiramate.

A relative amount of every bead population in the complete formulation is determined on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile and will be discussed in more detail in Example 6.

In another embodiment, the formulation of the present invention comprises an extended release component as described above, and an immediate release component. The IR component may be an enhanced immediate release composition. The enhanced immediate release composition may be characterized by a faster *in vitro* topiramate release as compared to the IR formulation. Preferably, at least 80% of an active compound from the enhanced immediate release composition is released in a time period of not more than 30 minutes. More preferably, at least 50% of an active compound from the enhanced immediate release composition is released

US 8,663,683 B2

9

in a time period of not more than 10 minutes, and at least 25% is dissolved in a time period of not more than 5 minutes after the oral administration. In the most preferred embodiment of the present invention, at least 75% of the active compound is released from the EIR composition in a time period of not more than 10 minutes. The embodiment in which the IR component is an enhanced immediate release composition will be discussed in more details below.

In addition to topiramate and inactive excipients, the EIR composition of the present invention comprises at least one agent selected from a group consisting of complexing agents and enhancing agents.

Without any limitation, the enhancing agents suitable for the present invention may be selected from the solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. The representative, but non-limiting examples of these compounds are Vitamin E TPGS, amino acid such as glutamic acid and glycine, sorbitol, mannose, amylose, maltose, manitol, lactose, sucrose, glucose, xylitol, dextrins such as maltodextrin, Cremophor RH40 (glycerol-polyethylene glycol oxystearate), Gelucire 50/13 (PEG-32 glyceryl palmitostearate), sodium lauryl sulfate, Tween 80 (polyoxyethylene sorbitan monooleate), benzyl alcohol, Span 20 (sorbitan monolaurate), Poloxamer 407, PEG3350, PVP K25, oleic acid, Capmul GMO (glyceryl monooleate), sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, crosscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose, sodium bicarbonate, calcium citrate, sodium docusate, and menthol, among others. Enhancers can be combined to achieve multiple enhancement effects, for example, solubility enhancement combined with permeability enhancement and p-glycoprotein inhibition, or to provide a synergistic enhancement effect to achieve greater and more efficient enhancement. For example, polyglycolized glycerides (different grades of Gelucire) can be combined with sodium lauryl sulfate to achieve higher solubility enhancement as well as faster dissolution of topiramate.

In one embodiment, the EIR composition comprises a highly soluble complex of topiramate with a complexing agent that is represented by, but not limited to, cyclodextrins, including cyclodextrin derivatives, such as hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and alpha-cyclodextrin. The ratio of cyclodextrin to topiramate in the EIR formulation is preferably less than 20:1 and more preferably less than 5:1. In the most preferred embodiment, the complexing agent is hydroxypropyl beta cyclodextrin.

The highly soluble complex of topiramate and cyclodextrin is prepared by mixing topiramate and cyclodextrin together in the presence of water. The concentration of cyclodextrin is preferably high to facilitate the formation of topiramate-enhancer complex. In the case when the complexing agent is hydroxypropyl-beta-cyclodextrin, the concentration of the hydroxypropyl-beta-cyclodextrin solution used for mixing with topiramate is greater than 2%, preferably greater than 20%, and more preferably at least about 40%. The amount of topiramate is determined by a desired ratio of hydroxypropyl-beta-cyclodextrin to topiramate, which is preferably less than 20:1, and more preferably less than 5:1. The mixing time of

10

the complex solution is from about one hour to about 48 hours, and preferably from about 5 hours to about 24 hours. The addition of hydroxypropyl-beta-cyclodextrin and topiramate can be incremental to reduce the viscosity of the complex solution and to achieve better complexation.

In a further embodiment, the EIR component of the present invention is contained in at least one bead population. Topiramate EIR beads can be prepared using processes suitable for bead manufacturing, such as coating of a topiramate suspension, dispersion or solution onto an inert carrier, or by roller compaction, granulation, extrusion/spheronization, or powder coating, and are not limited by the examples cited therein. The enhancing agents of the present invention can be incorporated into the topiramate containing beads, or may be contained in other beads separated from the topiramate containing beads. By way of a non-limiting example, topiramate-containing EIR beads were prepared by coating topiramate dispersion onto an inert carrier such as sugar spheres. The topiramate dispersion, in addition to topiramate in the micronized form or in non-micronized form, can contain one or more enhancers, water and optionally a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

When the formulation is enhanced with complexing agents, the agents may be first mixed with topiramate and a suitable solvent such as water to form the complex. The topiramate-containing complex is then mixed with a binder solution prepared separately to give the coating dispersion. The coating dispersion is then sprayed onto the inert carrier such as sugar spheres using a fluid bed processor.

In an alternative embodiment of the invention, the formulation comprises at least one XR bead population, and at least one additional combination bead population consisting of the extended release beads that have an additional immediate release component layer coated on top of the release controlling coating. This layer may be formed by a suitable loading method such as solution/suspension/dispersion coating, powder coating or wet granulation.

In yet another embodiment, at least part (i.e., more than 0.01%, preferably at least 1%) of the active ingredient may be present in the formulation in a form of micronized particles with the size of from 1 μ m to 1000 μ m, preferably from 2 μ m to about 200 μ m, more preferably from 2 μ m to about 100 μ m. Further, one or more enhancers may be present in the formulations covered by this embodiment. The enhancers are selected from solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. Preferably, the enhancer is a solubility enhancer or a dissolution enhancer.

The topiramate formulation of the present invention may be formulated in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, sprinkles, or any other form suitable for oral administration.

In one embodiment of the invention, the dosage form is a gelatin capsule containing the XR component in a form of at least one population of beads, and an optional IR component. The IR component, when present, may be in a form of a powder, or may also be contained in at least one population of beads to achieve faster dissolution of topiramate (FIG. 5).

In an alternative embodiment, part of the total amount of the active ingredient may be incorporated into the aforementioned bead populations that will be contained inside an

US 8,663,683 B2

11

enclosure such as a capsule, and the rest of the active ingredient can be loaded on the outside of the enclosure by a suitable loading method such as solution/suspension/dispersion coating or powder coating or wet granulation. For example, a part of the immediate release topiramate formulation can be loaded by coating on the outside of a capsule that contains within it other populations of topiramate such as extended release topiramate. This dosage form can provide almost instantaneous dissolution of the initial portion of topiramate dose from the outside of the capsule, followed by a sustained release of the rest of topiramate from inside the capsule.

In a further embodiment of the invention, the dosage form is a tablet. Without imposing any limitations, this embodiment may be exemplified by a multilayered tablet that comprises at least one layer containing the extended release component, and at least one layer comprising the immediate release component, wherein the IR component may or may not be an EIR composition.

The last two embodiments are especially beneficial when fast onset of action followed by sustained release is preferred, as is for example in the cases of a breakthrough migraine episode.

The current invention additionally encompasses a method of preparing formulations of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile. The method comprises the following steps:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method comprises a step for providing an immediate release component, which may be an enhanced immediate release composition.

In another embodiment, the method includes a process for providing an extended release component contained in at least one population of beads characterized by its own rate of release, wherein the process includes the steps of:

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The exact amount of beads of every population incorporated into the formulation and into the final dosage form is determined using the linear superposition principle (WinNonLin) on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile (Example 6).

Release profiles of XR topiramate beads can be selectively adjusted, modified or stabilized by curing the beads at an elevated temperature. This process is well known in the art. However, it was unexpectedly discovered that curing the beads in the curing apparatus in the presence of at least one suitable solvent dramatically reduces the curing time necessary to produce a desired release profile and a level of stability. The curing process that previously required up to two weeks can be carried out by the method of current invention in several hours.

12

The assisting solvents can be selected from those solvents that can dissolve or partially dissolve the coating material, or those that can induce or assist the coalescence or molecular relaxation of the coating material, or those that can reduce electrostatic charge on the dosage forms during curing and those that can facilitate curing at a higher temperature. Examples of these solvents include but are not limited to organic solvents, such as alcohols, ketones, ethers, esters, amides, amines, hydrocarbons including substituted hydrocarbons such as chlorinated hydrocarbons and aromatic hydrocarbons, furans, sulfoxides, organic acids, phenols, super-critical fluids; ammonia; and water, buffered water, or water solutions of other inorganic or organic compounds, and their combinations. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

The curing of the dosage form normally is done in an apparatus that can operate at elevated temperatures and that can deliver the assisting solvents by means such as spray, injection, or vaporization. In the embodiment of the invention when the assisting solvent is sprayed or injected into the curing apparatus, the stream of solvent is introduced directly onto the coated beads. The amount of the solvent necessary to produce the desired effect, such as the desired release parameters and stabilization of the coating, depends on the nature of the solvent and the method of solvent delivery.

Typically, when the vaporization method is used, the organic solvents and aqueous solutions may be used in the wide range of vapor concentrations varying from 2% to more than 100%, providing an unsaturated, saturated or an oversaturated atmosphere. The pure water, however, has to be used in such an amount as to provide at least a saturated or, preferably, an oversaturated atmosphere in the curing apparatus. At least during the delivery of assisting solvents, the coated beads are mixed or agitated either continuously or in a pulsed manner.

In an alternative embodiment of the invention, hot water steam is introduced into the curing apparatus for a pre-selected period of time. The steam serves simultaneously as a solvent and as a source of heat for the beads. Introduction of steam is followed by a drying period.

This method of curing the release controlling coating results in many benefits including the dramatically shortened curing time, increased stability and modification of the release profile, and is not limited to topiramate containing beads, but includes the curing of any microparticles regardless of the drug.

Specifically, active ingredient containing beads, with or without the optional over-coat, are charged to a fluid bed processor or a pan coater and heated to a desired curing temperature range, for example 40° C. to 80° C. for sustained release dosage forms containing ethylcellulose (SURELEASE®), and 40° C. to 70° C. for sustained release dosage forms containing acrylic polymers (EUDRAGIT® RS and EUDRAGIT® RL). The assisting solvent or solvents, such as water or alcohol-water mixture, are sprayed onto the beads while mixing by, for example, fluidizing or rotating. Alternatively, the process is carried out in an oven where hot steam is introduced as previously discussed. Solvent-assisted curing is carried out to a desired curing time length, either in one curing period or in multiple, separate curing periods. The dosage forms can be further dried for a short period of time to remove residual solvents.

The solvent-assisted curing process significantly accelerates the curing of release controlling coating on active ingredient containing beads as compared to the heat-only curing of

US 8,663,683 B2

13

the same. In most instances, less than 4 hours of solvent-assisted curing resulted in more complete curing of the extended release dosage forms than 2 weeks of heat-only oven curing of the same dosage forms.

The present invention also presents a method of treatment or prevention of a pathological condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a novel topiramate formulation of the instant invention, wherein topiramate is released from the formulation at a sustained rate along the pre-determined release profile. The method of the current invention possesses the flexibility to selectively adjust the pharmacokinetics of the administered formulations depending on the nature of the condition and needs of the patients due to the novel design of the topiramate formulation that comprises an extended release component and an optional immediate release component, and the release profiles of both components can be selectively modified during the preparation process as described above to comply with the predetermined release profile.

The pathological condition that may be treated by a method of the present invention is a neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by the topiramate administration.

The neurological disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to, epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, perinatal hypoxia ischemia and related damage, chronic neurodegenerative disorders, acute neurodegeneration, and ALS.

Psychiatric disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, ADHD, impulse control disorders, border line personality disorder, addiction, and autism.

Formulations of the present invention may be also used for the treatment and prevention of diabetes and related disorders, such as type II diabetes mellitus, diabetic retinopathy, impaired oral glucose tolerance, diabetic skin lesions, dia-

14

betic neuropathy, Syndrome X and elevated blood glucose levels; ocular disorders, including but not limited to glaucoma and macular degeneration; cardiovascular disorders represented but not limited to elevated blood pressure and elevated lipids; obesity; asthma; autoimmune disorders; sleep apnea and sleep disorders. The formulations may be also used for inducing weight loss or promoting wound healing, or for any other condition, not specified above, wherein the use of topiramate is indicated.

The invention will be further illustrated by the following Examples, however, without restricting its scope to these embodiments.

EXAMPLES

Example 1

Extended Release Beads Preparation

Topiramate Drug Layering on Sugar Spheres—the "Core"

An aqueous suspension of 10-20% (w/w) topiramate (particle size 90% vol. NMT 30 micrometer, 50% vol. NMT 15 micrometer and 10% vol. NMT 5 micrometer) and 0.5-4% (w/w) HPMC or other aqueous binder can be used as the drug layering coating solution. A fluid bed suited for Wurster-spray is assembled and charged with inert carriers such as sugar spheres. The coating suspension is sprayed onto the bed to evenly coat the inert carriers to a desired topiramate loading level. Higher binder concentration in the coating solution may be used for smaller size inert carrier and higher topiramate loading. Inlet airflow rate and product temperature are adjusted to keep the batch from spray-drying the coating material or over-wetting the spheres.

Coating of the Core with a Release Controlling Coating

A dispersion of a cellulosic polymer such as ethylcellulose and methylcellulose can be used to coat the core in the current invention. Ethylcellulose dispersion (SURELEASE®) can be diluted to a final concentration of about 10% to about 20% and with or without the use of other ingredients such as pore formers. A fluid bed suited for Wurster-spray is assembled and charged with the cores prepared in Example 1. The release controlling coating dispersion is sprayed onto the bed to evenly coat the core to a desired coating level as exemplified in Table 1.

TABLE 1

Composition and process Parameters for the extended Release							
	XR1a	XR1b	XR1c	XR2a	XR2b	XR2c	XR2d
RC* coating material	Ethyl-cellulose (SURELEASE®)	Ethyl-cellulose (SURELEASE®)	Ethyl-cellulose (SURELEASE®)	Ethyl-cellulose (SURELEASE®)	Ethyl-cellulose (SURELEASE®)	Ethyl-cellulose (SURELEASE®)	Ethyl-cellulose (SURELEASE®)
Pore-former	—	—	OPADRY® Clear	—	—	OPADRY® Clear	OPADRY® Clear
RC coating material to pore-former ratio	—	—	80:20	—	—	80:20	80:20
RC coating level	2%	4%	3%	3%	3%	6.5%	6.5%
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.
Over-coat material	—	OPADRY® AMB White	OPADRY® AMB White	—	OPADRY® AMB White	—	OPADRY® AMB White
Over-coat coating level	—	1.5%	1.5%	—	1.5%	—	1.5%

US 8,663,683 B2

15

16

TABLE 1-continued

Composition and process Parameters for the extended Release							
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven
Topiramate Beads							
	XR3	XR4	XR5	XR6	XR7	XR8	
RC coating material	Ethylcellulose (SURE-LEASE ®)	Ethylcellulose (SURE-LEASE ®)	Ethylcellulose (SURE-LEASE ®)	Ethylcellulose (SURE-LEASE ®)	Ethylcellulose (SURE-LEASE ®)	Acrylic polymers (EUDRAGIT ® RL30D/RS30D)	
Pore-former	—	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	Cellulosic polymers (OPADRY ® Clear)	—	
RC coating material to pore-former ratio	—	80:20	80:20	80:20	85:15	—	
RC coating level	3.7%	3.1%	5.2%	9.5%	15%	15%	
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	
Over-coat material	—	—	—	—	—	—	
Over-coat coating level	—	—	—	—	—	—	
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, fluid bed/5% alcohol- water, or oven	Fluid bed/ water, fluid bed/5% alcohol- water, or oven	

*RC—Release Controlling

Example 2

Method of

Topiramate-Hydroxypropyl-Beta-Cyclodextrin
Complex Bead Preparation

Approximately half of the intended amount of topiramate was added to the water with constant mixing followed by sprinkling of hydroxypropyl-beta-cyclodextrin into the dispersion. Once the dispersion became significantly less viscous, more drug substance was added followed by sprinkling

of more hydroxypropyl-beta-cyclodextrin. The drug and hydroxypropyl-beta-cyclodextrin addition steps were repeated, and the dispersion was mixed for 12-18 hours. Separately, hydroxypropylmethylcellulose was dissolved in water. The above topiramate-hydroxypropyl-beta-cyclodextrin dispersion and hydroxypropylmethylcellulose solution were mixed together for 15 to 30 minutes and the mixture was screened through an 80-mesh sieve. The resultant dispersion was sprayed onto sugar spheres using a fluid bed processor to yield the enhanced immediate release beads (Table 2).

TABLE 2

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions				
Component	Percentage (w/w) in Beads			
	EIR-1 (HPBCD:Drug = 3:2)*	EIR-2 (HPBCD:Drug = 3:2)*	EIR-3 (HPBCD:Drug = 1:1)*	EIR-4 (HPBCD:Drug = 1:2)*
Topiramate	25.0	3.3	28.9	33.3
Hydroxypropyl-beta-cyclodextrin	37.5	4.95	28.9	16.7
Hydroxypropylmethylcellulose	3.1	0.41	2.4	4.2
Sugar spheres	34.4	91.34	39.8	45.8

*HPBCD:Drug - Hydroxypropyl-beta-cyclodextrin to drug substance ratio

US 8,663,683 B2

17

Example 3

Topiramate EIR Beads Containing Non-Complexing Enhancers

Topiramate is dispersed in a binder solution, such as hydroxypropylmethylcellulose solution, that contains an appropriate amount of enhancer or enhancers such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGE) and sodium lauryl sulfate combination, polyoxyl hydrogenated castor oil (different grades of Cremophor RH), polyglycolized glycerides (different grades of Gelucire), polyglycolized glycerides (different grades of Gelucire) combined with sodium lauryl sulfate, or combinations thereof. The resultant dispersion is sprayed onto an inert carrier such as sugar spheres using a fluid bed processor to achieve a desired drug load (Table 3).

TABLE 3

Enhanced Immediate Release Topiramate Bead Compositions			
Component	Percentage (w/w) in Beads		
	EIR-5	EIR-6	EIR-7
Topiramate	36.8	37.9	36.4
Sodium lauryl sulfate	0.7	0.5	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	7.3	—	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	9.1
Polyglycolized glycerides (Gelucire 50/13)	—	4.7	—
Hydroxypropylmethylcellulose	4.6	4.8	4.5
Sugar spheres	50.6	52.1	50.0

Example 4

Topiramate EIR Beads Containing Micronized Particles

Miconized or non-miconized topiramate is dispersed in a solution with or without heating, optionally containing dissolution enhancing agents such as mannose, maltose, mannitol, lactose, maltodextrin and sodium starch glucolate, and optionally containing one or more additional enhancers such as PEG3350, sodium lauryl sulfate, sodium docusate, polyoxyethylene sorbitan monooleate and Poloxamers, under such process parameters that topiramate particles that remain undissolved have a particle size of about 2 micron to about 30 micron. A particle size reduction device such as a homogenizer can also be used to reduce the particle size of undissolved topiramate. The resultant topiramate dispersion is then sprayed onto inert carriers such as sugar spheres in a coating processor such as a fluid bed processor. The formulations obtained are represented in the Table 4:

TABLE 4

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Topiramate	3.2	26.0	25.0	3.2	26.0	26.0
Mannose	0.4	5.0	3.3	2.0	10.0	10.0

18

TABLE 4-continued

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Maltrin 250	—	—	1.0	1.0	—	—
PEG3350	1.0	15.0	—	—	—	10.0
Sodium lauryl sulfate	—	—	—	—	0.5	—
Hydroxypropyl-beta-cyclodextrin	—	—	37.5	—	—	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	—	—	—	—	2.0	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	—	—	—	2.0
Sugar spheres	95.4	54.0	33.2	93.8	61.5	52.0

Example 5

Method of Curing Beads

The topiramate beads coated with a release controlling coating, with or without an overcoat, can be cured using the above-mentioned solvent-assisted curing process, or using the heat-only curing process, to a desired curing level and preferably to complete curing.

Specifically, the core is coated to a desired coating level with a solution or dispersion of the release controlling coating material, with or without the above-mentioned additives such as pore-formers, using a fluid bed processor or any other suitable apparatus for coating of the core. Product temperature is controlled at a desirable range, for example 20° C. to 60° C. for the coating of ethylcellulose (SURELEASE®) and 20° C. to 60° C. for acrylic polymers (EUDRAGIT® RL and EUDRAGIT® RS grades). An optional overcoat with materials such as cellulosic polymers (various OPADRY®) is applied thereafter. Curing of the sustained release topiramate beads is carried out either in an oven at 40° C. to 80° C. for SURELEASE® containing beads or at 40° C. to 70° C. for EUDRAGIT® RL or RS containing beads, or in a fluid bed processor with or without the use of assisting solvents at similar product temperatures.

For curing that uses assisting solvents, the assisting solvent can be delivered through top spray, bottom spray, side spray or injection, or introduced by vaporization. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

Example 6

Sustained Release Formulations of Topiramate

a. Plasma concentration versus time curves for the topiramate formulations containing extended release and immediate release bead populations are simulated using WinNonlin Version 5.0.1 based on the pharmacokinetic data on the separate bead populations that were generated in a comparative randomized single-dose 6-way crossover study in healthy

US 8,663,683 B2

19

adult volunteers. The study included administration of a 50 mg oral dose of three extended release compositions, designated here as XR1, XR2 and XR3, two immediate release compositions ((TOPAMAX®, Ortho-McNeil Neurologics, Inc.) (25 mg BID), and an immediate release bead formulation) and an enhanced immediate release (IR) bead composition. The single dose topiramate plasma concentration profiles for XR1, XR2 and XR3 are shown in FIG. 3. The single dose topiramate plasma concentration profiles for IR are shown in FIG. 4. The data are projected to a steady-state (SS) with a 24 h dosing interval for the sustained release compositions and a 12 h dosing interval for TOPAMAX®, using the linear superposition principle (WinNonlin). The extended release populations XR1, XR2 and XR3, and an immediate release (IR) population are selected in such a way as to be defined by at least one of the three following sets of conditions:

1. for the steady state,

$$\text{for XR1, } 1.70C_{\max IR} \geq C_{\max XR1} \geq 1.30C_{\max IR}$$

$$\text{for XR2, } 0.40C_{\max IR} \geq C_{\max XR2} \geq 0.20C_{\max IR}$$

$$\text{for XR3, } 0.25C_{\max IR} \geq C_{\max XR3} \geq 0.05C_{\max IR}$$

2. for in-vitro dissolution,

$$\text{for XR1, } 1.5 \text{ h} \leq T_{80\%} \leq 4 \text{ h}$$

$$\text{for XR2, } 5 \text{ h} \leq T_{80\%} \leq 8 \text{ h}$$

$$\text{for XR3, } 8 \text{ h} \leq T_{80\%} \leq 10 \text{ h}$$

3. for a single initial dose in-vivo,

$$\text{for XR1, } 4 \text{ h} \leq T_{\max} \leq 8.5 \text{ h}$$

$$\text{for XR2, } T_{\max} \geq 16 \text{ h}$$

$$\text{for XR3, } T_{\max} \geq 16 \text{ h.}$$

Optionally, the immediate release bead population is composed of enhanced immediate release (EIR) beads such that at least one condition is true: a. for the steady state, $2.40 C_{\max IR} \geq C_{\max EIR} \geq 1.20 C_{\max IR}$; b. for in-vitro dissolution, $T_{80\%} \leq 30 \text{ min}$; c. for a single initial dose in-vivo, $T_{\max} \leq 2 \text{ h}$.

The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 5 below. These formulations are selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.

TABLE 5

Composition and Pharmacokinetic data of Multi-bead Formulations							
	#1	#2	#3	#4	#5	#6	#7
% XR1	20	50	0	10	10	15	0
% XR2	80	0	85	85	80	70	100
% XR3	0	50	0	0	0	15	0
% IR	0	0	15	5	10	0	0
Rel. BA (%), SS	98.5	100.5	96.6	97.4	97.6	97.3	96.0
Degree of fluctuation, SS	0.15	0.22	0.14	0.14	0.15	0.13	0.09

b. based on the results of WinNonlin simulation discussed in part (a), formulations #1 (A), #3 (B), and #4 (C) were tested in the comparative randomized multi-dose 4-way study following a once a day 50 mg oral dose of three controlled release formulations and a 25 mg twice a day oral doses of TOPAMAX® in healthy adult volunteers.

20

The results of the study are summarized in Table 6 and FIG. 6:

TABLE 6

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (TOPAMAX ®)
% XR1	20	0	10	—
% XR2	80	86	84	—
% XR3	0	0	0	—
% IR	0	14	6	—
Rel. BA (%), SS	92	93	95	100
Relative Degree of fluctuation, SS	73%	72%	66%	100%

What is claimed is:

1. A sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient that is released in a continuous manner from the formulation along a pre-determined release profile, wherein the formulation comprises:

an extended release (XR) component comprising at least one population of beads, wherein greater than or equal to 80% of the topiramate contained therein is released in vitro in less than or equal to about 4 hours, and

(ii) an immediate release (IR) component, wherein 80% of the topiramate contained therein is released in vitro in not more than 1 hour,

wherein each bead population of the XR component is coated with its own release controlling coating and characterized by its own rate of release.

2. The formulation of claim 1, wherein the immediate release component comprises a complexing agent, an enhancing agent, or both.

3. The formulation of claim 2, wherein the complexing agent is a cyclodextrin selected from a group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, and derivatives thereof.

4. The formulation of claim 2, wherein the enhancing agent is selected from a group comprising solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizers, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors and combinations thereof.

5. The formulation of claim 4, wherein the enhancing agent is selected from a group consisting of d-alpha tocopheryl polyethylene glycol succinate, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans, glycerolpolyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, croscopolvone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose, substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol and combinations thereof.

US 8,663,683 B2

21

6. The formulation of claim 1, wherein at least a part of the active ingredient is in a form of micronized particles.

7. The formulation of claim 6, wherein the particles have an average size of from about 2 μm to about 100 μm .

8. The formulation of claim 1, wherein the total amount of topiramate in the formulation is from 0.5 to 3000 mg.

9. The formulation of claim 1, wherein the beads comprise an inert carrier, topiramate, an optional enhancing agent, and a release controlling coating comprising a coating material and optionally a pore former and other excipients.

10. The formulation of claim 9, wherein the inert carrier is selected from a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres.

11. The formulation of claim 9, wherein the enhancing agent is selected from a group consisting of solubility enhancers, dissolution enhancers, permeability enhancers, stabilizers, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors and combinations thereof.

12. The formulation of claim 9, wherein the coating material is selected from a group consisting of ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates and copolymers thereof; and/or the pore former is selected from a group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomers, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly (α - ω)alkylenediols; inorganic compounds selected from a group consisting of alkali metal salts and alkaline earth metal salts, and combinations thereof.

13. The formulation of claim 1, wherein the pre-determined release profile comprises a sustained rate of release after an initial immediate release.

14. The formulation of claim 1, suitable for once-a-day oral administration.

22

15. The formulation of claim 1, wherein the IR component is coated on top of the at least one population of beads of the XR component.

16. The formulation of claim 9, wherein the enhancing agent is contained in a layer separate from the release controlling coating.

17. The formulation of claim 1, further comprising at least one enhancing agent, wherein the enhancing agent is incorporated into the formulation in the form of a powder or of a population of beads that are optionally characterized by a controlled rate of release, and wherein the enhancing agent is separated from the active ingredient.

18. A method for the treatment or prevention of a neurological and/or psychiatric condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a sustained release formulation of topiramate according to claim 1.

19. The method of claim 18, wherein the condition is selected from a group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, and amyotrophic lateral sclerosis.

20. The formulation of claim 1, which is a capsule, a tablet, a pill, a caplet, a troche, a pouch or sprinkles.

21. The formulation of claim 20, wherein the tablet is a multilayered tablet comprising at least one layer comprising the extended release component, and at least one layer comprising the immediate release component.

22. The formulation of claim 1, further comprising a pharmaceutically active ingredient in combination with topiramate.

23. The method of claim 19, wherein the condition is epilepsy.

24. The method of claim 19, wherein the condition is migraine.

* * * * *

Exhibit D



US008877248B1

(12) **United States Patent**
Liang et al.

(10) **Patent No.:** **US 8,877,248 B1**
(45) **Date of Patent:** ***Nov. 4, 2014**

(54) **SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE**

(71) Applicant: **Supernus Pharmaceuticals, Inc.,**
Rockville, MD (US)

(72) Inventors: **Likan Liang**, Boyds, MD (US); **Hua Wang**, Clarksville, MD (US);
Padmanabh P. Bhatt, Rockville, MD (US); **Michael L. Vieira**, Gaithersburg, MD (US)

(73) Assignee: **Supernus Pharmaceuticals, Inc.,**
Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/330,423**

(22) Filed: **Jul. 14, 2014**

Related U.S. Application Data

(63) Continuation of application No. 12/926,936, filed on Dec. 17, 2010, which is a continuation of application No. 11/941,475, filed on Nov. 16, 2007, now Pat. No. 8,298,576.

(60) Provisional application No. 60/859,502, filed on Nov. 17, 2006.

(51) **Int. Cl.**
A61K 9/16 (2006.01)
A61K 9/50 (2006.01)
A61K 31/7048 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 9/5042** (2013.01); **A61K 31/7048** (2013.01)
USPC **424/490**; 514/25; 427/2.21

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,528,378 A 10/1950 Manheimer et al.
2,675,619 A 4/1954 Cone
2,677,700 A 5/1954 Jackson et al.
2,781,354 A 2/1957 Mannheimer et al.
2,979,578 A 4/1961 Curtis
2,996,431 A 8/1961 Barry
3,036,118 A 5/1962 Jackson et al.
3,139,383 A 6/1964 Neville et al.
3,535,307 A 10/1970 Moss et al.
3,811,444 A 5/1974 Heller et al.
3,829,506 A 8/1974 Schmolka et al.
3,962,414 A 6/1976 Michaels
3,992,518 A 11/1976 Chien et al.
4,066,747 A 1/1978 Capozza
4,070,347 A 1/1978 Schmitt
4,079,038 A 3/1978 Choi et al.

4,083,949 A 4/1978 Benedikt
4,093,709 A 6/1978 Choi et al.
4,290,426 A 9/1981 Luschen et al.
4,434,153 A 2/1984 Urquhart et al.
4,513,006 A 4/1985 Maryanoff et al.
4,721,613 A 1/1988 Urquhart et al.
4,727,064 A 2/1988 Pitha
4,752,470 A 6/1988 Mehta
4,757,128 A 7/1988 Domb et al.
4,853,229 A 8/1989 Theeuwes
4,938,763 A 7/1990 Dunn et al.
4,997,904 A 3/1991 Domb
5,030,447 A 7/1991 Joshi et al.
5,175,235 A 12/1992 Domb et al.
5,180,589 A 1/1993 Joshi et al.
5,225,202 A 7/1993 Hodges et al.
5,256,440 A 10/1993 Appel et al.
5,378,475 A 1/1995 Smith et al.
5,478,577 A 12/1995 Sackler et al.
5,500,227 A 3/1996 Oshlack et al.
5,576,311 A 11/1996 Guy
5,753,693 A 5/1998 Shank
5,760,007 A 6/1998 Shank et al.
5,773,019 A 6/1998 Ashton et al.
5,935,933 A 8/1999 Shank et al.
5,955,096 A 9/1999 Santos et al.
5,985,312 A 11/1999 Jacob et al.
5,998,380 A 12/1999 Ehrenberg et al.
6,123,965 A 9/2000 Jacob et al.
6,156,348 A 12/2000 Santos et al.
6,159,501 A 12/2000 Skinhoj
6,191,117 B1 2/2001 Kozachuk

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1130352 A 9/1996
WO WO 93/21906 A1 11/1993

(Continued)

OTHER PUBLICATIONS

US 6,103,281, 08/2000, DelDuca et al. (withdrawn).

(Continued)

Primary Examiner — Suzanne Ziska

(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP; Sunit Talapatra

(57) **ABSTRACT**

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

20 Claims, 6 Drawing Sheets

US 8,877,248 B1

Page 2

(56)

References Cited

U.S. PATENT DOCUMENTS

6,197,346 B1 3/2001 Mathiowitz et al.
 6,201,010 B1 3/2001 Cottrell
 6,217,908 B1 4/2001 Mathiowitz et al.
 6,235,311 B1 5/2001 Ullah et al.
 6,248,363 B1 6/2001 Patel et al.
 6,294,192 B1 9/2001 Patel et al.
 6,319,903 B1 11/2001 Carrazana et al.
 6,344,215 B1 2/2002 Bettman et al.
 6,365,187 B2 4/2002 Mathiowitz et al.
 6,368,586 B1 4/2002 Jacob et al.
 6,479,467 B1 11/2002 Buchanan et al.
 6,503,884 B1 1/2003 Ehrenberg et al.
 6,514,531 B1 2/2003 Alaux et al.
 6,524,620 B2 2/2003 Chen et al.
 6,559,293 B1 5/2003 Almarsson et al.
 6,562,865 B1 5/2003 Codd et al.
 6,569,463 B2 5/2003 Patel et al.
 6,696,091 B2 2/2004 Thakur et al.
 6,699,840 B2 3/2004 Almarsson et al.
 6,797,283 B1 9/2004 Edgren et al.
 6,923,988 B2 8/2005 Patel et al.
 7,018,609 B2 3/2006 Hwang Pun et al.
 7,195,778 B2 3/2007 Fleshner-Barak et al.
 7,611,722 B2 11/2009 Lerner et al.
 7,737,133 B2 6/2010 Devane et al.
 7,763,635 B2 7/2010 Kidane et al.
 2002/0044962 A1 4/2002 Cherukuri et al.
 2002/0054907 A1 5/2002 Devane et al.
 2002/0064563 A1 5/2002 Thakur et al.
 2002/0150616 A1 10/2002 Vandecruys
 2003/0017972 A1 1/2003 Pun et al.
 2003/0064097 A1 4/2003 Patel et al.
 2003/0072802 A1 4/2003 Cutler
 2003/0091630 A1 5/2003 Louie-Helm et al.
 2003/0133985 A1 7/2003 Louie-Helm et al.
 2003/0147952 A1 8/2003 Lim et al.
 2003/0157173 A1 8/2003 Percel et al.
 2003/0166581 A1 9/2003 Almarsson et al.
 2003/0215496 A1 11/2003 Patel et al.
 2003/0225002 A1 12/2003 Livingstone
 2004/0002462 A1 1/2004 Najarian
 2004/0022844 A1 2/2004 Hasenzahl et al.
 2004/0028729 A1 2/2004 Shojaei et al.
 2004/0028735 A1 2/2004 Kositprapa
 2004/0052843 A1 3/2004 Lerner et al.
 2004/0053853 A1 3/2004 Almarsson et al.
 2004/0082519 A1 4/2004 Hedner et al.
 2004/0091529 A1 5/2004 Edgren et al.
 2004/0096501 A1 5/2004 Vaya et al.
 2004/0109894 A1 6/2004 Shefer et al.
 2004/0115262 A1 6/2004 Jao et al.
 2004/0122104 A1 6/2004 Hirsh et al.
 2004/0132826 A1 7/2004 Hirsh et al.
 2004/0156901 A1 8/2004 Thakur et al.
 2004/0157785 A1 8/2004 Connor
 2004/0185097 A1 9/2004 Kannan et al.
 2004/0234601 A1 11/2004 Legrand et al.
 2004/0258758 A1 12/2004 Gustow et al.
 2005/0053653 A1 3/2005 Kidane et al.
 2005/0058707 A1 3/2005 Reyes et al.
 2005/0069587 A1 3/2005 Modi et al.
 2005/0106242 A1 5/2005 Yan et al.
 2005/0106247 A1 5/2005 Venkatesh et al.
 2005/0129765 A1 6/2005 Li et al.
 2005/0136108 A1 6/2005 Yam et al.
 2005/0169982 A1 8/2005 Almarsson et al.
 2005/0169992 A1 8/2005 Jao et al.
 2005/0175697 A1 8/2005 Edgren et al.
 2005/0191343 A1 9/2005 Liang
 2005/0220596 A1 10/2005 Gaedy et al.
 2006/0018933 A1 1/2006 Vaya et al.
 2006/0018934 A1 1/2006 Vaya et al.
 2006/0024365 A1 2/2006 Vaya et al.
 2006/0034927 A1 2/2006 Casadevall et al.
 2006/0078609 A1 4/2006 Vandecruys et al.

2006/0105045 A1 5/2006 Buchanan et al.
 2006/0121112 A1* 6/2006 Jenkins et al. 424/468
 2006/0147527 A1 7/2006 Bachmann et al.
 2006/0223762 A1 10/2006 Ehrenberg et al.
 2006/0233892 A1 10/2006 Hendrix
 2007/0212411 A1 9/2007 Fawzy et al.
 2008/0085306 A1* 4/2008 Nangia et al. 424/458
 2008/0131501 A1 6/2008 Liang et al.
 2011/0287099 A1 11/2011 Liang et al.

FOREIGN PATENT DOCUMENTS

WO WO 01/37808 A1 5/2001
 WO WO 02/03984 A2 1/2002
 WO WO 02/43731 A3 6/2002
 WO WO 2004/022037 A1 3/2004
 WO WO 2004/078162 A1 9/2004
 WO WO 2004/078163 A2 9/2004
 WO WO 2005/030166 A1 4/2005
 WO WO 2005/079748 A2 9/2005
 WO WO 2006/009403 A1 1/2006
 WO WO 2006/119153 A2 11/2006
 WO WO 2007/002318 1/2007

OTHER PUBLICATIONS

Adin et al., "Topiramate Serum Concentration-to-Dose Ratio," *Therapeutic Drug Monitoring*, Jun. 2004; 26(3):251-257.
 Bahk et al., "Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study," *Progress in Neuropsychopharmacology & Biological Psychiatry*, 2005, 29(1):115-121.
 Beaumanoir, Anne, "The Landau-Kleffner syndrome", In: Roger et al., Eds. *Epileptic Syndromes in Infancy, Childhood, and Adolescence*, 2nd Ed., London, England: John Libby, pp. 231-244, 1992.
 Berge et al., "Pharmaceutical Salts", *J. Pharm. Sci.*, Jan. 1977, 66(1): 1-19.
 Berlant, Jeffery L., M.D., Ph.D., "Topiramate in Posttraumatic Stress Disorder: Preliminary Clinical Observations," *J. Clin. Psychiatry*, 2001, 62(Suppl 17):60-63.
 Brandes et al., "Topiramate for Migraine Prevention," *JAMA*, Feb. 25, 2004, 291(8):965-973.
 Carpenter et al., "Do obese depressed patients respond to topiramate? A retrospective chart review," *J. Affect. Disord.*, 2002, 69(1-3):251-255.
 Chen et al., "Combination Treatment of Clozapine and Topiramate in Resistant Rapid-Cycling Bipolar Disorder," *Clin. Neuropharmacol.*, May-Jun. 2005, 28(3):136-138.
 Coleman et al., "Polymer reviewed: A practical guide to polymer miscibility," *Jul. 1990*, 31:1187-1230.
 Contin et al., "Topiramate Therapeutic Monitoring in Patients with Epilepsy: Effect of Concomitant Antiepileptic Drugs," *Ther. Drug Monit.*, 2002, 24(3):332-337.
 D'Amico et al., "Topiramate in migraine prophylaxis," *Neurological Sciences*, 2005, 26(Suppl 2):S130-S133.
 Deckers et al., "Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed," *Epilepsia*, 2000, 41(11):1364-1374.
 Diener et al., "Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control," *J. Neurol.*, 2004, 251(8):943-950.
 Dorado et al., "Topiramato en enfermedades comorbidas: epilepsia y migraña," *Rev. Neurol.*, 2006, 43(4):193-196.
 Duchene et al., "Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration," *Drug Dev. Ind. Pharm.*, 1988, 14(2&3):283-318.
 Erfurth et al., "Bupropion as Add-On Strategy in Difficult-to-Treat Bipolar Depressive Patients," *Neuropsychobiology*, 2002, 45(Suppl 1):33-36.
 Felmeister, Alvin Ph.D., "Powders," *Remington's Pharm. Sci.*, 14th Ed., 1970, Chapter 86, 1626-1628.
 Ferrari et al., "Influence of Dosage, Age, and Co-Medication on Plasma Topiramate Concentrations in Children and Adults with

US 8,877,248 B1

Page 3

(56)

References Cited

OTHER PUBLICATIONS

Severe Epilepsy and Preliminary Observations on Corrections with Clinical Response," *Therapeutic Drug Monitoring*, 2003, 25(6):700-708.

Ferrari et al., "Rizatriptan: a new milestone in migraine treatment," *Cephalalgia*, 2000, 20(Suppl 1):1.

Fincher, Julian H., "Particle Size of Drugs and Its Relationship to Absorption and Activity," *J. Pharm. Sci.*, Nov. 1968, 57(11):1825-1835.

Fisher et al., "Synergism between Topiramate and Budipine in Refractory Status in Epilepticus in the Rat," *Epilepsia*, 2004, 45(11):1300-1307.

François et al., "The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy," *Epilepsy Research*, 2006, 72:147-163.

Gurny et al., "Bioadhesive intraoral release systems: design, testing and analysis," *Biomaterials*, Nov. 1984, 5:336-340.

Hershey et al., "Effectiveness of Topiramate in the Prevention of Childhood Headaches," *Sep. 2002*;42(8):810-818.

Hoes et al., "The Application of Drug-Polymer Conjugates in Chemotherapy," *Drug Carrier Systems*, 1989, 9:57-109.

Hollander et al., "Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder," *Int. Clin. Psychopharmacol.*, 2006, 21(3): 189-191.

International Search Report and Written Opinion mailed Sep. 2, 2008, in PCT/US2007/19208. 10 pages.

Ioannides-Demos et al., "Pharmacotherapy for Obesity," *Drugs*, 2005, 65(10):1391-1418.

Johnson et al., "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial," *The Lancet*, May 17, 2003, 361(9370):1677-1685.

Kellett et al., "Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic," *J. Neurol. Neurosurg. and Psych.*, 1999;66:759-763.

Lainez et al., "Topiramate in the Prophylactic Treatment of Cluster Headache," *Headache*, Jul./Aug. 2003, 43(7):784-789.

Lalonde et al., "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese *ob/ob* mice," *Physiology & Behavior*, 2004, 80(4):415-420.

Lee et al., "The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy," *Epilepsia*, 2003; 44(3):339-347.

Lehr et al., "Intestinal Transit of Bioadhesive Microspheres in an in situ Loop in the Rat—A Comparative Study with Copolymers and Blends Based on Poly(acrylic acid)," *Journal of Controlled Release*, 1990, 13:51-62.

Leong et al., "Polymeric controlled drug delivery," *Adv. Drug Delivery Rev.*, 1987, 1:199-233.

Linhardt, Robert J. "Biodegradable Polymers for Controlled Release of Drugs," *Controlled Release of Drugs*, 1989, Chapter 2, 53-95.

Liu et al., "Preparation, characterization and in vivo evaluation of formulation of baicalin with hydroxypropyl-beta-cyclodextrin," *International Journal of Pharmaceuticals*, 2006, 312:137-147.

Longer, Mark A., Ph.D., "Sustained-Release Drug Delivery Systems," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 91, 1676-1693.

Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis," *Inter. J. of Pharm.*, 1994, 112:105-116.

Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment," *Inter. J. of Pharm.*, 1994, 112:117-124.

Luszczki et al., "Interactions of Lamotrigine with Topiramate and First-Generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis," *Epilepsia*, 2003, 44(8):1003-1013.

Mathew et al., "Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate," *Headache*, Sep. 2002, 42(8):796-803.

McElroy et al., "Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A Randomized, Placebo-Controlled Trial," *Am. J. Psychiatry*, Feb. 2003, 160(2):255-261.

Meador et al., "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers," *Neurology*, Jun. 2005, 64:2108-2114.

Mikos et al., "Interaction of Polymer Microspheres with Mucin Gels as a Means of Characterizing Polymer Retention on Mucus," *Journal of Colloid and Interface Science*, May 1991, 143(2): 366-373.

Morton et al., "Diagnosis and treatment of epilepsy in children and adolescents," *Drugs*, Mar. 1996, 51(3):399-414.

Mosek et al., "Topiramate in the treatment of refractory chronic daily headache. An open trial," *Journal of Headache and Pain*, 2005, 6:77-80.

O'Connor et al., "Powders," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 88, 1615-1632.

Park et al., "Alternative Approaches to Oral Controlled Drug Delivery: Bioadhesives and In-Situ Systems," *Recent Advances in Drug Delivery*, Plenum Press, New York, 1984, 163-183.

Pascual et al., "Testing the combination beta-blocker plus topiramate in refractory migraine," *Acta Neurol. Scand.*, 2007, 115(2):81-83.

Physician's Desk Reference, 60th Edition, 2006, pp. 2438-2447, entry for TOPAMAX®.

Physicians' Desk Reference 59th edition, 2541-2548 (2005).

Physician's Desk Reference, 56th ed., 2590-2595 (2002).

Pies, Ronald M.D., "Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review," *Annals of Clinical Psychiatry*, Dec. 2002, 14(4):223-232.

Porter, Stuart C., Ph.D., "Coating of Pharmaceutical Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, Chapter 90, 1666-1675.

Potter et al., "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Determine the Efficacy of Topiramate in the Prophylactic Treatment of Migraine," *Neurology*, Apr. 2000, 54(Suppl 3):A15.

Rudnic et al., "Oral Solid Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 89, 1633-1665.

Silberstein et al., "Topiramate in Migraine Prevention," *Arch. Neurol.*, Apr. 2004, 61(4):490-495.

Siniscalchi et al., "Combined topiramate and clonazepam therapy in a patient affected by essential tremor," *Parkinsonism Relat. Disord.*, 2007, 13(2):129-130.

Smart et al., "An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery," *J. Pharm. Pharmacol.*, 1984, 36:295-299.

Sofuoglu et al., "Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers," *Psychopharmacology*, 2006, 184(3-4): 645-651.

Storey et al., "Topiramate in Migraine Prevention: A Double-Blind Placebo-Controlled Study," *Headache*, Nov./Dec. 2001, 41(10):968-975.

Thompson et al., "Effects of topiramate on cognitive function," *J. Neurol. Neurosurg. and Psych.*, 2000; 69:634-641.

Toplak et al., "Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind placebo-controlled study," *Int. J. Obes.*, 2007, 31(1):138-146.

Von Seggern et al., "Efficacy of Topiramate in Migraine Prophylaxis: A Retrospective Chart Analysis," *Neurology*, Apr. 2000, 54(Suppl 3):A267-A268.

Weber, Marcus Vinicius Keche, M.D., "Topiramate for Obstructive Sleep Apnea and Snoring," *Am. J. Psychiatry*, May 2002, 159(5):872-873.

Winkelman, John W., "Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate," *Sleep Medicine*, 2003, 4(3):243-246.

* cited by examiner

Fig.1

80% release time vs. %Wt. gain of Release-Controlling Coating

For Surelease® coated Extended Release Beads





Fig. 2

80% release time vs. % Wt. gain of Release-Controlling Coating

For Surelease®/ Opadry® coated Extended Release Beads



U.S. Patent


Nov. 4, 2014

Sheet 3 of 6

US 8,877,248 B1

Fig. 3

Mean (n= 16) PK Profiles from Bead Populations XR1, XR2 and XR3



U.S. Patent


Nov. 4, 2014

Sheet 4 of 6

US 8,877,248 B1

Fig. 4

Mean (n= 16) PK Profiles from the Immediate Release Formulations



U.S. Patent

Nov. 4, 2014

Sheet 5 of 6

US 8,877,248 B1

Fig.5

Dissolution Profiles of Immediate Release Formulations





Fig.6. Mean PK Profiles for Sustained Release Formulations A, B, and C



US 8,877,248 B1

1

**SUSTAINED-RELEASE FORMULATIONS OF
TOPIRAMATE****CROSS-REFERENCE TO RELATED
APPLICATIONS**

The present application is a Continuation of U.S. application Ser. No. 12/926,936, filed Dec. 17, 2010, which is a Continuation of U.S. application Ser. No. 11/941,475, filed Nov. 16, 2007, which claims benefit of U.S. Provisional Application No. 60/859,502, filed Nov. 17, 2006, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Topiramate is a sulfamate substituted monosaccharide which under the trade name TOPAMAX® (Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J., U.S.A.) has been approved for use as an antiepileptic agent, as an adjuvant therapy for patients with partial onset seizures or primary generalized tonic-clonic seizures, and for the prevention of migraine. See generally, Physician's Desk Reference, 60th ed., 2538-2447 (2006); see also, U.S. Pat. No. 4,513,006.

For the treatment of epilepsy, the recommended dose of Topamax® is 400 mg/day in one or multiple doses (Physician's Desk Reference, 60th ed., 2538-2447 (2006)). For adults with epilepsy, treatment is initiated with a dose of 25-50 mg/day, with the dose being titrated in increments of 25-50 mg at weekly intervals to the recommended or effective dose.

Topamax® is an immediate release formulation. Adverse effects associated with the administration of Topamax® include, but are not limited to, somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, diplopia, renal calculi (kidney stones), hepatic failure, pancreatitis, renal tubular acidosis, acute myopia and secondary angle closure glaucoma (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Hence, though topiramate has a relatively long half-life of 21 hours in vivo, it has not been prescribed (or formulated) as a single, daily-dose, in part due to severe side-effects that often result with peak plasma levels of the drug when taken in high doses. Instead, Topamax® is typically taken in multiple, "divided" doses, usually twice-daily ("BID"). However, administration of the medicament in this manner is cumbersome and patients can forget to take their medication in a timely manner. What is more, each administration of a dose is associated with a peak in plasma concentrations of the drug, and the fluctuations associated with the peaks and valleys of blood plasma levels of the drug are undesirable. Therefore, there is a need for a formulation of topiramate, which reduces or eliminates the side effects associated with peaking and fluctuating plasma levels of the drug and preferably may be administered in a once-daily regimen.

New, highly soluble and bioavailable forms of topiramate are also needed in order to increase the safety and effectiveness of the drug.

The instant invention addresses these and other needs by providing a modified formulation of topiramate characterized by a sustained, non-pulsatile release of an active ingredient. This invention additionally provides an effective, once-daily dosage form of topiramate or salts thereof, which not only enables an effective single daily dose regimen to improve patient compliance but may also reduce some of the side

2

effects of topiramate compared to the current or higher daily doses of immediate release topiramate formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sustained release formulation of topiramate for the treatment or prevention of a pathological condition in a mammalian subject, characterized by a sustained rate of topiramate release along a pre-determined release profile.

It is yet another object of the present invention to provide topiramate formulation wherein topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect associated with the topiramate treatment.

It is a further object of the present invention to provide a sustained release formulation of topiramate that can be administered orally once a day.

It is an object of the present invention to provide a sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient, wherein the active ingredient is released from the formulation at a sustained rate along a pre-determined release profile, and wherein the sustained release formulation comprises an extended release (XR) component and an optional immediate release (IR) component.

In one embodiment of the invention, the extended release component is contained in at least one population of beads coated with a release controlling coating. The above-mentioned coating is specific for every bead population and determines its rate of release. Thus, every given bead population included into the formulation is characterized by its own specific rate of release.

In another embodiment of the invention, the sustained release topiramate formulation comprises an immediate release component in addition to an extended release component.

In a preferred embodiment of the invention, the immediate release component is an enhanced immediate release (EIR) composition.

The formulation of the present invention may be incorporated in any oral dosage form such as represented by, but not limited to, a tablet, a pill, a capsule, a troche, a sachet, and sprinkles.

It is yet another object of the present invention to provide a method of preparation of a sustained release formulation of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile, the method comprising the steps of:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method of preparation additionally includes a process for providing an XR component contained in at least one population of beads, wherein every population of beads is characterized by its own rate of release. This process comprises the steps of

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;

US 8,877,248 B1

3

3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and

4. incorporating the beads into the formulation.

The method may optionally include a process for preparation of an IR component, which optionally is an enhanced immediate release (EIR) composition. The enhanced immediate release composition includes at least one agent selected from a group comprising complexing agents and enhancing agents. Without any limitations, the enhancing agents useful in the present invention may be selected from solubilizing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors or combinations thereof.

It is yet another object of the present invention to provide a method of treatment or prevention of a pathological condition in a mammalian subject by orally administering to the subject a therapeutically effective amount of a sustained release topiramate formulation of the instant invention. The pathological conditions that may be treated by the method of the present invention include neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by topiramate administration.

DEFINITIONS

For the purposes of this invention, the term "topiramate" includes topiramate or any pharmaceutically acceptable salts thereof.

An "immediate release formulation" refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.

For the purposes of this application, an enhancing agent ("enhancer") is defined as any non-pharmaceutically active ingredient that improves the therapeutic potential of a formulation.

The term "enhanced immediate release composition" as used herein describes an immediate release composition improved in terms of a therapeutic potential or treatment modality.

"Sustained release" is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.

By "prolonged period of time" it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.

As used herein, unless otherwise noted, "rate of release" or "release rate" of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the "T.sub.x" value, where "x" is the percent of drug that has been released.

The release rates referred to herein are determined by placing a dosage form to be tested in a medium in an appropriate dissolution bath. Aliquots of the medium, collected at pre-set

4

intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.

"C" denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as "drug plasma concentration", "plasma drug concentration" or "plasma concentration" which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as C_{time}, as in C_{9 hr} or C_{4 hr}, etc.

The maximum plasma drug concentration during the dosing period is referenced as C_{max}, while C_{min} refers to the minimum blood plasma drug concentration at the end of a dosing interval; and C_{ave} refers to an average concentration during the dosing interval.

The "degree of fluctuation" is defined as a quotient (C_{max} - C_{min})/C_{ave}.

Persons of skill in the art will appreciate that blood plasma drug concentrations obtained in individual subjects will vary due to interpatient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a drug plasma concentration is listed, the value listed is the calculated mean value based on values obtained from a groups of subjects tested.

The term "bioavailability" refers to an extent to which—and sometimes rate at which—the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.

"AUC" is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.

Side effect is defined herein as a secondary and usually adverse effect of a drug.

The term "beads", as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease® coated extended release beads.

FIG. 2 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease®/Opadry® coated extended release beads.

FIG. 3 shows mean (n=16) pharmacokinetic profiles for bead populations XR1, XR2 and XR3.

FIG. 4 shows mean (n=16) pharmacokinetic profiles for the immediate release formulations.

FIG. 5 shows the dissolution profiles of Topamax®, topiramate IR beads, and topiramate enhanced immediate release beads.

FIG. 6 shows mean PK Profiles for Sustained Release Formulations A, B, and C.


DETAILED DESCRIPTION OF THE INVENTION

Topiramate is a sulfamate-substituted monosaccharide having the chemical name 2,3,4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate. The molecular formula of

US 8,877,248 B1

5

topiramate is C₁₂H₂₁NO₈S, and its chemical structure is represented by formula below:



Topiramate is a white crystalline powder that is soluble in alkaline solutions containing sodium hydroxide or sodium phosphate, soluble in acetone, dimethylsulfoxide and ethanol. However, the solubility of topiramate in water at room temperature is only about 9.8 mg/ml. Topiramate is not extensively metabolized and is excreted largely through the urine (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Topiramate pharmacokinetics are linear, producing a dose proportional increase in blood plasma concentration levels with increased dosing, and is not significantly affected by food. Patients taking topiramate over prolonged period of time did not develop resistance to the drug. Following oral administration of an immediate release dosage form, topiramate is rapidly absorbed with plasma drug concentrations peaking in approximately 2 hours. The mean elimination half-life is reported to be about 21 hours.

Currently, topiramate is administered in multiple daily doses in part due to the severe side effects exhibited by the immediate release product, especially when taken in a high single dose.

A sustained release topiramate formulation that will be suitable for once-a-day administration and will result in the diminished level or severity of side effects is needed.

The present invention provides sustained release formulation of topiramate wherein the total daily dose of topiramate is provided in an effective once-daily dose while minimizing fluctuations in the blood plasma drug concentration.

The current invention also provides for formulations of topiramate wherein the maximum plasma concentration of topiramate is attenuated as compared to the same amount of topiramate administered as an immediate release formulation BID; therefore some of the side effects of topiramate, such as CNS side effects including but not limited to dizziness, paresthesia, nervousness, psychomotor slowing, confusion, and difficulty with concentration/attention, observed when taking the immediate release product, may be reduced or eliminated.

Formulations of the instant invention are characterized by a maximum steady state plasma concentration (C_{max}) of topiramate which is higher than the minimal therapeutically effective concentration, and is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

In one embodiment, the novel formulations provide for a relative C_{max} in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID. In the other embodiment, the invention provides for the C_{max} which is lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. The C_{min} of the topiramate formulation of the present invention is about equal or higher than a C_{min} of an equivalent amount of immediate release topiramate formulation given BID.

6

Compared to the immediate release topiramate formulation, the sustained release topiramate formulations attenuate the C_{max} of topiramate while extending the coverage of plasma concentration above the minimum plasma concentration required therapeutic efficacy. The formulation of the current invention provides for a relative steady state AUC in the range of 80% to 125%, while minimizing the degree of fluctuation, which is preferably in the range of 25% to 90%, as compared to an equivalent amount of immediate release topiramate formulation given in two divided doses (Table 5 and 6).

The present invention additionally provides a sustained release topiramate formulation for the treatment or prevention of a pathological condition in a mammalian subject wherein topiramate is released from the formulation at a sustained rate along a pre-determined release profile. Such release is achieved by incorporation into the formulation of an extended release component (XR) and an optional immediate release component (IR).

The relative amount of each component in the topiramate formulation of the present invention is determined according to the purpose of administration and a pre-determined release profile, and the total amount of topiramate in the formulation varies from 0.5 mg to about 3000 mg. In other words, topiramate or its salt is present in the composition in an amount of from about 0.5% to about 85% by weight, and preferably of from about 2% to about 70% by weight. The term "about" has been recited here and throughout the specification to account for variations, which can arise from inaccuracies in measurement inherent and understood by those of ordinary skill in the chemical and pharmaceutical arts.

The XR component of the formulation of the present invention releases topiramate in a continuous manner and is adjusted in such a way that 80% of the active ingredient is released in vitro in the predetermined period of time. By way of example, and by no means limiting the scope of the invention, the period of time may be not more than 24 hours, not more than 16 hours, not more than 12 hours, not more than 8 hours, or not more than 4 hours, depending on desired attributes of the final product.

In one embodiment, the extended release (XR) component is contained in at least one population of beads coated with a coating that modifies and controls the release of topiramate from the beads (release controlling coating). The release controlling coating is specific for every population of beads and determines the rate of release of topiramate from the given bead population.

The beads useful in the formulation of the present invention comprise an inert carrier, topiramate, a binder, an aforementioned release controlling coating and optionally, an overcoat that provides additional protection from moisture, static charge reduction, taste masking and coloring attributes to the particulates.

The inert carriers useful in the present invention may be selected from, but are not limited to, a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres. The inert carrier is present in an amount of from about 15% to about 99% by weight, and preferably in an amount of from about 40% to about 97% by weight.

Topiramate is introduced to the inert carrier by techniques known to one skilled in the art, such as drug layering, powder coating, extrusion/spheronization, roller compaction or granulation. Preferably, the introduction method is drug layering by spraying a suspension of topiramate and a binder onto the inert carrier.

The binder may be present in the bead formulation in an amount of from about 0.1% to about 15% by weight, and

US 8,877,248 B1

7

preferably of from about 0.2% to about 10% by weight. Binders include, but are not limited to starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, or polyvinylpyrrolidone.

The release controlling coating specific for every bead population comprises a coating material, and, optionally, a pore former and other excipients. The coating material is preferably selected from a group comprising cellulosic polymers, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and cellulose acetate phthalate; polyvinyl alcohol; acrylic polymers such as polyacrylates, polymethacrylates and copolymers thereof, and other water-based or solvent-based coating materials. The release-controlling coating is population-specific in the sense that the rate of release of topiramate from every bead population is controlled by at least one parameter of the release controlling coating, such as the nature of the coating, coating level, type and concentration of a pore former, process parameters and combinations thereof. Thus, changing a parameter, such as a pore former concentration, or the conditions of the curing, as will be discussed in more details below, (see Example 5) allows to change the release of topiramate from any given bead population and to selectively adjust the formulation to the pre-determined release profile. The release profile, in its turn, may be chosen or modified in such a way as to achieve the best treatment modality depending on the specific needs of the patient population and the nature of the condition.

For example, with all things being equal, there exists a mathematical relationship between the release controlling coating level among the cured beads and the 80% in vitro release time. Pre-determined target profiles can therefore be achieved by the interpolation or extrapolation of the relationship curve. For example, when the release controlling coating comprises only ethylcellulose (Surelease®) as a coating material, a logarithmic relationship exists between the % weight gain with the coating and the 80% release time in an in-vitro dissolution test (FIG. 1):

$$\text{Log}(T_{80\% \text{ release}}) = a(\% \text{ coating}) + b.$$

When ethylcellulose/HPMC (Surelease®/Opadry®) mixture is used, for example, 85:15 mixture or 80:20 mixture, a linear relationship exists between the % weight gain with the coating and the 80% release time in an in-vitro dissolution test (FIG. 2):

$$T_{80\% \text{ release}} = a(\% \text{ coating}) + b.$$

Pore formers suitable for use in the release controlling coating herein can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, Carbowaxes, Carbopol, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium

8

bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like.

The release controlling coating in the current invention can further comprise other additives known in the art such as plasticizers, anti-adherents, glidants, and antifoams.

In some embodiments, it may be further desirable to optionally coat the XR beads with an "overcoat," to provide, e.g., moisture protection, static charge reduction, taste-masking, flavoring, coloring, and/or polish or other cosmetic appeal to the beads. Suitable coating materials for such an overcoat are known in the art, and include, but are not limited to, cellulosic polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and microcrystalline cellulose, or combinations thereof (for example various Opadry® coating materials).

Topiramate-containing beads of the present invention may additionally contain enhancers that may be exemplified by, but not limited to, solubility enhancers, dissolution enhancers, absorption enhancers, permeability enhancers, stabilizers, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, and multidrug resistance protein inhibitors. Alternatively, the formulation can also contain enhancers that are separated from the topiramate beads, for example in a separate population of beads or as a powder. In yet another embodiment, the enhancer(s) may be contained in a separate layer on a topiramate-containing bead either under or above the release controlling coating.

The beads may further comprise other pharmaceutically active agents suitable for use in combination with topiramate for treatment or prevention of a pathological condition. The additional pharmaceutically active agents, without limitation, may be represented by analgesic and anti-inflammatory compounds such as COX-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs such as opiates and morphinomimetics, synthetic drugs with narcotic properties such as tramadol; anticonvulsants such as valproic acid or its derivatives, carbamazepine, oxcarbazepine, gabapentin, and lamotrigine; anorectics or anti-obesity agents such as sibutramine or other, orlistat or other pancreatic lipase inhibitors, diethylpropion, fluoxetine, bupropion, amphetamine, methamphetamine, sertraline, zonisamide, and metformin, as well as medications associated with weight-gain, such as sulfonylurea derivatives, insulin, and thiazolidinediones whose weight-gain effect is tempered by topiramate; anti-hypertensive agents such as diuretics, anti-adrenergics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, vasodilators, centrally acting adrenergic drugs, and adrenergic neuron blockers; mood stabilizers such as various forms/salts of lithium, Omega-3 fatty acids and others known in the art, drugs for treatment or prevention of migraines, such as ergot derivatives or triptans, or any other pharmaceutical or nutraceutical ingredient that can be safely and beneficially combined with topiramate.

A relative amount of every bead population in the complete formulation is determined on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile and will be discussed in more detail in Example 6.

In another embodiment, the formulation of the present invention comprises an extended release component as described above, and an immediate release component. The IR component may be an enhanced immediate release composition. The enhanced immediate release composition may be characterized by a faster in vitro topiramate release as compared to the IR formulation. Preferably, at least 80% of an active compound from the enhanced immediate release com-

US 8,877,248 B1

9

position is released in a time period of not more than 30 minutes. More preferably, at least 50% of an active compound from the enhanced immediate release composition is released in a time period of not more than 10 minutes, and at least 25% is dissolved in a time period of not more than 5 minutes after the oral administration. In the most preferred embodiment of the present invention, at least 75% of the active compound is released from the EIR composition in a time period of not more than 10 minutes. The embodiment in which the IR component is an enhanced immediate release composition will be discussed in more details below.

In addition to topiramate and inactive excipients, the EIR composition of the present invention comprises at least one agent selected from a group consisting of complexing agents and enhancing agents.

Without any limitation, the enhancing agents suitable for the present invention may be selected from the solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. The representative, but non-limiting examples of these compounds are Vitamin E TPGS, amino acid such as glutamic acid and glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans such as maltodextrin, Cremophor RH40 (glycerol-polyethylene glycol oxystearate), Gelucire 50/13 (PEG-32 glyceryl palmitostearate), sodium lauryl sulfate, Tween 80 (polyoxyethylene sorbitan monooleate), benzyl alcohol, Span 20 (sorbitan monolaurate), Poloxamer 407, PEG3350, PVP K25, oleic acid, Capmul GMO (glyceryl monooleate), sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, crosscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose, sodium bicarbonate, calcium citrate, sodium docusate, and menthol, among others. Enhancers can be combined to achieve multiple enhancement effects, for example, solubility enhancement combined with permeability enhancement and p-glycoprotein inhibition, or to provide a synergistic enhancement effect to achieve greater and more efficient enhancement. For example, polyglycolized glycerides (different grades of Gelucire) can be combined with sodium lauryl sulfate to achieve higher solubility enhancement as well as faster dissolution of topiramate.

In one embodiment, the EIR composition comprises a highly soluble complex of topiramate with a complexing agent that is represented by, but not limited to, cyclodextrins, including cyclodextrin derivatives, such as hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and alpha-cyclodextrin. The ratio of cyclodextrin to topiramate in the EIR formulation is preferably less than 20:1 and more preferably less than 5:1. In the most preferred embodiment, the complexing agent is hydroxypropyl beta cyclodextrin.

The highly soluble complex of topiramate and cyclodextrin is prepared by mixing topiramate and cyclodextrin together in the presence of water. The concentration of cyclodextrin is preferably high to facilitate the formation of topiramate-enhancer complex. In the case when the complexing agent is hydroxypropyl-beta-cyclodextrin, the concentration of the hydroxypropyl-beta-cyclodextrin solution used for mixing with topiramate is greater than 2%, preferably greater than 20%, and more preferably at least about 40%. The amount of

10

topiramate is determined by a desired ratio of hydroxypropyl-beta-cyclodextrin to topiramate, which is preferably less than 20:1, and more preferably less than 5:1. The mixing time of the complex solution is from about one hour to about 48 hours, and preferably from about 5 hours to about 24 hours. The addition of hydroxypropyl-beta-cyclodextrin and topiramate can be incremental to reduce the viscosity of the complex solution and to achieve better complexation.

In a further embodiment, the EIR component of the present invention is contained in at least one bead population. Topiramate EIR beads can be prepared using processes suitable for bead manufacturing, such as coating of a topiramate suspension, dispersion or solution onto an inert carrier, or by roller compaction, granulation, extrusion/spheronization, or powder coating, and are not limited by the examples cited therein. The enhancing agents of the present invention can be incorporated into the topiramate containing beads, or may be contained in other beads separated from the topiramate containing beads. By way of a non-limiting example, topiramate-containing EIR beads were prepared by coating topiramate dispersion onto an inert carrier such as sugar spheres. The topiramate dispersion, in addition to topiramate in the micronized form or in non-micronized form, can contain one or more enhancers, water and optionally a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

When the formulation is enhanced with complexing agents, the agents may be first mixed with topiramate and a suitable solvent such as water to form the complex. The topiramate-containing complex is then mixed with a binder solution prepared separately to give the coating dispersion. The coating dispersion is then sprayed onto the inert carrier such as sugar spheres using a fluid bed processor.

In an alternative embodiment of the invention, the formulation comprises at least one XR bead population, and at least one additional combination bead population consisting of the extended release beads that have an additional immediate release component layer coated on top of the release controlling coating. This layer may be formed by a suitable loading method such as solution/suspension/dispersion coating, powder coating or wet granulation.

In yet another embodiment, at least part (i.e., more than 0.01%, preferably at least 1%) of the active ingredient may be present in the formulation in a form of micronized particles with the size of from 1 μ m to 1000 μ m, preferably from 2 μ m to about 200 μ m, more preferably from 2 μ m to about 100 μ m. Further, one or more enhancers may be present in the formulations covered by this embodiment. The enhancers are selected from solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. Preferably, the enhancer is a solubility enhancer or a dissolution enhancer.

The topiramate formulation of the present invention may be formulated in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, sprinkles, or any other form suitable for oral administration.

In one embodiment of the invention, the dosage form is a gelatin capsule containing the XR component in a form of at least one population of beads, and an optional IR component. The IR component, when present, may be in a form of a powder, or may also be contained in at least one population of beads to achieve faster dissolution of topiramate (FIG. 5).

US 8,877,248 B1

11

In an alternative embodiment, part of the total amount of the active ingredient may be incorporated into the aforementioned bead populations that will be contained inside an enclosure such as a capsule, and the rest of the active ingredient can be loaded on the outside of the enclosure by a suitable loading method such as solution/suspension/dispersion coating or powder coating or wet granulation. For example, a part of the immediate release topiramate formulation can be loaded by coating on the outside of a capsule that contains within it other populations of topiramate such as extended release topiramate. This dosage form can provide almost instantaneous dissolution of the initial portion of topiramate dose from the outside of the capsule, followed by a sustained release of the rest of topiramate from inside the capsule.

In a further embodiment of the invention, the dosage form is a tablet. Without imposing any limitations, this embodiment may be exemplified by a multilayered tablet that comprises at least one layer containing the extended release component, and at least one layer comprising the immediate release component, wherein the IR component may or may not be an EIR composition.

The last two embodiments are especially beneficial when fast onset of action followed by sustained release is preferred, as is for example in the cases of a breakthrough migraine episode.

The current invention additionally encompasses a method of preparing formulations of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile. The method comprises the following steps:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method comprises a step for providing an immediate release component, which may be an enhanced immediate release composition.

In another embodiment, the method includes a process for providing an extended release component contained in at least one population of beads characterized by its own rate of release, wherein the process includes the steps of:

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The exact amount of beads of every population incorporated into the formulation and into the final dosage form is determined using the linear superposition principle (WinNonLin) on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile (Example 6).

Release profiles of XR topiramate beads can be selectively adjusted, modified or stabilized by curing the beads at an elevated temperature. This process is well known in the art. However, it was unexpectedly discovered that curing the beads in the curing apparatus in the presence of at least one suitable solvent dramatically reduces the curing time necessary to produce a desired release profile and a level of stabil-

12

ity. The curing process that previously required up to two weeks can be carried out by the method of current invention in several hours.

The assisting solvents can be selected from those solvents that can dissolve or partially dissolve the coating material, or those that can induce or assist the coalescence or molecular relaxation of the coating material, or those that can reduce electrostatic charge on the dosage forms during curing and those that can facilitate curing at a higher temperature. Examples of these solvents include but are not limited to organic solvents, such as alcohols, ketones, ethers, esters, amides, amines, hydrocarbons including substituted hydrocarbons such as chlorinated hydrocarbons and aromatic hydrocarbons, furans, sulfoxides, organic acids, phenols, super-critical fluids; ammonia; and water, buffered water, or water solutions of other inorganic or organic compounds, and their combinations. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

The curing of the dosage form normally is done in an apparatus that can operate at elevated temperatures and that can deliver the assisting solvents by means such as spray, injection, or vaporization. In the embodiment of the invention when the assisting solvent is sprayed or injected into the curing apparatus, the stream of solvent is introduced directly onto the coated beads. The amount of the solvent necessary to produce the desired effect, such as the desired release parameters and stabilization of the coating, depends on the nature of the solvent and the method of solvent delivery.

Typically, when the vaporization method is used, the organic solvents and aqueous solutions may be used in the wide range of vapor concentrations varying from 2% to more than 100%, providing an unsaturated, saturated or an oversaturated atmosphere. The pure water, however, has to be used in such an amount as to provide at least a saturated or, preferably, an oversaturated atmosphere in the curing apparatus. At least during the delivery of assisting solvents, the coated beads are mixed or agitated either continuously or in a pulsed manner.

In an alternative embodiment of the invention, hot water steam is introduced into the curing apparatus for a pre-selected period of time. The steam serves simultaneously as a solvent and as a source of heat for the beads. Introduction of steam is followed by a drying period.

This method of curing the release controlling coating results in many benefits including the dramatically shortened curing time, increased stability and modification of the release profile, and is not limited to topiramate containing beads, but includes the curing of any microparticles regardless of the drug.

Specifically, active ingredient containing beads, with or without the optional over-coat, are charged to a fluid bed processor or a pan coater and heated to a desired curing temperature range, for example 40° C. to 80° C. for sustained release dosage forms containing ethylcellulose (Surelease®), and 40° C. to 70° C. for sustained release dosage forms containing acrylic polymers (Eudragit® RS and Eudragit® RL). The assisting solvent or solvents, such as water or alcohol-water mixture, are sprayed onto the beads while mixing by, for example, fluidizing or rotating. Alternatively, the process is carried out in an oven where hot steam is introduced as previously discussed. Solvent-assisted curing is carried out to a desired curing time length, either in one curing period or in multiple, separate curing periods. The dosage forms can be further dried for a short period of time to remove residual solvents.

US 8,877,248 B1

15

16

TABLE 1-continued

Over-coat material	—	Opadry® AMB White	Opadry® AMB White	—	Opadry® AMB White	—	Opadry® AMB White
Over-coat coating level	—	1.5%	1.5%	—	1.5%	—	1.5%
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven
Topiramate Beads							
	XR3	XR4	XR5	XR6	XR7	XR8	
RC coating material	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Acrylic polymers (Eudragit® RL30D/RS30D)	
Pore-former	—	Cellulosic polymers (Opadry® Clear)	Cellulosic polymers (Opadry® Clear)	Cellulosic polymers (Opadry® Clear)	Cellulosic polymers (Opadry® Clear)	—	
RC coating material to pore-former ratio	—	80:20	80:20	80:20	85:15	—	
RC coating level	3.7%	3.1%	5.2%	9.5%	15%	15%	
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	
Over-coat material	—	—	—	—	—	—	
Over-coat coating level	—	—	—	—	—	—	
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, fluid bed/5% alcohol- water, or oven	Fluid bed/ water, fluid bed/5% alcohol- water, or oven	

*RC - Release Controlling

Example 2

Method of
Topiramate-Hydroxypropyl-beta-cyclodextrin
Complex Bead Preparation

Approximately half of the intended amount of topiramate was added to the water with constant mixing followed by sprinkling of hydroxypropyl-beta-cyclodextrin into the dispersion. Once the dispersion became significantly less viscous, more drug substance was added followed by sprinkling of more hydroxypropyl-beta-cyclodextrin. The drug and hydroxypropyl-beta-cyclodextrin addition steps were repeated, and the dispersion was mixed for 12-18 hours. Separately, hydroxypropylmethylcellulose was dissolved in water. The above topiramate-hydroxypropyl-beta-cyclodextrin dispersion and hydroxypropylmethylcellulose solution were mixed together for 15 to 30 minutes and the mixture was screened through an 80-mesh sieve. The resultant dispersion was sprayed onto sugar spheres using a fluid bed processor to yield the enhanced immediate release beads (Table 2).

TABLE 2

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions				
Component	Percentage (w/w) in Beads			
	EIR-1 (HPBCD: Drug = 3:2)*	EIR-2 (HPBCD: Drug = 3:2)*	EIR-3 (HPBCD: Drug = 1:1)*	EIR-4 (HPBCD: Drug = 1:2)*
Topiramate	25.0	3.3	28.9	33.3
Hydroxypropyl-beta-cyclodextrin	37.5	4.95	28.9	16.7
Hydroxypropylmethylcellulose	3.1	0.41	2.4	4.2
Sugar spheres	34.4	91.34	39.8	45.8

*HPBCD:Drug - Hydroxypropyl-beta-cyclodextrin to drug substance ratio

Example 3

Topiramate EIR Beads Containing Non-Complexing
Enhancers

Topiramate is dispersed in a binder solution, such as hydroxypropylmethylcellulose solution, that contains an appropriate amount of enhancer or enhancers such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin

US 8,877,248 B1

17

E TPGS) and sodium lauryl sulfate combination, polyoxyl hydrogenated castor oil (different grades of Cremophor RH), polyglycolized glycerides (different grades of Gelucire), polyglycolized glycerides (different grades of Gelucire) combined with sodium lauryl sulfate, or combinations thereof. The resultant dispersion is sprayed onto an inert carrier such as sugar spheres using a fluid bed processor to achieve a desired drug load (Table 3).

TABLE 3

Enhanced Immediate Release Topiramate Bead Compositions			
Component	Percentage (w/w) in Beads		
	EIR-5	EIR-6	EIR-7
Topiramate	36.8	37.9	36.4
Sodium lauryl sulfate	0.7	0.5	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	7.3	—	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	9.1
Polyglycolized glycerides (Gelucire 50/13)	—	4.7	—
Hydroxypropylmethylcellulose	4.6	4.8	4.5
Sugar spheres	50.6	52.1	50.0

Example 4

Topiramate EIR Beads Containing Micronized Particles

Miconized or non-micronized topiramate is dispersed in a solution with or without heating, optionally containing dissolution enhancing agents such as mannose, maltose, mannitol, lactose, maltodextrin and sodium starch glucolate, and optionally containing one or more additional enhancers such as PEG3350, sodium lauryl sulfate, sodium docusate, polyoxyethylene sorbitan monooleate and Poloxamers, under such process parameters that topiramate particles that remain undissolved have a particle size of about 2 micron to about 30 micron. A particle size reduction device such as a homogenizer can also be used to reduce the particle size of undissolved topiramate. The resultant topiramate dispersion is then sprayed onto inert carriers such as sugar spheres in a coating processor such as a fluid bed processor. The formulations obtained are represented in the Table 4:

TABLE 4

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Topiramate	3.2	26.0	25.0	3.2	26.0	26.0
Mannose	0.4	5.0	3.3	2.0	10.0	10.0
Maltrin 250	—	—	1.0	1.0	—	—
PEG3350	1.0	15.0	—	—	—	10.0
Sodium lauryl sulfate	—	—	—	—	0.5	—
Hydroxypropyl-beta-cyclodextrin	—	37.5	—	—	—	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	—	—	—	—	2.0	—

18

TABLE 4-continued

	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	—	—	—	2.0
Sugar spheres	95.4	54.0	33.2	93.8	61.5	52.0

Example 5

Method of Curing Beads

The topiramate beads coated with a release controlling coating, with or without an overcoat, can be cured using the above-mentioned solvent-assisted curing process, or using the heat-only curing process, to a desired curing level and preferably to complete curing.

Specifically, the core is coated to a desired coating level with a solution or dispersion of the release controlling coating material, with or without the above-mentioned additives such as pore-formers, using a fluid bed processor or any other suitable apparatus for coating of the core. Product temperature is controlled at a desirable range, for example 20° C. to 60° C. for the coating of ethylcellulose (Surelease®) and 20° C. to 60° C. for acrylic polymers (Eudragit® RL and Eudragit® RS grades). An optional overcoat with materials such as cellulosic polymers (various Opadry®) is applied thereafter. Curing of the sustained release topiramate beads is carried out either in an oven at 40° C. to 80° C. for Surelease® containing beads or at 40° C. to 70° C. for Eudragit® RL or RS containing beads, or in a fluid bed processor with or without the use of assisting solvents at similar product temperatures.

For curing that uses assisting solvents, the assisting solvent can be delivered through top spray, bottom spray, side spray or injection, or introduced by vaporization. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

Example 6

Sustained Release Formulations of Topiramate

a. Plasma concentration versus time curves for the topiramate formulations containing extended release and immediate release bead populations are simulated using WinNonlin Version 5.0.1 based on the pharmacokinetic data on the separate bead populations that were generated in a comparative randomized single-dose 6-way crossover study in healthy adult volunteers. The study included administration of a 50 mg oral dose of three extended release compositions, designated here as XR1, XR2 and XR3, two immediate release compositions ((Topamax®, Ortho-McNeil Neurologics, Inc.) (25 mg BID), and an immediate release bead formulation) and an enhanced immediate release (IR) bead composition. The single dose topiramate plasma concentration profiles for XR1, XR2 and XR3 are shown in FIG. 3. The single dose topiramate plasma concentration profiles for IR are shown in FIG. 4. The data are projected to a steady-state (SS) with a 24 h dosing interval for the sustained release compo-

US 8,877,248 B1

19

sitions and a 12 h dosing interval for Topamax, using the linear superposition principle (WinNonlin). The extended release populations XR1, XR2 and XR3, and an immediate release (IR) population are selected in such a way as to be defined by at least one of the three following sets of conditions:

1. for the steady state,
for XR1, $1.70C_{maxIR} \geq C_{maxXR1} \geq 1.30C_{maxIR}$
for XR2, $0.40C_{maxIR} \geq C_{maxXR2} \geq 0.20C_{maxIR}$
for XR3, $0.25C_{maxIR} \geq C_{maxXR3} \geq 0.05C_{maxIR}$
2. for in-vitro dissolution,
for XR1, $1.5 \text{ h} \leq T_{80\%} \leq 4 \text{ h}$
for XR2, $5 \text{ h} \leq T_{80\%} \leq 8 \text{ h}$
for XR3, $8 \text{ h} \leq T_{80\%} \leq 10 \text{ h}$
3. for a single initial dose in-vivo,
for XR1, $4 \text{ h} \leq T_{max} \leq 8.5 \text{ h}$
for XR2, $T_{max} \geq 16 \text{ h}$
for XR3, $T_{max} \geq 16 \text{ h}$.

Optionally, the immediate release bead population is composed of enhanced immediate release (EIR) beads such that at least one condition is true: a. for the steady state, $2.40 C_{maxIR} \geq C_{maxEIR} \geq 1.20 C_{maxIR}$; b. for in-vitro dissolution, $T_{80\%} \leq 30 \text{ min}$; c. for a single initial dose in-vivo, $T_{max} \leq 2 \text{ h}$.

The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 5 below. These formulations are selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.

TABLE 5

Composition and Pharmacokinetic data of Multi-bead Formulations							
	#1	#2	#3	#4	#5	#6	#7
% XR1	20	50	0	10	10	15	0
% XR2	80	0	85	85	80	70	100
% XR3	0	50	0	0	0	15	0
% IR	0	0	15	5	10	0	0
Rel. BA (%)	98.5	100.5	96.6	97.4	97.6	97.3	96.0
Degree of fluctuation, SS	0.15	0.22	0.14	0.14	0.15	0.13	0.09

b. based on the results of WinNonlin simulation discussed in part (a), formulations #1 (A), #3 (B), and #4 (C) were tested in the comparative randomized multi-dose 4-way study following a once a day 50 mg oral dose of three controlled release formulations and a 25 mg twice a day oral doses of Topamax® in healthy adult volunteers.

The results of the study are summarized in Table 6 and FIG. 6:

TABLE 6

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (Topamax)
% XR1	20	0	10	—
% XR2	80	86	84	—
% XR3	0	0	0	—
% IR	0	14	6	—

20

TABLE 6-continued

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (Topamax)
Rel. BA (%), SS	92	93	95	100
Relative Degree of fluctuation, SS	73%	72%	66%	100%

What is claimed is:

1. A sustained release formulation of topiramate comprising topiramate as an active ingredient, which is released from the formulation along a pre-determined release profile, the formulation comprising:

(a) an extended release (XR) topiramate-containing component, comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,

(b) an immediate release (IR) topiramate-containing component comprising:

(i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or

(ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrins, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, croscopolvone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof,

wherein the XR component releases topiramate in a continuous manner and such that greater than or equal to about 80% of the topiramate is released in vitro in less than or equal to about 4 hours.

2. The formulation of claim 1, wherein the XR component is contained in at least one population of beads.

3. The formulation of claim 1, comprising an IR component such that 80% of the topiramate is released in not more than 1 hour.

4. The formulation according to claim 1, wherein the XR component further comprises a binder selected from the group consisting of starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

5. The formulation according to claim 1, wherein the XR component further comprises a pore former selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomer,

US 8,877,248 B1

21

diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; alkali metal salts and alkaline earth metal salts, and combinations thereof.

6. The formulation of claim 1, wherein at least a part of the active ingredient is in a form of micronized particles.

7. The formulation of claim 1, wherein the formulation is in a dosage form of a capsule or sprinkles.

8. The formulation of claim 1, wherein the total amount of topiramate in the formulation is from 0.5 to 3000 mg.

9. The formulation of claim 1, wherein the XR component comprises an inert carrier selected from the group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres.

10. The formulation of claim 1, wherein the release controlling coating comprises ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates or copolymers thereof.

11. The formulation of claim 1, wherein the formulation provides for a maximum steady state plasma concentration (C_{max}) of topiramate which is in the range from 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

12. The formulation of claim 1, wherein the formulation provides for a relative steady state AUC in the range of 80% to 125% of the AUC of the same amount of topiramate administered as an immediate release formulation BID.

13. The formulation of claim 1, further comprising an additional pharmaceutically active ingredient in combination with topiramate.

14. A sustained release formulation of topiramate comprising topiramate as an active ingredient, which is released from the formulation along a pre-determined release profile, the formulation comprising:

(a) an extended release (XR) topiramate-containing component, comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,

(b) an immediate release (IR) topiramate-containing component comprising:

(i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or

(ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol,

22

sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, croscopolone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof,

wherein the XR component releases topiramate in a continuous manner and such that greater than or equal to about 80% of the topiramate is released in vitro in less than or equal to about 12 hours.

15. A method of treatment of a neurological and/or psychiatric condition selected from the group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, and amyotrophic lateral sclerosis (ALS), comprising orally administering to a mammalian subject a therapeutically effective amount of a sustained release formulation according to claim 1.

16. The method of claim 15, wherein the condition is epilepsy.

17. The method of claim 15, wherein the condition is migraine.

18. A method of treatment of a neurological and/or psychiatric condition selected from the group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, and amyotrophic lateral sclerosis (ALS), comprising orally administering to a mammalian subject a therapeutically effective amount of a sustained release formulation according to claim 14.

19. The method of claim 18, wherein the condition is epilepsy.

20. The method of claim 18, wherein the condition is migraine.

* * * * *

Exhibit E



US008889191B2

(12) **United States Patent**
Liang et al.

(10) **Patent No.:** **US 8,889,191 B2**
(45) **Date of Patent:** ***Nov. 18, 2014**

(54) **SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE**

(75) Inventors: **Likan Liang**, Boyds, MD (US); **Hua Wang**, Clarksville, MD (US); **Padmanabh P. Bhatt**, Rockville, MD (US); **Michael L. Vieira**, Gaithersburg, MD (US)

(73) Assignee: **Supernus Pharmaceuticals, Inc.**, Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/926,936**

(22) Filed: **Dec. 17, 2010**

(65) **Prior Publication Data**

US 2011/0287103 A1 Nov. 24, 2011

Related U.S. Application Data

(63) Continuation of application No. 11/941,475, filed on Nov. 16, 2007, now Pat. No. 8,298,576.

(60) Provisional application No. 60/859,502, filed on Nov. 17, 2006.

(51) **Int. Cl.**

A61K 9/16 (2006.01)

A61K 9/24 (2006.01)

A61K 9/50 (2006.01)

A61K 31/357 (2006.01)

A61K 47/48 (2006.01)

B82Y 5/00 (2011.01)

(52) **U.S. Cl.**

CPC **A61K 9/1676** (2013.01); **A61K 9/209** (2013.01); **A61K 9/5078** (2013.01); **A61K 9/5084** (2013.01); **A61K 31/357** (2013.01); **A61K 47/48969** (2013.01); **B82Y 5/00** (2013.01)

USPC **424/490**; 427/2.21; 514/25

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,528,378 A 10/1950 Mannheimer et al.
2,675,619 A 4/1954 Cone
2,677,700 A 5/1954 Jackson et al.
2,781,354 A 2/1957 Mannheimer et al.
2,979,578 A 4/1961 Curtis
2,996,431 A 8/1961 Barry

3,036,118 A 5/1962 Jackson et al.
3,139,383 A 6/1964 Neville et al.
3,535,307 A 10/1970 Moss et al.
3,811,444 A 5/1974 Heller et al.
3,829,506 A 8/1974 Schmolka et al.
3,962,414 A 6/1976 Michaels
3,992,518 A 11/1976 Chien et al.
4,066,747 A 1/1978 Capozza
4,070,347 A 1/1978 Schmitt
4,079,038 A 3/1978 Choi et al.
4,083,949 A 4/1978 Benedikt
4,093,709 A 6/1978 Choi et al.
4,290,426 A 9/1981 Luschen et al.
4,434,153 A 2/1984 Urquhart et al.
4,513,006 A 4/1985 Maryanoff et al.
4,721,613 A 1/1988 Urquhart et al.
4,727,064 A 2/1988 Pitha
4,752,470 A 6/1988 Mehta
4,757,128 A 7/1988 Domb et al.
4,853,229 A 8/1989 Theeuwes
4,938,763 A 7/1990 Dunn et al.
4,997,904 A 3/1991 Domb
5,030,447 A 7/1991 Joshi et al.
5,175,235 A 12/1992 Domb et al.
5,180,589 A 1/1993 Joshi et al.
5,225,202 A 7/1993 Hodges et al.
5,256,440 A 10/1993 Appel et al.
5,378,475 A 1/1995 Smith et al.
5,478,577 A 12/1995 Sackler et al.
5,500,227 A 3/1996 Oshlack et al.
5,576,311 A 11/1996 Guy
5,753,693 A 5/1998 Shank
5,760,007 A 6/1998 Shank et al.
5,773,019 A 6/1998 Ashton et al.
5,935,933 A 8/1999 Shank et al.
5,955,096 A 9/1999 Santos et al.
5,985,312 A 11/1999 Jacob et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1130352 A 9/1996
WO WO 93/21906 A1 11/1993

(Continued)

OTHER PUBLICATIONS

US 6,103,281, 08/2000, DelDuca et al. (withdrawn).

(Continued)

Primary Examiner — Suzanne Ziska

(74) Attorney, Agent, or Firm — Foley & Lardner LLP; Sunit Talapatra

(57) **ABSTRACT**

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

24 Claims, 6 Drawing Sheets

US 8,889,191 B2

Page 2

(56)

References Cited

U.S. PATENT DOCUMENTS

5,998,380 A 12/1999 Ehrenberg et al.
6,123,965 A 9/2000 Jacob et al.
6,156,348 A 12/2000 Santos et al.
6,159,501 A 12/2000 Skinhoj
6,191,117 B1 2/2001 Kozachuk
6,197,346 B1 3/2001 Mathiowitz et al.
6,201,010 B1 3/2001 Cottrell
6,217,908 B1 4/2001 Mathiowitz et al.
6,235,311 B1 5/2001 Ullah et al.
6,248,363 B1 6/2001 Patel et al.
6,294,192 B1 9/2001 Patel et al.
6,319,903 B1 11/2001 Carrazana et al.
6,344,215 B1 2/2002 Bettman et al.
6,365,187 B2 4/2002 Mathiowitz et al.
6,368,586 B1 4/2002 Jacob et al.
6,479,467 B1 11/2002 Buchanan et al.
6,503,884 B1 1/2003 Ehrenberg et al.
6,514,531 B1 2/2003 Alaux et al.
6,524,620 B2 2/2003 Cheng et al.
6,559,293 B1 * 5/2003 Almarsson et al. 536/18.7
6,562,865 B1 5/2003 Codd et al.
6,569,463 B2 5/2003 Patel et al.
6,696,091 B2 2/2004 Thakur et al.
6,699,840 B2 3/2004 Almarsson et al.
6,797,283 B1 9/2004 Edgren et al.
6,923,988 B2 8/2005 Patel et al.
7,018,609 B2 3/2006 Hwang Pun et al.
7,195,778 B2 3/2007 Fleshner-Barak et al.
7,611,722 B2 11/2009 Lerner et al.
7,737,133 B2 6/2010 Devane et al.
7,763,635 B2 7/2010 Kidane et al.
2002/0044962 A1 4/2002 Cherukuri et al.
2002/0054907 A1 5/2002 Devane et al.
2002/0064563 A1 5/2002 Thakur et al.
2002/0150616 A1 10/2002 Vandecruys
2003/0017972 A1 1/2003 Pun et al.
2003/0064097 A1 4/2003 Patel et al.
2003/0072802 A1 4/2003 Cutler
2003/0091630 A1 5/2003 Louie-Helm et al.
2003/0133985 A1 7/2003 Louie-Helm et al.
2003/0147952 A1 8/2003 Lim et al.
2003/0157173 A1 8/2003 Percel et al.
2003/0166581 A1 9/2003 Almarsson et al.
2003/0215496 A1 11/2003 Patel et al.
2003/0225002 A1 12/2003 Livingstone
2004/0002462 A1 1/2004 Najarian
2004/0022844 A1 2/2004 Hasenzahl et al.
2004/0028735 A1 2/2004 Kositprapa
2004/0052843 A1 3/2004 Lerner et al.
2004/0053853 A1 3/2004 Almarsson et al.
2004/0082519 A1 4/2004 Hedner et al.
2004/0091529 A1 5/2004 Edgren et al.
2004/0096501 A1 5/2004 Vaya et al.
2004/0109894 A1 6/2004 Shefer et al.
2004/0115262 A1 6/2004 Jao et al.
2004/0122104 A1 6/2004 Hirsh et al.
2004/0132826 A1 7/2004 Hirsh et al.
2004/0156901 A1 8/2004 Thakur et al.
2004/0157785 A1 8/2004 Connor
2004/0185097 A1 9/2004 Kannan et al.
2004/0234601 A1 11/2004 Legrand et al.
2004/0258758 A1 12/2004 Gustow et al.
2005/0053653 A1 3/2005 Kidane et al.
2005/0058707 A1 3/2005 Reyes et al.
2005/0069587 A1 3/2005 Modi et al.
2005/0106242 A1 5/2005 Yan et al.
2005/0106247 A1 5/2005 Venkatesh et al.
2005/0129765 A1 6/2005 Li et al.
2005/0136108 A1 6/2005 Yam et al.
2005/0169982 A1 8/2005 Almarsson et al.
2005/0169992 A1 8/2005 Jao et al.
2005/0175697 A1 8/2005 Edgren et al.
2005/0191343 A1 9/2005 Liang
2005/0220596 A1 10/2005 Gaedy et al.
2006/0018933 A1 1/2006 Vaya et al.

2006/0018934 A1 1/2006 Vaya et al.
2006/0024365 A1 2/2006 Vaya et al.
2006/0034927 A1 2/2006 Casadevall et al.
2006/0078609 A1 4/2006 Vandecruys et al.
2006/0105045 A1 5/2006 Buchanan et al.
2006/0121112 A1 * 6/2006 Jenkins et al. 424/468
2006/0147527 A1 7/2006 Bachmann et al.
2006/0223762 A1 10/2006 Ehrenberg et al.
2006/0233892 A1 10/2006 Hendrix
2007/0212411 A1 9/2007 Fawzy et al.
2008/0085306 A1 * 4/2008 Nangia et al. 424/458
2008/0131501 A1 6/2008 Liang et al.

FOREIGN PATENT DOCUMENTS

WO WO 01/37808 A1 5/2001
WO WO 02/03984 A2 1/2002
WO WO 02/043731 A3 6/2002
WO WO 2004/022037 A1 3/2004
WO WO 2004/078162 A1 9/2004
WO WO 2004/078163 A2 9/2004
WO WO 2005/030166 A1 4/2005
WO WO 2005/079748 A2 9/2005
WO WO 2006/009403 A1 1/2006
WO WO 2006/119153 A2 11/2006
WO WO 2007/002318 1/2007

OTHER PUBLICATIONS

U.S. Appl. No. 12/926,931, filed Dec. 17, 2010, Liang et al.
Adin et al., "Topiramate Serum Concentration-to-Dose Ratio," *Therapeutic Drug Monitoring*, Jun. 2004; 26(3):251-257.
Bahk et al., "Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study," *Progress in Neuropsychopharmacology & Biological Psychiatry*, 2005, 29(1):115-121.
Beaumanoir, Anne, "The Landau-Kleffner syndrome", In: Roger et al., Eds. *Epileptic Syndromes in Infancy, Childhood, and Adolescence*, 2nd Ed., London, England: John Libby, pp. 231-244, 1992.
Berge et al., "Pharmaceutical Salts", *J. Pharm. Sci.*, Jan. 1977, 66(1): 1-19.
Bertant, Jeffery L., M.D., Ph.D., "Topiramate in Posttraumatic Stress Disorder: Preliminary Clinical Observations," *J. Clin. Psychiatry*, 2001, 62(Suppl 17):60-63.
Brandes et al., "Topiramate for Migraine Prevention," *JAMA*, Feb. 25, 2004, 291(8):965-973.
Carpenter et al., "Do obese depressed patients respond to topiramate? A retrospective chart review," *J. Affect. Disord.*, 2002, 69(1-3):251-255.
Chen et al., "Combination Treatment of Clozapine and Topiramate in Resistant Rapid-Cycling Bipolar Disorder," *Clin. Neuropharmacol.*, May-Jun. 2005, 28(3):136-138.
Coleman et al., "Polymer reviewed: A practical guide to polymer miscibility," *Jul. 1990*, 31:1187-1230.
Contin et al., "Topiramate Therapeutic Monitoring in Patients with Epilepsy: Effect of Concomitant Antiepileptic Drugs," *Ther. Drug Monit.*, 2002, 24(3):332-337.
D'Amico et al., "Topiramate in migraine prophylaxis," *Neurological Sciences*, 2005, 26(Suppl 2):S130-S133.
Deckers et al., "Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed," *Epilepsia*, 2000, 41(11):1364-1374.
Diener et al., "Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control," *J. Neurol.*, 2004, 251(8):943-950.
Dorado et al., "Topiramato en enfermedades comorbidas: epilepsia y migraña," *Rev. Neurol.*, 2006, 43(4):193-196.
Duchene et al., "Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration," *Drug Dev. Ind. Pharm.*, 1988, 14(2&3):283-318.
Erfurth et al., "Bupropion as Add-On Strategy in Difficult-to-Treat Bipolar Depressive Patients," *Neuropsychobiology*, 2002, 45(Suppl 1):33-36.
Felmeister, Alvin Ph.D., "Powders," *Remington's Pharm. Sci.*, 14th Ed., 1970, Chapter 86, 1626-1628.

US 8,889,191 B2

Page 3

(56)

References Cited

OTHER PUBLICATIONS

- Ferrari et al., "Influence of Dosage, Age, and Co-Medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response," *Therapeutic Drug Monitoring*, 2003, 25(6):700-708.
- Ferrari et al., "Rizatriptan: a new milestone in migraine treatment," *Cephalalgia*, 2000, 20(Suppl 1):1.
- Fincher, Julian H., "Particle Size of Drugs and Its Relationship to Absorption and Activity," *J. Pharm. Sci.*, Nov. 1968, 57(11):1825-1835.
- Fisher et al., "Synergism between Topiramate and Budipine in Refractory Status Epilepticus in the Rat," *Epilepsia*, 2004, 45(11):1300-1307.
- François et al., "The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy," *Epilepsy Research*, 2006, 72:147-163.
- Gurny et al., "Bioadhesive intraoral release systems: design, testing and analysis," *Biomaterials*, Nov. 1984, 5:336-340.
- Hershey et al., "Effectiveness of Topiramate in the Prevention of Childhood Headaches," *Headache*, Sep. 2002;42(8):810-818.
- Hoes et al., "The Application of Drug-Polymer Conjugates in Chemotherapy," *Drug Carrier Systems*, 1989, 9:57-109.
- Hollander et al., "Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder," *Int. Clin. Psychopharmacol.*, 2006, 21(3): 189-191.
- International Search Report and Written Opinion mailed Sep. 2, 2008, in PCT/US2007/19208, 10 pages.
- Ioannides-Demos et al., "Pharmacotherapy for Obesity," *Drugs*, 2005, 65(10):1391-1418.
- Johnson et al., "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial," *The Lancet*, May 17, 2003, 361(9370):1677-1685.
- Kellett et al., "Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic," *J. Neurol. Neurosurg. and Psych.*, 1999;66:759-763.
- Lainez et al., "Topiramate in the Prophylactic Treatment of Cluster Headache," *Headache*, Jul./Aug. 2003, 43(7):784-789.
- Lalonde et al., "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese *ob/ob* mice," *Physiology & Behavior*, 2004, 80(4):415-420.
- Lee et al., "The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy," *Epilepsia*, 2003; 44(3):339-347.
- Lehr et al., "Intestinal Transit of Bioadhesive Microspheres in an in situ Loop in the Rat—A Comparative Study with Copolymers and Blends Based on Poly(acrylic acid)," *Journal of Controlled Release*, 1990, 13:51-62.
- Leong et al., "Polymeric controlled drug delivery," *Adv. Drug Delivery Rev.*, 1987, 1:199-233.
- Linhardt, Robert J. "Biodegradable Polymers for Controlled Release of Drugs," *Controlled Release of Drugs*, 1989, Chapter 2, 53-95.
- Liu et al., "Preparation, characterization and in vivo evaluation of formulation of baicalin with hydroxypropyl-beta-cyclodextrin," *International Journal of Pharmaceutics*, 2006, 312:137-147.
- Longer, Mark A., Ph.D., "Sustained-Release Drug Delivery Systems," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 91, 1676-1693.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis," *Inter. J. of Pharm.*, 1994, 112:105-116.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment," *Inter. J. of Pharm.*, 1994, 112:117-124.
- Luszczki et al., "Interactions of Lamotrigine with Topiramate and First-Generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis," *Epilepsia*, 2003, 44(8):1003-1013.
- Mathew et al., "Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate," *Headache*, Sep. 2002, 42(8):796-803.
- McElroy et al., "Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A Randomized, Placebo-Controlled Trial," *Am. J. Psychiatry*, Feb. 2003, 160(2):255-261.
- Meador et al., "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers," *Neurology*, Jun. 2005, 64:2108-2114.
- Mikos et al., "Interaction of Polymer Microspheres with Mucin Gels as a Means of Characterizing Polymer Retention on Mucus," *Journal of Colloid and Interface Science*, May 1991, 143(2): 366-373.
- Morton et al., "Diagnosis and treatment of epilepsy in children and adolescents," *Drugs*, Mar. 1996, 51(3):399-414.
- Mosek et al., "Topiramate in the treatment of refractory chronic daily headache. An open trial," *Journal of Headache and Pain*, 2005, 6:77-80.
- O'Connor et al., "Powders," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 88, 1615-1632.
- Park et al., "Alternative Approaches to Oral Controlled Drug Delivery: Bioadhesives and In-Situ Systems," *Recent Advances in Drug Delivery*, Plenum Press, New York, 1984, 163-183.
- Pascual et al., "Testing the combination beta-blocker plus topiramate in refractory migraine," *Acta Neurol. Scand.*, 2007, 115(2):81-83.
- Physician's Desk Reference, 60th Edition, 2006, pp. 2438-2447, entry for TOPAMAX®.
- Physicians' Desk Reference 59th edition, 2541-2548 (2005).
- Physician's Desk Reference, 56th ed., 2590-2595 (2002).
- Pies, Ronald M.D., "Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review," *Annals of Clinical Psychiatry*, Dec. 2002, 14(4):223-232.
- Porter, Stuart C., Ph.D., "Coating of Pharmaceutical Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 90, 1666-1675.
- Potter et al., "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Determine the Efficacy of Topiramate in the Prophylactic Treatment of Migraine," *Neurology*, Apr. 2000, 54(Suppl 3):A15.
- Rudnic et al., "Oral Solid Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 89, 1633-1665.
- Silberstein et al., "Topiramate in Migraine Prevention," *Arch. Neurol.*, Apr. 2004, 61(4):490-495.
- Siniscalchi et al., "Combined topiramate and clonazepam therapy in a patient affected by essential tremor," *Parkinsonism Relat. Disord.*, 2007, 13(2):129-130.
- Smart et al., "An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery," *J. Pharm. Pharmacol.*, 1984, 36:295-299.
- Sofuoglu et al., "Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers," *Psychopharmacology*, 2006, 184(3-4): 645-651.
- Storey et al., "Topiramate in Migraine Prevention: A Double-Blind Placebo-Controlled Study," *Headache*, Nov./Dec. 2001, 41(10):968-975.
- Thompson et al., "Effects of topiramate on cognitive function," *J. Neurol. Neurosurg and Psych.*, 2000; 69:634-641.
- Toplak et al., "Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind placebo-controlled study," *Int. J. Obes.*, 2007, 31(1):138-146.
- Von Seggem et al., "Efficacy of Topiramate in Migraine Prophylaxis: A Retrospective Chart Analysis," *Neurology*, Apr. 2000, 54(Suppl 3):A267-A268.
- Weber, Marcus Vinicius Keche, M.D., "Topiramate for Obstructive Sleep Apnea and Snoring," *Am. J. Psychiatry*, May 2002, 159(5):872-873.
- Winkelman, John W., "Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate," *Sleep Medicine*, 2003, 4(3):243-246.

* cited by examiner

U.S. Patent

Nov. 18, 2014


Sheet 1 of 6

US 8,889,191 B2

Fig.1

80% release time vs. %Wt. gain of Release-Controlling Coating

For Surelease® coated Extended Release Beads



U.S. Patent

Nov. 18, 2014


Sheet 2 of 6

US 8,889,191 B2

Fig. 2

80% release time vs. % Wt. gain of Release-Controlling Coating

For Surelease®/ Opadry® coated Extended Release Beads



U.S. Patent


Nov. 18, 2014

Sheet 3 of 6

US 8,889,191 B2

Fig. 3

Mean (n= 16) PK Profiles from Bead Populations XR1, XR2 and XR3



U.S. Patent


Nov. 18, 2014

Sheet 4 of 6

US 8,889,191 B2

Fig. 4

Mean (n= 16) PK Profiles from the Immediate Release Formulations



U.S. Patent

Nov. 18, 2014

Sheet 5 of 6

US 8,889,191 B2

Fig.5

Dissolution Profiles of Immediate Release Formulations





Fig.6. Mean PK Profiles for Sustained Release Formulations A, B, and C



US 8,889,191 B2

1

**SUSTAINED-RELEASE FORMULATIONS OF
TOPIRAMATE****CROSS-REFERENCE TO RELATED
APPLICATIONS**

The present application is a Continuation of U.S. application Ser. No. 11/941,475, filed Nov. 16, 2007, which claims benefit of U.S. Provisional Application No. 60/859,502, filed Nov. 17, 2006, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Topiramate is a sulfamate substituted monosaccharide which under the trade name TOPAMAX® (Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J., U.S.A.) has been approved for use as an antiepileptic agent, as an adjuvant therapy for patients with partial onset seizures or primary generalized tonic-clonic seizures, and for the prevention of migraine. See generally, Physician's Desk Reference, 60th ed., 2538-2447 (2006); see also, U.S. Pat. No. 4,513,006.

For the treatment of epilepsy, the recommended dose of Topamax® is 400 mg/day in one or multiple doses (Physician's Desk Reference, 60th ed., 2538-2447 (2006)). For adults with epilepsy, treatment is initiated with a dose of 25-50 mg/day, with the dose being titrated in increments of 25-50 mg at weekly intervals to the recommended or effective dose.

Topamax® is an immediate release formulation. Adverse effects associated with the administration of Topamax® include, but are not limited to, somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, diplopia, renal calculi (kidney stones), hepatic failure, pancreatitis, renal tubular acidosis, acute myopia and secondary angle closure glaucoma (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Hence, though topiramate has a relatively long half-life of 21 hours in vivo, it has not been prescribed (or formulated) as a single, daily-dose, in part due to severe side-effects that often result with peak plasma levels of the drug when taken in high doses. Instead, Topamax® is typically taken in multiple, "divided" doses, usually twice-daily ("BID"). However, administration of the medicament in this manner is cumbersome and patients can forget to take their medication in a timely manner. What is more, each administration of a dose is associated with a peak in plasma concentrations of the drug, and the fluctuations associated with the peaks and valleys of blood plasma levels of the drug are undesirable. Therefore, there is a need for a formulation of topiramate, which reduces or eliminates the side effects associated with peaking and fluctuating plasma levels of the drug and preferably may be administered in a once-daily regimen.

New, highly soluble and bioavailable forms of topiramate are also needed in order to increase the safety and effectiveness of the drug.

The instant invention addresses these and other needs by providing a modified formulation of topiramate characterized by a sustained, non-pulsatile release of an active ingredient. This invention additionally provides an effective, once-daily dosage form of topiramate or salts thereof, which not only enables an effective single daily dose regimen to improve patient compliance but may also reduce some of the side

2

effects of topiramate compared to the current or higher daily doses of immediate release topiramate formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sustained release formulation of topiramate for the treatment or prevention of a pathological condition in a mammalian subject, characterized by a sustained rate of topiramate release along a pre-determined release profile.

It is yet another object of the present invention to provide topiramate formulation wherein topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect associated with the topiramate treatment.

It is a further object of the present invention to provide a sustained release formulation of topiramate that can be administered orally once a day.

It is an object of the present invention to provide a sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient, wherein the active ingredient is released from the formulation at a sustained rate along a pre-determined release profile, and wherein the sustained release formulation comprises an extended release (XR) component and an optional immediate release (IR) component.

In one embodiment of the invention, the extended release component is contained in at least one population of beads coated with a release controlling coating. The above-mentioned coating is specific for every bead population and determines its rate of release. Thus, every given bead population included into the formulation is characterized by its own specific rate of release.

In another embodiment of the invention, the sustained release topiramate formulation comprises an immediate release component in addition to an extended release component.

In a preferred embodiment of the invention, the immediate release component is an enhanced immediate release (EIR) composition.

The formulation of the present invention may be incorporated in any oral dosage form such as represented by, but not limited to, a tablet, a pill, a capsule, a troche, a sachet, and sprinkles.

It is yet another object of the present invention to provide a method of preparation of a sustained release formulation of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile, the method comprising the steps of:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method of preparation additionally includes a process for providing an XR component contained in at least one population of beads, wherein every population of beads is characterized by its own rate of release. This process comprises the steps of

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;

US 8,889,191 B2

3

3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and

4. incorporating the beads into the formulation.

The method may optionally include a process for preparation of an IR component, which optionally is an enhanced immediate release (EIR) composition. The enhanced immediate release composition includes at least one agent selected from a group comprising complexing agents and enhancing agents. Without any limitations, the enhancing agents useful in the present invention may be selected from solubilizing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors or combinations thereof.

It is yet another object of the present invention to provide a method of treatment or prevention of a pathological condition in a mammalian subject by orally administering to the subject a therapeutically effective amount of a sustained release topiramate formulation of the instant invention. The pathological conditions that may be treated by the method of the present invention include neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by topiramate administration.

DEFINITIONS

For the purposes of this invention, the term "topiramate" includes topiramate or any pharmaceutically acceptable salts thereof.

An "immediate release formulation" refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.

For the purposes of this application, an enhancing agent ("enhancer") is defined as any non-pharmaceutically active ingredient that improves the therapeutic potential of a formulation.

The term "enhanced immediate release composition" as used herein describes an immediate release composition improved in terms of a therapeutic potential or treatment modality.

"Sustained release" is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.

By "prolonged period of time" it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.

As used herein, unless otherwise noted, "rate of release" or "release rate" of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the "T.sub.x" value, where "x" is the percent of drug that has been released.

The release rates referred to herein are determined by placing a dosage form to be tested in a medium in an appropriate dissolution bath. Aliquots of the medium, collected at pre-set

4

intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.

"C" denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as "drug plasma concentration", "plasma drug concentration" or "plasma concentration" which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as C_{time}, as in C_{9 hr} or C_{4 hr}, etc.

The maximum plasma drug concentration during the dosing period is referenced as C_{max}, while C_{min} refers to the minimum blood plasma drug concentration at the end of a dosing interval; and C_{ave} refers to an average concentration during the dosing interval.

The "degree of fluctuation" is defined as a quotient (C_{max} - C_{min})/C_{ave}.

Persons of skill in the art will appreciate that blood plasma drug concentrations obtained in individual subjects will vary due to interpatient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a drug plasma concentration is listed, the value listed is the calculated mean value based on values obtained from a groups of subjects tested.

The term "bioavailability" refers to an extent to which—and sometimes rate at which—the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.

"AUC" is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.

Side effect is defined herein as a secondary and usually adverse effect of a drug.

The term "beads", as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease® coated extended release beads.

FIG. 2 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease®/Opadry® coated extended release beads.

FIG. 3 shows mean (n=16) pharmacokinetic profiles for bead populations XR1, XR2 and XR3.

FIG. 4 shows mean (n=16) pharmacokinetic profiles for the immediate release formulations.

FIG. 5 shows the dissolution profiles of Topamax®, topiramate IR beads, and topiramate enhanced immediate release beads.

FIG. 6 shows mean PK Profiles for Sustained Release Formulations A, B, and C.


DETAILED DESCRIPTION OF THE INVENTION

Topiramate is a sulfamate-substituted monosaccharide having the chemical name 2,3,4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate. The molecular formula of

US 8,889,191 B2

5

topiramate is C₁₂H₂₁NO₈S, and its chemical structure is represented by formula below:



Topiramate is a white crystalline powder that is soluble in alkaline solutions containing sodium hydroxide or sodium phosphate, soluble in acetone, dimethylsulfoxide and ethanol. However, the solubility of topiramate in water at room temperature is only about 9.8 mg/ml. Topiramate is not extensively metabolized and is excreted largely through the urine (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Topiramate pharmacokinetics are linear, producing a dose proportional increase in blood plasma concentration levels with increased dosing, and is not significantly affected by food. Patients taking topiramate over prolonged period of time did not develop resistance to the drug. Following oral administration of an immediate release dosage form, topiramate is rapidly absorbed with plasma drug concentrations peaking in approximately 2 hours. The mean elimination half-life is reported to be about 21 hours.

Currently, topiramate is administered in multiple daily doses in part due to the severe side effects exhibited by the immediate release product, especially when taken in a high single dose.

A sustained release topiramate formulation that will be suitable for once-a-day administration and will result in the diminished level or severity of side effects is needed.

The present invention provides sustained release formulation of topiramate wherein the total daily dose of topiramate is provided in an effective once-daily dose while minimizing fluctuations in the blood plasma drug concentration.

The current invention also provides for formulations of topiramate wherein the maximum plasma concentration of topiramate is attenuated as compared to the same amount of topiramate administered as an immediate release formulation BID; therefore some of the side effects of topiramate, such as CNS side effects including but not limited to dizziness, parathesia, nervousness, psychomotor slowing, confusion, and difficulty with concentration/attention, observed when taking the immediate release product, may be reduced or eliminated.

Formulations of the instant invention are characterized by a maximum steady state plasma concentration (C_{max}) of topiramate which is higher than the minimal therapeutically effective concentration, and is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. In one embodiment, the novel formulations provide for a relative C_{max} in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID. In the other embodiment, the invention provides for the C_{max} which is lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. The C_{min} of the topiramate formulation of the present invention is about equal or higher than a C_{min} of an equivalent amount of immediate release topiramate formulation given BID.

Compared to the immediate release topiramate formulation, the sustained release topiramate formulations attenuate

6

the C_{max} of topiramate while extending the coverage of plasma concentration above the minimum plasma concentration required therapeutic efficacy. The formulation of the current invention provides for a relative steady state AUC in the range of 80% to 125%, while minimizing the degree of fluctuation, which is preferably in the range of 25% to 90%, as compared to an equivalent amount of immediate release topiramate formulation given in two divided doses (Table 5 and 6).

The present invention additionally provides a sustained release topiramate formulation for the treatment or prevention of a pathological condition in a mammalian subject wherein topiramate is released from the formulation at a sustained rate along a pre-determined release profile. Such release is achieved by incorporation into the formulation of an extended release component (XR) and an optional immediate release component (IR).

The relative amount of each component in the topiramate formulation of the present invention is determined according to the purpose of administration and a pre-determined release profile, and the total amount of topiramate in the formulation varies from 0.5 mg to about 3000 mg. In other words, topiramate or its salt is present in the composition in an amount of from about 0.5% to about 85% by weight, and preferably of from about 2% to about 70% by weight. The term "about" has been recited here and throughout the specification to account for variations, which can arise from inaccuracies in measurement inherent and understood by those of ordinary skill in the chemical and pharmaceutical arts.

The XR component of the formulation of the present invention releases topiramate in a continuous manner and is adjusted in such a way that 80% of the active ingredient is released in vitro in the predetermined period of time. By way of example, and by no means limiting the scope of the invention, the period of time may be not more than 24 hours, not more than 16 hours, not more than 12 hours, not more than 8 hours, or not more than 4 hours, depending on desired attributes of the final product.

In one embodiment, the extended release (XR) component is contained in at least one population of beads coated with a coating that modifies and controls the release of topiramate from the beads (release controlling coating). The release controlling coating is specific for every population of beads and determines the rate of release of topiramate from the given bead population.

The beads useful in the formulation of the present invention comprise an inert carrier, topiramate, a binder, an aforementioned release controlling coating and optionally, an overcoat that provides additional protection from moisture, static charge reduction, taste masking and coloring attributes to the particulates.

The inert carriers useful in the present invention may be selected from, but are not limited to, a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres. The inert carrier is present in an amount of from about 15% to about 99% by weight, and preferably in an amount of from about 40% to about 97% by weight.

Topiramate is introduced to the inert carrier by techniques known to one skilled in the art, such as drug layering, powder coating, extrusion/spheronization, roller compaction or granulation. Preferably, the introduction method is drug layering by spraying a suspension of topiramate and a binder onto the inert carrier.

The binder may be present in the bead formulation in an amount of from about 0.1% to about 15% by weight, and preferably of from about 0.2% to about 10% by weight. Binders include, but are not limited to starches, microcrystal-

US 8,889,191 B2

7

line cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, or polyvinylpyrrolidone.

The release controlling coating specific for every bead population comprises a coating material, and, optionally, a pore former and other excipients. The coating material is preferably selected from a group comprising cellulosic polymers, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and cellulose acetate phthalate; polyvinyl alcohol; acrylic polymers such as polyacrylates, polymethacrylates and copolymers thereof, and other water-based or solvent-based coating materials. The release-controlling coating is population-specific in the sense that the rate of release of topiramate from every bead population is controlled by at least one parameter of the release controlling coating, such as the nature of the coating, coating level, type and concentration of a pore former, process parameters and combinations thereof. Thus, changing a parameter, such as a pore former concentration, or the conditions of the curing, as will be discussed in more details below, (see Example 5) allows to change the release of topiramate from any given bead population and to selectively adjust the formulation to the pre-determined release profile. The release profile, in its turn, may be chosen or modified in such a way as to achieve the best treatment modality depending on the specific needs of the patient population and the nature of the condition.

For example, with all things being equal, there exists a mathematical relationship between the release controlling coating level among the cured beads and the 80% in vitro release time. Pre-determined target profiles can therefore be achieved by the interpolation or extrapolation of the relationship curve. For example, when the release controlling coating comprises only ethylcellulose (Surelease®) as a coating material, a logarithmic relationship exists between the % weight gain with the coating and the 80% release time in an in-vitro dissolution test (FIG. 1):

$$\text{Log}(T_{80\% \text{ release}}) = a(\% \text{ coating}) + b.$$

When ethylcellulose/HPMC (Surelease®/Opadry®) mixture is used, for example, 85:15 mixture or 80:20 mixture, a linear relationship exists between the % weight gain with the coating and the 80% release time in an in-vitro dissolution test (FIG. 2):

$$T_{80\% \text{ release}} = a(\% \text{ coating}) + b.$$

Pore formers suitable for use in the release controlling coating herein can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, Carbowaxes, Carbopol, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like.

8

The release controlling coating in the current invention can further comprise other additives known in the art such as plasticizers, anti-adherents, glidants, and antifoams.

In some embodiments, it may be further desirable to optionally coat the XR beads with an "overcoat," to provide, e.g., moisture protection, static charge reduction, taste-masking, flavoring, coloring, and/or polish or other cosmetic appeal to the beads. Suitable coating materials for such an overcoat are known in the art, and include, but are not limited to, cellulosic polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and microcrystalline cellulose, or combinations thereof (for example various Opadry® coating materials).

Topiramate-containing beads of the present invention may additionally contain enhancers that may be exemplified by, but not limited to, solubility enhancers, dissolution enhancers, absorption enhancers, permeability enhancers, stabilizers, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, and multidrug resistance protein inhibitors. Alternatively, the formulation can also contain enhancers that are separated from the topiramate beads, for example in a separate population of beads or as a powder. In yet another embodiment, the enhancer(s) may be contained in a separate layer on a topiramate-containing bead either under or above the release controlling coating.

The beads may further comprise other pharmaceutically active agents suitable for use in combination with topiramate for treatment or prevention of a pathological condition. The additional pharmaceutically active agents, without limitation, may be represented by analgesic and anti-inflammatory compounds such as COX-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs such as opiates and morphinomimetics, synthetic drugs with narcotic properties such as tramadol; anticonvulsants such as valproic acid or its derivatives, carbamazepine, oxcarbazepine, gabapentin, and lamotrigine; anorectics or anti-obesity agents such as sibutramine or other, orlistat or other pancreatic lipase inhibitors, diethylpropion, fluoxetine, bupropion, amphetamine, methamphetamine, sertraline, zonisamide, and metformin, as well as medications associated with weight-gain, such as sulfonylurea derivatives, insulin, and thiazolidinediones whose weight-gain effect is tempered by topiramate; anti-hypertensive agents such as diuretics, anti-adrenergics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, vasodilators, centrally acting adrenergic drugs, and adrenergic neuron blockers; mood stabilizers such as various forms/salts of lithium, Omega-3 fatty acids and others known in the art, drugs for treatment or prevention of migraines, such as ergot derivatives or triptans, or any other pharmaceutical or nutraceutical ingredient that can be safely and beneficially combined with topiramate.

A relative amount of every bead population in the complete formulation is determined on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile and will be discussed in more detail in Example 6.

In another embodiment, the formulation of the present invention comprises an extended release component as described above, and an immediate release component. The IR component may be an enhanced immediate release composition. The enhanced immediate release composition may be characterized by a faster in vitro topiramate release as compared to the IR formulation. Preferably, at least 80% of an active compound from the enhanced immediate release composition is released in a time period of not more than 30 minutes. More preferably, at least 50% of an active compound from the enhanced immediate release composition is released

US 8,889,191 B2

9

in a time period of not more than 10 minutes, and at least 25% is dissolved in a time period of not more than 5 minutes after the oral administration. In the most preferred embodiment of the present invention, at least 75% of the active compound is released from the EIR composition in a time period of not more than 10 minutes. The embodiment in which the IR component is an enhanced immediate release composition will be discussed in more details below.

In addition to topiramate and inactive excipients, the EIR composition of the present invention comprises at least one agent selected from a group consisting of complexing agents and enhancing agents.

Without any limitation, the enhancing agents suitable for the present invention may be selected from the solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. The representative, but non-limiting examples of these compounds are Vitamin E TPGS, amino acid such as glutamic acid and glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans such as maltodextrin, Cremophor RH40 (glycerol-polyethylene glycol oxystearate), Gelucire 50/13 (PEG-32 glyceryl palmitostearate), sodium lauryl sulfate, Tween 80 (polyoxyethylene sorbitan monooleate), benzyl alcohol, Span 20 (sorbitan monolaurate), Poloxamer 407, PEG3350, PVP K25, oleic acid, Capmul GMO (glyceryl monooleate), sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose, sodium bicarbonate, calcium citrate, sodium docusate, and menthol, among others. Enhancers can be combined to achieve multiple enhancement effects, for example, solubility enhancement combined with permeability enhancement and p-glycoprotein inhibition, or to provide a synergistic enhancement effect to achieve greater and more efficient enhancement. For example, polyglycolized glycerides (different grades of Gelucire) can be combined with sodium lauryl sulfate to achieve higher solubility enhancement as well as faster dissolution of topiramate.

In one embodiment, the EIR composition comprises a highly soluble complex of topiramate with a complexing agent that is represented by, but not limited to, cyclodextrins, including cyclodextrin derivatives, such as hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and alpha-cyclodextrin. The ratio of cyclodextrin to topiramate in the EIR formulation is preferably less than 20:1 and more preferably less than 5:1. In the most preferred embodiment, the complexing agent is hydroxypropyl beta cyclodextrin.

The highly soluble complex of topiramate and cyclodextrin is prepared by mixing topiramate and cyclodextrin together in the presence of water. The concentration of cyclodextrin is preferably high to facilitate the formation of topiramate-enhancer complex. In the case when the complexing agent is hydroxypropyl-beta-cyclodextrin, the concentration of the hydroxypropyl-beta-cyclodextrin solution used for mixing with topiramate is greater than 2%, preferably greater than 20%, and more preferably at least about 40%. The amount of topiramate is determined by a desired ratio of hydroxypropyl-beta-cyclodextrin to topiramate, which is preferably less than 20:1, and more preferably less than 5:1. The mixing time of

10

the complex solution is from about one hour to about 48 hours, and preferably from about 5 hours to about 24 hours. The addition of hydroxypropyl-beta-cyclodextrin and topiramate can be incremental to reduce the viscosity of the complex solution and to achieve better complexation.

In a further embodiment, the EIR component of the present invention is contained in at least one bead population. Topiramate EIR beads can be prepared using processes suitable for bead manufacturing, such as coating of a topiramate suspension, dispersion or solution onto an inert carrier, or by roller compaction, granulation, extrusion/spheronization, or powder coating, and are not limited by the examples cited therein. The enhancing agents of the present invention can be incorporated into the topiramate containing beads, or may be contained in other beads separated from the topiramate containing beads. By way of a non-limiting example, topiramate-containing EIR beads were prepared by coating topiramate dispersion onto an inert carrier such as sugar spheres. The topiramate dispersion, in addition to topiramate in the micronized form or in non-micronized form, can contain one or more enhancers, water and optionally a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

When the formulation is enhanced with complexing agents, the agents may be first mixed with topiramate and a suitable solvent such as water to form the complex. The topiramate-containing complex is then mixed with a binder solution prepared separately to give the coating dispersion. The coating dispersion is then sprayed onto the inert carrier such as sugar spheres using a fluid bed processor.

In an alternative embodiment of the invention, the formulation comprises at least one XR bead population, and at least one additional combination bead population consisting of the extended release beads that have an additional immediate release component layer coated on top of the release controlling coating. This layer may be formed by a suitable loading method such as solution/suspension/dispersion coating, powder coating or wet granulation.

In yet another embodiment, at least part (i.e., more than 0.01%, preferably at least 1%) of the active ingredient may be present in the formulation in a form of micronized particles with the size of from 1 μ m to 1000 μ m, preferably from 2 μ m to about 200 μ m, more preferably from 2 μ m to about 100 μ m. Further, one or more enhancers may be present in the formulations covered by this embodiment. The enhancers are selected from solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. Preferably, the enhancer is a solubility enhancer or a dissolution enhancer.

The topiramate formulation of the present invention may be formulated in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, sprinkles, or any other form suitable for oral administration.

In one embodiment of the invention, the dosage form is a gelatin capsule containing the XR component in a form of at least one population of beads, and an optional IR component. The IR component, when present, may be in a form of a powder, or may also be contained in at least one population of beads to achieve faster dissolution of topiramate (FIG. 5).

In an alternative embodiment, part of the total amount of the active ingredient may be incorporated into the aforementioned bead populations that will be contained inside an

US 8,889,191 B2

11

enclosure such as a capsule, and the rest of the active ingredient can be loaded on the outside of the enclosure by a suitable loading method such as solution/suspension/dispersion coating or powder coating or wet granulation. For example, a part of the immediate release topiramate formulation can be loaded by coating on the outside of a capsule that contains within it other populations of topiramate such as extended release topiramate. This dosage form can provide almost instantaneous dissolution of the initial portion of topiramate dose from the outside of the capsule, followed by a sustained release of the rest of topiramate from inside the capsule.

In a further embodiment of the invention, the dosage form is a tablet. Without imposing any limitations, this embodiment may be exemplified by a multilayered tablet that comprises at least one layer containing the extended release component, and at least one layer comprising the immediate release component, wherein the IR component may or may be not an EIR composition.

The last two embodiments are especially beneficial when fast onset of action followed by sustained release is preferred, as is for example in the cases of a breakthrough migraine episode.

The current invention additionally encompasses a method of preparing formulations of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile. The method comprises the following steps:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method comprises a step for providing an immediate release component, which may be an enhanced immediate release composition.

In another embodiment, the method includes a process for providing an extended release component contained in at least one population of beads characterized by its own rate of release, wherein the process includes the steps of:

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The exact amount of beads of every population incorporated into the formulation and into the final dosage form is determined using the linear superposition principle (WinNonLin) on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile (Example 6).

Release profiles of XR topiramate beads can be selectively adjusted, modified or stabilized by curing the beads at an elevated temperature. This process is well known in the art. However, it was unexpectedly discovered that curing the beads in the curing apparatus in the presence of at least one suitable solvent dramatically reduces the curing time necessary to produce a desired release profile and a level of stability. The curing process that previously required up to two weeks can be carried out by the method of current invention in several hours.

12

The assisting solvents can be selected from those solvents that can dissolve or partially dissolve the coating material, or those that can induce or assist the coalescence or molecular relaxation of the coating material, or those that can reduce electrostatic charge on the dosage forms during curing and those that can facilitate curing at a higher temperature. Examples of these solvents include but are not limited to organic solvents, such as alcohols, ketones, ethers, esters, amides, amines, hydrocarbons including substituted hydrocarbons such as chlorinated hydrocarbons and aromatic hydrocarbons, furans, sulfoxides, organic acids, phenols, super-critical fluids; ammonia; and water, buffered water, or water solutions of other inorganic or organic compounds, and their combinations. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

The curing of the dosage form normally is done in an apparatus that can operate at elevated temperatures and that can deliver the assisting solvents by means such as spray, injection, or vaporization. In the embodiment of the invention when the assisting solvent is sprayed or injected into the curing apparatus, the stream of solvent is introduced directly onto the coated beads. The amount of the solvent necessary to produce the desired effect, such as the desired release parameters and stabilization of the coating, depends on the nature of the solvent and the method of solvent delivery.

Typically, when the vaporization method is used, the organic solvents and aqueous solutions may be used in the wide range of vapor concentrations varying from 2% to more than 100%, providing an unsaturated, saturated or an over-saturated atmosphere. The pure water, however, has to be used in such an amount as to provide at least a saturated or, preferably, an oversaturated atmosphere in the curing apparatus. At least during the delivery of assisting solvents, the coated beads are mixed or agitated either continuously or in a pulsed manner.

In an alternative embodiment of the invention, hot water steam is introduced into the curing apparatus for a pre-selected period of time. The steam serves simultaneously as a solvent and as a source of heat for the beads. Introduction of steam is followed by a drying period.

This method of curing the release controlling coating results in many benefits including the dramatically shortened curing time, increased stability and modification of the release profile, and is not limited to topiramate containing beads, but includes the curing of any microparticles regardless of the drug.

Specifically, active ingredient containing beads, with or without the optional over-coat, are charged to a fluid bed processor or a pan coater and heated to a desired curing temperature range, for example 40° C. to 80° C. for sustained release dosage forms containing ethylcellulose (Surelease®), and 40° C. to 70° C. for sustained release dosage forms containing acrylic polymers (Eudragit® RS and Eudragit® RL). The assisting solvent or solvents, such as water or alcohol-water mixture, are sprayed onto the beads while mixing by, for example, fluidizing or rotating. Alternatively, the process is carried out in an oven where hot steam is introduced as previously discussed. Solvent-assisted curing is carried out to a desired curing time length, either in one curing period or in multiple, separate curing periods. The dosage forms can be further dried for a short period of time to remove residual solvents.

The solvent-assisted curing process significantly accelerates the curing of release controlling coating on active ingredient containing beads as compared to the heat-only curing of

US 8,889,191 B2

15

16

TABLE 1-continued

method	or oven	or oven	or oven	or oven	or oven	or oven	or oven
Topiramate Beads							
	XR3	XR4	XR5	XR6	XR7	XR8	
RC coating material	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Acrylic polymers (Eudragit® RL30D/RS30D)	
Pore-former	—	Cellulosic polymers (Opadry® Clear)	Cellulosic polymers (Opadry® Clear)	Cellulosic polymers (Opadry® Clear)	Cellulosic polymers (Opadry® Clear)	—	
RC coating Material to pore-former ratio	—	80:20	80:20	80:20	85:15	—	
RC coating level	3.7%	3.1%	5.2%	9.5%	15%	15%	
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	
Over-coat material	—	—	—	—	—	—	
Over-coat coating level	—	—	—	—	—	—	
Curing method	Fluid bed/water, or oven	Fluid bed/water, or oven	Fluid bed/water, or oven	Fluid bed/water, or oven	Fluid bed/water, fluid bed/5% alcohol-water, or oven	Fluid bed/water, fluid bed/5% alcohol-water, or oven	

*RC—Release Controlling

Example 2

Method of Topiramate-Hydroxypropyl-Beta-Cyclodextrin

Complex Bead Preparation

Approximately half of the intended amount of topiramate was added to the water with constant mixing followed by sprinkling of hydroxypropyl-beta-cyclodextrin into the dispersion. Once the dispersion became significantly less viscous, more drug substance was added followed by sprinkling of more hydroxypropyl-beta-cyclodextrin. The drug and hydroxypropyl-beta-cyclodextrin addition steps were repeated, and the dispersion was mixed for 12-18 hours. Separately, hydroxypropylmethylcellulose was dissolved in water. The above topiramate—hydroxypropyl-beta-cyclodextrin dispersion and hydroxypropylmethylcellulose solution were mixed together for 15 to 30 minutes and the mixture was screened through an 80-mesh sieve. The resultant dispersion was sprayed onto sugar spheres using a fluid bed processor to yield the enhanced immediate release beads (Table 2).

TABLE 2

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions				
Percentage (w/w) in Beads				
Component	EIR-1 (HPBCD: Drug = 3:2)*	EIR-2 (HPBCD: Drug = 3:2)*	EIR-3 (HPBCD: Drug = 1:1)*	EIR-4 (HPBCD: Drug = 1:2)*
Topiramate	25.0	3.3	28.9	33.3
Hydroxypropyl-beta-cyclodextrin	37.5	4.95	28.9	16.7
Hydroxypropylmethylcellulose	3.1	0.41	2.4	4.2

30

TABLE 2-continued

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions

35

Percentage (w/w) in Beads

Component	EIR-1 (HPBCD: Drug = 3:2)*	EIR-2 (HPBCD: Drug = 3:2)*	EIR-3 (HPBCD: Drug = 1:1)*	EIR-4 (HPBCD: Drug = 1:2)*
Sugar spheres	34.4	91.34	39.8	45.8

40

45

*HPBCD: Drug—Hydroxypropyl-beta-cyclodextrin to drug substance ratio

Example 3

Topiramate EIR Beads Containing Non-Complexing Enhancers

55

60

65

Topiramate is dispersed in a binder solution, such as hydroxypropylmethylcellulose solution, that contains an appropriate amount of enhancer or enhancers such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) and sodium lauryl sulfate combination, polyoxyl hydrogenated castor oil (different grades of Cremophor RH), polyglycolized glycerides (different grades of Gelucire), polyglycolized glycerides (different grades of Gelucire) combined with sodium lauryl sulfate, or combinations thereof. The resultant dispersion is sprayed onto an inert carrier such as sugar spheres using a fluid bed processor to achieve a desired drug load (Table 3).

US 8,889,191 B2

17

TABLE 3

Enhanced Immediate Release Topiramate Bead Compositions			
Component	Percentage (w/w) in Beads		
	EIR-5	EIR-6	EIR-7
Topiramate	36.8	37.9	36.4
Sodium lauryl sulfate	0.7	0.5	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	7.3	—	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	9.1
Polyglycolized glycerides (Gelucire 50/13)	—	4.7	—
Hydroxypropylmethylcellulose	4.6	4.8	4.5
Sugar spheres	50.6	52.1	50.0

Example 4

Topiramate EIR Beads Containing Micronized Particles

Miconized or non-miconized topiramate is dispersed in a solution with or without heating, optionally containing dissolution enhancing agents such as mannose, maltose, mannitol, lactose, maltodextrin and sodium starch glucolate, and optionally containing one or more additional enhancers such as PEG3350, sodium lauryl sulfate, sodium docusate, polyoxyethylene sorbitan monooleate and Poloxamers, under such process parameters that topiramate particles that remain undissolved have a particle size of about 2 micron to about 30 micron. A particle size reduction device such as a homogenizer can also be used to reduce the particle size of undissolved topiramate. The resultant topiramate dispersion is then sprayed onto inert carriers such as sugar spheres in a coating processor such as a fluid bed processor. The formulations obtained are represented in the Table 4:

TABLE 4

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Topiramate	3.2	26.0	25.0	3.2	26.0	26.0
Mannose	0.4	5.0	3.3	2.0	10.0	10.0
Maltrin 250	—	—	1.0	1.0	—	—
PEG3350	1.0	15.0	—	—	—	10.0
Sodium lauryl sulfate	—	—	—	—	0.5	—
Hydroxypropyl-beta-cyclodextrin	—	—	37.5	—	—	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	—	—	—	—	2.0	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	—	—	—	2.0
Sugar spheres	95.4	54.0	33.2	93.8	61.5	52.0

Example 5

Method of Curing Beads

The topiramate beads coated with a release controlling coating, with or without an overcoat, can be cured using the

18

above-mentioned solvent-assisted curing process, or using the heat-only curing process, to a desired curing level and preferably to complete curing.

Specifically, the core is coated to a desired coating level with a solution or dispersion of the release controlling coating material, with or without the above-mentioned additives such as pore-formers, using a fluid bed processor or any other suitable apparatus for coating of the core. Product temperature is controlled at a desirable range, for example 20° C. to 60° C. for the coating of ethylcellulose (Surelease®) and 20° C. to 60° C. for acrylic polymers (Eudragit® RL and Eudragit® RS grades). An optional overcoat with materials such as cellulosic polymers (various Opadry®) is applied thereafter. Curing of the sustained release topiramate beads is carried out either in an oven at 40° C. to 80° C. for Surelease® containing beads or at 40° C. to 70° C. for Eudragit® RL or RS containing beads, or in a fluid bed processor with or without the use of assisting solvents at similar product temperatures.

For curing that uses assisting solvents, the assisting solvent can be delivered through top spray, bottom spray, side spray or injection, or introduced by vaporization. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

Example 6

Sustained Release Formulations of Topiramate

a. Plasma concentration versus time curves for the topiramate formulations containing extended release and immediate release bead populations are simulated using WinNonlin Version 5.0.1 based on the pharmacokinetic data on the separate bead populations that were generated in a comparative randomized single-dose 6-way crossover study in healthy adult volunteers. The study included administration of a 50 mg oral dose of three extended release compositions, designated here as XR1, XR2 and XR3, two immediate release compositions ((Topamax®, Ortho-McNeil Neurologics, Inc.) (25 mg BID), and an immediate release bead formulation) and an enhanced immediate release (IR) bead composition. The single dose topiramate plasma concentration profiles for XR1, XR2 and XR3 are shown in FIG. 3. The single dose topiramate plasma concentration profiles for IR are shown in FIG. 4. The data are projected to a steady-state (SS) with a 24 h dosing interval for the sustained release compositions and a 12 h dosing interval for Topamax, using the linear superposition principle (WinNonlin). The extended release populations XR1, XR2 and XR3, and an immediate release (IR) population are selected in such a way as to be defined by at least one of the three following sets of conditions

1. for the steady state,

$$\text{for XR1, } 1.70C_{\text{maxIR}} \geq C_{\text{maxXR1}} \geq 1.30C_{\text{maxIR}}$$

$$\text{for XR2, } 0.40C_{\text{maxIR}} \geq C_{\text{maxXR2}} \geq 0.20C_{\text{maxIR}}$$

$$\text{for XR3, } 0.25C_{\text{maxIR}} \geq C_{\text{maxXR3}} \geq 0.05C_{\text{maxIR}}$$

2. for in-vitro dissolution,

$$\text{for XR1, } 1.5 \text{ h} \leq T_{80\%} \leq 4 \text{ h}$$

$$\text{for XR2, } 5 \text{ h} \leq T_{80\%} \leq 8 \text{ h}$$

$$\text{for XR3, } 8 \text{ h} \leq T_{80\%} \leq 10 \text{ h}$$

US 8,889,191 B2

19

3. for a single initial dose in-vivo,

for XR1, $4\text{ h} \leq T_{\text{max}} \leq 8.5\text{ h}$

for XR2, $T_{\text{max}} \geq 16\text{ h}$

for XR3, $T_{\text{max}} \geq 16\text{ h}$.

Optionally, the immediate release bead population is composed of enhanced immediate release (EIR) beads such that at least one condition is true: a. for the steady state, $2.40C_{\text{maxIR}} \geq C_{\text{maxEIR}} \geq 1.20C_{\text{maxIR}}$; b. for in-vitro dissolution, $T_{80\%} \leq 30\text{ min}$; c. for a single initial dose in-vivo, $T_{\text{max}} \leq 2\text{ h}$.

The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 5 below. These formulations are selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.

TABLE 5

Composition and Pharmacokinetic data of Multi-bead Formulations							
	#1	#2	#3	#4	#5	#6	#7
% XR1	20	50	0	10	10	15	0
% XR2	80	0	85	85	80	70	100
% XR3	0	50	0	0	0	15	0
% IR	0	0	15	5	10	0	0
Rel. BA (%), SS	98.5	100.5	96.6	97.4	97.6	97.3	96.0
Degree of fluctuation, SS	0.15	0.22	0.14	0.14	0.15	0.13	0.09

b. based on the results of WinNonlin simulation discussed in part (a), formulations #1 (A), #3 (B), and #4 (C) were tested in the comparative randomized multi-dose 4-way study following a once a day 50 mg oral dose of three controlled release formulations and a 25 mg twice a day oral doses of Topamax® in healthy adult volunteers.

The results of the study are summarized in Table 6 and FIG. 6:

TABLE 6

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (Topamax®)
% XR1	20	0	10	—
% XR2	80	86	84	—
% XR3	0	0	0	—
% IR	0	14	6	—
Rel. BA (%), SS	92	93	95	100
Relative Degree of fluctuation, SS	73%	72%	66%	100%

What is claimed is:

1. A method of treatment of a neurological and/or psychiatric condition in a mammalian subject, comprising orally administering to said subject in need thereof a therapeutically effective amount of a sustained release formulation of 2,3:4, 5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate (topiramate), wherein all of the topiramate is released in a continuous manner from the formulation, wherein at least 85% by weight of the total topiramate in the formulation is contained in an extended release (XR) component compris-

20

ing at least two populations of beads coated with a release controlling coating and each having its own rate of release, and wherein at least one of the at least two XR populations releases 80% of the topiramate contained therein in vitro in not more than 4 hours.

2. The method of claim 1, wherein said formulation provides for a maximum steady state plasma concentration (C_{max}) of topiramate which is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

3. The method of claim 2, wherein said C_{max} is higher than the minimal therapeutically effective concentration, but lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

4. The method of claim 2, wherein said C_{max} is in the range of 80% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

5. The method of claim 1, wherein said formulation provides for a relative steady state AUC in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID.

6. The method of claim 1, wherein said formulation provides for a degree of fluctuation in the range of 25% to 90% as compared to the same amount of topiramate administered as an immediate release formulation BID.

7. The method of claim 1, wherein said beads comprise an inert carrier, topiramate, an optional enhancer, and a release controlling coating that comprises a coating material and optionally a pore former.

8. The method of claim 7, wherein said inert carrier is selected from the group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres.

9. The method of claim 7, wherein said pore former is selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomers, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α-ω)alkylenediols; inorganic compounds; alkali metal salts and alkaline earth metal salts, and combinations thereof.

10. The method of claim 7, wherein said enhancer is selected from the group consisting of solubility enhancers, dissolution enhancers, permeability enhancers, stabilizing agents, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors and combinations thereof.

11. The method of claim 1, wherein a specific amount of each bead population is determined according to a pre-determined release profile.

12. The method of claim 1, wherein the sustained release is after an initial immediate release.

13. The method of claim 1, wherein said formulation is administered orally once a day.

14. The method of claim 1, having a reduced level of undesirable CNS side effects as compared to the same amount of topiramate administered as an immediate release formulation BID.

15. The method of claim 1, wherein the total amount of topiramate in the formulation is from 0.5 mg to 3000 mg.

US 8,889,191 B2

21

16. The method of claim 1, wherein said formulation is in a dosage form of a tablet, a pill, a capsule, a caplet, a troche, a pouch, or sprinkles.

17. The formulation of claim 1, further comprising an immediate release (IR) component.

18. The method of claim 17, wherein said IR component comprises topiramate and (a) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, and cyclodextrin derivative and/or (b) an enhancing agent selected from the group consisting of solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors and combinations thereof.

19. The method of claim 18, wherein said IR component exhibits a release profile such that 80% of the active ingredient is dissolved in not more than 30 min.

20. The method of claim 19, wherein said IR component exhibits a release profile selected from the group consisting of: a) a dissolution of at least 50% of the active ingredient in not more than 10 minutes; b) a dissolution of at least 70% of the active ingredient in not more than 10 minutes; c) a dissolution of at least 25% of the active ingredient in not more than 5 minutes; d) a dissolution of at least 40% of the active

22

ingredient in not more than 5 minutes; and e) a dissolution of at least 55% of the active ingredient in not more than 5 minutes.

21. The method of claim 7, wherein said coating material is selected from the group consisting of ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates and copolymers thereof.

22. The method of claim 1, wherein the condition is selected from the group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, and amyotrophic lateral sclerosis.

23. The method of claim 22, wherein the condition is epilepsy.

24. The method of claim 22, wherein the condition is migraine.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 8,889,191 B2
APPLICATION NO. : 12/926936
DATED : November 18, 2014
INVENTOR(S) : Likan Liang et al.

Page 1 of 1


It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

Col. 21, claim 17, line 4, "formulation" should be --method--.

Col. 21, claim 17, line 4, "further comprising" should be --wherein the formulation further comprises--.

Signed and Sealed this
Thirtieth Day of December, 2014

A handwritten signature in black ink, reading "Michelle K. Lee". The signature is fluid and cursive, with the first letters of each name being capitalized and prominent.

Michelle K. Lee
Deputy Director of the United States Patent and Trademark Office

Exhibit F

US008992989B2

(12) **United States Patent**
Liang et al.(10) **Patent No.:** **US 8,992,989 B2**
(45) **Date of Patent:** ***Mar. 31, 2015**(54) **SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE**(71) Applicant: **Supernus Pharmaceuticals, Inc.,**
Rockville, MD (US)(72) Inventors: **Likan Liang**, Boyds, MD (US); **Hua Wang**, Clarksville, MD (US);
Padmanabh P. Bhatt, Rockville, MD (US); **Michael L. Vieira**, Gaithersburg, MD (US)(73) Assignee: **Supernus Pharmaceuticals, Inc.,**
Rockville, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/499,462**(22) Filed: **Sep. 29, 2014**(65) **Prior Publication Data**

US 2015/0017249 A1 Jan. 15, 2015

Related U.S. Application Data

(63) Continuation of application No. 14/330,423, filed on Jul. 14, 2014, now Pat. No. 8,877,248, which is a continuation of application No. 12/926,936, filed on Dec. 17, 2010, now Pat. No. 8,889,191, which is a continuation of application No. 11/941,475, filed on Nov. 16, 2007, now Pat. No. 8,298,576.

(60) Provisional application No. 60/859,502, filed on Nov. 17, 2006.

(51) **Int. Cl.****A61K 9/14** (2006.01)**A61K 9/50** (2006.01)**A61K 31/357** (2006.01)**A61K 47/48** (2006.01)(52) **U.S. Cl.**CPC **A61K 9/5047** (2013.01); **A61K 31/357** (2013.01); **A61K 47/48969** (2013.01)USPC **424/495**; 514/454(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,528,378 A 10/1950 Mannheimer et al.
2,675,619 A 4/1954 Cone
2,677,700 A 5/1954 Jackson et al.
2,781,354 A 2/1957 Mannheimer et al.
2,979,578 A 4/1961 Curtis
2,996,431 A 8/1961 Barry
3,036,118 A 5/1962 Jackson et al.
3,139,383 A 6/1964 Neville et al.
3,535,307 A 10/1970 Moss et al.3,811,444 A 5/1974 Heller et al.
3,829,506 A 8/1974 Schmolka et al.
3,962,414 A 6/1976 Michaels
3,992,518 A 11/1976 Chien et al.
4,066,747 A 1/1978 Capozza
4,070,347 A 1/1978 Schmitt
4,079,038 A 3/1978 Choi et al.
4,083,949 A 4/1978 Benedikt
4,093,709 A 6/1978 Choi et al.
4,290,426 A 9/1981 Luschen et al.
4,434,153 A 2/1984 Urquhart et al.
4,513,006 A 4/1985 Maryanoff et al.
4,721,613 A 1/1988 Urquhart et al.
4,727,064 A 2/1988 Pitha
4,752,470 A 6/1988 Mehta
4,757,128 A 7/1988 Domb et al.
4,853,229 A 8/1989 Theeuwes
4,938,763 A 7/1990 Dunn et al.
4,997,904 A 3/1991 Domb
5,030,447 A 7/1991 Joshi et al.
5,175,235 A 12/1992 Domb et al.
5,180,589 A 1/1993 Joshi et al.
5,225,202 A 7/1993 Hodges et al.
5,256,440 A 10/1993 Appel et al.
5,378,475 A 1/1995 Smith et al.
5,478,577 A 12/1995 Sackler et al.
5,500,227 A 3/1996 Oshlack et al.
5,576,311 A 11/1996 Guy
5,753,693 A 5/1998 Shank
5,760,007 A 6/1998 Shank et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1130352 A 9/1996
WO WO 93/21906 A1 11/1993

(Continued)

OTHER PUBLICATIONS

Adin et al., "Topiramate Serum Concentration-to-Dose Ratio," *Therapeutic Drug Monitoring*, Jun. 2004; 26(3):251-257.Bahk et al., "Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study," *Progress in Neuropsychopharmacology & Biological Psychiatry*, 2005, 29(1):115-121.Beaumanoir, Anne, "The Landau-Kleffner syndrome", In: Roger et al., Eds. *Epileptic Syndromes in Infancy, Childhood, and Adolescence*, 2nd Ed., London, England: John Libby, pp. 231-244, 1992.Berge et al., "Pharmaceutical Salts", *J. Pharm. Sci.*, Jan. 1977, 66(1): 1-19.

(Continued)

Primary Examiner — Suzanne Ziska(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP; Sunit Talapatra(57) **ABSTRACT**

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

20 Claims, 6 Drawing Sheets

US 8,992,989 B2

Page 2

(56)

References Cited

U.S. PATENT DOCUMENTS

5,773,019 A 6/1998 Ashton et al.
 5,935,933 A 8/1999 Shank et al.
 5,955,096 A 9/1999 Santos et al.
 5,985,312 A 11/1999 Jacob et al.
 5,998,380 A 12/1999 Ehrenberg et al.
 6,123,965 A 9/2000 Jacob et al.
 6,156,348 A 12/2000 Santos et al.
 6,159,501 A 12/2000 Skinhoj
 6,191,117 B1 2/2001 Kozachuk
 6,197,346 B1 3/2001 Mathiowitz et al.
 6,201,010 B1 3/2001 Cottrell
 6,217,908 B1 4/2001 Mathiowitz et al.
 6,235,311 B1 5/2001 Ullah et al.
 6,248,363 B1 6/2001 Patel et al.
 6,294,192 B1 9/2001 Patel et al.
 6,319,903 B1 11/2001 Carrazana et al.
 6,344,215 B1 2/2002 Bettman et al.
 6,365,187 B2 4/2002 Mathiowitz et al.
 6,368,586 B1 4/2002 Jacob et al.
 6,479,467 B1 11/2002 Buchanan et al.
 6,503,884 B1 1/2003 Ehrenberg et al.
 6,514,531 B1 2/2003 Alaux et al.
 6,524,620 B2 2/2003 Cheng et al.
 6,559,293 B1 5/2003 Almarsson et al.
 6,562,865 B1 5/2003 Codd et al.
 6,569,463 B2 5/2003 Patel et al.
 6,696,091 B2 2/2004 Thakur et al.
 6,699,840 B2 3/2004 Almarsson et al.
 6,797,283 B1 9/2004 Edgren et al.
 6,923,988 B2 8/2005 Patel et al.
 7,018,609 B2 3/2006 Hwang Pun et al.
 7,195,778 B2 3/2007 Fleshner-Barak et al.
 7,611,722 B2 11/2009 Lerner et al.
 7,737,133 B2 6/2010 Devane et al.
 7,763,635 B2 7/2010 Kidane et al.
 2002/0044962 A1 4/2002 Cherukuri et al.
 2002/0054907 A1 5/2002 Devane et al.
 2002/0064563 A1 5/2002 Thakur et al.
 2002/0150616 A1 10/2002 Vandecruys
 2003/0017972 A1 1/2003 Pun et al.
 2003/0064097 A1 4/2003 Patel et al.
 2003/0072802 A1 4/2003 Cutler
 2003/0091630 A1 5/2003 Louie-Helm et al.
 2003/0133985 A1 7/2003 Louie-Helm et al.
 2003/0147952 A1 8/2003 Lim et al.
 2003/0157173 A1 8/2003 Percel et al.
 2003/0166581 A1 9/2003 Almarsson et al.
 2003/0215496 A1 11/2003 Patel et al.
 2003/0225002 A1 12/2003 Livingstone
 2004/0002462 A1 1/2004 Najarian
 2004/0022844 A1 2/2004 Hasenzahl et al.
 2004/0028729 A1 2/2004 Shojaei et al.
 2004/0028735 A1 2/2004 Kositprapa
 2004/0052843 A1 3/2004 Lerner et al.
 2004/0053853 A1 3/2004 Almarsson et al.
 2004/0082519 A1 4/2004 Hedner et al.
 2004/0091529 A1 5/2004 Edgren et al.
 2004/0096501 A1 5/2004 Vaya et al.
 2004/0109894 A1 6/2004 Shefer et al.
 2004/0115262 A1 6/2004 Jao et al.
 2004/0122104 A1 6/2004 Hirsh et al.
 2004/0132826 A1 7/2004 Hirsh et al.
 2004/0156901 A1 8/2004 Thakur et al.
 2004/0157785 A1 8/2004 Connor
 2004/0185097 A1 9/2004 Kannan et al.
 2004/0234601 A1 11/2004 Legrand et al.
 2004/0258758 A1 12/2004 Gustow et al.
 2005/0053653 A1 3/2005 Kidane et al.
 2005/0058707 A1 3/2005 Reyes et al.
 2005/0069587 A1 3/2005 Modi et al.
 2005/0106242 A1 5/2005 Yan et al.
 2005/0106247 A1 5/2005 Venkatesh et al.
 2005/0129765 A1 6/2005 Li et al.
 2005/0136108 A1 6/2005 Yam et al.
 2005/0169982 A1 8/2005 Almarsson et al.

2005/0169992 A1 8/2005 Jao et al.
 2005/0175697 A1 8/2005 Edgren et al.
 2005/0191343 A1 9/2005 Liang
 2005/0220596 A1 10/2005 Gaedy et al.
 2006/0018933 A1 1/2006 Vaya et al.
 2006/0018934 A1 1/2006 Vaya et al.
 2006/0024365 A1 2/2006 Vaya et al.
 2006/0034927 A1 2/2006 Casadevall et al.
 2006/0078609 A1 4/2006 Vandecruys et al.
 2006/0105045 A1 5/2006 Buchanan et al.
 2006/0121112 A1 6/2006 Jenkins et al.
 2006/0147527 A1 7/2006 Bachmann et al.
 2006/0223762 A1 10/2006 Ehrenberg et al.
 2006/0233892 A1 10/2006 Hendrix
 2007/0212411 A1 9/2007 Fawzy et al.
 2008/0085306 A1 4/2008 Nangia et al.
 2008/0131501 A1 6/2008 Liang et al.
 2011/0287099 A1 11/2011 Liang et al.

FOREIGN PATENT DOCUMENTS

WO WO 01/37808 A1 5/2001
 WO WO 02/03984 A2 1/2002
 WO WO 02/43731 A3 6/2002
 WO WO 2004/022037 A1 3/2004
 WO WO 2004/078162 A1 9/2004
 WO WO 2004/078163 A2 9/2004
 WO WO 2005/030166 A1 4/2005
 WO WO 2005/079748 A2 9/2005
 WO WO 2006/009403 A1 1/2006
 WO WO 2006/119153 A2 11/2006
 WO WO 2007/002318 1/2007

OTHER PUBLICATIONS

Berlant, Jeffery L., M.D., Ph.D., "Topiramate in Posttraumatic Stress Disorder: Preliminary Clinical Observations," J. Clin. Psychiatry, 2001, 62(Suppl 17):60-63.
 Brandes et al., "Topiramate for Migraine Prevention," JAMA, Feb. 25, 2004, 291(8):965-973.
 Carpenter et al., "Do obese depressed patients respond to topiramate? A retrospective chart review," J. Affect. Disord., 2002, 69(1-3):251-255.
 Chen et al., "Combination Treatment of Clozapine and Topiramate in Resistant Rapid-Cycling Bipolar Disorder," Clin. Neuropharmacol., May-Jun. 2005, 28(3):136-138.
 Coleman et al., "Polymer reviewed: A practical guide to polymer miscibility," Jul. 1990, 31:1187-1230.
 Conlin et al., "Topiramate Therapeutic Monitoring in Patients with Epilepsy: Effect of Concomitant Antiepileptic Drugs," Ther. Drug Monit., 2002, 24(3):332-337.
 D'Amico et al., "Topiramate in migraine prophylaxis," Neurological Sciences, 2005, 26(Suppl 2):S130-S133.
 Deckers et al., "Selection of Antiepileptic Drug Polytherapy Based on Mechanisms of Action: The Evidence Reviewed," Epilepsia, 2000, 41(11):1364-1374.
 Diener et al., "Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control," J. Neurol., 2004, 251(8):943-950.
 Dorado et al., "Topiramato en enfermedades comorbidas: epilepsia y migrana," Rev. Neurol., 2006, 43(4):193-196.
 Duchene et al., "Pharmaceutical and Medical Aspects of Bioadhesive Systems for Drug Administration," Drug Dev. Ind. Pharm., 1988, 14(2&3):283-318.
 Erfurth et al., "Bupropion as Add-On Strategy in Difficult-to-Treat Bipolar Depressive Patients," Neuropsychobiology, 2002, 45(Suppl 1):33-36.
 Felmeister, Alvin Ph.D., "Powders," Remington's Pharm. Sci., 14th Ed., 1970, Chapter 86, 1626-1628.
 Ferrari et al., "Influence of Dosage, Age, and Co-Medication on Plasma Topiramate Concentrations in Children and Adults with Severe Epilepsy and Preliminary Observations on Correlations with Clinical Response," Therapeutic Drug Monitoring 2003, 25(6):700-708.
 Ferrari et al. "Rizatriptan: a new milestone in migraine treatment," Cephalalgia, 2000, 20(Suppl 1):1.

US 8,992,989 B2

Page 3

(56)

References Cited

OTHER PUBLICATIONS

- Fincher, Julian H., "Particle Size of Drugs and Its Relationship to Absorption and Activity," *J. Pharm. Sci.*, Nov. 1968, 57(11):1825-1835.
- Fisher et al., "Synergism between Topiramate and Budipine in Refractory Status Epilepticus in the Rat," *Epilepsia*, 2004, 45(11):1300-1307.
- François et al., "The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy," *Epilepsy Research*, 2006, 72:147-163.
- Gurny et al., "Bioadhesive intraoral release systems: design, testing and analysis," *Biomaterials*, Nov. 1984, 5:336-340.
- Hershey et al., "Effectiveness of Topiramate in the Prevention of Childhood Headaches," *Headache*, Sep. 2002;42(8):810-818.
- Hoes et al., "The Application of Drug-Polymer Conjugates in Chemotherapy," *Drug Carrier Systems*, 1989, 9:57-109.
- Hollander et al., "Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder," *Int. Clin. Psychopharmacol.*, 2006, 21(3): 189-191.
- International Search Report and Written Opinion mailed Sep. 2, 2008, in PCT/US2007/19208, 10 pages.
- Ioannides-Demos et al., "Pharmacotherapy for Obesity," *Drugs*, 2005, 65(10):1391-1418.
- Johnson et al., "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial," *The Lancet*, May 17, 2003, 361(9370):1677-1685.
- Kellet et al., "Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic," *J. Neurol. Neurosurg. and Psych.*, 1999;66:759-763.
- Lainez et al., "Topiramate in the Prophylactic Treatment of Cluster Headache," *Headache*, Jul./Aug. 2003, 43(7):784-789.
- Lalonde et al., "Additive effects of leptin and topiramate in reducing fat deposition in lean and obese *ob/ob* mice," *Physiology & Behavior*, 2004, 80(4):415-420.
- Lee et al., "The Effects of Adjunctive Topiramate on Cognitive Function in Patients with Epilepsy," *Epilepsia*, 2003, 44(3):339-347.
- Lehr et al., "Intestinal Transit of Bioadhesive Microspheres in an in situ Loop in the Rat—A Comparative Study with Copolymers and Blends Based on Poly(acrylic acid)," *Journal of Controlled Release*, 1990, 13:51-62.
- Leong et al., "Polymeric controlled drug delivery," *Adv. Drug Delivery Rev.*, 1987, 1:199-233.
- Linhardt, Robert J. "Biodegradable Polymers for Controlled Release of Drugs," *Controlled Release of Drugs*, 1989, Chapter 2, 53-95.
- Liu et al., "Preparation, characterization and in vivo evaluation of formulation of baicalin with hydroxypropyl-beta-cyclodextrin," *International Journal of Pharmaceutics*, 2006, 312:137-147.
- Longer, Mark A., Ph.D., "Sustained-Release Drug Delivery Systems," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 91, 1676-1693.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 1. Analysis," *Inter. J. of Pharm.*, 1994, 112:105-116.
- Lu et al., "Dimensionless presentation for drug release from a coated pure drug bead: 2. Experiment," *Inter. J. of Pharm.*, 1994, 112:117-124.
- Luszczki et al., "Interactions of Lamotrigine with Topiramate and First-Generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis," *Epilepsia*, 2003, 44(8):1003-1013.
- Mathew et al., "Prophylaxis of Migraine, Transformed Migraine, and Cluster Headache with Topiramate," *Headache*, Sep. 2002, 42(8):796-803.
- McElroy et al., "Topiramate in the Treatment of Binge Eating Disorder Associated with Obesity: A Randomized, Placebo-Controlled Trial," *Am. J. Psychiatry*, Feb. 2003, 160(2):255-261.
- Meador et al., "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers," *Neurology*, Jun. 2005, 64:2108-2114.
- Mikos et al., "Interaction of Polymer Microspheres with Mucin Gels as a Means of Characterizing Polymer Retention on Mucus," *Journal of Colloid and Interface Science*, May 1991, 143(2): 366-373.
- Morton et al., "Diagnosis and treatment of epilepsy in children and adolescents," *Drugs*, Mar. 1996, 51(3):399-414.
- Mosek et al., "Topiramate in the treatment of refractory chronic daily headache. An open trial," *Journal of Headache and Pain*, 2005, 6:77-80.
- O'Connor et al., "Powders," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 88, 1615-1632.
- Park et al., "Alternative Approaches to Oral Controlled Drug Delivery: Bioadhesives and In-Situ Systems," *Recent Advances in Drug Delivery*, Plenum Press, New York, 1984, 163-183.
- Pascual et al., "Testing the combination beta-blocker plus topiramate in refractory migraine," *Acta Neurol. Scand.*, 2007, 115(2):81-83.
- Physician's Desk Reference, 69th Edition, 2006, pp. 2438-2447, entry for TOPAMAX®.
- Physicians' Desk Reference 59th edition, 2541-2548 (2005).
- Physician's Desk Reference, 56th ed., 2590-2595 (2002).
- Pies, Ronald M.D. "Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review," *Annals of Clinical Psychiatry*, Dec. 2002, 14(4):223-232.
- Porter, Stuart C., Ph.D., "Coating of Pharmaceutical Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 90, 1666-1675.
- Potter et al., "A Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Determine the Efficacy of Topiramate in the Prophylactic Treatment of Migraine," *Neurology*, Apr. 2000, 54(Suppl 3):A15.
- Rudnic et al., "Oral Solid Dosage Forms," *Remington's Pharmaceutical Sciences*, 18th Edition, 1990, Chapter 89, 1633-1665.
- Silberstein et al., "Topiramate in Migraine Prevention," *Arch. Neurol.*, Apr. 2004, 61(4):490-495.
- Siniscalchi et al., "Combined topiramate and clonazepam therapy in a patient affected by essential tremor," *Parkinsonism Relat. Disord.*, 2007, 13(2):129-130.
- Smart et al., "An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery," *J. Pharm. Pharmacol.*, 1984, 36:295-299.
- Sofuoglu et al., "Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers," *Psychopharmacology*, 2006, 184(3-4): 645-651.
- Storey et al., "Topiramate in Migraine Prevention: A Double-Blind Placebo-Controlled Study," *Headache*, Nov./Dec. 2001, 41(10):968-975.
- Thompson et al., "Effects of topiramate on cognitive function," *J. Neurol. Neurosurg and Psych.*, 2000; 69:634-641.
- Toplak et al., "Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind placebo-controlled study," *Int. J. Obes.*, 2007, 31(1):138-146.
- Von Seggern et al., "Efficacy of Topiramate in Migraine Prophylaxis: A Retrospective Chart Analysis," *Neurology*, Apr. 2000, 54(Suppl 3):A267-A268.
- Weber, Marcus Vinicius Keche, M.D., "Topiramate for Obstructive Sleep Apnea and Snoring," *Am. J. Psychiatry*, May 2002, 159(5):872-873.
- Winkelman, John W., "Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate," *Sleep Medicine*, 2003, 4(3):243-246.
- US 6,103,281, 08/2000, DelDuca et al. (withdrawn)

U.S. Patent

Mar. 31, 2015


Sheet 1 of 6

US 8,992,989 B2

Fig.1

80% release time vs. %Wt. gain of Release-Controlling Coating

For Surelease® coated Extended Release Beads



U.S. Patent

Mar. 31, 2015


Sheet 2 of 6

US 8,992,989 B2

Fig. 2

80% release time vs. % Wt. gain of Release-Controlling Coating

For Surelease®/ Opadry® coated Extended Release Beads



U.S. Patent


Mar. 31, 2015

Sheet 3 of 6

US 8,992,989 B2

Fig. 3

Mean (n= 16) PK Profiles from Bead Populations XR1, XR2 and XR3



U.S. Patent


Mar. 31, 2015

Sheet 4 of 6

US 8,992,989 B2

Fig. 4

Mean (n= 16) PK Profiles from the Immediate Release Formulations



U.S. Patent


Mar. 31, 2015

Sheet 5 of 6

US 8,992,989 B2

Fig.5

Dissolution Profiles of Immediate Release Formulations




U.S. Patent

Mar. 31, 2015

Sheet 6 of 6

US 8,992,989 B2

Fig.6. Mean PK Profiles for Sustained Release Formulations A, B, and C



US 8,992,989 B2

1

**SUSTAINED-RELEASE FORMULATIONS OF
TOPIRAMATE****CROSS-REFERENCE TO RELATED
APPLICATIONS**

The present application is a Continuation of U.S. application Ser. No. 14/330,423, filed Jul. 14, 2014, which is a Continuation of U.S. application Ser. No. 12/926,936, filed Dec. 17, 2010, which is a Continuation of U.S. application Ser. No. 11/941,475, filed Nov. 16, 2007, which claims benefit of U.S. Provisional Application No. 60/859,502, filed Nov. 17, 2006, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Topiramate is a sulfamate substituted monosaccharide which under the trade name TOPAMAX® (Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J., U.S.A.) has been approved for use as an antiepileptic agent, as an adjuvant therapy for patients with partial onset seizures or primary generalized tonic-clonic seizures, and for the prevention of migraine. See generally, Physician's Desk Reference, 60th ed., 2538-2447 (2006); see also, U.S. Pat. No. 4,513,006.

For the treatment of epilepsy, the recommended dose of Topamax® is 400 mg/day in one or multiple doses (Physician's Desk Reference, 60th ed., 2538-2447 (2006)). For adults with epilepsy, treatment is initiated with a dose of 25-50 mg/day, with the dose being titrated in increments of 25-50 mg at weekly intervals to the recommended or effective dose.

Topamax® is an immediate release formulation. Adverse effects associated with the administration of Topamax® include, but are not limited to, somnolence, dizziness, ataxia, speech disorders and related speech problems, psychomotor slowing, abnormal vision, difficulty with memory, paresthesia, diplopia, renal calculi (kidney stones), hepatic failure, pancreatitis, renal tubular acidosis, acute myopia and secondary angle closure glaucoma (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Hence, though topiramate has a relatively long half-life of 21 hours in vivo, it has not been prescribed (or formulated) as a single, daily-dose, in part due to severe side-effects that often result with peak plasma levels of the drug when taken in high doses. Instead, Topamax® is typically taken in multiple, "divided" doses, usually twice-daily ("BID"). However, administration of the medicament in this manner is cumbersome and patients can forget to take their medication in a timely manner. What is more, each administration of a dose is associated with a peak in plasma concentrations of the drug, and the fluctuations associated with the peaks and valleys of blood plasma levels of the drug are undesirable. Therefore, there is a need for a formulation of topiramate, which reduces or eliminates the side effects associated with peaking and fluctuating plasma levels of the drug and preferably may be administered in a once-daily regimen.

New, highly soluble and bioavailable forms of topiramate are also needed in order to increase the safety and effectiveness of the drug.

The instant invention addresses these and other needs by providing a modified formulation of topiramate characterized by a sustained, non-pulsatile release of an active ingredient. This invention additionally provides an effective, once-daily dosage form of topiramate or salts thereof, which not only enables an effective single daily dose regimen to improve patient compliance but may also reduce some of the side

2

effects of topiramate compared to the current or higher daily doses of immediate release topiramate formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a sustained release formulation of topiramate for the treatment or prevention of a pathological condition in a mammalian subject, characterized by a sustained rate of topiramate release along a pre-determined release profile.

It is yet another object of the present invention to provide topiramate formulation wherein topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect associated with the topiramate treatment.

It is a further object of the present invention to provide a sustained release formulation of topiramate that can be administered orally once a day.

It is an object of the present invention to provide a sustained release formulation of topiramate for oral administration to a mammalian subject comprising topiramate as an active ingredient, wherein the active ingredient is released from the formulation at a sustained rate along a pre-determined release profile, and wherein the sustained release formulation comprises an extended release (XR) component and an optional immediate release (IR) component.

In one embodiment of the invention, the extended release component is contained in at least one population of beads coated with a release controlling coating. The above-mentioned coating is specific for every bead population and determines its rate of release. Thus, every given bead population included into the formulation is characterized by its own specific rate of release.

In another embodiment of the invention, the sustained release topiramate formulation comprises an immediate release component in addition to an extended release component.

In a preferred embodiment of the invention, the immediate release component is an enhanced immediate release (EIR) composition.

The formulation of the present invention may be incorporated in any oral dosage form such as represented by, but not limited to, a tablet, a pill, a capsule, a troche, a sachet, and sprinkles.

It is yet another object of the present invention to provide a method of preparation of a sustained release formulation of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile, the method comprising the steps of:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method of preparation additionally includes a process for providing an XR component contained in at least one population of beads, wherein every population of beads is characterized by its own rate of release. This process comprises the steps of

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;

US 8,992,989 B2

3

3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and

4. incorporating the beads into the formulation.

The method may optionally include a process for preparation of an IR component, which optionally is an enhanced immediate release (EIR) composition. The enhanced immediate release composition includes at least one agent selected from a group comprising complexing agents and enhancing agents. Without any limitations, the enhancing agents useful in the present invention may be selected from solubilizing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, stabilizing agents, enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors or combinations thereof.

It is yet another object of the present invention to provide a method of treatment or prevention of a pathological condition in a mammalian subject by orally administering to the subject a therapeutically effective amount of a sustained release topiramate formulation of the instant invention. The pathological conditions that may be treated by the method of the present invention include neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by topiramate administration.

DEFINITIONS

For the purposes of this invention, the term "topiramate" includes topiramate or any pharmaceutically acceptable salts thereof.

An "immediate release formulation" refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.

For the purposes of this application, an enhancing agent ("enhancer") is defined as any non-pharmaceutically active ingredient that improves the therapeutic potential of a formulation.

The term "enhanced immediate release composition" as used herein describes an immediate release composition improved in terms of a therapeutic potential or treatment modality.

"Sustained release" is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.

By "prolonged period of time" it is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.

As used herein, unless otherwise noted, "rate of release" or "release rate" of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of a total drug dose released per hour. Drug release rates for dosage forms are typically measured as an in vitro rate of drug release, i.e., a quantity of drug released from the dosage form per unit time measured under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from the dosage form is referred to as the "T.sub.x" value, where "x" is the percent of drug that has been released.

The release rates referred to herein are determined by placing a dosage form to be tested in a medium in an appropriate dissolution bath. Aliquots of the medium, collected at pre-set

4

intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.

"C" denotes the concentration of drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter. For convenience, this concentration may be referred to herein as "drug plasma concentration", "plasma drug concentration" or "plasma concentration" which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as C_{time}, as in C_{9 hr} or C_{4 hr}, etc.

The maximum plasma drug concentration during the dosing period is referenced as C_{max}, while C_{min} refers to the minimum blood plasma drug concentration at the end of a dosing interval; and C_{ave} refers to an average concentration during the dosing interval.

The "degree of fluctuation" is defined as a quotient (C_{max} - C_{min})/C_{ave}.

Persons of skill in the art will appreciate that blood plasma drug concentrations obtained in individual subjects will vary due to interpatient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a drug plasma concentration is listed, the value listed is the calculated mean value based on values obtained from a groups of subjects tested.

The term "bioavailability" refers to an extent to which—and sometimes rate at which—the active moiety (drug or metabolite) enters systemic circulation, thereby gaining access to the site of action.

"AUC" is the area under the plasma concentration-time curve and is considered to be the most reliable measure of bioavailability. It is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.

Side effect is defined herein as a secondary and usually adverse effect of a drug.

The term "beads", as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease® coated extended release beads.

FIG. 2 shows the time of release of 80% of the drug vs. % wt. gain of release controlling coating for cured Surelease®/Opadry® coated extended release beads.

FIG. 3 shows mean (n=16) pharmacokinetic profiles for bead populations XR1, XR2 and XR3.

FIG. 4 shows mean (n=16) pharmacokinetic profiles for the immediate release formulations.

FIG. 5 shows the dissolution profiles of Topamax®, topiramate IR beads, and topiramate enhanced immediate release beads.

FIG. 6 shows mean PK Profiles for Sustained Release Formulations A, B, and C.


DETAILED DESCRIPTION OF THE INVENTION

Topiramate is a sulfamate-substituted monosaccharide having the chemical name 2,3,4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate. The molecular formula of

US 8,992,989 B2

5

topiramate is C₁₂H₂₁NO₈S, and its chemical structure is represented by formula below:



Topiramate is a white crystalline powder that is soluble in alkaline solutions containing sodium hydroxide or sodium phosphate, soluble in acetone, dimethylsulfoxide and ethanol. However, the solubility of topiramate in water at room temperature is only about 9.8 mg/ml. Topiramate is not extensively metabolized and is excreted largely through the urine (Physician's Desk Reference, 60th ed., 2538-2447 (2006)).

Topiramate pharmacokinetics are linear, producing a dose proportional increase in blood plasma concentration levels with increased dosing, and is not significantly affected by food. Patients taking topiramate over prolonged period of time did not develop resistance to the drug. Following oral administration of an immediate release dosage form, topiramate is rapidly absorbed with plasma drug concentrations peaking in approximately 2 hours. The mean elimination half-life is reported to be about 21 hours.

Currently, topiramate is administered in multiple daily doses in part due to the severe side effects exhibited by the immediate release product, especially when taken in a high single dose.

A sustained release topiramate formulation that will be suitable for once-a-day administration and will result in the diminished level or severity of side effects is needed.

The present invention provides sustained release formulation of topiramate wherein the total daily dose of topiramate is provided in an effective once-daily dose while minimizing fluctuations in the blood plasma drug concentration.

The current invention also provides for formulations of topiramate wherein the maximum plasma concentration of topiramate is attenuated as compared to the same amount of topiramate administered as an immediate release formulation BID; therefore some of the side effects of topiramate, such as CNS side effects including but not limited to dizziness, paresthesia, nervousness, psychomotor slowing, confusion, and difficulty with concentration/attention, observed when taking the immediate release product, may be reduced or eliminated.

Formulations of the instant invention are characterized by a maximum steady state plasma concentration (C_{max}) of topiramate which is higher than the minimal therapeutically effective concentration, and is in the range of 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. In one embodiment, the novel formulations provide for a relative C_{max} in the range of 80% to 125%, as compared to the same amount of topiramate administered as an immediate release formulation BID. In the other embodiment, the invention provides for the C_{max} which is lower than the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID. The C_{min} of the topiramate formulation of the present invention is about equal or higher than a C_{min} of an equivalent amount of immediate release topiramate formulation given BID.

Compared to the immediate release topiramate formulation, the sustained release topiramate formulations attenuate the C_{max} of topiramate while extending the coverage of

6

plasma concentration above the minimum plasma concentration required therapeutic efficacy. The formulation of the current invention provides for a relative steady state AUC in the range of 80% to 125%, while minimizing the degree of fluctuation, which is preferably in the range of 25% to 90%, as compared to an equivalent amount of immediate release topiramate formulation given in two divided doses (Table 5 and 6).

The present invention additionally provides a sustained release topiramate formulation for the treatment or prevention of a pathological condition in a mammalian subject wherein topiramate is released from the formulation at a sustained rate along a pre-determined release profile. Such release is achieved by incorporation into the formulation of an extended release component (XR) and an optional immediate release component (IR).

The relative amount of each component in the topiramate formulation of the present invention is determined according to the purpose of administration and a pre-determined release profile, and the total amount of topiramate in the formulation varies from 0.5 mg to about 3000 mg. In other words, topiramate or its salt is present in the composition in an amount of from about 0.5% to about 85% by weight, and preferably of from about 2% to about 70% by weight. The term "about" has been recited here and throughout the specification to account for variations, which can arise from inaccuracies in measurement inherent and understood by those of ordinary skill in the chemical and pharmaceutical arts.

The XR component of the formulation of the present invention releases topiramate in a continuous manner and is adjusted in such a way that 80% of the active ingredient is released in vitro in the predetermined period of time. By way of example, and by no means limiting the scope of the invention, the period of time may be not more than 24 hours, not more than 16 hours, not more than 12 hours, not more than 8 hours, or not more than 4 hours, depending on desired attributes of the final product.

In one embodiment, the extended release (XR) component is contained in at least one population of beads coated with a coating that modifies and controls the release of topiramate from the beads (release controlling coating). The release controlling coating is specific for every population of beads and determines the rate of release of topiramate from the given bead population.

The beads useful in the formulation of the present invention comprise an inert carrier, topiramate, a binder, an aforementioned release controlling coating and optionally, an overcoat that provides additional protection from moisture, static charge reduction, taste masking and coloring attributes to the particulates.

The inert carriers useful in the present invention may be selected from, but are not limited to, a group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres. The inert carrier is present in an amount of from about 15% to about 99% by weight, and preferably in an amount of from about 40% to about 97% by weight.

Topiramate is introduced to the inert carrier by techniques known to one skilled in the art, such as drug layering, powder coating, extrusion/spheronization, roller compaction or granulation. Preferably, the introduction method is drug layering by spraying a suspension of topiramate and a binder onto the inert carrier.

The binder may be present in the bead formulation in an amount of from about 0.1% to about 15% by weight, and preferably of from about 0.2% to about 10% by weight. Binders include, but are not limited to starches, microcrystal-

US 8,992,989 B2

7

line cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, or polyvinylpyrrolidone.

The release controlling coating specific for every bead population comprises a coating material, and, optionally, a pore former and other excipients. The coating material is preferably selected from a group comprising cellulosic polymers, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, and cellulose acetate phthalate; polyvinyl alcohol; acrylic polymers such as polyacrylates, polymethacrylates and copolymers thereof, and other water-based or solvent-based coating materials. The release-controlling coating is population-specific in the sense that the rate of release of topiramate from every bead population is controlled by at least one parameter of the release controlling coating, such as the nature of the coating, coating level, type and concentration of a pore former, process parameters and combinations thereof. Thus, changing a parameter, such as a pore former concentration, or the conditions of the curing, as will be discussed in more details below, (see Example 5) allows to change the release of topiramate from any given bead population and to selectively adjust the formulation to the pre-determined release profile. The release profile, in its turn, may be chosen or modified in such a way as to achieve the best treatment modality depending on the specific needs of the patient population and the nature of the condition.

For example, with all things being equal, there exists a mathematical relationship between the release controlling coating level among the cured beads and the 80% in vitro release time. Pre-determined target profiles can therefore be achieved by the interpolation or extrapolation of the relationship curve. For example, when the release controlling coating comprises only ethylcellulose (Surelease®) as a coating material, a logarithmic relationship exists between the % weight gain with the coating and the 80% release time in an in-vitro dissolution test (FIG. 1):

$$\text{Log}(T_{80\% \text{ release}}) = a(\% \text{ coating}) + b.$$

When ethylcellulose/HPMC (Surelease®/Opadry®) mixture is used, for example, 85:15 mixture or 80:20 mixture, a linear relationship exists between the % weight gain with the coating and the 80% release time in an in-vitro dissolution test (FIG. 2):

$$T_{80\% \text{ release}} = a(\% \text{ coating}) + b.$$

Pore formers suitable for use in the release controlling coating herein can be organic or inorganic agents, and include materials that can be dissolved, extracted or leached from the coating in the environment of use. Examples of pore formers include but are not limited to organic compounds such as mono-, oligo-, and polysaccharides including sucrose, glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran; polymers soluble in the environment of use such as water-soluble hydrophilic polymers, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, Carbowaxes, Carbopol, and the like, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols, or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; inorganic compounds such as alkali metal salts, lithium carbonate, sodium chloride, sodium bromide, potassium chloride, potassium sulfate, potassium phosphate, sodium acetate, sodium citrate, suitable calcium salts, and the like.

8

The release controlling coating in the current invention can further comprise other additives known in the art such as plasticizers, anti-adherents, glidants, and antifoams.

In some embodiments, it may be further desirable to optionally coat the XR beads with an "overcoat," to provide, e.g., moisture protection, static charge reduction, taste-masking, flavoring, coloring, and/or polish or other cosmetic appeal to the beads. Suitable coating materials for such an overcoat are known in the art, and include, but are not limited to, cellulosic polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and microcrystalline cellulose, or combinations thereof (for example various Opadry® coating materials).

Topiramate-containing beads of the present invention may additionally contain enhancers that may be exemplified by, but not limited to, solubility enhancers, dissolution enhancers, absorption enhancers, permeability enhancers, stabilizers, complexing agents, enzyme inhibitors, p-glycoprotein inhibitors, and multidrug resistance protein inhibitors. Alternatively, the formulation can also contain enhancers that are separated from the topiramate beads, for example in a separate population of beads or as a powder. In yet another embodiment, the enhancer(s) may be contained in a separate layer on a topiramate-containing bead either under or above the release controlling coating.

The beads may further comprise other pharmaceutically active agents suitable for use in combination with topiramate for treatment or prevention of a pathological condition. The additional pharmaceutically active agents, without limitation, may be represented by analgesic and anti-inflammatory compounds such as COX-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), narcotic drugs such as opiates and morphinomimetics, synthetic drugs with narcotic properties such as tramadol; anticonvulsants such as valproic acid or its derivatives, carbamazepine, oxcarbazepine, gabapentin, and lamotrigine; anorectics or anti-obesity agents such as sibutramine or other, orlistat or other pancreatic lipase inhibitors, diethylpropion, fluoxetine, bupropion, amphetamine, methamphetamine, sertraline, zonisamide, and metformin, as well as medications associated with weight-gain, such as sulfonylurea derivatives, insulin, and thiazolidinediones whose weight-gain effect is tempered by topiramate; anti-hypertensive agents such as diuretics, anti-adrenergics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists, aldosterone antagonists, vasodilators, centrally acting adrenergic drugs, and adrenergic neuron blockers; mood stabilizers such as various forms/salts of lithium, Omega-3 fatty acids and others known in the art, drugs for treatment or prevention of migraines, such as ergot derivatives or triptans, or any other pharmaceutical or nutraceutical ingredient that can be safely and beneficially combined with topiramate.

A relative amount of every bead population in the complete formulation is determined on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile and will be discussed in more detail in Example 6.

In another embodiment, the formulation of the present invention comprises an extended release component as described above, and an immediate release component. The IR component may be an enhanced immediate release composition. The enhanced immediate release composition may be characterized by a faster in vitro topiramate release as compared to the IR formulation. Preferably, at least 80% of an active compound from the enhanced immediate release composition is released in a time period of not more than 30 minutes. More preferably, at least 50% of an active compound from the enhanced immediate release composition is released

US 8,992,989 B2

9

in a time period of not more than 10 minutes, and at least 25% is dissolved in a time period of not more than 5 minutes after the oral administration. In the most preferred embodiment of the present invention, at least 75% of the active compound is released from the EIR composition in a time period of not more than 10 minutes. The embodiment in which the IR component is an enhanced immediate release composition will be discussed in more details below.

In addition to topiramate and inactive excipients, the EIR composition of the present invention comprises at least one agent selected from a group consisting of complexing agents and enhancing agents.

Without any limitation, the enhancing agents suitable for the present invention may be selected from the solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. The representative, but non-limiting examples of these compounds are Vitamin E TPGS, amino acid such as glutamic acid and glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans such as maltodextrin, Cremophor RH40 (glycerol-polyethylene glycol oxystearate), Gelucire 50/13 (PEG-32 glyceryl palmitostearate), sodium lauryl sulfate, Tween 80 (polyoxyethylene sorbitan monooleate), benzyl alcohol, Span 20 (sorbitan monolaurate), Poloxamer 407, PEG3350, PVP K25, oleic acid, Capmul GMO (glyceryl monooleate), sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, HPMC, substituted hydroxypropylcellulose, microcrystalline cellulose, sodium bicarbonate, calcium citrate, sodium docusate, and menthol, among others. Enhancers can be combined to achieve multiple enhancement effects, for example, solubility enhancement combined with permeability enhancement and p-glycoprotein inhibition, or to provide a synergistic enhancement effect to achieve greater and more efficient enhancement. For example, polyglycolized glycerides (different grades of Gelucire) can be combined with sodium lauryl sulfate to achieve higher solubility enhancement as well as faster dissolution of topiramate.

In one embodiment, the EIR composition comprises a highly soluble complex of topiramate with a complexing agent that is represented by, but not limited to, cyclodextrins, including cyclodextrin derivatives, such as hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, and alpha-cyclodextrin. The ratio of cyclodextrin to topiramate in the EIR formulation is preferably less than 20:1 and more preferably less than 5:1. In the most preferred embodiment, the complexing agent is hydroxypropyl beta cyclodextrin.

The highly soluble complex of topiramate and cyclodextrin is prepared by mixing topiramate and cyclodextrin together in the presence of water. The concentration of cyclodextrin is preferably high to facilitate the formation of topiramate-enhancer complex. In the case when the complexing agent is hydroxypropyl-beta-cyclodextrin, the concentration of the hydroxypropyl-beta-cyclodextrin solution used for mixing with topiramate is greater than 2%, preferably greater than 20%, and more preferably at least about 40%. The amount of topiramate is determined by a desired ratio of hydroxypropyl-beta-cyclodextrin to topiramate, which is preferably less than 20:1, and more preferably less than 5:1. The mixing time of

10

the complex solution is from about one hour to about 48 hours, and preferably from about 5 hours to about 24 hours. The addition of hydroxypropyl-beta-cyclodextrin and topiramate can be incremental to reduce the viscosity of the complex solution and to achieve better complexation.

In a further embodiment, the EIR component of the present invention is contained in at least one bead population. Topiramate EIR beads can be prepared using processes suitable for bead manufacturing, such as coating of a topiramate suspension, dispersion or solution onto an inert carrier, or by roller compaction, granulation, extrusion/spheronization, or powder coating, and are not limited by the examples cited therein. The enhancing agents of the present invention can be incorporated into the topiramate containing beads, or may be contained in other beads separated from the topiramate containing beads. By way of a non-limiting example, topiramate-containing EIR beads were prepared by coating topiramate dispersion onto an inert carrier such as sugar spheres. The topiramate dispersion, in addition to topiramate in the micronized form or in non-micronized form, can contain one or more enhancers, water and optionally a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and polyvinyl alcohol.

When the formulation is enhanced with complexing agents, the agents may be first mixed with topiramate and a suitable solvent such as water to form the complex. The topiramate-containing complex is then mixed with a binder solution prepared separately to give the coating dispersion. The coating dispersion is then sprayed onto the inert carrier such as sugar spheres using a fluid bed processor.

In an alternative embodiment of the invention, the formulation comprises at least one XR bead population, and at least one additional combination bead population consisting of the extended release beads that have an additional immediate release component layer coated on top of the release controlling coating. This layer may be formed by a suitable loading method such as solution/suspension/dispersion coating, powder coating or wet granulation.

In yet another embodiment, at least part (i.e., more than 0.01%, preferably at least 1%) of the active ingredient may be present in the formulation in a form of micronized particles with the size of from 1 μ m to 1000 μ m, preferably from 2 μ m to about 200 μ m, more preferably from 2 μ m to about 100 μ m. Further, one or more enhancers may be present in the formulations covered by this embodiment. The enhancers are selected from solubility enhancing agents, dissolution enhancing agents, absorption enhancing agents, penetration enhancing agents, surface active agents, such as non-ionic surfactants, ionic surfactants or combinations thereof; stabilizers that include antioxidants, preservatives, buffering agents, bases and other known in the art; enzyme inhibitors, p-glycoprotein inhibitors, multidrug resistance protein inhibitors, or any combinations thereof. Preferably, the enhancer is a solubility enhancer or a dissolution enhancer.

The topiramate formulation of the present invention may be formulated in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, sprinkles, or any other form suitable for oral administration.

In one embodiment of the invention, the dosage form is a gelatin capsule containing the XR component in a form of at least one population of beads, and an optional IR component. The IR component, when present, may be in a form of a powder, or may also be contained in at least one population of beads to achieve faster dissolution of topiramate (FIG. 5).

In an alternative embodiment, part of the total amount of the active ingredient may be incorporated into the aforementioned bead populations that will be contained inside an

US 8,992,989 B2

11

enclosure such as a capsule, and the rest of the active ingredient can be loaded on the outside of the enclosure by a suitable loading method such as solution/suspension/dispersion coating or powder coating or wet granulation. For example, a part of the immediate release topiramate formulation can be loaded by coating on the outside of a capsule that contains within it other populations of topiramate such as extended release topiramate. This dosage form can provide almost instantaneous dissolution of the initial portion of topiramate dose from the outside of the capsule, followed by a sustained release of the rest of topiramate from inside the capsule.

In a further embodiment of the invention, the dosage form is a tablet. Without imposing any limitations, this embodiment may be exemplified by a multilayered tablet that comprises at least one layer containing the extended release component, and at least one layer comprising the immediate release component, wherein the IR component may or may be not an EIR composition.

The last two embodiments are especially beneficial when fast onset of action followed by sustained release is preferred, as is for example in the cases of a breakthrough migraine episode.

The current invention additionally encompasses a method of preparing formulations of topiramate, comprising an extended release component, and an optional immediate release component, wherein topiramate is released from the formulation at the sustained rate along the pre-determined release profile. The method comprises the following steps:

1. determining the desired release profile;
2. determining specific amounts of the extended release component and the immediate release component necessary to produce the pre-determined release profile; and
3. incorporating the specified amounts of the components into the formulation.

In one embodiment, the method comprises a step for providing an immediate release component, which may be an enhanced immediate release composition.

In another embodiment, the method includes a process for providing an extended release component contained in at least one population of beads characterized by its own rate of release, wherein the process includes the steps of:

1. forming at least one population of topiramate-containing beads;
2. coating each population of beads with its own coating solution;
3. curing the coating for a period of time to produce a release controlling coating specific for each bead population, and
4. incorporating the beads into the formulation.

The exact amount of beads of every population incorporated into the formulation and into the final dosage form is determined using the linear superposition principle (WinNonLin) on the basis of the pharmacokinetic data of the separate bead populations and the pre-determined release profile (Example 6).

Release profiles of XR topiramate beads can be selectively adjusted, modified or stabilized by curing the beads at an elevated temperature. This process is well known in the art. However, it was unexpectedly discovered that curing the beads in the curing apparatus in the presence of at least one suitable solvent dramatically reduces the curing time necessary to produce a desired release profile and a level of stability. The curing process that previously required up to two weeks can be carried out by the method of current invention in several hours.

12

The assisting solvents can be selected from those solvents that can dissolve or partially dissolve the coating material, or those that can induce or assist the coalescence or molecular relaxation of the coating material, or those that can reduce electrostatic charge on the dosage forms during curing and those that can facilitate curing at a higher temperature. Examples of these solvents include but are not limited to organic solvents, such as alcohols, ketones, ethers, esters, amides, amines, hydrocarbons including substituted hydrocarbons such as chlorinated hydrocarbons and aromatic hydrocarbons, furans, sulfoxides, organic acids, phenols, super-critical fluids; ammonia; and water, buffered water, or water solutions of other inorganic or organic compounds, and their combinations. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

The curing of the dosage form normally is done in an apparatus that can operate at elevated temperatures and that can deliver the assisting solvents by means such as spray, injection, or vaporization. In the embodiment of the invention when the assisting solvent is sprayed or injected into the curing apparatus, the stream of solvent is introduced directly onto the coated beads. The amount of the solvent necessary to produce the desired effect, such as the desired release parameters and stabilization of the coating, depends on the nature of the solvent and the method of solvent delivery.

Typically, when the vaporization method is used, the organic solvents and aqueous solutions may be used in the wide range of vapor concentrations varying from 2% to more than 100%, providing an unsaturated, saturated or an over-saturated atmosphere. The pure water, however, has to be used in such an amount as to provide at least a saturated or, preferably, an oversaturated atmosphere in the curing apparatus. At least during the delivery of assisting solvents, the coated beads are mixed or agitated either continuously or in a pulsed manner.

In an alternative embodiment of the invention, hot water steam is introduced into the curing apparatus for a pre-selected period of time. The steam serves simultaneously as a solvent and as a source of heat for the beads. Introduction of steam is followed by a drying period.

This method of curing the release controlling coating results in many benefits including the dramatically shortened curing time, increased stability and modification of the release profile, and is not limited to topiramate containing beads, but includes the curing of any microparticles regardless of the drug.

Specifically, active ingredient containing beads, with or without the optional over-coat, are charged to a fluid bed processor or a pan coater and heated to a desired curing temperature range, for example 40° C. to 80° C. for sustained release dosage forms containing ethylcellulose (Surelease®), and 40° C. to 70° C. for sustained release dosage forms containing acrylic polymers (Eudragit® RS and Eudragit® RL). The assisting solvent or solvents, such as water or alcohol-water mixture, are sprayed onto the beads while mixing by, for example, fluidizing or rotating. Alternatively, the process is carried out in an oven where hot steam is introduced as previously discussed. Solvent-assisted curing is carried out to a desired curing time length, either in one curing period or in multiple, separate curing periods. The dosage forms can be further dried for a short period of time to remove residual solvents.

The solvent-assisted curing process significantly accelerates the curing of release controlling coating on active ingredient containing beads as compared to the heat-only curing of

US 8,992,989 B2

13

the same. In most instances, less than 4 hours of solvent-assisted curing resulted in more complete curing of the extended release dosage forms than 2 weeks of heat-only oven curing of the same dosage forms.

The present invention also presents a method of treatment or prevention of a pathological condition in a mammalian subject, comprising orally administering to the subject a therapeutically effective amount of a novel topiramate formulation of the instant invention, wherein topiramate is released from the formulation at a sustained rate along the pre-determined release profile. The method of the current invention possesses the flexibility to selectively adjust the pharmacokinetics of the administered formulations depending on the nature of the condition and needs of the patients due to the novel design of the topiramate formulation that comprises an extended release component and an optional immediate release component, and the release profiles of both components can be selectively modified during the preparation process as described above to comply with the predetermined release profile.

The pathological condition that may be treated by a method of the present invention is a neurological condition, psychiatric condition, diabetes and related disorders, cardiovascular condition, obesity, and any other condition or disorder that may be treated or prevented by the topiramate administration.

The neurological disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to, epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, perinatal hypoxia ischemia and related damage, chronic neurodegenerative disorders, acute neurodegeneration, and ALS.

Psychiatric disorders that may be treated or prevented by a formulation of the present invention include, but are not limited to bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, ADHD, impulse control disorders, border line personality disorder, addiction, and autism.

Formulations of the present invention may be also used for the treatment and prevention of diabetes and related disorders, such as type II diabetes mellitus, diabetic retinopathy, impaired oral glucose tolerance, diabetic skin lesions, dia-

14

betic neuropathy, Syndrome X and elevated blood glucose levels; ocular disorders, including but not limited to glaucoma and macular degeneration; cardiovascular disorders represented but not limited to elevated blood pressure and elevated lipids; obesity; asthma; autoimmune disorders; sleep apnea and sleep disorders. The formulations may be also used for inducing weight loss or promoting wound healing, or for any other condition, not specified above, wherein the use of topiramate is indicated.

The invention will be further illustrated by the following Examples, however, without restricting its scope to these embodiments.

EXAMPLES

Example 1

Extended Release Beads Preparation

Topiramate Drug Layering on Sugar Spheres—The “Core”

An aqueous suspension of 10-20% (w/w) topiramate (particle size 90% vol. NMT 30 micrometer, 50% vol. NMT 15 micrometer and 10% vol. NMT 5 micrometer) and 0.5-4% (w/w) HPMC or other aqueous binder can be used as the drug layering coating solution. A fluid bed suited for Wursterspray is assembled and charged with inert carriers such as sugar spheres. The coating suspension is sprayed onto the bed to evenly coat the inert carriers to a desired topiramate loading level. Higher binder concentration in the coating solution may be used for smaller size inert carrier and higher topiramate loading. Inlet airflow rate and product temperature are adjusted to keep the batch from spray-drying the coating material or over-wetting the spheres.

Coating of the Core with a Release Controlling Coating

A dispersion of a cellulosic polymer such as ethylcellulose and methylcellulose can be used to coat the core in the current invention. Ethylcellulose dispersion (Surelease®) can be diluted to a final concentration of about 10% to about 20% and with or without the use of other ingredients such as pore formers. A fluid bed suited for Wurster-spray is assembled and charged with the cores prepared in Example 1. The release controlling coating dispersion is sprayed onto the bed to evenly coat the core to a desired coating level as exemplified in Table 1.

TABLE 1

[illegible]

US 8,992,989 B2

15

16

TABLE 1-continued

Composition and process Parameters for the extended Release						
Topiramate Beads						
	XR3	XR4	XR5	XR6	XR7	XR8
RC coating material	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Ethylcellulose (Surelease)	Acrylic polymers (Eudragit® RL30D/RS30D)
Pore-former	—	Cellulosic polymers (Opadry® Clear) 80:20	Cellulosic polymers (Opadry® Clear) 80:20	Cellulosic polymers (Opadry® Clear) 80:20	Cellulosic polymers (Opadry® Clear) 85:15	—
RC coating material to pore-former ratio	—	—	—	—	—	—
RC coating level	3.7%	3.1%	5.2%	9.5%	15%	15%
Product temperature during coating	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.	20° C.-60° C.
Over-coat material	—	—	—	—	—	—
Over-coat coating level	—	—	—	—	—	—
Curing method	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, or oven	Fluid bed/ water, fluid bed/ 5% alcohol-water, or oven	Fluid bed/ water, fluid bed/ 5% alcohol-water, or oven

*RC—Release Controlling

Example 2

30

Example 3

Method of
Topiramate-Hydroxypropyl-beta-cyclodextrin
Complex Bead Preparation

35

Topiramate EIR Beads Containing Non-Complexing
Enhancers

Approximately half of the intended amount of topiramate was added to the water with constant mixing followed by sprinkling of hydroxypropyl-beta-cyclodextrin into the dispersion. Once the dispersion became significantly less viscous, more drug substance was added followed by sprinkling of more hydroxypropyl-beta-cyclodextrin. The drug and hydroxypropyl-beta-cyclodextrin addition steps were repeated, and the dispersion was mixed for 12-18 hours. Separately, hydroxypropylmethylcellulose was dissolved in water. The above topiramate—hydroxypropyl-beta-cyclodextrin dispersion and hydroxypropylmethylcellulose solution were mixed together for 15 to 30 minutes and the mixture was screened through an 80-mesh sieve. The resultant dispersion was sprayed onto sugar spheres using a fluid bed processor to yield the enhanced immediate release beads (Table 2).

50

Topiramate is dispersed in a binder solution, such as hydroxypropylmethylcellulose solution, that contains an appropriate amount of enhancer or enhancers such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) and sodium lauryl sulfate combination, polyoxyl hydrogenated castor oil (different grades of Cremophor RH), polyglycolized glycerides (different grades of Gelucire), polyglycolized glycerides (different grades of Gelucire) combined with sodium lauryl sulfate, or combinations thereof. The resultant dispersion is sprayed onto an inert carrier such as sugar spheres using a fluid bed processor to achieve a desired drug load (Table 3).

TABLE 3

Hydroxypropyl-beta-cyclodextrin - Topiramate EIR Bead Compositions				
Component	Percentage (w/w) in Beads			
	EIR-1 (HPBCD: Drug = 3:2)*	EIR-2 (HPBCD: Drug = 3:2)*	EIR-3 (HPBCD: Drug = 1:1)*	EIR-4 (HPBCD: Drug = 1:2)*
Topiramate	25.0	3.3	28.9	33.3
Hydroxypropyl-beta-cyclodextrin	37.5	4.95	28.9	16.7
Hydroxypropyl-methylcellulose	3.1	0.41	2.4	4.2
Sugar spheres	34.4	91.34	39.8	45.8

*HPBCD:Drug—Hydroxypropyl-beta-cyclodextrin to drug substance ratio

Enhanced Immediate Release Topiramate Bead Compositions			
Component	Percentage (w/w) in Beads		
	EIR-5	EIR-6	EIR-7
Topiramate	36.8	37.9	36.4
Sodium lauryl sulfate	0.7	0.5	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	7.3	—	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	9.1
Polyglycolized glycerides (Gelucire 50/13)	—	4.7	—
Hydroxypropylmethylcellulose	4.6	4.8	4.5
Sugar spheres	50.6	52.1	50.0

55

60

65

US 8,992,989 B2

17

Example 4

Topiramate EIR Beads Containing Micronized Particles

Micronized or non-micronized topiramate is dispersed in a solution with or without heating, optionally containing dissolution enhancing agents such as mannose, maltose, mannitol, lactose, maltodextrin and sodium starch glucolate, and optionally containing one or more additional enhancers such as PEG3350, sodium lauryl sulfate, sodium docusate, polyoxyethylene sorbitan monooleate and Poloxamers, under such process parameters that topiramate particles that remain undissolved have a particle size of about 2 micron to about 30 micron. A particle size reduction device such as a homogenizer can also be used to reduce the particle size of undissolved topiramate. The resultant topiramate dispersion is then sprayed onto inert carriers such as sugar spheres in a coating processor such as a fluid bed processor. The formulations obtained are represented in the Table 4:

TABLE 4

Topiramate EIR Beads containing micronized particles						
	Percentage (w/w) in Beads					
	EIR-8	EIR-9	EIR-10	EIR-11	EIR-12	EIR-13
Topiramate	3.2	26.0	25.0	3.2	26.0	26.0
Mannose	0.4	5.0	3.3	2.0	10.0	10.0
Maltrin 250	—	—	1.0	1.0	—	—
PEG3350	1.0	15.0	—	—	—	10.0
Sodium lauryl sulfate	—	—	—	—	0.5	—
Hydroxypropyl-beta-cyclodextrin	—	—	37.5	—	—	—
D-alpha-tocopheryl polyethylene glycol 1000 succinate	—	—	—	—	2.0	—
Polyoxyl hydrogenated castor oil (Cremophor RH40)	—	—	—	—	—	2.0
Sugar spheres	95.4	54.0	33.2	93.8	61.5	52.0

Example 5

Method of Curing Beads

The topiramate beads coated with a release controlling coating, with or without an overcoat, can be cured using the above-mentioned solvent-assisted curing process, or using the heat-only curing process, to a desired curing level and preferably to complete curing.

Specifically, the core is coated to a desired coating level with a solution or dispersion of the release controlling coating material, with or without the above-mentioned additives such as pore-formers, using a fluid bed processor or any other suitable apparatus for coating of the core. Product temperature is controlled at a desirable range, for example 20° C. to 60° C. for the coating of ethylcellulose (Surelease®) and 20° C. to 60° C. for acrylic polymers (Eudragit® RL and Eudragit® RS grades). An optional overcoat with materials such as cellulosic polymers (various Opadry®) is applied thereafter. Curing of the sustained release topiramate beads is carried out either in an oven at 40° C. to 80° C. for Surelease® containing beads or at 40° C. to 70° C. for Eudragit® RL or

18

RS containing beads, or in a fluid bed processor with or without the use of assisting solvents at similar product temperatures.

For curing that uses assisting solvents, the assisting solvent can be delivered through top spray, bottom spray, side spray or injection, or introduced by vaporization. Preferably, water, water-alcohol mixture, water-ketone mixture, water-ammonia mixture, or water-organic acid (for example water-acetic acid) mixture, or combinations thereof are used as the assisting solvents.

Example 6

Sustained Release Formulations of Topiramate

a. Plasma concentration versus time curves for the topiramate formulations containing extended release and immediate release bead populations are simulated using WinNonlin Version 5.0.1 based on the pharmacokinetic data on the separate bead populations that were generated in a comparative randomized single-dose 6-way crossover study in healthy adult volunteers. The study included administration of a 50 mg oral dose of three extended release compositions, designated here as XR1, XR2 and XR3, two immediate release compositions ((Topamax®, Ortho-McNeil Neurologics, Inc.) (25 mg BID), and an immediate release bead formulation) and an enhanced immediate release (IR) bead composition. The single dose topiramate plasma concentration profiles for XR1, XR2 and XR3 are shown in FIG. 3. The single dose topiramate plasma concentration profiles for IR are shown in FIG. 4. The data are projected to a steady-state (SS) with a 24 h dosing interval for the sustained release compositions and a 12 h dosing interval for Topamax, using the linear superposition principle (WinNonlin). The extended release populations XR1, XR2 and XR3, and an immediate release (IR) population are selected in such a way as to be defined by at least one of the three following sets of conditions:

1. for the steady state,

for XR1, $1.70C_{maxIR} \geq C_{maxXR1} \geq 1.30C_{maxIR}$

for XR2, $0.40C_{maxIR} \geq C_{maxXR2} \geq 0.20C_{maxIR}$

for XR3, $0.25C_{maxIR} \geq C_{maxXR3} \geq 0.05C_{maxIR}$

2. for in-vitro dissolution,

for XR1, $1.5 \text{ h} \leq T_{80\%} \leq 4 \text{ h}$

for XR2, $5 \text{ h} \leq T_{80\%} \leq 8 \text{ h}$

for XR3, $8 \text{ h} \leq T_{80\%} \leq 10 \text{ h}$

3. for a single initial dose in-vivo,

for XR1, $4 \text{ h} \leq T_{max} \leq 8.5 \text{ h}$

for XR2, $T_{max} \geq 16 \text{ h}$

for XR3, $T_{max} \geq 16 \text{ h}$.

Optionally, the immediate release bead population is composed of enhanced immediate release (EIR) beads such that at least one condition is true: a. for the steady state, $2.40C_{maxIR} \geq C_{maxEIR} \geq 1.20C_{maxIR}$; b. for in-vitro dissolution, $T_{80\%} \leq 30 \text{ min}$; c. for a single initial dose in-vivo, $T_{max} \leq 2 \text{ h}$.

The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 5 below. These formulations are selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.

US 8,992,989 B2

19

TABLE 5

Composition and Pharmacokinetic data of Multi-bead Formulations							
	#1	#2	#3	#4	#5	#6	#7
% XR1	20	50	0	10	10	15	0
% XR2	80	0	85	85	80	70	100
% XR3	0	50	0	0	0	15	0
% IR	0	0	15	5	10	0	0
Rel. BA (%), SS	98.5	100.5	96.6	97.4	97.6	97.3	96.0
Degree of fluctuation, SS	0.15	0.22	0.14	0.14	0.15	0.13	0.09

b. based on the results of WinNonlin simulation discussed in part (a), formulations #1 (A), #3 (B), and #4 (C) were tested in the comparative randomized multi-dose 4-way study following a once a day 50 mg oral dose of three controlled release formulations and a 25 mg twice a day oral doses of Topamax® in healthy adult volunteers.

The results of the study are summarized in Table 6 and FIG. 6:

TABLE 6

Pharmacokinetic study data for Multi-bead Formulations				
	#1 A	#3 B	#4 C	Control (Topamax®)
% XR1	20	0	10	—
% XR2	80	86	84	—
% XR3	0	0	0	—
% IR	0	14	6	—
Rel. BA (%), SS	92	93	95	100
Relative Degree of fluctuation, SS	73%	72%	66%	100%

What is claimed is:

1. A sustained release formulation of topiramate comprising topiramate as an active ingredient, which is released immediately and continuously upon administration from the formulation, the formulation comprising:

(a) an extended release (XR) topiramate-containing component, comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,

(b) an immediate release (IR) topiramate-containing component comprising:

(i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or

(ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrans, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, croscarmellose sodium, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, micro-

20

crystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof,

wherein the XR component exhibits a maximum plasma concentration of topiramate in vivo between 4 and 8.5 hours, inclusive, after a single initial dose.

2. The formulation of claim 1, wherein the XR component is contained in at least one population of beads.

3. The formulation of claim 1, comprising an IR component such that 80% of the topiramate is released in not more than 1 hour.

4. The formulation according to claim 1, wherein the XR component further comprises a binder selected from the group consisting of starches, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, and polyvinylpyrrolidone.

5. The formulation according to claim 1, wherein the XR component further comprises a pore former selected from the group consisting of glucose, fructose, mannitol, mannose, galactose, sorbitol, pullulan, dextran, hydroxyalkylcelluloses, carboxyalkylcelluloses, hydroxypropylmethylcellulose, cellulose ethers, acrylic resins, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyethylene oxide, carbomer, diols, polyols, polyhydric alcohols, polyalkylene glycols, polyethylene glycols, polypropylene glycols or block polymers thereof, polyglycols, poly(α - ω)alkylenediols; alkali metal salts and alkaline earth metal salts, and combinations thereof.

6. The formulation of claim 1, wherein at least a part of the active ingredient is in a form of micronized particles.

7. The formulation of claim 1, wherein the formulation is in a dosage form of a capsule or sprinkles.

8. The formulation of claim 1, wherein the total amount of topiramate in the formulation is from 0.5 to 3000 mg.

9. The formulation of claim 1, wherein the XR component comprises an inert carrier selected from the group consisting of cellulose spheres, silicon dioxide, starch and sugar spheres.

10. The formulation of claim 1, wherein the release controlling coating comprises ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol, polyacrylates, polymethacrylates or copolymers thereof.

11. The formulation of claim 1, wherein the formulation provides for a maximum steady state plasma concentration (C_{max}) of topiramate which is in the range from 50% to 125% of the maximum plasma concentration produced by the same amount of topiramate administered as an immediate release formulation BID.

12. The formulation of claim 1, wherein the formulation provides for a relative steady state AUC in the range of 80% to 125% of the AUC of the same amount of topiramate administered as an immediate release formulation BID.

13. The formulation of claim 1, further comprising an additional pharmaceutically active ingredient in combination with topiramate.

US 8,992,989 B2

21

14. A sustained release formulation of topiramate comprising topiramate as an active ingredient, which is released immediately and continuously upon administration from the formulation, the formulation comprising:

- (a) an extended release (XR) topiramate-containing component, comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,
- (b) an immediate release (IR) topiramate-containing component comprising:
 - (i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or
 - (ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrins, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof,

wherein the XR component exhibits a maximum plasma concentration of topiramate in vivo at 16 or more hours after a single initial dose.

15. A method of treatment of a neurological and/or psychiatric condition selected from the group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, and amyotrophic lateral sclerosis (ALS), comprising orally administering to a mammalian subject a therapeutically effective amount of a sustained release formulation of topiramate comprising topiramate as an active ingredient, the formulation comprising:

- (a) an extended release (XR) topiramate-containing component, comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,
- (b) an immediate release (IR) topiramate-containing component comprising:
 - (i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or
 - (ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrins, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol,

22

sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof,

wherein administration of the formulation releases topiramate immediately and continuously and wherein the XR component exhibits a maximum plasma concentration of topiramate in vivo between 4 and 8.5 hours, inclusive, after a single initial dose.

16. The method of claim 15, wherein the condition is epilepsy.

17. The method of claim 15, wherein the condition is migraine.

18. A method of treatment of a neurological and/or psychiatric condition selected from the group consisting of epilepsy, migraine, essential tremor, restless limb syndrome, cluster headaches, neuralgia, neuropathic pain, Tourette's syndrome, infantile spasms, bipolar disorder, dementia, depression, psychosis, mania, anxiety, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), impulse control disorders, border line personality disorder, addiction, autism, chronic neurodegenerative disorders, acute neurodegeneration, and amyotrophic lateral sclerosis (ALS), comprising orally administering to a mammalian subject a therapeutically effective amount of a sustained release formulation of topiramate comprising topiramate as an active ingredient, the formulation comprising:

- (a) an extended release (XR) topiramate-containing component, comprising a coating material selected from the group consisting of cellulosic polymers and acrylic polymers, and, optionally,
- (b) an immediate release (IR) topiramate-containing component comprising:
 - (i) a complexing agent selected from the group consisting of hydroxypropyl-beta-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin, cyclodextrin, and cyclodextrin derivative, and/or
 - (ii) an enhancing agent selected from the group consisting of Vitamin E TPGS, glutamic acid, glycine, sorbitol, mannose, amylose, maltose, mannitol, lactose, sucrose, glucose, xylitol, dextrins, glycerol-polyethylene glycol oxystearate, polyethylene glycol-32 glyceryl palmitostearate, sodium lauryl sulfate, polyoxyethylene sorbitan monooleate, benzyl alcohol, sorbitan monolaurate, polyethylene-polypropylene glycol, polyethylene glycol-3350, polyvinylpyrrolidone-K25, oleic acid, glyceryl monooleate, sodium benzoate, cetyl alcohol, sucrose stearate, crospovidone, sodium starch glycolate, croscarmellose sodium, carboxymethylcellulose, starch, pregelatinized starch, hydroxypropylmethylcellulose (HPMC), substituted hydroxypropylcellulose, microcrystalline cellulose sodium bicarbonate, calcium citrate, sodium docusate, menthol, and combinations thereof,

wherein administration of the formulation releases topiramate immediately and continuously and wherein the XR

US 8,992,989 B2

23

component exhibits a maximum plasma concentration of topiramate in vivo at 16 or more hours after a single initial dose.

19. The method of claim **18**, wherein the condition is epilepsy.

20. The method of claim **18**, wherein the condition is migraine.

24

* * * * *